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Preface
This book is an outcome of a partnership between the Max Planck Institute (MPI) for
Innovation and Competition and the South Centre, which jointly organized a Global
Forum on Intellectual Property, Access to Medicine and Innovation in Munich on 9–
10 December 2019.
The MPI is more than 50 years old, but it was less than 20 years ago that its
research focus began to change quite fundamentally. In the first decades after its
foundation, the Institute academically supported and accompanied efforts to achieve
a certain standard of protection on the international level. At that time, there was
hardly any consideration of the implications of the intellectual property system for
countries at different levels of technological and economic development.
Much changed in the 1990s, however—not least with the creation of the WTO
and the entry into force of the Agreement on Trade Related Aspects of Intellectual
property Rights (the TRIPS Agreement) in 1994. One year later, in 1995, the South
Centre was launched and began its work, at a time when it was becoming increas-
ingly doubtful whether high standards of intellectual property protection would
produce comparable benefits for all countries, regardless of their level of develop-
ment. The South Centre published in 1997 ‘The TRIPS Agreement. A Guide for the
South. The Uruguay Round Agreement on Trade-Related Intellectual Property
Rights’, one of the first analysis of the ‘flexibilities’ allowed by the TRIPS Agree-
ment, the main theme of the Global Forum referred to above.
It took a little more time before a differentiated view began to gain ground at the
MPI, but a new era began in 2002 with a change in the management of the Institute.
The question of how to avoid dysfunctional effects of IP rights in certain areas and
contexts became more and more important.
Naturally, these perspectives brought into focus countries whose development
depended much more on policies other than strong intellectual property protection.
How little their own industries benefitted from high protection standards became
particularly obvious when primarily foreign rather than local companies used the
domestic intellectual property system to protect their own inventions, creations, or
trademarks.
v
While in earlier years, the MPI’s activities in Asia or Latin America, for instance,
were targeted at explaining the meaning and rationale of high standards of IP
protection, the view became much more cautious under the new perspective. In the
first instance, the Institute tried to understand the socio-economic context of a
country, and supported local academics, but also legislators and national
policymakers in the analysis and assertion of their specific needs.
This cautious approach to research activities and target-oriented support mean-
while has become a tradition of the MPI, especially in Southeast Asia and partly in
Africa. A new and special focus, however, now lies on Latin America. An initiative
started there a few years ago with ‘Smart IP for Latin America’. Its purpose above all
is to promote cooperation among the states concerned, but also to increase awareness
for specific interests these countries may have and commonly defend. The topic of
the Global Forum—access to medicine—is just one of many examples.
The South Centre, on its part, has worked extensively on intellectual property,
particularly but not only in relation to access to medicines. As an intergovernmental
organization of developing countries, it has focused on the analysis of the intellectual
property system as it may affect development strategies, including the disciplines of
the TRIPS Agreement and the standards of protection established pursuant to free
trade agreements. A key area of work has been the extent to which that Agreement
leaves policy space to implement intellectual property policies suited to different
national scenarios in the developing world. The Global Forum jointly convened with
the MPI gave the South Centre an opportunity to gather scholars and professionals of
developed and developing countries to review current trends and advance in the
understanding of the issues at stake with a focus in the area of intellectual property
and medicines.
In this context, this book examines topics of particular relevance for shaping
intellectual property regimes that take into account public health concerns. It pro-
vides not only deep analyses but options for the interpretation of existing regulations
or the adoption of new legislation that, being consistent with the TRIPS Agreement,
can allow the judiciary and policy makers to take such concerns into account. In
different chapters, the book addresses various dimensions of the flexibilities allowed
under the TRIPS Agreement. Although there is a significant literature and statements
on the subject, such as the ‘Declaration on Patent Protection. Regulatory Sovereignty
under TRIPS’ elaborated under the auspices of the MPI,1 the book contains new
reflections and examines recent developments in case law and legislation.
The covered issues include how the TRIPS Agreement can be interpreted to
implement its flexibilities, the use of competition law to promote access to medi-
cines, the role of cooperation in the examination of patent applications, patentability
requirements, the impact of TRIPS plus provisions (such as the linkage between
patents and drug regulatory approvals), the patentability in the area of CRISPR
genome editing technologies, as well as an analysis of the scope of exceptions and
limitations to exclusive rights provided for by the Agreement, such as the exhaustion
1Available at https://www.mpg.de/8132986/Patent-Declaration.pdf.
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of rights and parallel imports, compulsory licenses, the ‘Bolar exemption’, and
procedural mechanisms like pre-grant oppositions. The implications of the protec-
tion of test data are also examined.
While celebrating the opportunity of working together in organizing the Global
Forum, we hope that this book will assist policy makers and judges and provide new
inputs for academic research. While, as mentioned, there is a differentiated impact of
intellectual property rights depending on the level of development of the country
where it applies, the reconciliation of such rights with public health interests,
particularly in relation to access to medicines, is a matter of concern for all countries.
Geneva, Switzerland Carlos M. Correa
München, Germany Reto M. Hilty
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Interpreting the Flexibilities Under
the TRIPS Agreement
Carlos M. Correa
Abstract While the TRIPS Agreement provides for minimum standards of protec-
tion of intellectual property, it leaves certain degree of policy space for WTO
members, whether developed or developing countries, to implement the Agree-
ment’s provisions in different manners, to legislate in areas not subject to the
minimum standards under the Agreement, and to develop legal interpretations of
such provisions to determine the scope and content of the applicable obligations.
This paper focuses on some aspects of how panels and the Appellate Body of the
WTO have interpreted said provisions. The paper also draws general conclusions for
the implementation of TRIPS flexibilities, which are of crucial importance for the
design of a pro-competitive intellectual property system and, in particular, for
achieving public health objectives, as specifically recognized by the Doha Declara-
tion on TRIPS and Public Health.
1 Introduction
While the Agreement on Trade-Related Aspects of Intellectual Property Rights (‘the
TRIPS Agreement’) has had a major impact in framing national laws on intellectual
property rights (IPRs)—notably in developing countries—and has led to some
degree of harmonization of such laws, it is not a uniform law on IPRs.
One the one hand, the TRIPS Agreement provides for minimum standards,
thereby allowing the members of the World Trade Organization (WTO) to adopt
broader protections.1 Many such ‘TRIPS-plus’ protections have been established
through free trade agreements signed by the US and the European Union with
C. M. Correa (*)
South Centre, Geneva, Switzerland
e-mail: director@southcentre.int
1Article 1.1 of the TRIPS Agreement makes it clear, however, that no WTO member is obliged to
grant such a broader protection. See, e.g., Correa (2020b), p. 21.
© The Author(s) 2022
C. M. Correa, R. M. Hilty (eds.), Access to Medicines and Vaccines,
https://doi.org/10.1007/978-3-030-83114-1_1
1
developing country partners.2 Examples of such TRIPS-plus protections include
(in the area of patents) the extension of the patent term in order to compensate for
delays in the grant of a patent or the marketing approval of a pharmaceutical
product,3 data exclusivity,4 and what is known as ‘patent linkage’,5 among others.
On the other hand, the TRIPS Agreement leaves some room for WTO members,
whether developed or developing countries, to implement the Agreement’s pro-
visions in different manners, to legislate in areas not subject to the minimum
standards under the Agreement, and to develop legal interpretations of such pro-
visions to determine the scope and content of the applicable obligations.
The possibility, and admissibility, of differences in the implementation of the
provisions of the TRIPS Agreement are expressly recognized in Article 1.1 of the
Agreement: “Members shall be free to determine the appropriate method of
implementing the provisions of this Agreement within their own legal system and
practice.” Competition law, which may be applied to control the acquisition or
exercise of IPRs, is an example of the second situation in which the Agreement
does not provide a binding standard.6 The room for different interpretations may
result from the absence of definitions. One example is the lack of a definition of the
concept of ‘invention,’ which differs among countries and allows WTO members
not to grant patents, for instance, on developments without a technical effect (such as
under European law), or to grant or not grant patents on genetic materials.7 In many
cases, the space for different interpretations derives from general expressions or
ambiguities in the text resulting from compromises reached in the negotiation of the
Agreement. An outstanding example is the WTO members’ right to grant compul-
sory licenses due to lack of working of a patent, an issue indirectly referred to in
Article 27.1 of said Agreement.8 The task of the interpreter is particularly daunting
when the text includes general terms such as “reasonably,” “unreasonably,”9
“unjustifiable,”10 or “unjustifiably.”11
The actual policy space available under the TRIPS Agreement—beyond those
areas not covered under the Agreement—depends, in the last instance, on the
2See, e.g., Morin and Surbeck (2020).
3See, e.g., The Law Library of Congress, Global Legal Research Center (2016). Available from:
https://www.loc.gov/law/help/patent-terms/patent-term-extensions-adjustments.pdf.
4Shaikh (2016).
5Son et al. (2018). Available from: https://doi.org/10.1186/s12992-018-0423-0.
6UNDP (2015b). Available from: https://www.undp.org/content/undp/en/home/librarypage/hiv-
aids/using-competition-law-to-promote-access-to-medicine.html.
7Minn (2016).
8Article 27.1 in fine: “. . .patents shall be available and patent rights enjoyable without discrimina-
tion as to the place of invention, the field of technology and whether products are imported or
locally produced.” See, e.g., Correa (2005). See also below.
9A large number of provisions in the TRIPS Agreement uses these terms, e.g., Articles 8.2, 13, 15.5,
25.5, 26.2, 30. 31(b), 31(l), 34.2, 37, 1, 39.2(c), 41, 43.
10Article 4(d) of the TRIPS Agreement.
11Article 20 of the TRIPS Agreement.
2 C. M. Correa
interpretation of the Agreement’s provisions. This paper focuses on some aspects of
how panels and the Appellate Body of the WTO have interpreted said provisions. It
discusses, first, the concept of ‘TRIPS flexibilities’ and the possible types of such
flexibilities as found in the legislation of developing and developed countries.
Second, the paper discusses the references to such flexibilities in WTO jurispru-
dence. Third, it briefly refers to some of the principles of interpretation that are
relevant for the use of TRIPS flexibilities, including the value of dispute settlement
rulings, the search for the ordinary meaning of the terms used, the context, and the
object and purpose of the treaty. Fourth, it discusses the legal status of the Doha
Declaration on the TRIPS Agreement and Public Health adopted at the 4th WTO
Ministerial Conference in November 2001.12 There is no attempt in this paper to
analyze the specific content of the rulings in TRIPS-related disputes; however, the
paper does draw some general conclusions for the implementation of such flexibil-
ities, which are of crucial importance for the design of a pro-competitive intellectual
property system and, in particular, for achieving public health objectives
(as specifically recognized by the Doha Declaration).13
2 Defining the TRIPS Flexibilities
The terminology used to refer to the policy space available for the implementation of
the TRIPS Agreement has evolved. Expressions such as “room to maneuver,”
“margins of freedom,” “safeguards,” and “margin of discretion” were used in the
early studies and reports that identified various aspects of such space.14 Currently,
the diversity of legislative options available under said Agreement is generally
known as ‘TRIPS flexibilities.’
The term ‘flexibility’ appears in the Preamble (sixth paragraph) and in Article
66.1 of the TRIPS Agreement but it is used there with a broader meaning. It indicates
that least-developed countries (LDCs) are not bound to comply with the TRIPS
Agreement obligations (except Articles 3 through 5) during the transition period:
In view of the special needs and requirements of least-developed country Members, their
economic, financial and administrative constraints, and their need for flexibility to create a
viable technological base, such Members shall not be required to apply the provisions of this
Agreement, other than Articles 3, 4 and 5, for a period of ...15
12Available from: https://www.who.int/medicines/areas/policy/tripshealth.pdf?ua¼1. Hereinafter,
“the Doha Declaration.”
13See, e.g., Velásquez et al. (2020). https://www.southcentre.int/book-by-the-south-centre-2020/
#more-14014.
14Germán Velásquez (2013), p. 5. https://www.southcentre.int/wp-content/uploads/2013/05/
RP47_WTO-role-in-IP-and-access-to-medicines_EN.pdf.
15Emphasis added.
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The terminology ‘TRIPS flexibilities’ does include the exemption for LDCs, but it
also encompasses possible variations in the manner in which the TRIPS Agree-
ment’s provisions are interpreted and implemented as they are applied to countries
actually subject to them. Such terminology was used for the first time with this latter
meaning in the context of the WTO in paragraph 4 of the Doha Declaration.16 Said
paragraph states:
4. We agree that the TRIPS Agreement does not and should not prevent Members from
taking measures to protect public health. Accordingly, while reiterating our commitment to
the TRIPS Agreement, we affirm that the Agreement can and should be interpreted and
implemented in a manner supportive of WTOMembers' right to protect public health and, in
particular, to promote access to medicines for all. In this connection, we reaffirm the right of
WTO Members to use, to the full, the provisions in the TRIPS Agreement, which provide
flexibility for this purpose.17
The Declaration confirmed the availability of a number of flexibilities. Its adop-
tion was a response to the concerns of developing countries about the obstacles they
faced when seeking to implement measures to promote access to affordable medi-
cines, without limitation to certain diseases, in the interest of public health.18
Since the adoption of the Doha Declaration, the concept of ‘TRIPS flexibilities’
has been referenced in a vast body of literature, especially (but not only) in relation to
access to medicines,19 and in numerous resolutions of UN agencies20 and bodies,
including the World Health Organization (WHO), the Human Right Council
(HRC),21 and the UN Assembly, as well as in reports of the UN Special Rapporteur
16Paragraph 17 of the general Doha Ministerial Declaration states: “We stress the importance we
attach to implementation and interpretation of the Agreement on Trade-Related Aspects of Intel-
lectual Property Rights (TRIPS Agreement) in a manner supportive of public health, by promoting
both access to existing medicines and research and development into new medicines and, in this
connection, are adopting a separate Declaration.” https://www.wto.org/english/thewto_e/minist_e/
min01_e/mindecl_e.htm.
17Emphasis added.
18The Council for TRIPS convened special sessions (which were held in June, August, and
September of 2001) to deal with the relationship between health and TRIPS. See, e.g., the sub-
missions made by the European Communities and their Members States on the relationship between
the provisions of the TRIPS Agreement and access to medicines, IP/C/W/280 (12 June 2001); and
submissions by the African Group, Barbados, Bolivia, Brazil, Cuba, Dominican Republic, Ecuador,
Honduras, India, Indonesia, Jamaica, Pakistan, Paraguay, Philippines, Peru, Sri Lanka, Thailand,
and Venezuela on TRIPS and public health, IP/C/W/296 (29 June 2001). See also Council for
TRIPS Special Discussion on Intellectual Property and Access to Medicines, IP/C/M/31
(10 July 2001).
19See, e.g., Velásquez et al. (2020). https://www.southcentre.int/book-by-the-south-centre-2020/
#more-14014.
20One of the first studies on TRIPS flexibilities was published by the UNCTAD (1996). https://
unctad.org/en/docs/ite1_en.pdf.
21On the relationship between the TRIPS Agreement and the human right to health, see, e.g., Sellin
(2015). https://link.springer.com/article/10.1007/s40802-015-0047-5#Abs1.
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on the Right to Health.22 For instance, the World Health Assembly (WHA) urged
member states “to consider, whenever necessary, adapting national legislation in
order to use to the full the flexibilities contained in the Agreement on Trade-Related
Aspects of Intellectual Property Rights (TRIPS)”.23 The Global Strategy and Plan of
Action on Public Health, Innovation and Intellectual Property24 explicitly referred to
the flexibilities reaffirmed by the Doha Declaration, including the research exception
(Element 2.4e), the transitional period for least-developed countries (LDCs) (Ele-
ment 6.1b), and the regulatory exception or “Bolar exception” (Element 6.3a). A
2011 resolution adopted by the HRC, and subsequent resolutions on the matter, also
noted the governments’ right to use, to the fullest extent, the provisions of the TRIPS
Agreement, the Doha Declaration, and the WTO General Council Decision of
30 August 2003 in the context of the HIV/AIDS epidemic.25 Importantly, Goal
3. Target 3.b of the Sustainable Development Goals (SDGs), as adopted by the UN
General Assembly, also refers to the TRIPS flexibilities:
Goal 3. Target 3.b: Support the research and development of vaccines and medicines for the
communicable and noncommunicable diseases that primarily affect developing countries,
provide access to affordable essential medicines and vaccines, in accordance with the Doha
Declaration on the TRIPS Agreement and Public Health, which affirms the right of devel-
oping countries to use to the full the provisions in the Agreement on Trade-Related Aspects
of Intellectual Property Rights regarding flexibilities to protect public health, and, in
particular, provide access to medicines for all.26
There is no agreed-upon definition of ‘TRIPS flexibilities.’ In accordance with a
WIPO document, the term “flexibilities” means that there are “different options
through which TRIPS obligations can be transposed into national law so that
national interests are accommodated and yet TRIPS provisions and principles are
complied with.”27 That concept implies that the legislative options made are com-
patible with the TRIPS Agreement and, hence, fully legitimate. Although this
remark may be deemed trite , it is important to make it in view of the reluctance of
some developed countries to accept the use of such flexibilities, and even to exert
pressures on or apply retaliatory trade sanctions against countries that do comply
with the Agreement’s obligations. This position is well reflected in the continuous
22See, e.g., WHO, WIPO, and WTO (2012). https://www.wipo.int/edocs/pubdocs/en/global_
challenges/628/wipo_pub_628.pdf.
23WHA 56.27, “Intellectual property rights, innovation and public health” (28 May 2003). Avail-
able from: https://apps.who.int/gb/archive/pdf_files/WHA56/ea56r27.pdf?ua¼1. For a list of WHO
resolutions referring to intellectual property, see Germán Velásquez, Carlos M. Correa, and Vitor
Ido, op. cit., pp. 73–75.
24Available from: https://www.who.int/phi/implementation/phi_globstat_action/en/. See, Germán
Velásquez (2019).
25See, https://www.ohchr.org/EN/Issues/HIV/Pages/Documents.aspx.
26Resolution adopted by the General Assembly on 25 September United Nations General Assembly
(2015), A/RES/70/1. https://www.un.org/ga/search/view_doc.asp?symbol¼A/RES/70/1&
Lang¼E.
27WIPO (2010), p. 11. https://www.wipo.int/meetings/en/doc_details.jsp?doc_id¼142068.
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use by the US of the Special Section 301 of the US Trade Act 1974,28 and in the
European Commission Staff Working Document on the protection and enforcement
of intellectual property rights in third countries.29
There are different types of TRIPS flexibilities. Some refer to the scope and extent
of the substantive rights to be recognized under the Agreement,30 and others to the
ways in which such rights can be enforced. One way of grouping flexibilities is also
to take into account “the point in time at which Members may resort to them: (i) in
the process of the acquisition of the right; (ii) defining the scope of the right; and (iii)
when enforcing the right.”31 As noted in one report, those flexibilities
. . .sometimes are made very explicit (as in the right of each WTO Member to choose its
national regime of exhaustion of IP rights, hence allowing parallel imports), and in other
instances follow from the use of general and open terms in TRIPS provisions (such as
legitimate interests, justifiability, ordre public and morality) that WTOMember can – within
the limits of accepted principles of treaty interpretation in public international law – interpret
and implement in accordance with their public policy preferences.32
Given the possible variations in national regimes in interpreting and
implementing the TRIPS Agreement, it would be an impossible task to identify all
flexibilities. They can be found in all the areas covered by the Agreement, and they
can be identified as new circumstances arise. Thus, the exception to copyright
protection, which is of particular importance to ensure access to knowledge and
preserve a robust public domain,33 needs to be considered in light of technological
developments.34 WIPO’s Database on Flexibilities in the Intellectual Property Sys-
tem35 provides information on just fourteen TRIPS flexibilities as provided for in the
national laws of some countries, but the list is certainly much longer and their use in
national laws and regulations more extensive. As noted, the type and use of such
flexibilities have been widely explored, most particularly in relation to public health
policies and access to medicines,36 in academic literature, numerous reports, and
28See, e.g., Correa (2020a).
29European Commission (2020). https://trade.ec.europa.eu/doclib/docs/2020/january/tradoc_
158561.pdf.
30The ‘scope’ of a right delimits the boundaries and defines its content; the ‘extent’ refers to the
legal limitations on the exercise of the right.
31WIPO (2010), op. cit., p. 12.
32Ruse-Khan and Puutio (2017), p. 10. Available from: https://www.unescap.org/sites/default/files/
IPR%20Handbook.pdf.
33See, e.g., Geiger et al. (2013). https://digitalcommons.wcl.american.edu/cgi/viewcontent.cgi?
article¼1041&context¼research.
34Eger and Scheufen (2012). https://www.researchgate.net/publication/280043122_The_past_and_
the_future_of_copyright_law_technological_change_and_beyond.
35Available from: https://www.wipo.int/ip-development/en/agenda/flexibilities/database.html.
36See, e.g., Germán Velásquez, Carlos M. Correa, and Vitor Ido, op. cit.
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other sources of information.37 Box 1 includes references to some of the flexibilities
available in the field of public health.
Box 1 Public health-related TRIPS flexibilities
(1) Flexibility in the choice of patentability criteria, including for chemical
entities and biologics—WTO members have considerable policy space
to define what an ‘invention’ is and to apply rigorous standards of
patentability to avoid the grant of patents that, without making a genuine
technical contribution, may distort market competition.
(2) Compulsory license—Widely recognized in the legislation of developed
and developing countries—and granted since the adoption of the TRIPS
Agreement by administrations or courts in countries such as Thailand,
Ecuador, Indonesia, India, USA, Italy, and Germany—compulsory
licenses may be necessary to correct market distortions (abuses of market
power, unfair pricing, refusal to license, etc.).
(3) Government use—In many cases governments may decide, consistently
with the TRIPS Agreement, to use patented inventions for
non-commercial purposes, such as for ensuring the supply of essential
medicines.
(4) Compulsory licenses for the supply of medicines to countries with a
lack of or insufficient manufacturing capacity—Compulsory licenses
exclusively for the export of medicines can be granted under the amend-
ment introduced to the TRIPS Agreement in 2017 and the waiver adopted
by WTO in 2003.
(5) Test data protection—The TRIPS Agreement (Article 39.3) requires
WTO members to protect test data against unfair competition, which
does not create exclusive rights. The Agreement is complied with if
legislation on unfair competition is implemented to protect such data.
(6) Exemptions) for LDCs—LDCs need not grant patents for pharmaceuti-
cals and test data protection at least until 2033 under the extended
transition period provided for under Article 66.1 of the TRIPS
Agreement.
(7) Parallel importation—Importing protected medicines from any country
where they can be purchased cheaper than locally is consistent with the
TRIPS Agreement.
(8) Pre and post patent grant opposition—Procedures before patent offices
provide for the possibility for third parties to contribute to the
(continued)
37See, e.g., Medicines Law & Policy, The TRIPS Flexibilities Database. Available from: http://
tripsflexibilities.medicineslawandpolicy.org/. See also, The Graduate Institute Geneva, Knowledge
Portal on Innovation and Access to Medicines. https://www.knowledgeportalia.org/.
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Box 1 (continued)
examination process through ‘observations’ or ‘oppositions,’ whether
before or after the grant of a patent, or both.
(9) Use of competition law to address the misuse of IPRs—Competition
law may be applied to correct market distortions created through the
abuse of IPRs.
(10) Bolar exception—‘Bolar exceptions’ are important to accelerate the
entry of generic products and promote a dynamic market for medicines.
(11) Research or experimentation exception—This exception allows
research to be conducted by third parties on patented inventions, for
instance, to improve on them or derive new inventions.
(12) Disclosure requirement, particularly for biologics—The full and pre-
cise disclosure of an invention is crucial for the patent system to perform
its informational function. This is particularly relevant for biologicals,
which cannot be described in the same way as medicines produced by
chemical synthesis
(13) Flexibilities in enforcement of IP—Measures to enforce IPRs—such as
reversal of the burden of proof, determination of infringement by equiv-
alence and damages, and border measures—if overly broad, may distort
competition by discouraging or preventing market entry and the avail-
ability of generic medicines. Provisional injunctions need to be cau-
tiously granted so as not to distort the market dynamics, generally after
giving the alleged infringer an opportunity to articulate his defense.
Permanent injunctions may be denied for public health reasons under
certain circumstances.
(14) Security exception—Compliance with obligations under the TRIPS
Agreement can be suspended, inter alia, in cases of emergency in inter-
national relations, such as in the case of a pandemic (Article 73 (b) of the
Agreement).
Source: adapted from South Centre, “A Public Health Approach to Intel-
lectual Property Rights: Public Health Related Flexibilities in the TRIPS
Agreement,” available from: https://ipaccessmeds.southcentre.int/wp-con
tent/uploads/2018/12/Public-Health-Related-Flexibilities-in-the-TRIPS-
Agreement.pdf.
Any WTO member can make use of the TRIPS flexibilities, as applicable, in
order to attain public health or other public objectives and, in fact, both developed
and developing countries have done so. Thus, the flexibility in the TRIPS Agreement
permitted the US to maintain a double-novelty standard depending on whether the
disclosure of the invention had taken place within or outside the territory of the US
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(35 USC section 102 (a)).38 In defending this flexibility, which has allowed for the
misappropriation of genetic resources and traditional knowledge,39 the US held that
in the TRIPS Agreement there was “no prescription as to howWTOMembers define
what inventions are to be considered ‘new’ within their domestic systems” and,
hence, that its legislation was “perfectly consistent with the provisions of the TRIPS
Agreement.”40 Another example in the US is the doctrine that allows US courts not
to grant a permanent injunction despite the proven existence of an infringement of
IPRs, in accordance with the precedent set by the US Supreme Court in the
eBay vs. MercExchange case.41 There are also many examples in Europe42 where,
for instance, the European Parliament’s Resolution of 2 March 2017 on EU options
for improving access to medicines (2016/2057(INI)) emphasized “that the European
Patent Office (EPO) and the Member States should only grant patents on medicinal
products that strictly fulfil the patentability requirements of novelty, inventive step
and industrial applicability, as enshrined in the European Patent Convention” (par-
agraph 48).43 More recent examples are the amendments to the patent laws in
Canada and Germany to address the COVID-19 emergency. Bill C 13 2020 of
Canada,44 for instance, added a new section to the Patent Act implementing a new
type of compulsory license for patents:
19.4 (1) The Commissioner shall, on the application of the Minister of Health, authorize the
Government of Canada and any person specified in the application to make, construct, use
and sell a patented invention to the extent necessary to respond to the public health
emergency described in the application.
38According to this section, “[a] person shall be entitled to a patent unless the invention was known
or used by others in this country, or patented or described in a printed publication in this or a foreign
country, before the invention thereof by the applicant for patent, or the invention was patented or
described in a printed publication in this or a foreign country or in public use or on sale in this
country, more than one year prior to the date of the application for patent in the United States.” This




40See, Document IP/Q3/USA/1 (1 May 1998). As a result of the relative novelty requirement of the
US, several patents were granted to researchers or firms relating to or consisting of genetic materials





41eBay Inc. v. MercExchange, L.L.C., 547 U.S. 388 (2006), https://www.supremecourt.gov/
opinions/05pdf/05-130.pdf.
42For the use of TRIPS flexibilities in relation to plant patents, see, e.g., Correa (2014). https://
www.southcentre.int/wp-content/uploads/2014/11/RP55_Patent-Protection-for-Plants_EN.pdf.
See also, Prifti (2015).
43Available from: https://www.europarl.europa.eu/doceo/document/TA-8-2017-0061_EN.html.
44Available from: https://www.parl.ca/DocumentViewer/en/43-1/bill/C-13/royal-assent.
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In Germany, an amendment to the Patent Act provided that an invention relating
to medicinal products, including narcotics; the active ingredients, starting materials,
and auxiliary materials for these products; medical devices; laboratory diagnostics;
aids; personal protective equipment; and products for disinfection of the products
shall be used in the interest of public welfare (“öffentliche Wohlfahrt”) or in the
interest of the security of the Federation.45
3 TRIPS Flexibilities in WTO Jurisprudence
Despite the TRIPS Agreement being one of the most controversial components of
the WTO system, and that it has given rise to a large number of proceedings under
the Dispute Settlement Understanding, a relatively small number of cases has
reached the phase of a panel or Appellate Body intervention.
Paradoxically, although the adoption of the TRIPS Agreement essentially was
aimed at disciplining developing countries, who have been forced to make massive
legislative changes to adapt to the Agreement’s high minimum standards,46 most
disputes leading to the establishment of a panel have been against developed
countries (two against the US,47 two against the European Communities and their
Member States,48 two against Canada,49 and one against Australia50). Only two
developing countries were subject to such procedures:51 India (two complaints
45Fuchs (2020). https://www.twobirds.com/en/news/articles/2020/germany/covid-19-new-german-
legislation-to-fight-pandemic-may-affect-granted-patents.
46See, e.g., Correa (2011a).
47See, DS 160 Panel Report United States— Section 110(5) of US Copyright Act (2010); Appellate
Body report DS 176 United States — Section 211 Omnibus Appropriations Act of 1998 (2002).
48See, DS 174 Panel Report European Communities — Protection of Trademarks and Geograph-
ical Indications for Agricultural Products and Foodstuffs (2005); DS 290 Panel Report, European
Communities— Protection of Trademarks and Geographical Indications for Agricultural Products
and Foodstuffs (2005).
49See, Report of the WTO Panel, Canada—Patent Protection for Pharmaceutical Products,
WT/DS114/R; Report of the Appellate Body, Canada—Term of Patent Protection, WT/DS170/
AB/R (2000).
50See Panel Report in DS435, 441, 458, 467, Australia — Certain Measures Concerning Trade-
marks, Geographical Indications and Other Plain Packaging Requirements Applicable to Tobacco
Products and Packaging (2018) (hereinafter, “Australia—Tobacco Plain Packaging”). The panel
report was appealed by Honduras and the Dominican Republic (see, https://www.wto.org/english/
tratop_e/dispu_e/cases_e/ds441_e.htm). The report of the Appellate Body was issued on June
9, 2020 (WT/DS435/AB/R WT/DS441/AB/R). On the situation of the Appellate Body as a result




51A violation to the TRIPS Agreement was incidentally invoked in the Indonesia-Autos case in
relation to the protection of trademarks. The panel, however, found that the United States had not
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concerning the implementation of Article 70.8, the so called “mailbox” provision)52
and China (criminal sanctions for copyright infringement and other issues).53 Only
four developing countries (Indonesia, Cuba, Honduras, and the Dominican Repub-
lic) have been complaining parties (against Australia in the tobacco plain packaging
case) in WTO disputes under the TRIPS Agreement that have reached such stage.54
In other cases of disputes initiated against developing countries, no panel was
established. One example was a complaint by the US against Argentina on patents
and test data protection.55 A mutually agreed-upon solution was communicated to
the Dispute Settlement Body (DSB) on 20 June 2002. However, the parties did not
reach a common understanding on the interpretation of Article 39.3 of the TRIPS
Agreement, nor on the application of Article 70.7.56 Argentina has not to date
introduced the data exclusivity regime that the US claimed would remedy the
(unproven) violation of Article 39.3. Another example, further discussed below,
was the US challenge in January 2001 against Brazilian legislation that authorizes
the granting of compulsory licenses and parallel imports in instances when patents
are not worked.57 The dispute ended several months later when the US complaint
was withdrawn.58
The panel and Appellate Body reports produced in relation to the disputes
mentioned above have, in practice, addressed the policy space available under the
TRIPS Agreement, but they have only occasionally referred to the concept of
‘flexibilities.’ In China—Intellectual Property Rights, for instance, third parties
demonstrated that Indonesia was in breach of its TRIPS obligations (Report of the WTO Panel,
Indonesia—Certain Measures Affecting The Automobile Industry, WT/DS 54/R, WT/DS 55/R,
WT/DS 59/R, WT/DS 64/R (1998), para. 11.1–11.43).
52See Report of the Appellate Body, India-Patent Protection for Pharmaceutical and Agricultural
Chemical Products, WT/DS50/AB/R (1998) and Report of the WTO Panel, India—Patent Protec-
tion for Pharmaceutical and Agricultural Chemical Products, WT/DS79/R (1998) (hereinafter,
“India—Patents (US)”).
53See Panel Report in lDS362, China—Measures Affecting the Protection and Enforcement of
Intellectual Property Rights (2009) (hereinafter, “China—Intellectual Property Rights”).
54Brazil requested the US consultations with regard to provisions of US legislation that limits the
right to use or sell any federally-owned invention only to a licensee that agrees that any products
embodying the invention or produced through the use of the invention will be manufactured
substantially in the United States. See, United States—US Patents Code, WT/DS224/1 (7 February
2001). In DS 408, India complained about border measures imposed on the transit of medicines.
See, European Union and a Member State—Seizure of Generic Drugs in Transit (2010). These
cases were not ultimately pursued.
55Argentina—Patent Protection for Pharmaceuticals and Test Data Protection for Agricultural
Chemicals, WT/DS171 (6 May 1999) and Argentina-Certain Measures on the Protection of Patents
and Test Data, WT/DS196 (30 May 2000).
56See, Notification of Mutually Agreed Solution According to the Conditions Set Forth in the
Agreement (IP/D/18/Add.1, IP/D/22/Add.1).
57See, Brazil—Measures Affecting Patent Protection, Request for the Establishment of a Panel by
the United States, WT/DS199/3 (9 January 2001).
58Brazil—Measures Affecting Patent Protection, Notification of Mutually Agreed Solution,
WT/DS199/4, G/L/454, IP/D/23/Add.1 (19 July 2001).
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alluded to the ‘flexibility’ allowed by the TRIPS Agreement in relation to the
definition of ‘commercial scale.’59 The US noted, with respect to Article 1.1 of the
Agreement, that the provision “only offers flexibility in how a Member implements
TRIPS obligations and does not exempt a Member from full compliance with TRIPS
obligations.”60 In this case the panel confirmed that the TRIPS Agreement does not
mandate specific forms of legislation.61 In relation to the US claim that China did not
comply with Article 61 of the TRIPS Agreement, it stated:
The Panel may not simply assume that a Member must give its authorities wide discretion to
determine what is on a commercial scale in any given case, and may not simply assume that
thresholds, including numerical tests, are inconsistent with the relative benchmark in the first
sentence of Article 61 of the TRIPS Agreement. As long as a Member in fact provides for
criminal procedures and penalties to be applied in cases of wilful trademark counterfeiting or
copyright piracy on a commercial scale, it will comply with this obligation. If it is alleged
that a Member's method of implementation does not so provide in such cases, that allegation
must be proven with evidence. . .(para. 7.602).
A few references to the ‘flexibilities’ allowed by the prohibition contained in
Article 20 of the TRIPS Agreement can be found in the panel report in Australia—
Tobacco Plain Packaging. For instance, the panel stated:
On their face, the explicit prohibitions contained in Article 20 of the TRIPS Agreement and
Article 2.2 of the TBT Agreement respectively must be read and, absent a conflict, applied
together. The principle of harmonious reading dictates that the flexibilities implicitly left by
those prohibitions also need to be viewed together, without a priori giving precedence to one
over, and to the exclusion of, the other.62
The panel in the same case also referred, as discussed below, to the Doha
Declaration as a “re-affirmation by Members of the flexibilities provided in the
TRIPS Agreement in relation to measures taken for the protection of public
health”;63 the concept of TRIPS flexibilities was also alluded to, for example, by
Brazil and Thailand as third parties64 and by the panel itself (para. 7.2407 and
7.2408). Interestingly, the Appellate Body in Australia—Tobacco Plain Packaging
referred to the concept of Members’ ‘regulatory autonomy’ in encumbering the use
of trademarks by special requirements under Article 20.65
59See, China—Intellectual Property Rights, para. 7.484, 7.493, 7.597, and 7.678.
60Idem, para. 7.199.
61Para 7.602.
62Australia—Tobacco Plain Packaging, para. 7.100.
63Idem, para. 7.2408.
64Idem, para. 7.2391 and 2387.
65Appellate Body Report, op. cit., para. 6.697.
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4 Interpretation of the TRIPS Agreement66
This section considers some principles for and aspects of the interpretation of the
TRIPS Agreement particularly relevant for the application of the TRIPS flexibilities.
4.1 Precedential Value of GATT/WTO Jurisprudence
Neither the GATT nor the WTO jurisprudence have precedential value; however,
even if unrelated to intellectual property, such jurisprudence may influence and
provide guidance for future rulings on the TRIPS Agreement.67 One issue of
particular relevance is whether jurisprudence on subjects other than those covered
by this Agreement should be used to interpret it. The panel in India—Patent
Protection for Pharmaceutical and Agricultural Chemical Products, for instance,
held that although the TRIPS Agreement has a “relatively self-contained, sui generis
status within theWTO,” it also was “an integral part of the WTO system, which itself
builds upon the experience of over nearly half a century under the GATT 1947.”68 In
United States—Section 110(5) of the U.S. Copyright Act, while the panel noted that
caution was required when interpreting the TRIPS Agreement provisions in the light
of precedents developed in GATT dispute settlement practice, it stated that
given that the agreements covered by the WTO form a single, integrated legal system, we
deem it appropriate to develop interpretations of the legal protection conferred on intellectual
property right holders under the TRIPS Agreement which are not incompatible with the
treatment conferred to products under the GATT, or in respect of services and service
suppliers under the GATS, in the light of pertinent dispute settlement practice.69
The application of general GATT and WTO jurisprudence to cases involving the
TRIPS Agreement would ignore the specificity of intellectual property issues and
one major difference between the TRIPS Agreement and other WTO covered
agreements: the former provides for disciplines on intellectual property rights,
which are private rights,70 the exercise of which may restrain rather than facilitate
international trade (as in the case of other WTO agreements). The private rights
nature of intellectual property rights was highlighted in the panel report in China—
Intellectual Property Rights:
66This section is partially based on Carlos Correa, op. cit., 2005, which examines other aspects,
such as the role of the negotiating history and the application of prior intellectual property
conventions incorporated into the TRIPS Agreement;—,; see also Kennedy (2016).




70See, the Preamble to the TRIPS Agreement, fourth paragraph.
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Viewed in context, the phrase “shall have the authority” does not require Members to take
any action in the absence of an application or request. Therefore, a condition that authority
shall only be available upon application or request seems to be assumed in much of Sections
2, 3 and 4 of Part III. This is consistent with the nature of intellectual property rights as
private rights, as recognized in the fourth recital of the preamble of the TRIPS Agreement.
Acquisition procedures for substantive rights and civil enforcement procedures generally
have to be initiated by the right holder and not ex officio.71
One corollary of this, for instance, is that in contrast to the general GATT/WTO
jurisprudence, the exceptions in the TRIPS Agreement need not to be read narrowly,
but instead with the aim of achieving the objectives as defined in Article 7 (see
below). Notably, intellectual property rights constitute exceptions in terms of Article
XX(d) of GATT and, hence, their restrictive effects should not be augmented but
mitigated through the interpretation of the scope and extent of the conferred exclu-
sive rights.72 The exceptions to exclusive rights are crucial to preserve market
dynamics and achieve a diversity of public interests; they are a key component of
the TRIPS flexibilities.73
4.2 Ordinary Meaning
The GATT andWTO panels, as well as the WTO Appellate Body, have relied on the
interpretive method codified by the Vienna Convention on the Law of the Treaties
(VCLT). One of the basic steps for interpretation under Article 31 of the VCLT is the
determination of the ‘ordinary meaning’ of the terms employed in the treaty,
provided that “a special meaning shall be given to a term if it is established that
the parties so intended” (Article 31.4). Many WTO panel and Appellate Body
reports clearly indicate that such ordinary meaning is searched in the dictionary in
order to clarify the scope and content of the relevant texts.74 Thus, the Appellate
Body in EC – Chicken Cuts states: "The Appellate Body observed that dictionaries
are a useful starting point” for the analysis of 'ordinary meaning' of a treaty term, but they are
not necessarily dispositive. The ordinary meaning of a treaty term must be ascertained
according to the particular circumstances of each case. Importantly, the ordinary meaning
71Panel Report, lDS362, China—Measures Affecting the Protection and Enforcement of Intellec-
tual Property Rights, op. cit., para 7.247. See also, para. 7.135. See also, para. 7.247, 7.135, 7.241,
and 7.530; and Australia—Tobacco Plain Packaging, footnote 4472.
72See, e.g., Okediji (2017).
73Rodrigues Jr. (2012). https://www.researchgate.net/publication/288719106_The_general_excep
tion_clauses_of_the_TRIPS_agreement_Promoting_sustainable_development.
74See, e.g., the elaboration DS 160 Panel Report, United States — Section 110(5) of US Copyright
Act (2010); Appellate Body report DS 176, United States — Section 211 Omnibus Appropriations
Act of 1998 (2002).
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of a treaty term must be seen in the light of the intention of the parties “as expressed in the
words used by them against the light of the surrounding circumstances.”75
In China—Intellectual Property Rights, the panel observed that
the general rule of treaty interpretation in Article 31 of the Vienna Convention refers in
paragraph 1 to the ordinary meaning of the terms of the treaty, read in context. Where the
terms are a single term, or ordinarily used together, then the treaty interpreter should refer to
the ordinary meaning of that single term, or of each term in the particular context of each
other. This is a distinct exercise from that in paragraph 4 of Article 31 of the Vienna
Convention which requires a “special meaning” to be given to a term if it is established
that the parties so intended. No party to this dispute considers that a “special meaning”
should be given to the phrase "on a commercial scale," and nor does the Panel.76
While the rule regarding the ordinary meaning seems clear, an important question
relates to the temporal aspect of the interpretation, that is, whether panels and
Appellate Body should rely on the meaning of a term at the time of negotiation or
adoption of an agreement, or whether they would be authorized to apply an evolu-
tionary approach, that is, to rely on the meaning of a term at the time of its
interpretation. Two approaches exist on this issue:
. . .the principle of contemporaneity, according to which the terms of a treaty are to be
interpreted according to the meaning which they possessed, or which would have been
attributed to them, and in the light of current linguistic usage, at the time when the treaty was
originally concluded. Opposed to that is the dynamic approach, very often also labelled
‘evolutionary’ interpretation, which seeks to establish the meaning of a treaty at the time of
its interpretation.77
In Canada—Patent Protection for Pharmaceutical Products, the panel examined
the status of the legislation at the time of the negotiation of the Agreement to
determine the concept of “legitimate interest” as contained in Article 30:
Moreover, the Panel believed that it was significant that concerns about regulatory review
exceptions in general, although well known at the time of the TRIPS negotiations, were
apparently not clear enough, or compelling enough, to make their way explicitly into the
recorded agenda of the TRIPS negotiation. The Panel believed that Article 30’s “legitimate
interests” concept should not be used to decide, through adjudication, a normative policy
issue that is still obviously a matter of unresolved political debate.78
75Appellate Body Report in EC – Chicken Cuts, para. 175, quoting Appellate Body Report in US –
Softwood Lumber IV, para. 59, and referring to Appellate Body Reports in US – Offset Act (Byrd
Amendment), para. 248, and US – Gambling, para. 166, and quoting McNair (1961), p. 365.
76Para 7.558.
77Dörr and Schmalenbach (2012). Available from: https://link.springer.com/chapter/10.1007%
2F978-3-642-19291-3_34, para. 58 (emphasis in the original), para. 23 (emphasis in the original).
On the importance of the principle of “contemporaneity” in treaty interpretation, see also, Brownlie
(1998), p. 627.
78Canada—Patent Protection for Pharmaceutical Products, para. 7.82.
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The WTO jurisprudence has adopted in some cases the evolutionary method of
interpretation.79 InUnited States—Section 110(5) of the US Copyright Act, reference
was made to the WIPO Copyright Treaty (WCT) adopted in 1996, 2 years after the
TRIPS Agreement. The panel stated that the WCT should be viewed as “relevant to
seek contextual guidance ... when developing interpretations that avoid conflicts
within the overall multilateral copyright framework . . .”80 Although it noted that the
statement concerning WCT’s Article 10 adopted by the signatory parties did not fall
under the Vienna Convention rules on a subsequent agreement on the same matter or
subsequent practice, the recourse to a post-TRIPS treaty to interpret a provision of
the TRIPS Agreement constitutes a troubling precedent as long as it may lead to
interpretations unduly expanding the Agreement’s obligations. This is particularly
the case in the light of technological developments and the increase of the level of
protection beyond the standards of the TRIPS Agreement resulting from free trade
agreements.81
It is also worth noting that article 71 of the TRIPS Agreement specifically
provides for the TRIPS Council to review the Agreement “in the light of any relevant
new developments, which might warrant modification or amendment of this Agree-
ment,” thereby suggesting that any further ‘developments’ in intellectual property
law need to be incorporated on the basis of WTO members’ consensus, rather than
via interpretation.
4.3 Context
In accordance with Article 31 of the VCLT, the terms in a treaty need to be
considered taking their context into account. The preambles of WTO agreements
have often been considered as the relevant context for the interpretation of particular
provisions.82 In India–Patents (US), the Appellate Body referred to the Preamble of
the TRIPS Agreement for the interpretation of Article 70.8(a): “The Panel’s inter-
pretation here is consistent with the object and purpose of the TRIPS Agreement.”
According to the Appellate Body, the object and purpose of the Agreement is, inter
alia, “the need to promote effective and adequate protection of intellectual property
rights.”83 References to the preamble were also made in China—Intellectual
79In United States – Import Prohibition of Certain Shrimp and Shrimp Products, WT/DS58/AB/R,
para. 130 (1998), the Appellate Body held that certain terms in the WTO Agreements are not
“static” but evolutionary, in relation to the term “exhaustible natural resources” as it appears in
GATT Article XX(g) (para. 127, 130).
80United States—Section 110(5) of the U.S. Copyright Act, para. 6.70.
81See, e.g., Ruse-Khan (2017) (forthcoming, Netherlands Yearbook of International Law); Max
Planck Institute for Innovation & Competition Research Paper, No. 18-02; University of Cambridge
Faculty of Law Research Paper, No. 3/2018. https://ssrn.com/abstract¼3082718.
82See, e.g. Carlos Correa, op. cit., 2020, Chapter 1.
83See, https://www.wto.org/english/docs_e/legal_e/27-trips_02_e.htm.
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Property Rights.84 The Preamble of the Agreement on Technical Barriers to Trade
was largely invoked as well by the panel in Australia—Tobacco Plain Packaging.85
The appropriate choice of treaty provisions that provide the context for
interpreting other provisions is crucial. One example is the interpretation of Article
27.1 in fine. As noted above, the US initiated a case against Brazil arguing that
Article 68 of the Brazilian patent law, which authorizes the government to grant a
compulsory license if the patent owner fails to work the patent, was inconsistent with
Article 27.1 in fine of the TRIPS Agreement. In accordance to this provisions,
“patents shall be available and patent rights enjoyable without discrimination as to
the place of invention, the field of technology and whether products are imported or
locally produced.” Key to addressing the US argument is identifying the context for
the interpretation of this phrase in Article 27.1. In fact, this text incorporated a
compromise reached, at the final stages of the negotiation of the Agreement, between
developed and developing countries since the latter wanted to preserve the possibil-
ity of granting compulsory licenses for the lack or insufficient working of a patent.86
Developing countries expressed the concern that Article 27.1 could be read in a
way that restricts the use of compulsory licenses, for instance, on the grounds of lack
of working, as specifically provided for under Article 5A of the Paris Convention for
the Protection of Industrial Property. In fact, the “patent rights” referred to in Article
27.1 are defined in Article 28.1, which only requires the granting of negative rights
with regard to the exploitation of the invention, that is, the right to prevent third
parties from using (without authorization) the patented invention. Hence, a proper
interpretation of Article 27.1 read in conjunction with Article 28.1, based on the
rules of the Vienna Convention, indicates that the products mentioned in Article 27.1
are infringing products, not the products of the patent owner itself, since patents only
confer exclusionary and not positive rights. In other words, Article 27.1—if read in
the context of Article 28 of the Agreement—forbids discrimination between infring-
ing imported and infringing locally-made products, but it does not prevent the
establishment of differential obligations with regard to non-infringing imported
and locally-made products (i.e., products made or imported by the patent owner or
with his/her consent). Hence, it does not outlaw compulsory licenses for lack of
working.
The principle of “effective interpretation” (or “l’effet utile”) requires that a treaty
must be interpreted in such a way as to give meaning and effect to all the terms of the
treaty. This is certainly possible with respect to Article 27.1 in fine. This
non-discrimination clause may apply, for instance, to a case in which the rights
enjoyed by patent owners differ depending on whether the alleged infringing goods
have been locally produced or imported. For instance, Section 337 of the U.S. Tariff
Act was found inconsistent with the GATT in United States—Section 337 of the
84See, para. 7.135.
85See, e.g., para. 7.2398.
86UNCTAD and ICTSD (2005), p. 467. https://unctad.org/en/PublicationsLibrary/ictsd2005d1_en.
pdf.
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Tariff Act of 1930, since it accorded less favorable treatment to imported products
challenged as infringing on US patents than the treatment accorded to similarly
challenged products of United States origin.87
Another example in which the correct identification of the context for a provision
may have decisive effects relates to Article 39.3, which has been interpreted by the
US and the European Commission as requiring the grant of exclusive rights (‘data
exclusivity’) with respect to test data for pharmaceuticals and agrochemical prod-
ucts. This interpretation is clearly inviable in light of Article 39.1 which provides an
essential contextual element and only requires protection against unfair commercial
practices, which does not entail such exclusive rights.88
In engaging in the difficult task of clarifying the meaning of ‘unjustifiably’ in
Article 20 of the TRIPS Agreement, the panel in Australia—Tobacco Plain Pack-
aging elaborated on the context of that provision. It specifically alluded to the
Preamble and Articles 7 and 8 of the Agreement:
We first note that the first recital of the preamble to the TRIPS Agreement expresses a key
objective of the TRIPS Agreement, namely to “reduce distortions and impediments to
international trade” and takes into account the need, on one hand, “to promote effective
and adequate protection of intellectual property rights” and, on the other, “to ensure that
measures and procedures to enforce intellectual property rights do not themselves become
barriers to legitimate trade” (para. 7.2398).
We also consider that Article 7 entitled “Objectives” and Article 8 entitled “Principles”
provide relevant context (para 7.2399).
Articles 7 and 8, together with the preamble of the TRIPS Agreement, set out general goals
and principles underlying the TRIPS Agreement, which are to be borne in mind when
specific provisions of the Agreement are being interpreted in their context and in light of the
object and purpose of the Agreement. As the panel in Canada – Pharmaceutical Patents
observed in interpreting the terms of Article 30 of the TRIPS Agreement, “[b]oth the goals
and the limitations stated in Articles 7 and 8.1 must obviously be borne in mind when doing
so as well as those of other provisions of the TRIPS Agreement which indicate its object and
purposes” (para. 7.2402).
The panel further elaborated on the ‘balance’ suggested by Articles 7 and 8.1 of
the TRIPS Agreement and, in particular, on the fact that the Agreement did not
intend to prevent WTO members from adopting measures to protect public interests,
such as public health. It stated:
Article 7 reflects the intention of establishing and maintaining a balance between the societal
objectives mentioned therein. Article 8.1, for its part, makes clear that the provisions of the
TRIPS Agreement are not intended to prevent the adoption, by Members, of laws and
regulations pursuing certain legitimate objectives, specifically, measures “necessary to
protect public health and nutrition” and “promote the public interest in sectors of vital
importance to their socio-economic and technological development,” provided that such
measures are consistent with the provisions of the Agreement (para. 7.2403).
87See, e.g., Haedicke (2000), p. 1774.
88See, e.g., Correa (2011b).
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Article 8 offers, in our view, useful contextual guidance for the interpretation of the term
“unjustifiably” in Article 20. Specifically, the principles reflected in Article 8.1 express the
intention of drafters of the TRIPS Agreement to preserve the ability for WTO Members to
pursue certain legitimate societal interests, at the same time as it confirms their recognition
that certain measures adopted by WTO Members for such purposes may have an impact on
IP rights, and requires that such measures be “consistent with the provisions of the [TRIPS]
Agreement” (para. 7.2404).
The specific objectives expressly identified in Article 8.1 do not, in our view, necessarily
exhaust the scope of what may constitute a valid basis for the “justifiability” of encum-
brances on the use of trademarks under Article 20. However, their identification in Article
8.1 may shed light on the types of recognized “societal interests” that may provide a basis for
the justification of measures under the specific terms of Article 20, and unquestionably
identify public health as such a recognized societal interest (para. 7.2406).
In summary, while the Preamble and Articles 7 and 8 of the TRIPS Agreement
provide the context for the interpretation of all its provisions, as suggested by the
examples above, the careful choice of other specific provisions to examine the scope
and extent of particular obligations is key to preserving the flexibilities under that
agreement.
4.4 Object and Purpose
As noted, the interpretative method codified by the VCLT—as spelled out in Articles
31 and 32 of the VCLT—relies on the textual interpretation of treaty provisions. The
reference, however, to the ‘object and purpose’ of the treaty as one of the elements
for interpretation has been understood by some courts as leaving room to consider
the ‘intention’ of the negotiating parties or to apply a teleological approach.89 It has
been noted, for instance, that the European Court of Human Rights, “has developed
its own version of these rules of interpretation—a version that tracks the three
traditional approaches to treaty interpretation: the textual approach, the subjective
approach, and the teleological approach.90 However, as noted by two commentators,
The consideration of object and purpose finds its limits in the ordinary meaning of the text
of the treaty. It may only be used to bring one of the possible ordinary meanings of the terms
to prevail and cannot establish a reading that clearly cannot be expressed with the words used
in the text.91
The quoted authors note in this regard the opinion in the Iran-US Claims Tribunal
which pointed out:
Even when one is dealing with the object and purpose of a treaty, which is the most
important part of the treaty’s context, the object and purpose does not constitute an element
89Linderfalk (2007), p. 205. https://www.corteidh.or.cr/tablas/r32592.pdf.
90See, e.g., Dothan (2019), p. 765; iCourts Working Paper Series, No. 141. https://ssrn.com/
abstract¼3241331.
91Oliver Dörr and Kirsten Schmalenbach, op. cit., para 58.
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independent of that context. The object and purpose is not to be considered in isolation from
the terms of the treaty; it is intrinsic to its text. It follows that, under Article 31 of the Vienna
Convention, a treaty’s object and purpose is to be used only to clarify the text, not to provide
independent sources of meaning that contradict the clear text.92
In the case of the WTO agreements, adherence to the treaty text and avoiding
‘activism’ in the interpretation of their provisions is of utmost importance—as
shown by recent debates on the functioning of the Appellate Body93—so as not to
expand the Members’ obligations or create new ones, and to provide certainty to
their trade relations.
Notably, under Article 4.2 of the Dispute Settlement Understanding (“DSU”),
panels and the Appellate Body are mandated to ‘clarify’ the various WTO agree-
ments, and in doing so they cannot add to or diminish the rights and obligations
provided in such agreements. Moreover, Article 4.9 provides that the DSU does not
prejudice a government's right to seek an ‘authoritative interpretation’ of any of
those agreements from the Ministerial Conference or General Council of the WTO.
Hence, the WTO attempts to introduce a difficult distinction between ‘clarification’
and ‘interpretation.’ The panels and Appellate Body reports regularly note, however,
that they ‘interpret’ the provisions invoked by the members in accordance to the
VLCT rules. This has indeed been the case in those disputes referring to the TRIPS
Agreement.94
However, although the literal interpretation is the basic rule of interpretation
under Article 31 (1) of the VCLT as recognized in the Convention itself, in some
cases the textual reading of a provision or a term thereof in its context may still leave
ambiguity as to the legal meaning of a text. At this point, the identification of the
‘object and purpose’ of the treaty, conceived as part of the literal interpretation and
not as a separate step, acquires particular importance. It is difficult to think of
judgments that are absolutely neutral in terms of the policy objectives enshrined in
the treaty.
Identifying the object and purpose of the TRIPS Agreement is different from
characterizing the purpose of intellectual property rights, as the objectives pursued
by governments with these rights, as well as the way of implementing them, may
differ significantly, even while they comply with the standards of the Agreement and
other applicable international treaties). There is no global, uniform system of
intellectual property protection.
In Canada—Patent Protection for Pharmaceutical Products, the panel elaborated
on the policy objective of patent laws. It stated:
The normal practice of exploitation by patent owners, as with owners of any other intellec-
tual property right, is to exclude all forms of competition that could detract significantly from
the economic returns anticipated from a patent’s grant of market exclusivity . . . Patent laws
92Iran-United States Claims Tribunal, Federal Reserve Bank of New York v. Bank Markazi (n 19)
para 58.
93See, e.g., Danish and Aileen Kwa, op. cit.
94See, e.g., M. Kennedy, op. cit., 2016.
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establish a carefully defined period of market exclusivity as an inducement to innovation,
and the policy of those laws cannot be achieved unless patent owners are permitted to take
effective advantage of that inducement once it has been defined.95
This view seems to suggest that obtaining ‘economic returns’ as an ‘inducement
to innovation’ is what underpins patent policies. It is not consistent with the purpose
of the TRIPS Agreement as reflected in Articles 7 and 8. This approach overlooks
that patents, as well as other intellectual property rights, can and should be designed
and implemented to achieve public rather than private interests, including the
diffusion of technical knowledge, technological progress, and access to the out-
comes of innovation.96 Thus, in 1917, the US Supreme Court noted that “the primary
purpose of that [patent] law is not to create private fortunes, but is to promote the
progress of science and the useful arts.”97
Articles 7 (‘Objectives’) and 8 (‘Principles’) of the TRIPS Agreement are key for
the determination of the object and purpose of the Agreement, in conjunction, as
discussed below, with the Doha Declaration as a subsequent agreement among the
parties. Importantly, those provisions are not just hortatory provisions98 but have
been incorporated—upon the demand of developing countries during the negotia-
tions99—among the prescriptive provisions of the Agreement.
In Canada–Patent Term, the Appellate Body referred to the need to interpret
Article 70.1 of the Agreement as having particular regard to the object and purpose
of the treaty, but it eluded an interpretation and application of Articles 7 and 8:
[W]e note that our findings in this appeal do not in any way prejudge the applicability of
Article 7 or Article 8 of the TRIPS Agreement in possible future cases with respect to
measures to promote the policy objectives of the WTO Members that are set out in those
Articles. Those Articles still await appropriate interpretation.100
The Panel Report in Canada—Pharmaceutical Patents dealt more specifically
with the question of the ‘object and purpose’ of the TRIPS Agreement. It relied to
this end on Articles 7 and 8 for that determination, but in conjunction with other
provisions of the Agreement. It stated:
Article 30’s very existence amounts to a recognition that the definition of patent rights
contained in Article 28 would need certain adjustments. On the other hand, the three limiting
conditions attached to Article 30 testify strongly that the negotiators of the Agreement did
not intend Article 30 to bring about what would be equivalent to a renegotiation of the basic
balance of the Agreement. Obviously, the exact scope of Article 30’s authority will depend
on the specific meaning given to its limiting conditions. The words of those conditions must
95Canada—Patent Protection for Pharmaceutical Products, supra note 23, para. 7.55.
96See, paragraph 4 of the Doha Declaration.
97Motion Picture Patents Co. v. Universal Film Co. [1917] 243 U. S. 502.
98See, e.g., “TRIPS provisions as interpreted by the WTO dispute settlement organs”, Law
Explorer. https://lawexplores.com/trips-provisions-as-interpreted-by-the-wto-dispute-settlement-
organs/.
99See, Carlos Correa, op. cit., 2020, pp. 83–95.
100Appellate Body Report, Canada – Term of Patent Protection, WT/DS170/AB/R (18 September
2000), para. 101. https://www.wto.org/english/tratop_e/dispu_e/170abr_e.pdf.
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be examined with particular care on this point. Both the goals and the limitations stated in
Articles 7 and 8.1 must obviously be borne in mind when doing so as well as those of other
provisions of the TRIPS Agreement which indicate its object and purposes.101
It is unclear what “other provisions of the TRIPS Agreement which indicate its
object and purposes” are suggested by the panel. While there might be different
perceptions about the object and purpose of the TRIPS Agreement—as the debates
between developed and developing countries have shown during the negotiation and
after the adoption of the TRIPS Agreement102—the panels and Appellate Body need
to be guided by the text of the Agreement and not by the individual views of the
members of those bodies.
Paragraph 5(a) of the Doha Declaration confirmed the importance of Articles
7 and 8 for the interpretation of the TRIPS Agreement:
Accordingly and in the light of paragraph 4 above, while maintaining our commitments in
the TRIPS Agreement, we recognize that these flexibilities include:
a. In applying the customary rules of interpretation of public international law, each
provision of the TRIPS Agreement shall be read in the light of the object and purpose
of the Agreement as expressed, in particular, in its objectives and principles.
The wording of this paragraph (“in particular”) suggests that while Articles 7 and
8 are determinant in defining the object and purpose of the Agreement, other pro-
visions of the Agreement, as well as the preambular provisions, can also contribute
to the determination of its object and purpose. Such may be the case, for instance, of
Article 41.2 which states: “Procedures concerning the enforcement of intellectual
property rights shall be fair and equitable . . .” This provision makes it clear that one
purpose of the Agreement is to ensure that the enforcement of intellectual property
rights (as mandated in Part III of the Agreement) is ‘fair and equitable’ to all the
parties concerned, and that it does not provide undue advantages to the right holders
over third parties in judicial or administrative procedures, or vice versa.
An interesting elaboration on the object and purpose of the TRIPS Agreement
based on Articles 7 and 8 was undertaken by the panel in Australia—Tobacco Plain
Packaging.103 The panel largely relied on the Doha Declaration to address this issue.
It noted:
We note in this respect that the Doha Declaration, adopted by Ministers on 14 November
2001, provides that, “[i]n applying the customary rules of interpretation of public interna-
tional law, each provision of the TRIPS Agreement shall be read in the light of the object and
purpose of the Agreement as expressed, in particular, in its objectives and principles” (para.
7.2407).
While this statement was made in the specific context of a re-affirmation by Members of the
flexibilities provided in the TRIPS Agreement in relation to measures taken for the protec-
tion of public health, we note that paragraph 5 of the Doha Declaration is formulated in
101See, Canada—Patent Protection for Pharmaceutical Products, supra note 23, para. 7.26.
102Shadlen (2004). Available from: https://link.springer.com/article/10.1007%2FBF02686283.
103Romero (2020b). Available from: https://www.southcentre.int/policy-brief-79-june-2020/.
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general terms, inviting the interpreter of the TRIPS Agreement to read “each provision of the
TRIPS Agreement” in the light of the object and purpose of the Agreement, as expressed in
particular in its objectives and principles. As described above, Articles 7 and 8 have central
relevance in establishing the objectives and principles that, according to the Doha Declara-
tion, express the object and purpose of the TRIPS Agreement relevant to its interpretation
(7.2408).
The Appellate Body essentially followed the panel’s views on this matter. It
clarified, however, that the conclusions reached regarding the purpose of the TRIPS
Agreement are supported by Articles 7 and 8, and that the analysis of the Doha
Declaration reconfirmed the panel’s findings. It held:
The Panel also remarked that the societal interests referred to in Article 8 may provide a basis
of the justification of measures under Article 20. Thus, we agree with Australia that, in any
event, the reliance on the Doha Declaration was not of decisive importance for the Panel's
reasoning since the Panel had reached its conclusions about the contextual relevance of
Articles 7 and 8 of the TRIPS Agreement to the interpretation of Article 20 before it turned to
the Doha Declaration. The Panel relied on the Doha Declaration simply to reconfirm its
previous conclusions regarding the contextual relevance of Articles 7 and 8 of the TRIPS
Agreement (6.658).
This analysis and the observations above show that the WTO case law has
considered Articles 7 and 8, both as part of the context for interpretation and as
defining elements of the object and purpose of the TRIPS Agreement. It confirms the
relevance of said provisions for the interpretation of other provisions in the
Agreement.
4.4.1 Legal Weight of the Doha Declaration
In order to give authority to its argument regarding the relevance of Articles 7 and
8 for the interpretation of the TRIPS Agreement’s provisions, the panel in
Australia—Tobacco Plain Packaging specifically elaborated on the legal weight of
the Doha Declaration. This is one of the most distinct (and welcome) contributions
of this panel’s report, as it is the first time in which the normative effects of that
Declaration have been considered in WTO jurisprudence.
In someWTO disputes prior to the Australia tobacco case, the issue of subsequent
practices as an element for interpretation of the TRIPS provisions was very cau-
tiously considered. Thus, in Canada—Patent Protection for Pharmaceutical Prod-
ucts, the panel considered comparative law in order to determine whether the interest
claimed as “legitimate” by the EC was a “widely recognized policy norm.”104 In
United States—Section 110(5) of the US Copyright Act, the panel confirmed its
conclusion with reference to examples of “state practice” of members of the Berne
Union and WTO, but it warned that it “did not wish to express a view on whether
these are sufficient to constitute ‘subsequent practice’ within the meaning of Article
104Para.7.77.
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31(3)(b) of the Vienna Convention.”105 In China—Intellectual Property Rights, the
panel rejected certain material submitted by China to prove a “subsequent practice”
in the application of the TRIPS Agreement within the meaning of Article 31(3) of the
Vienna Convention. The panel considered that it lacked “the breadth to constitute a
common, consistent, discernible pattern of acts or pronouncements” and that “the
content of the material does not imply agreement on the interpretation of Article
61 of the TRIPS Agreement.”106
A key panel assertion in the referenced case against Australia is that the Doha
Declaration must be considered a ‘subsequent agreement’ as defined in the
VCLT.107 In accordance with Article 31.3(a) of the VCLT, “any subsequent agree-
ment between the parties regarding the interpretation of the treaty or the application
of its provisions” shall be taken into account, together with the context.108 It is worth
noting that the International Law Commission adopted in its 2018 report “Draft
Conclusions on Subsequent Agreements and Subsequent Practice in Relation to the
Interpretation of Treaties”109 which, in accordance with one commentator, suggests
a “subtle elevation of subsequent agreement and subsequent practice,” which would
thereby become an integral part of the main rule of interpretation.110
In making reference to the Appellate Body ruling in US – Clove Cigarettes (para.
262), the panel stated:
This paragraph of the Doha Declaration may, in our view, be considered to constitute a
“subsequent agreement” of WTO Members within the meaning of Article 31(3)(a) of the
Vienna Convention. As the Appellate Body has clarified:
Based on the text of Article 31(3)(a) of the Vienna Convention, we consider that a
decision adopted by Members may qualify as a “subsequent agreement between the parties”
regarding the interpretation of a covered agreement or the application of its provisions if:
(i) the decision is, in a temporal sense, adopted subsequent to the relevant covered agree-
ment; and (ii) the terms and content of the decision express an agreement between Members
on the interpretation or application of a provision of WTO law (para. 7.2409).
The panel’s view rebuts the United States Trade Representative' (USTR) opinion
expressed upon the conclusion of the Doha Conference that the Doha Declaration
merely was a “political declaration.”111 As noted by a commentator, “[d]
istinguishing legal claims from non-legal or political claims, such as access to
105See, United States—Section 110(5) of the U.S. Copyright Act, para. 6.55, n. 68.
106Para. 7.581.
107For an early analysis on this subject, see, Correa (2002), p. 45. https://apps.who.int/iris/handle/
10665/67345.
108See, e.g., Stefan Kadelbach (2018). http://www.qil-qdi.org/international-law-commission-and-
role-of-subsequent-practice-as-a-means-of-interpretation-under-articles-31-and-32-vclt/.
109United Nations (2018). https://legal.un.org/ilc/reports/2018/english/a_73_10_advance.pdf.
110Tladi (2018). https://www.ejiltalk.org/is-the-international-law-commission-elevating-subse
quent-agreements-and-subsequent-practice/.
111USTR Fact Sheet Summarizing Results from WTO Doha Meeting, 15 November 2001.
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essential medicines, can deprive them of their status as rights and thereby serve to
legitimize an unjust status quo.”112
The panel further explored the legal status of the Doha Declaration under WTO
law, noting that although being a ‘declaration,’ it was adopted by a consensus
decision at the WTO Conference. The panel argued as follows:
In this instance, the instrument at issue is a “declaration,” rather than a “decision.” However,
the Doha Declaration was adopted by a consensus decision of WTOMembers, at the highest
level, on 14 November 2001 on the occasion of the Fourth Ministerial Conference of the
WTO, subsequent to the adoption of the WTO Agreement, Annex 1C of which comprises
the TRIPS Agreement. The terms and contents of the decision adopting the Doha Declara-
tion express, in our view, an agreement between Members on the approach to be followed in
interpreting the provisions of the TRIPS Agreement. This agreement, rather than reflecting a
particular interpretation of a specific provision of the TRIPS Agreement, confirms the
manner in which “each provision” of the Agreement must be interpreted, and thus “bears
specifically” on the interpretation of each provision of the TRIPS Agreement (7.2410).
This paragraph reiterates the characterization of the Doha Declaration as a
‘subsequent agreement’ under the VCLT and adds two important elements: its
adoption ‘at the highest level’ and an agreement ‘on the approach’ to be followed
in interpreting each provision of the Agreement. This ‘approach’ is reflected in
paragraph 5(a) of the Declaration quoted above but also in the rest of the Declaration,
particularly as it makes a clear case for protecting public health, a key public interest
and a matter of respect and realization of human rights, in implementing the TRIPS
Agreement.113
The panel’s analysis on the Doha Declaration does not aim, however, at asserting
its legal value per se but its role as a confirmation that Articles 7 and 8 of the TRIPS
Agreement provide both the context and define the object and purpose of the
Agreement. The panel stated in this regard:
The guidance provided by the Doha Declaration is consistent, as the Declaration itself
suggests, with the applicable rules of interpretation, which require a treaty interpreter to
take account of the context and object and purpose of the treaty being interpreted, and
confirms in our view that Articles 7 and 8 of the TRIPS Agreement provide important
context for the interpretation of Article 20 (7.2411).
The analysis of the legal status of the Doha Declaration is one of the most
significant contributions by the panel in Australia—Tobacco Plain Packaging. It
supported the panel’s conclusion with respect to the justifiability of the plain
packaging measures adopted by that country and, hence, their consistency with
Article 20 of the TRIPS Agreement.114
112Gathii (2002), p. 315. https://pdfs.semanticscholar.org/a3a6/65016915476d1088
fea2e7f4e97baf2f0f03.pdf.
113See, e.g., Carlos Correa, op cit., 2002; Velasquez, Correa, and Ido, op. cit, 2020; UNDP (2015a).
https://www.undp.org/content/undp/en/home/librarypage/hiv-aids/doha10yearson.html.
114Romero (2020a). https://www.southcentre.int/research-paper-108-april-2020/.
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5 Conclusions
The notion that the TRIPS Agreement is not a uniform law and that it allows WTO
members some room to maneuver in interpreting and implementing the Agreement’s
obligations is well established in the literature and numerous resolutions by UN
agencies and bodies. The adoption of the Doha Declaration, and several rulings by
panels and the Appellate Body, point in the same direction. An evolution is percep-
tible in the WTO jurisprudence on the matter. In particular, the most recent panel
report in Australia—Tobacco Plain Packaging shows the explicit acceptance of the
concept of TRIPS flexibilities in WTO case law and their role in preserving the
required policy space to pursue public policies such as public health. This is an
important development that could provide the basis for a further step in that
jurisprudence: the integration of human rights law, as a component of international
law, in the analysis of the obligations imposed by that Agreement and of the leeway
that states should preserve for the realization of such rights.115
The extent to which the TRIPS flexibilities can be implemented at the national
level without the risk of trade retaliations depends on the way the Agreement’s
provisions are interpreted by panels and the Appellate Body. Several issues need to
be addressed in considering how such provisions should be interpreted, consistently
with the interpretive method codified by the VCLT.While the search for the ordinary
meaning of the terms used is a well-established methodology, divergences may exist
with regard to whether they should be deemed as ‘static’ or ‘evolutionary.’ An
evolutionary approach creates the risk of unduly expanding the obligations under the
Agreement, as actively promoted by some developed countries through free trade
agreements. The adequate determination of the context—beyond the Preamble and
Articles 7 and 8—for interpretation of a particular provision is also important, as it
may decisively influence the determination of the scope and extent of the obligation
under the Agreement. Similarly, the understanding on the object and purpose of the
Agreement plays an important role. The WTO jurisprudence seems to have firmly
admitted that such a determination is to be based on said Articles 7 and 8.
The impact of the TRIPS Agreement on public health and, particularly, access to
medicines has been one of the most sensitive issues since its adoption. This issue has
been key in promoting debates and analyses on the TRIPS flexibilities (although
they are also important in relation to other public interests, such as access to
knowledge or food security). In this regard, the panel ruling in the case against
Australia on plain packaging has confirmed the legal status of the Doha Declara-
tion—seen by some as a merely political instrument—as a ‘decision’ taken by
consensus that constitutes a ‘subsequent agreement’ among the WTO members.
This is also an important development as it suggests that a pro-public health
interpretation is not only tenable but also mandated, and confirms the room that
115See, e.g., Sellin (2015), pp. 445–473. https://link.springer.com/article/10.1007/s40802-015-
0047-5.
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governments have to confidently adopt pro-public health measures without fearing
the risk of costly and burdensome litigation under the DSU.
References
Brownlie I (1998) Principles of public international law. p. 627
Correa C (2002) Implications of the Doha Declaration on the TRIPS agreement and public health.
World Health Organization, Geneva, p 45. Available from https://apps.who.int/iris/handle/
10665/67345
Correa C (2005) The TRIPS Agreement from the perspective of developing countries. In:
Macrory P, Appleton A, Plummer M (eds) The World Trade Organization: legal, economic
and political analysis. Springer, Berlin, p 2005
Correa C (2011a) Globalisation and intellectual property rights. The struggle of developing
countries to influence TRIPS. In: Alam S, Klein N, Overland J (eds) Globalisation and the
quest for social and environmental justice: the relevance of international law in an evolving
World Order. Routledge, Milton Park
Correa C (2011b) Test data protection: rights conferred under the TRIPS Agreement and some
effects of TRIPS-plus standards. In: Dreyfuss RC, Strandburg KJ (eds) The law and theory of
trade secrecy. A handbook of contemporary research. Edward Elgar, Cheltenham
Correa C (2014) Patent protection for plants: legal options for developing countries. Research Paper
No. 55. South Centre, Geneva. Available from https://www.southcentre.int/wp-content/uploads/
2014/11/RP55_Patent-Protection-for-Plants_EN.pdf
Correa C (2020a) Special Section 301: US interference with the design and implementation
of National Patent Laws. Research Paper 115. South Centre, Geneva. Available from https://
www.southcentre.int/research-paper-115-july-2020/
Correa C (2020b) Trade Related Aspects of Intellectual Property Rights. A commentary on the
TRIPS Agreement, 2nd edn. Oxford University Press, p 21
Danish and Aileen Kwa (2019) Crisis at the WTO’s Appellate Body (AB): why the AB is important
for developing members. Policy Brief No. 69. South Centre, Geneva. Available from https://
www.southcentre.int/wp-content/uploads/2019/12/PB69_Crisis-at-the-WTO%E2%80%99s-
Appellate-Body-AB-Why-the-AB-is-Important-for-Developing-Members_EN-1.pdf
Dörr O, Schmalenbach K (2012) Article 31. General rule of interpretation. In: Vienna Convention
on the law of treaties – a commentary. Springer, Berlin. Available from https://link.springer.
com/chapter/10.1007%2F978-3-642-19291-3_34
Dothan S (2019) The three traditional approaches to treaty interpretation: a current application to the
European Court of Human Rights. Fordham Int Law J 42:765; iCourts Working Paper Series,
No. 141. Available from: https://ssrn.com/abstract¼3241331
Eger T, Scheufen M (2012) The past and the future of copyright law: technological change and
beyond”. In Liber Amicorum Boudewijn Bouckaert. Die Keure. Available from https://www.
researchgate.net/publication/280043122_The_past_and_the_future_of_copyright_law_techno
logical_change_and_beyond
European Commission (2020) Report on the protection and enforcement of intellectual property
rights in third countries. Commission staff working document. Available from https://trade.ec.
europa.eu/doclib/docs/2020/january/tradoc_158561.pdf
Flowers Z (2019) The role of precedent and stare decisis in the World Trade Organization’s dispute
settlement body. Int J Legal Information 47(2):90–104
Fuchs S (2020) COVID-19: New German legislation to fight pandemic may affect granted German
patents. Available from https://www.twobirds.com/en/news/articles/2020/germany/covid-19-
new-german-legislation-to-fight-pandemic-may-affect-granted-patents
Interpreting the Flexibilities Under the TRIPS Agreement 27
Gathii JT (2002) The legal status of the Doha Declaration on TRIPS and public health under the
Vienna Convention of the Law of Treaties. Harv J Law Technol 15(2):315. Available from
https://pdfs.semanticscholar.org/a3a6/65016915476d1088fea2e7f4e97baf2f0f03.pdf
Geiger C, Gervais D, Senftleben M (2013) The three-step test revisited: how to use the test’s
flexibility in national copyright law. PIJIP Research Paper Series. Available from https://
digitalcommons.wcl.american.edu/cgi/viewcontent.cgi?article¼1041&context¼research
Germán Velásquez (2013) Access to medicines and intellectual property: the contribution of the
World Health Organization. Research Paper No. 47. South Centre, Geneva, p 5. Available from
https://www.southcentre.int/wp-content/uploads/2013/05/RP47_WTO-role-in-IP-and-access-
to-medicines_EN.pdf
Germán Velásquez (2019) Medicines and intellectual property: 10 years of the WHO global
strategy. Research Paper No. 100. South Centre, Geneva
Haedicke M (2000) U.S. imports, TRIPS and Section 337 of the Tariff Act of 1930. Int Rev Indus
Property Copyright Law 31(7/8):1774
Howse R (2000) The Canadian medicine panel: a dangerous precedent in dangerous times. J World
Intellectual Property 3(4). Available from https://onlinelibrary.wiley.com/doi/abs/10.1111/j.
1747-1796.2000.tb00139.x
Kadelbach S (2018) The International Law Commission and role of subsequent practice as a means
of interpretation under Articles 31 and 32 VCLT. Questions of International Law. Available
from http://www.qil-qdi.org/international-law-commission-and-role-of-subsequent-practice-as-
a-means-of-interpretation-under-articles-31-and-32-vclt/
Kennedy M (2016) WTO dispute settlement and the TRIPS agreement: applying intellectual
property standards in a trade law framework. Cambridge University Press, Cambridge
Linderfalk U (2007) On the interpretation of treaties: the modern international law as expressed in
the 1969 Vienna Convention on the Law of Treaties. Springer, Berlin, p 205. Available from
https://www.corteidh.or.cr/tablas/r32592.pdf
McNair (1961) The law of treaties. Clarendon Press, Oxford, p 365
Mgbeoji I (2006) Global biopiracy: patents, plants, and indigenous knowledge. UBC Press,





Minn M (2016) Patenting of genetic research in Europe and the U.S.: a questionable future for
diagnostic methods and personalized medicines. Biotechnology Law Report 38(2). Available
from https://www.liebertpub.com/doi/10.1089/blr.2019.29108.mm
Morin J-F, Surbeck J (2020) Mapping the new frontier of international IP law: introducing a TRIPs-
plus dataset. World Trade Rev 19(1)
Okediji RL (ed) (2017) Copyright law in an age of limitations and exceptions. Cambridge
University Press, Cambridge. Available from https://books.google.fr/books?
id¼3lpEDgAAQBAJ&pg¼PA241&lpg¼PA241&dq¼copyright+exception+interpretation
+ar t ic le+30+ruth&source¼bl&ots¼7MCIdWRbq7&sig¼ACfU3U2kCly0QaU-
z P X h b 8 3 g b 8 Q c S F 8 U t w & h l ¼e n & s a ¼X & v e d¼2 a h U K E w j U 4 N C b y -
zpAhURnxQKHXg0AtoQ6AEwBHoECAkQAQ#v¼onepage&q¼copyright%20exception%
20interpretation%20article%2030%20ruth&f¼false
Prifti V (2015) The breeder’s exception to patent rights – analysis of compliance with article 30 of
the TRIPS Agreement. Springer, Berlin
Reid J (2019) Biopiracy: the struggle for traditional knowledge rights. Am Indian Law Rev 34(1).
Available from https://digitalcommons.law.ou.edu/cgi/viewcontent.cgi?article¼1121&
context¼ailr
Rodrigues EB Jr (2012) The general exception clauses of the TRIPS agreement: promoting
sustainable development. Cambridge University Press, Cambridge. Available from https://
28 C. M. Correa
www.researchgate.net/publication/288719106_The_general_exception_clauses_of_the_
TRIPS_agreement_Promoting_sustainable_development
Romero T (2020a) Public health and plain packaging of tobacco: an intellectual property perspec-
tive. Research Paper No. 108. South Centre, Geneva. Available from: https://www.southcentre.
int/research-paper-108-april-2020/
Romero T (2020b) Articles 7 and 8 as the basis for interpretation of the TRIPS Agreement. Policy
Brief No. 79. South Centre, Geneva. Available from https://www.southcentre.int/policy-brief-
79-june-2020/
Ruse-Khan HG (2017) From TRIPS to FTAs and back: re-conceptualising the role of a multilateral
IP framework in a TRIPS-plus world. Forthcoming, Netherlands Yearbook of International
Law; Max Planck Institute for Innovation & Competition Research Paper, No. 18-02; University
of Cambridge Faculty of Law Research Paper, No. 3/2018. Available from: https://ssrn.com/
abstract¼3082718
Ruse-Khan HG, Puutio TA (2017) A handbook on negotiating development oriented intellectual
property provisions in trade and investment agreements. UNESCAP, Bangkok, p 10. Available
from https://www.unescap.org/sites/default/files/IPR%20Handbook.pdf
Sellin JA (2015) Does one size fit all? Patents, the right to health and access to medicines.
Netherlands Int Law Rev 62:445–473. Available from https://link.springer.com/article/10.
1007/s40802-015-0047-5
Shadlen K (2004) Patents and pills, power and procedure: the north-south politics of public health in
the WTO. St Comp Int Dev 39, 76–108. Available from https://link.springer.com/article/10.
1007%2FBF02686283
Shaikh OH (2016) Access to medicine versus test data exclusivity – Safeguarding flexibilities under
international law. Springer, Berlin
Son KB, Lopert R, Gleeson D, Lee TJ (2018) Moderating the impact of patent linkage on access to
medicines: lessons from variations in South Korea, Australia, Canada, and the United States.
Globalization and Health vol. 14. Available from https://doi.org/10.1186/s12992-018-0423-0
The Graduate Institute Geneva, Knowledge Portal on Innovation and Access to Medicines. Avail-
able from: https://www.knowledgeportalia.org/. Last accessed 12 Feb 2021
The Law Library of Congress, Global Legal Research Center (2016) Patent Term Extensions and
Adjustments
Tladi D (2018) Is the International Law Commission elevating subsequent agreements and subse-
quent practice? EJIL:Talk! Available from https://www.ejiltalk.org/is-the-international-law-
commission-elevating-subsequent-agreements-and-subsequent-practice/
UNCTAD (1996) The TRIPS agreement and developing countries. Available from https://unctad.
org/en/docs/ite1_en.pdf
UNCTAD & ICTSD (2005) Resource book on TRIPS and development. Cambridge University
Press, Cambridge, p 467. Available from https://unctad.org/en/PublicationsLibrary/
ictsd2005d1_en.pdf
UNDP (2015a) The Doha Declaration 10 years on and its impact on access to medicines and the
right to health. Available from https://www.undp.org/content/undp/en/home/librarypage/hiv-
aids/doha10yearson.html
UNDP (2015b) Using competition law to promote access to medicine. Available from https://www.
undp.org/content/undp/en/home/librarypage/hiv-aids/using-competition-law-to-promote-
access-to-medicine.html
United Nations (2018) Report of the International Law Commission (A/73/10, 2018). Available
from https://legal.un.org/ilc/reports/2018/english/a_73_10_advance.pdf
Interpreting the Flexibilities Under the TRIPS Agreement 29
United Nations General Assembly (2015) A/RES/70/1. Available from https://www.un.org/ga/
search/view_doc.asp?symbol¼A/RES/70/1&Lang¼E
Velásquez G, Correa CM, Ido V (2020) Intellectual property, human rights and access to medicines:
a selected and annotated bibliography, 3rd edn. South Centre, Geneva. Available from https://
www.southcentre.int/book-by-the-south-centre-2020/#more-14014
WHO, WIPO, and WTO (2012) Promoting access to medical technologies and innovation -
intersections between public health, intellectual property and trade. Available from https://
www.wipo.int/edocs/pubdocs/en/global_challenges/628/wipo_pub_628.pdf
WIPO (2010) Patent related flexibilities in the multilateral legal framework and their legislative
implementation at the national and regional levels, p 11. Available from https://www.wipo.int/
meetings/en/doc_details.jsp?doc_id¼142068
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate
credit to the original author(s) and the source, provide a link to the Creative Commons license and
indicate if changes were made.
The images or other third party material in this chapter are included in the chapter’s Creative
Commons license, unless indicated otherwise in a credit line to the material. If material is not
included in the chapter’s Creative Commons license and your intended use is not permitted by
statutory regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder.
30 C. M. Correa
Intellectual Property Exhaustion
and Parallel Imports of Pharmaceuticals: A
Comparative and Critical Review
Irene Calboli
Abstract This Chapter addresses the topic of intellectual property (IP) exhaustion
in the context of the parallel trade of pharmaceuticals. These imports, which are
controversial in general, are more complex with respect to pharmaceuticals, which
require additional marketing and import authorizations. Nevertheless, individual
countries remain free to accept these imports under the flexibility of Article 6 of
the Agreement on Trade Related Aspects to Intellectual Property Rights (TRIPS
Agreement). This Chapter reviews several national approaches—in developed,
developing, and least developed countries (LDCs)—from the perspective of the
exhaustion of patent rights as well as other IP rights. Through this review, it
highlights that several countries today accept parallel trade. A large number of
these countries are, however, developed countries, whereas several developing
countries and LDCs instead prohibit parallel imports. This finding is perplexing,
and the reasons for this restrictive approach are unclear as developing countries and
LDCs need flexible policies and can largely benefit from parallel trade. In addition,
despite the claim by the pharmaceutical industry that parallel trade would increase
the price of medicines in these countries—as originator would increase prices due to
the fear of parallel imports—medicines are sold at lower prices mostly because of
governments’ pricing or after the expiration of patent protection. Based on this
review, this Chapter concludes that national legislations, which are not taking
advantage of the flexibility in Article 6 of the TRIPS Agreement, may consider
reviewing their policies and allow parallel imports.
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1 Introduction: The Relevance (and Resilience)
of the Principle of Intellectual Property Exhaustion
and Its Application to Pharmaceuticals
In this chapter, I explore the application of the principle of intellectual property
(IP) exhaustion to the parallel imports of pharmaceuticals and the impact that
different policies on exhaustion can have on these imports across selected jurisdic-
tions. The legal treatment of IP exhaustion continues to represent one of the most
debated and unresolved issues in international trade.1 In addition, the debate regard-
ing IP exhaustion and pharmaceuticals reflects the more complex debate on access to
medicines and public health, and how domestic policies on IP exhaustion can be
used to implement the existing IP-related flexibilities provided in the international
system.2 Several commentators have addressed this debate before, yet disagreements
and uncertainty continue to characterize this important area of IP and international
trade.
Moreover, domestic policies on IP exhaustion are not the only barrier to parallel
imports of pharmaceuticals, as these imports are also subjected to national marketing
approvals, import authorizations, and other formalities. In addition, in many
instances, national governments exert price control on the sale of pharmaceuticals,
in particular prescription medications. In other words, as commentators have noted,
pharmaceuticals are traded, and parallel traded, in “distorted” markets due to the
additional regulatory schemes and price control policies that apply to these products.
National competition laws are also important in the context of parallel imports of
pharmaceuticals, for example regarding excessive pricing or the validity of contrac-
tual clauses to block the products’ redistribution after they have first been put into the
market by the IP holders. Because of its limited scope, this Chapter only mentions
and does not analyzes in detail this complex ecosystem of parallel trade in pharma-
ceuticals.3 In practice, however, these factors remain very relevant, perhaps even
more relevant than domestic policies on IP exhaustion in certain instances. In
particular, in some countries, the actual impact of IP exhaustion on the admissibility
of parallel imports of pharmaceuticals is certainly minimal, if not irrelevant due to
the additional regulatory requirements and possible contractual limitations against
these imports.
1For a detailed analysis and summary of the relevant debates, see the contributions in Calboli and
Lee (2016). See also Ghosh and Calboli (2018); Fink 2004, p. 174); Maskus (2000), p. 1269;
Abbott (1998), pp. 607–636; Abbott 2000) http://ssrn.com/abstract¼1921856; Heath (1997),
p. 623; Jehoram (1996), p. 280; Hilke (1988), p. 75.
2For a discussion of the flexibilities and applications to pharmaceuticals and health care, see
El-Said (2010).
3For a comprehensive review of all these aspects, see Abbott (2016), p. 145 [hereinafter Abbott,
Parallel Trade in Pharmaceuticals]. See also Kyle (2007), p. 88 and Maskus (2001).
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In light of this, why then writing a chapter on this topic, if IP exhaustion may not
matter, or matter considerably less than originally thought, for the admissibility of
parallel imports of pharmaceuticals into national markets?
As I mentioned, the debate in this area remains complex and, even though
domestic policies on IP exhaustion are not the only aspect to consider, these policies
are still relevant, in particular when national governments are in favor of parallel
imports and grant the pharmaceuticals the necessary marketing approvals and import
authorizations. It is difficult to predict how often, in practice, national governments
would approve these imports, but certainly in these instances domestic policies on
exhaustion would make the difference in the legal treatment of the imports. Would
these be treated as legitimate imports or IP infringements? Moreover, domestic
policies on exhaustion not only can affect the imports of patented pharmaceuticals,
but also generics. In particular, national rules on trademark exhaustion can be used to
block parallel imports including of generics. While this may not affect countries with
the ability to produce generics domestically, it could affect countries without
manufacturing capacity. Instead, domestic policies favoring parallel imports could
facilitate the supply of medicines at lower prices than branded versions, or even the
supply of certain medicines altogether as originator companies often not directly
distribute certain medicines in some countries.
The chapter proceeds as follows. Section 2 presents an overview of the principle
of exhaustion in the context of international trade. This background leads to the
discussion on the legal treatment of parallel imports of pharmaceuticals. Section 3
explores the domestic policies on patent exhaustion in selected developed and
developing countries and elaborates on how different solutions—national, interna-
tional, or regional exhaustion—impact the parallel trade of pharmaceuticals in these
countries. Section 4 focuses on the impact of overlapping IP rights—notably trade-
marks and copyrights in addition to patents—to the parallel trade of pharmaceuticals.
This Section highlights how parallel imports can be affected by these overlaps, in
particular when a country adopts international patent exhaustion, but practices
national exhaustion for copyrights or trademarks. It also highlights that overlapping
rights can block parallel imports when the imported products, albeit genuine, carry
small quality differences from the products distributed into the importing countries
by IP holders.4 Section 5 concludes and highlights that several developed countries
adopt today more liberal policies on IP exhaustion, notably international exhaustion,
than several developing and least developed countries (LDCs), which follow instead
national exhaustion. This is certainly problematic for the latter countries and their
access to pharmaceuticals.
4See, e.g. Calboli (2014a), p. 151 [hereinafter Calboli, Avoidable Effects]; Calboli (2011), p. 1241
[hereinafter Calboli, Market Integration] (addressing in details the legal treatment of quality
differences in the context of trademark exhaustion).
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2 Intellectual Property Exhaustion and Paralle Trade:
General Considerations and Application
to Pharmaceuticals
The doctrine of IP exhaustion is crucial in IP theory, as it limits the rights of IP
holders to control the distribution of the products they have put in the market after
their first lawful release.5 This doctrine was developed in the nineteenth century to
balance the rights of IP holders and to prevent the use of their IP rights against the
lawful rights of retailers, second-hand dealers, and consumers to freely display,
advertise, and resell the products they lawfully purchased in the market, even if
those actions directly compete with the IP holders’ business activities in the same
market.6 Generally, there are not major controversies regarding the application of
this doctrine within national markets, at least regarding products whose quality has
not been changed and are resold nationally.7 In contrast, controversy has tradition-
ally characterized the debate over the application of the doctrine of exhaustion in the
context of international trade. In particular, the legal treatment of the phenomenon of
parallel imports—the imports of genuine products, imported into a country from
unauthorized third party importers after their first authorized sale by the IP holders
abroad8—is one of the few aspect of IP that has never been internationally harmo-
nized and discussion over the admissibility into national markets of these products
continue to date. The tension between the application of the principle IP exhaustion
and the movement of products across national border, in general and in the context of
pharmaceuticals, is addressed in this Section.
2.1 The Principle of Intellectual Property Exhaustion
in International Trade: An Overview
Professor Ghosh and I have extensively addressed the debates over the exhaustion
doctrine and cross-border trade in our recent book, Exhausting Intellectual Property
Rights: A Comparative Law and Policy Analysis.9 The surge in global trade over the
past century has heightened these debates, driven primarily by the concerns
5See, e.g., Ghosh and Calboli (2018), pp. 22–40.
6See Kohler (1900), p. 452. An English translation of Josef Kohler’s passages on exhaustion can be
found in Heath (2014a), p. 419, 424.
7With the exception of the transfer of digital goods and self-replicating technologies—two recent
phenomena that have been addressed by courts in several jurisdictions. See, e.g., Capitol Records,
LLC v. ReDigi Inc., 934 F. Supp. 2d 640 (S.D.N.Y 2013); Case C-128/11, UsedSoft GmbH
v. Oracle Int’l Corp., 2012 E.C.R. I-00000; Bowman v. Monsanto Co., 133 S.Ct. 1761 (2013);
Case No. C-428/09, Monsanto v. Cefetra, 2010 E.C.R. I-09961.
8Ghosh and Calboli (2018), pp. 41–64.
9Id.
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expressed against and in favor of the arbitrage of consumer goods from low-cost to
high-cost jurisdictions.10 Although IP holders are interested in the benefits of free
trade in reducing manufacturing costs and decreasing tariffs, quotas, and other trade
restrictions, they generally oppose parallel imports because of the competition the
imports create in the high cost domestic markets and the resulting loss of profits in
those markets.11 On the other side, supporters of parallel imports, including this
author, point specifically to the inconsistency of the international IP system, which
seeks harmonizing the IP system to eliminate barriers to trade and facilitate the
registration and enforcement of IP rights worldwide, yet does not equally harmonize
the free movement of products across jurisdictions to the same—in essence allowing
IP rights to possibly operate as an invisible barrier to otherwise legitimate trade.12
The issue of IP exhaustion is not addressed in any of the agreements administered
by the World Intellectual Property Organization (WIPO). Exhaustion, or lack of
agreement thereof, is mentioned explicitly only in Article 6 of the Agreement on
Trade Related Aspects to Intellectual Property Right (TRIPS Agreement), adopted
under the auspices of the Word Trade Organization (WTO). The provision famously
states that “nothing in this Agreement shall be used to address the issue of the
exhaustion of intellectual property rights.”13 Accordingly, the choice of exhaustion
regimes depends on national decisions about desirable economic outcomes based on
specific economic and trade-related factors, the size of national markets, the level of
development, and possibly the pressure exerted foreign governments. Essentially,
cross-border trade remains a form of national strategy, which may or may not include
economic integration, and in which nation states maintain their political indepen-
dence, while economic agents are permitted to engage in trade crossing their
respective countries.14
10Parallel imports can be divided into two specified categories: passive and active parallel imports.
See Fink (2004), pp. 171–188. The first category relates to the situation in which third party
importers purchase products in one country and sell them in another. The second identifies the
case of a foreign licensee, or authorized distributor abroad, who sell into the national market of the
IP holders without her consent. The latter case is less frequent and is often prohibited through
specific clauses in licensing agreements.
11For an excellent review of the economic studies on parallel imports, see Maskus (2016), p. 106
[hereinafter Maskus, Economic Perspective]. See also Saggi (2013), p. 131; Valletti and Szymanski
(2006), p. 499; Valletti (2006), p. 314; Chen and Maskus (2005), p. 1; Malueg and Schwartz
(1994), p. 187.
12SeeGhosh and Calboli (2018), pp. 41–64. See also Calboli (2002), p. 47 (advocating for a change
to international exhaustion in the EU).
13Agreement on Trade-Related Aspects of Intellectual Property Rights, April 15, 1994, Marrakesh
Agreement Establishing theWorld Trade Organization, Annex 1C, Legal Instrument—Result of the
Uruguay Rounds Vol. 31, 33 I.L.M. 83, 1869 U.N.T.S. 299 (1994), art. 6 [hereinafter TRIPS]. On
the drafting of Article 6 of TRIPS, see Jehoram (1999), pp. 495, 508 (noting that this provision
represents a compromise between two opposite approaches: “[t]he US Proposal [to introduce its
own national system,] national exhaustion[,] and the [pleas of] developing countries . . . for the
opposite,” international exhaustion). See also Yusuf (2016) p. 23, 26; Taubman et al. (2012),
pp. 18–20; Verma (1998), pp. 534, 539.
14Ghosh and Calboli (2018), pp. 44–48.
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As it is generally known, countries follow one of three systems: national,
regional, or international exhaustion.15 Under the principle of national exhaustion,
IP holders’ rights are exhausted after the first sale of a good or batch of goods, but
only if this first sale has occurred in the national territory.16 This regime is the least
friendly for international trade and permits IP holders to stop parallel imports at the
border or legitimately seize products after importation as IP infringements, even
though these are genuine goods.17 Instead, under the principle of regional exhaus-
tion, a compromising solution between the international and regional exhaustion, the
rights of IP holders are exhausted after the first sale of a good or batch of goods, but
only if the sale has occurred in one of the member countries of a regional organiza-
tion following this principle as a common rule for all members.18 Under this system,
the import of products originating from third countries from outside the region
remains unlawful and can be stopped as infringement.19 Finally, under the principle
of international exhaustion, IP holders’ rights to control the further distribution of a
good or batch of goods exhaust after the first sale of the goods regardless of the
country where this first sale has occurred.20 Undoubtedly the friendliest approach for
international trade, under this system parallel imports are considered lawful in the
country of importation, even though the country from which the goods are imported
may well apply a different system, i.e. national or regional exhaustion.21
National exhaustion should be contrasted with regional exhaustion, the rule that is
currently established in the European Union (EU as extended to the European
Economic Area, EEA)22 and the Organization Africaine pour la Propriete
Intellectuelle (OAPI).23 What contrasts regional from national exhaustion is that
regional exhaustion stems from the economic union of regions, but not necessarily
the political union. Still, the principle is often the product of courts, treaties, or
legislation.24 In the EU, for example, much of the credit for the system’s develop-
ment is due to the EU Commission and the Court of Justice of the EU (CJEU).25
15Id. at 10–11.
16See Rothchild (2016), p. 226. See also Ghosh and Calboli (2018), pp. 10–11.
17Ghosh and Calboli (2018), pp. 10–11.
18On the development of this principle in the EU, see Beier (1990), p. 131; Jehoram (1992), p. 622.
19See, e.g., Calboli (2002), p. 47 [hereinafter Calboli, Trademark Exhaustion in the EU] (discussing
the debate on the geographical extent of trademark exhaustion in the EU); Shea (1995), p. 463.
20Ghosh and Calboli (2018), pp. 10–11.
21Id.
22For a review, see Calboli (2019a), p. 22 [hereinafter Calboli, Comparing IP Exhaustion].
23See Accord portant révision de l'Accord de Bangui du 2 mars 1977 instituant une Organisation
Africaine de la Propriété Intellectuelle (Bangui (République centrafricaine), le 24 février 1999)
[hereinafter Bangui Agreement].
24Ghosh and Calboli (2018), pp. 63–64.
25See Jehoram (1992), p. 622; see also Beier (1990), p. 131. For example, the role of the Court of
Justice of the EU (CJEU) was crucial in clarifying and enforcing the rule of regional trademark
exhaustion in the EU. See Case C-335/96, Silhouette Int’l Schimed Gmbh & Co. KG v. Hartlauer
Handelsgesellschaft mbH, 30 I.I.C. 920 (1998); Case-173/98, Sebago, Inc. v. GB-Unic SA,
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Moreover, economic integration within the regional area generally arises prior to the
decision among member states to adopt the rule of regional exhaustion.26 It could be
argued (and this author believes) that, in a harmonized international trade system, in
which international organizations administer treaties, international exhaustion could
be the logical step following from national and regional exhaustion. However, the
TRIPS Agreement—and accordingly international trade construct supervised by the
WTO—makes exhaustion a matter of territoriality and national choice.27
In our book, Professor Ghosh and I discuss at length the complex set of policy
debates in this area.28 We also highlight how a meaningful assessment of exhaustion
policy needs to take into consideration economic implications, possibly through
empirical analysis of the relationships among exhaustion policy, international trade,
and IP. In this respect, we refer to several economic studies analyzing the effects of
parallel importation on market prices, consumers, producers, and importers.29
Through empirical studies, prominent economists found that in some instances,
price differences are due to marketing decisions by IP holders.30 These decisions
reflect the seeking of price differences across countries to attract licensees and
distributors in various jurisdictions that can take advantage of market conditions.
In this scenario, parallel importers seek to take advantage of arbitrage possibilities
arising from the ability to buy products at a low price and sell them at a high price,
depending on the legal regime.31 In other instances, however, price differences can
arise from decisions in separate countries independent from the marketing decisions
of the IP holders, for example because of higher product demand due to consumer
tastes or regulatory differences that translate into higher or lower prices depending
on the nature of the regulation.32 The latter consideration is relevant regarding the
2 C.M.L.R. 1317 (1999); Joined Cases C-414-416/99, Zino Davidoff SA v. A & G Imports Ltd.,
Levi Strauss & Co. v. Tesco Stores Ltd., and Levi Strauss & Co. v. Costco Wholesale UK Ltd.,
2001 E.C.R. I-8691.
26The principle of free movement of goods, for example, predates the adoption of the principle of
regional exhaustion in the EU and was already enshrined into the Treaty of Rome in 1957. See
Consolidated Version of the Treaty on the Functioning of the European Union, Mar. 30, 2010, 2010
O.J. (C 83) [hereinafter TFEU] as amended following the entering into force of the Treaty of Lisbon
on December 1, 2009. Treaty of Lisbon, Dec. 13, 2007, 2007 O.J. (C 306). Several decisions were
issued by the CJEU regarding the free movement of goods and the exercise of IP rights, before the
official adoption of the principle of regional exhaustion. See Joined Cases 56 & 58/64, Costen &
Grunding v. EC Comm’n, 1966 E.C.R. 299; Case 24/67, Parke Davis v. Centrafarm, 1968
E.C.R. 55; Case 40/70, Sirena v. Eda, 1971 E.C.R. 69; Case15/74, Centrafarm v. Sterling Drugs,
[1974] E.C.R. 1147; Case 187/80, Merck & Co. v. Stephar, [1981] E.C.R. 2063. See also Saggi
(2014), p. 125.
27Ghosh and Calboli (2018), pp. 63–64.
28Id. at 41–64.
29See Ganslandt and Maskus (2008), pp. 267–268; Ganslandt and Maskus (2004), p. 1035 [here-
inafter Ganslandt and Maskus (2004)]; Roy and Saggi (2012), p. 262.
30Ganslandt and Maskus (2004), p. 29.
31Id.
32Id. See also Ghosh and Calboli (2018), pp. 48–51.
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discussion of parallel imports in pharmaceuticals, which are subject to non IP-related
regulations and whose price is often negotiated by governments and not private
economic agents.33
Overall, looking at the spectrum of national solutions adopted on exhaustion and
the various interests at stake, two observations can be derived from the existing
studies. First, it seems the price differences of parallel imported products can be a
social benefit for importers and, in several instances, for the importing countries.
This could also be the case for parallel imported pharmaceuticals.34 Price differences
do matter for how national legal regimes on exhaustion are implemented both in a
particular country or region—that is, whether a country chooses national, regional,
or international exhaustion.35 This first observation has implications for the second,
notably that parallel importation is largely the result of price arbitrage arising from
differences in prices. Importers see a profit-making opportunity and respond by
buying low(er) and selling high(er). Here again, as empirical studies indicate, IP
holders can nonetheless respond strategically to these importers either by
pre-empting importation before it occurs through contractual clauses they can
enforce through litigation36 or marketing strategies—such as applying small differ-
ences in product quality in different countries or appealing to national tastes with
varied products. IP holders can also lobby for changes in national laws favoring
national exhaustion. Because of various strategic behaviors, the analysis of exhaus-
tion is complicated and the policy responses become more challenging, as one size
does not fit all. The approach under Article 6 of the TRIPS Agreement attempts to
allows flexibility for individual national responses within this complexity.37 How-
ever, as explained in the next Section, a system of international exhaustion does
promote free trade. In turn, this can lead to access to lowered prices products, or
access to products that would not be sold in certain countries altogether.38
33See discussion infra Part 2.2.
34Ghosh and Calboli (2018), p. 49.
35Id.
36Id., at 49–50.
37Id. at 63–64. See also Maskus (2016), p. 106; Chiappetta (2016), p. 125.
38For a relevant empirical study of the impact of parallel imports (although limited in geographical
scope), see National Economic Research Associates, The Economic Consequences of the Choice of
Regime in the Area of Trademarks: Final Report for DG XV of the European Commission 76-100
(1999). But see Kanavos et al. (2004) (finding neutral welfare effects as most of the benefits from
producers went to the parallel importers and not to consumers). See also Kanavos and Costa-i-Font
(2005), pp. 758, 772–775. A similar conclusion is supported by Ganslandt and Maskus (2004),
p. 1035 (finding the actual cost savings were small in a study of Sweden because the wholesale price
reductions were not passed on to hospitals and patients, instead the retailers and parallel importers
made larger margins).
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2.2 Patent Exhaustion and the Debate on Parallel Trade
of Pharmaceuticals
Unlike most products, pharmaceuticals “are developed, approved, manufactured,
traded, and used under complex and demanding regulatory schemes.”39 For strictly
regulated markets such as the U.S. or the EU, these regulatory schemes apply all the
way from the time of production of the active pharmaceutical ingredients.40 Still, in
all countries today, also developing countries, regulators must issue an official
marketing approval before the pharmaceuticals are put in the market.41 This
approval may vary in standards for “new” pharmaceuticals and “generic” versions
of previously approved pharmaceuticals.42 For new medicines, elaborate lists of
documents, including clinical trials and manufacturing, are necessary, while appli-
cants for generics need to present details of the “bioequivalence” of the compound
and manufacturing. Additionally, importers and distributors of pharmaceuticals are
generally subject to import regulations and procedures for product recalling and
other safety requirements.43
It is old news that bringing a new medicine to market is a costly and lengthy
processes. On average, a successful drug costs over $1 billion to develop, and only
one in several thousand compounds reaches the final approval stage.44 Since it is
relatively uncomplicated and inexpensive to copy the molecules of a new drug,
patents are a fundamental part of the industry for the exclusive rights granted through
patents. One of the main factors for the industry to obtain the maximum profitability
is also the possibility to sell the medicines at differentiated prices across different
countries. However, price setting for pharmaceuticals does not depend entirely on
the industry international pricing strategy. Instead, many national governments
control the prices pharmaceuticals are sold at nationally and later control these prices
within hospitals, pharmacies, and other distributors.45 Because of these negotiations,
in countries offering national healthcare schemes, prescription medications are
considerably less expensive than in other countries, while pricing of over the counter
medications are left more to the market rules.46 In some instances, national compe-
tition authorities have also determined when pricing was “excessive.”47 As noted
before, this complex regulatory ecosystem makes it even more important, from the
39Abbott (2016), p. 145.
40Id. at 148–149.
41Id.
42Id. For the process of developing generics, see the contributions in Shargel and Kanfer (2014).
43Abbott (2016), pp. 149–150.
44The Drug Development Process, United States Food and Drug Administration, https://www.fda.
gov/patients/learn-about-drug-and-device-approvals/drug-development-process.
45Abbott (2016), p. 150; Wasserman Rajec (2016), pp. 271, 283; Grabowski (2002), p. 533, 535.
46Abbott (2016), p. 150.
47See Abbott (2014), pp. 78–79.
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pharmaceutical industry’s viewpoint, that producers are able to prevent parallel trade
from lower priced into higher priced markers.48
A rule of national patent exhaustion is the most effective rule to facilitate national
price discrimination and block parallel imports of pharmaceuticals on the basis of
national patent enforcement.49 Representatives of the industry strongly support this
rule. To justify their support, they have argued that price discrimination is advanta-
geous not only for pharmaceutical producers, but also for developing countries, as
this rule allows producers to set higher prices in more affluent markets while
lowering prices in less affluent ones. This position has been supported by several
economists.50 Supporters of this view have argued that parallel imports could lead to
a price increase, and not a price reduction, in lower priced markets (and possibly to a
reduction of the supply of pharmaceuticals altogether) precisely to prevent possible
trade diversion by parallel importers of pharmaceuticals first sold in these markets.51
The industry also likes to point to the losses that parallel imports can bring to
pharmaceutical companies and the fact that these losses would inevitably lead to
less investments in R&D with consequential damage for pharmaceutical innova-
tion.52 The argument has been made that parallel imports also harbour counterfeited
products, which are certainly a growing threat for public health, especially in
developed countries.53
These positions have been largely rebutted, however, by proponents of interna-
tional patent exhaustion and convincingly.54 Supporters of international exhaustion
have highlighted that it is difficult to assess whether price discrimination effectively
benefits low income countries since many drugs are not sold at all in these coun-
tries55 or they are sold for a small section of the affluent population at the same price
as in higher-priced markets. Simply put, the assertions of the industry in this respect
are speculative, as there are no data comparing the prices of the same pharmaceu-
ticals in developed and developing countries, on a large scale and for a considerable
number of products. Similarly, it has been correctly stressed that the industry has not
presented compelling evidence that it would suffer severe losses and, in turn, these
losses would affect reinvestment in R&D. Instead, supporters of international
exhaustion noted that the industry spends large sums on the advertising and
48See Bale Jr (1999), p. 637 (arguing for the pharmaceutical industry).
49See supra Sect. 2.1.
50See Bale Jr (1999), p. 648 (noting that “[t]he threat of parallel trade takes away any incentive of
vaccine and pharmaceutical patent holders to make significant concessions to poorer countries”).
See also Varian (1985), p. 870; see also Schwartz (1990), p. 1259; Singham (2000), pp. 363, 407.
51Bale Jr (1999), p. 637.
52Id. See also Danzon (1998), p. 293.
53See, e.g., Delepierre et al. (2012), p. 247; Kelesidis et al. (2007), p. 214; Harper and Gellie (2006).
54See, e.g. Abbott (2007) (providing of a detailed and very convincing rebuke to the various
arguments called by the pharmaceutical industry in favour of national exhaustion and price
discrimination) [hereinafter Abbott, Economic and Social Welfare]. See also Owoeye (2015),
p. 359; Kumar Rai and Jagannathan (2012), p. 53.
55Abbott (2007), p. 8.
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promotion of “lifestyle” (highly profitable) drugs rather than reinvesting all their
profits in R&D.56 The argument about fake medicines is increasingly important as
the size of counterfeited medicines in developing countries has become a true
issue.57 This argument is not directly related to parallel imports, however, and
again no evidence has been brought that parallel importers—who are subject to
strict import controls and regulations no less than other imported medicines—are
necessarily linked to the increase of counterfeited medical products in national
markets.58
Accordingly, despite the pressure against parallel imports on the part of the
industry, it cannot be disputed that parallel imports of pharmaceuticals can have
beneficial effects for importing countries in terms of prices and access to pharma-
ceuticals. In particular, imports of lower priced pharmaceuticals can increase access
to medicines and, in turn, assist both patients and national governments in saving
costs, as several pharmaceuticals are provided through publicly funded health pro-
grams.59 Certainly, for this advantage to be true, the cost savings from the lower
point price of the medicines should be shared between importers, retailers, hospitals,
and ultimately patients and cannot be pocked only by the importers and the distrib-
utors.60 In this respect, the role of national governments remains crucial, as govern-
ments retain regulatory control on the importation of paralleled imported
pharmaceuticals. Governments should (and generally do) exercise price control for
these pharmaceuticals in order to impose that importers share the savings obtained
through the arbitrage of the pharmaceuticals across different national markets.61 It is
thus advisable that individual countries—above all developing countries and
LDCs—use the flexibility provided under Article 6 of the TRIPS Agreement and
practice the type of domestic exhaustion that best suits national needs in terms of
access to pharmaceuticals, thus international exhaustion.62
Opponents of parallel imports tried to argue soon after the adoption of the TRIPS
Agreement that Article 28 grants patent holders the right to “prevent third parties
from making, using, offering for sale, selling or importing” a product and thus it
56Id., at 8-9 (noting that “[this argument is based on the premise that higher levels of income will
lead to increased investments in R&D . . . [but] originator companies on average invest about 15%
of their gross income on R&D.]” Instead, it is noted that “[t]he industry spends a substantially
higher percentage of income on advertising, promotion and administration. Much of the advertising
and promotion costs are spent on “lifestyle” drugs such as Viagra. Considerable R&D spending is
directed to lifestyle products and minor variations on existing therapies (so-called “me too”
drugs).”).
57United Nations Interregional Crime and Justice Research Institute, Counterfeit Medicines and
Organised Crime (2012).
58Abbott (2007), pp. 9–10.
59See Ho (2011), p. 91.
60But see Kanavos and Costa-i-Font (2005), pp. 772–775; Ganslandt and Maskus (2004), p. 1035.
61Abbott (2007), pp. 9–10.
62See Musungu and Cecilia (2006).
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limits the application of Article 6.63 This argument was rebuked, however, and a
footnote in Article 28 confirms explicitly that the provision of Article 28 is subject to
Article 6.64 This point was further addressed by the Declaration on the TRIPS
Agreement and Public Health at the WTO Ministerial Conference held in Doha in
2001.65 The Doha Declaration focused on accessed to health and reinforced the right
of WTO members to take measures to protect public health, including issuing
compulsory licenses. In particular, paragraph 5(d) of the Doha Declaration clarified
that countries can adopt international exhaustion to allow the parallel importation of
lower-priced medicines for public health purposes under Article 6 of the TRIPS
Agreement and this cannot be challenged under the WTO dispute settlement
system.66
One controversial point remained after the Doha Declaration: whether pharma-
ceuticals produced under compulsory licences could be imported into foreign coun-
tries. These imports may represent the only option for access to medicines for some
of the LDCs, which cannot effectively avail themselves of compulsory licensing for
lack of manufacturing capacity. In fact, most LDCs are still not obliged to implement
pharmaceutical patents and clinical trial data protection, as the TRIPS Council
agreed in 2015 to extend the waiver, which was set to expire on January 1, 2016,
until 2033.67 Hence, manufacturing capacity is the highest barrier in these countries.
However, Article 31(f) of the TRIPS Agreement does not explicitly allow parallel
imports of compulsory licensed medicines. Instead, the provision allows compulsory
63TRIPS, supra note 13, Art. 28. See Bale Jr (1999), pp. 641–648. See also Kodak SA v Jumbo-
Markt AG, 4C. 24/1999/rnd, Dec. 7, 1999 (the Swiss Federal Supreme Court stated that: “Article
28 of the TRIPS Agreement gives the patent holder the right to prevent third parties from selling and
importing patented products”.).
64TRIPS, supra note 13, Art. 28 fn 6 (“this right [i.e. the right of importation], like all other rights
conferred under this Agreement in respect of the use, sale, importation or other distribution of
goods, is subject to the provisions of Article 6.”). De Carvalho (2010), p. 173.
65See Abbott (2002), p. 469. For a detailed review of the TRIPS Agreement and public health, see
Musungu (2016), p. 489. See also t’Hoen (2002), p. 27; Coriat and Orsenigo (2014); Velásquez
et al. (2020).
66Declaration on the TRIPS Agreement and Public Health (14 November 2001), Doc. WT/ MIN
(01)/DEC/2 (20 Nov. 2001) (“5(d)The effect of the provisions in the TRIPS Agreement that are
relevant to the exhaustion of intellectual property rights is to leave each Member free to establish its
own regime for such exhaustion without challenge, subject to the MFN and national treatment
provisions of Articles 3 and 4.”).
67Council for TRIPS, Extension of the Transitional Period Under Article 66.1 of the TRIPS
Agreement for Least Developed Country Members for Certain Obligations With Respect to
Pharmaceutical Products, IP/C/73 (Nov. 6, 2015). See also Daniel Benoliel & Timothy John
Chirwa, The Impact of Pharmaceutical Patents on Health Expenditures in Least-Developed
Countries, unpublished paper available at http://law.haifa.ac.il/images/Publications/
BenolielChirwa.pdf (comparing LDCs in OAPI with other LDCs and noting that patents are not a
primary obstacle to access to medicines in LDCs, as opposed to several other factors such as:
rational selection and use of drugs, affordable prices, unsustainable and inadequate funding, and
Reliable health and supply systems).
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licencing to be granted “predominantly” for the domestic market.68 Finally, in 2003,
WTO members agreed to facilitate LDCs to import medicines made under compul-
sory licensing if they are unable to manufacture the medicines themselves. This
resulted in the adoption of Article 31bis of the TRIPS Agreement in 2005.69 The
provision became effective in January 2017, after a sufficient number of countries
ratified the provision,70 even though the provision has not been invoked by any
LDCs in the context of parallel imports of compulsory licensed pharmaceuticals
to date.
3 National Solutions to Patent Exhaustion and Parallel
Trade of Pharmaceuticals
Because of the flexibility of Article 6 of the TRIPS Agreement, countries worldwide
can decide their national policy on patent exhaustion autonomously between
national, international, or regional exhaustion. Some countries also apply a differ-
entiated approach to the exhaustion of pharmaceuticals. In the following Section, I
review the domestic policies of selected countries in various continents.71 This
information is necessarily limited due to the impossibility to comprehensively
address all countries’ policies in this Chapter. In addition, as mentioned above, the
analysis does not extend to the national requirements each country applies regarding
the regulatory schemes for the marketing approval and import authorization for the
parallel imports of pharmaceuticals, which again remain a fundamental aspect of
imports of medicines (both by originator companies and parallel importers).
3.1 Selected Jurisdictions in Asia
Several countries in Asia72 follow a regime of international exhaustion related to
patent rights. This choice can be explained by the fact that several countries in Asia
are still developing countries or LDCs. For example, the two largest countries in
Asia, India and China, both practice international patent exhaustion. India’s
68TRIPS Agreement, supra note 13, Art. 31(f).
69Id., Art. 31bis. See Abbott (2005), p. 317; Abbott and Reichman (2007), p. 921.
70Zaheer Abbas and Riaz (2017), p. 451.
71For detailed overview in this respect, see World Intellectual Property Organization, Standard
Committee on Patents Electronic Forum, Questionnaire on Exceptions and Limitations of Patent
Rights, the database administered by the WIPO’s Standing Committee on Patents https://www.
wipo.int/scp/en/exceptions/ [hereinafter WIPO, Questionnaire on Patent Exceptions].
72Even if partially outdate now, a relevant resource for Asia is still Parallel Imports in Asia (Heath
2004).
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approach is based on Section 107A of the Indian Patent Act, as amended in 2002,
which provides that “[f]or the purpose of this Act, (b) importation of patented
products by any person from a person who is duly authorized under the law to
produce and sell or distribute the product, shall not be considered as an infringement
of patent rights”.73 In China, Article 69 of the Chinese Patent Law provides that the
following shall not be deemed to be patent right infringement “(1) after a patented
product or a product directly obtained by using the patented method is sold by the
patentee or sold by any unit or individual with the permission of the patentee, any
other person uses, offers to sell, sells or imports that product.”74 Previously, under
the rule of the Patent Law of China of 1985, the applicable rule was national patent
exhaustion. This was changed, however, with the entry into force of new 2008 Patent
Law, which provides for international patent exhaustion.75
Out of the ten members of the Association of South East Asian Nations
(ASEAN),76 three countries also practice international exhaustion. In particular,
Cambodia follows international patent exhaustion under its Law on the Patents,
Utility Model Certificates and Industrial Designs,77 even though Cambodia does not
currently provide patent protection for pharmaceuticals under the TRIPS Council’s
waiver for LDCs. International exhaustion is also adopted under the Patents Act of
Malaysia78 and the Intellectual Property Law of Vietnam.79 Other ASEAN coun-
tries, such as Brunei,80 Lao PDR81 (also an LDC), and Thailand82 do not have a
specific rule on patent exhaustion. In these countries, whether the parallel importa-
tion of genuine products sold overseas with the proprietors’ consent constituted
infringement may depend on the contents of the contracts signed between the parties
concerned. In Myanmar, a new Patent Law has been adopted in 2019, which is
currently pending for approval, even though it remains unclear how the principle of
73Patents (Amendment) Act, 2002, No. 38, Acts of Parliament, 2002 (India). See also Ghosh and
Calboli (2018), pp. 108–109; Pai (2016), pp. 324, 327; Gopalakrishnan and Agitha (2012), p. 229;
Basheer and Kochupillai (2009), p. 63.
74Patent Law of the People’s Republic of China (promulgated by the Standing Comm. Nat’l
People’s Cong., Dec. 27, 2008, effective Oct. 1, 2009) CN028 (China). See also Yu (2004),
pp. 25–38.
75See Yu and Yin (2016), pp. 308, 311. See also Ghosh and Calboli (2018), p. 109.
76For a discussion on ASEAN, including the principle of exhaustion and free movement, seeCalboli
(2019b), pp. 363–391.
77Law on Patents, Utility Models and Industrial Designs, Art. 44 (Cambodia).
78Patents Act 1983, as amended by the Patents (Amendment) Act 2006, § 58A (Malay.).
79Law on Intellectual Property (No. 50/2005/QH11 of Nov. 29, 2005), art. 125(2)(b) (Viet.).
80Constitution of Brunei Darussalam, Patents Order, Art. 83(3) (2011) (Brunei).
81Lao People’s Democratic Republic Intellectual Property Laws (Law No. 01/NA of 20 Dec. 2011)
(Lao PDR) [hereinafter Lao PDR Law].
82Patent Act B.E. 2522, as amended by the Patent Act (No. 2) B.E. 2535 and the Patent Act (No. 3)
B.E. 2542 (Thai.).
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patent exhaustion is addressed in the new law. Myanmar can also be exempted from
implementing patent protection for pharmaceuticals until 2033 (as an LDC).83
Other Asian countries follow a hybrid system. In particular, the 2016 Patent Law
of Indonesia84 grants patent owners the exclusive right to prohibit other parties from
“importing” the patented products or the products derived from the patented prod-
ucts.85 Yet, this provision does not apply, explicitly, to the imports of patented
pharmaceuticals that have been lawfully marketed outside Indonesia and have been
imported into Indonesia by third parties.86 Similarly, the Philippine Intellectual
Property Code87 includes the right to oppose unauthorized imports,88 but again
this provision does not apply to the imports of pharmaceuticals.89 Singapore also
follows a hybrid approach, but opposite to the approach adopted by Indonesia and
the Philippines. Notably, Singapore does not allow imports of patented pharmaceu-
ticals if the products have not been previously sold or distributed in Singapore by the
patent owner or with her consent.90 After the products have been marketed in
Singapore by the originator companies, then parallel imports are theoretically
allowed. However, also after the first released in the Singaporean market by the
patent holders, imports can still be blocked when the pharmaceuticals have been
parallel imported because of a breach in the contract between the patent holder and
her licensees, including outside Singapore.91 As parallel imports are often the results
of genuine products diverted from their original distributors into the distribution
channels of parallel importers, this principle effectively nullifies the possibility to
parallel imports pharmaceuticals into Singapore. This principle was introduced after
the US-Singapore trade agreement. On the other side, Singapore practices interna-
tional patent exhaustion for all other products.92
The remaining largest economies in Asia, Japan and Korea, do not have a specific
statutory policy on patent exhaustion, and their respective case law has led to
diverging position. In Japan, courts have largely recognized international patent
exhaustion.93 In particular, the Supreme Court stated that enforcing Japanese patents
would not be consistent with international trade, even though the Court did not
83At this time, the author could not locate the pending draft of the 2019 Patent Law (Myanmar), as
the draft is not published not available in any known database.
84Law of the Republic of Indonesia No. 13 of July 28, 2016, on Patents (Indon).
85Id. at art. 19(1)-(2) and art. 160.
86Id. at art. 167. This exception is based directly on the need to “to ensure a reasonable price and
satisfy the justice of a pharmaceutical product is necessary for human health.” Id. at Explanation to
art. 167.
87Intellectual Property Code, Rep. Act 8293, as amended by Rep. Act 10372 (Phil).
88Id. at § 72.
89Id.
90Patents Act (Ch. 221, 2005 Rev. Ed.) § 66(3)(a) (Sing.).
91Id. at §§ 66(3)(b) & (c).
92Id. at § 66(2)(g).
93Heath (2004), p. 51.
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directly acknowledge that Japan practices international exhaustion. The Court rec-
ognized the patent owner could prohibit the importation of goods through contrac-
tual restrictions and by indicating on the product that the patented item is not
intended for sale in Japan.94 In Korea, the Patent Act also does not elaborate on
the issue of patent exhaustion and judicial decisions led to an opposite interpreta-
tion—national exhaustion. This position makes of Korea one of the few Asian
countries choosing national patent exhaustion and it probably consistent with the
level of technological development of the country95 (even though the same could be
said for Japan). However, in 1981, precisely in a case related to the imports of Italian
pharmaceuticals from Switzerland into Korea, the Seoul District Court said the
foreign sale had also exhausted the rights in Korea.96 Still, the court fell short of
explaining the reasoning for the decision in that case and no later case confirmed nor
denied this position. It thus remains unclear if this decision changed the general view
in favor of national patent exhaustion in Korea, or if it could be supported that also
Korea decided through caselaw to follow a differentiated regime for the exhaustion
of pharmaceuticals (international) versus other patented products (national).97
3.2 Canada, United States, Australia, and New Zealand
Today, international patent exhaustion is the system of choice also in Canada and the
U.S., based on judicial precedents.98 Specifically in Canada, in the 1998 decision in
Eli Lilly & Co v Novopharm Ltd., the Supreme Court confirmed that, when a
patentee sells a patented product, the rights of the products exhaust as long as the
seller did not impose any restrictions on the subsequent distribution.99 Thus, the key
inquiry in Canada is today not where the goods were first sold, whether in or outside
Canada, but whether the products were sold with or without restrictions.100
The U.S. follows a very similar position. Notably, the traditional interpretation on
patent exhaustion was recently changed in favor of international exhaustion by the
2017 Supreme Court decision Impression Products v. Lexmark.101 Like in several
other countries, the U.S. Patent Act does not elaborate on the geographical extent of
the exhaustion of a patented product, or a product embodying patented process, after
94Id. at. 52–58.
95Byung-Il (2004), p. 73.
96Id. at 76–77 (citing the decision of the Seoul District Court in the case Ildong Pharmacie
v. Farmatalia Carlo Erba S.p.A., Mar. 14, 1981).
97Id. at 77.
98See Calboli, Comparing IP Exhaustion, supra note 22, at 32.
99Eli Lilly & Co. v. Novopharm Ltd., [1998] 2 S.C.R. 129.
100Id.
101Impression Prods., Inc. v. Lexmark Int’l, Inc., 581 U.S. 1523 (2017). See Ghosh and Calboli
(2018), pp. 88–102.
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the first sale of the products. In the past decades, several decisions by U.S. courts
adopted the position that the sale of an article in a foreign country does not exhaust
the U.S. patent.102 In its February 2016 decision in the Lexmark case, the U.S. Court
of Appeals for the Federal Circuit repeated this position. However, to the disbelief of
many in the U.S., the Supreme Court reversed and stated that the first sale of
products anywhere in the world exhausted the rights also in the U.S. Still, the
Court did not exclude that contractual restrictions could prevent the import of gray
market goods after the decision in Lexmark.103 Thus, also in the U.S., the key inquiry
may still be whether the products were sold with or without restrictions. Moreover,
regardless of the change in national policy, the imports of pharmaceuticals remain
subjects to the US regulatory schemes and the impact of Lexmark on these imports
is, in practice, non-existing.
On the other side, Australia follows a less trade friendly national policy and
favors national patent exhaustion. Also in Australia, however, the Patents Act does
not specifically address the issue.104 Notably, the Patent Act states that patent
holders have exclusive rights to exploit their inventions in Australia.105 The defini-
tion of “exploitation” is provided in the Patent Act and includes importation, similar
to the TRIPS Agreement and other national laws.106 This leads to the interpretation
that Australia practices national exhaustion. Patent law in Australia is also
constrained by the obligations under the Australia–United States trade agreement,
whose Article 17.9.4 states that “Each Party shall provide that the exclusive right of
the patent owner to prevent importation of a patented product, or a product that
results from a patented process, without the consent of the patent owner shall not be
limited by the sale or distribution of that product outside its territory, at least where
the patentee has placed restrictions on importation by contract or other means.”107
Similarly to Australia, also New Zealand does not allow parallel importation of
patented products.108 Here again, we have a hybrid system, however, as the Crown
has the authority to order parallel importation of pharmaceuticals under the Medi-
cines Act of 1981, notwithstanding the Patents Act.109 Of course, provided that the
products are in line with the requirements imposed under the country’s regulatory
schemes and import authorizations.
102See Ghosh and Calboli (2018), at 88-102 (citing Boesch v. Graff, 133 U.S. 697 (1890); Jazz
Photo Corp. v. Int’l Trade Comm’n, 264 F.3d 1094 (Fed. Cir. 2001); Lexmark Int'l,
Inc. v. Impression Prods. Inc., 816 F.3d 721, 771 (Fed. Cir. 2016)).
103Impression Products, Inc. v. Lexmark Int’l, Inc., 581 U.S. 1523 (2017).
104See Ghosh and Calboli (2018), pp. 107–108.
105Patents Act 1990 s 13 (Austl.).
106Id. at Schedule 1 (Austl.).
107Free Trade Agreement, U.S.-Austl., May 18, 2004, art. 17.9.4.
108See Ghosh and Calboli (2018), pp. 107–108; Susy Frankel, Test Tubes for Global Intellectual
Property Issues: Small Market Economies 178 (2015).
109Frankel, supra note 108, at 178 (citing Section 32A of the Medicines Act 1981, introduced by
the Medicines Amendment Act 1989). See also Patents Act, pt 2 (N.Z.).
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3.3 Selected Jurisdictions in Latin America
Like in Asia, most countries in Latin America follow the principle of international
patent exhaustion. There are important exceptions, however, to this rule.
The first exception is Mexico, which is surprising as both its partner members in
the North American Free Trade Agreement (NAFTA), Canada and the U.S., follow
now international patent exhaustion. Instead, Mexico practices national exhaustion.
Also, in Mexico, no specific language related to the exhaustion of patent rights is
found under the Mexican law. The Mexican Industrial Property Law clarifies,
however, that the rights conferred by a patent cannot be asserted against “any person
who markets, acquires or uses the patented product or the product obtained by means
of the patented process, after said product has been lawfully placed on the mar-
ket.”110 In the absence of a provision stating the opposite, the majoritarian interpre-
tation of the wording “the market” is that it only includes “national market.”111
National patent exhaustion is also the system adopted in Brazil. This position is
particularly perplexing in light of Brazil’s role in the parallel importation of phar-
maceuticals in the 1990s. Notably, Article 43 of Law 9.279 of 1996 provides
national exhaustion for patent and trademark rights regarding products
“manufactured in accordance with a process or product patent that has been placed
on the internal market directly by the patent holder or with his consent.”112 However,
under Article 68(4) of the same law, if the exploitation of the patent (and use of the
trademark) is made through importation of the product—that is, in the case where the
products are not manufactured in Brazil, third parties are allowed to import these
products after they have put them into the “market”, which is interpreted in this
instance as anywhere in the world.113 Accordingly, in this case, parallel imports are
admitted in Brazil.114
On the other side, Chile follows a system of international patent exhaustion as per
Article 49(5) of Law No. 19.039, according to which a “patent shall not confer the
right to prevent third parties from marketing the patent protected product, which
such parties have acquired lawfully after that product has been lawfully introduced
into the market of any country by the right owner or by a third party with the owner’s
110Mexican Industrial Property Law, art. 22. Ley de la Propiedad Industrial, Diario Oficial de la
Federación [D.O.F.] 27-06-1991, amended by D.O.F. 02-08-1994 (Mex.).
111See Correa and Correa (2016), p. 206.
112Lei No. 9.279, de 14 de Mayo de 1996, art. 43(4) (Braz.) [hereinafter Brazilian IP Law].
113Id., at art. 68(4). See also Correa and Correa (2016), p. 206.
114This provision finds its origin of the requirement of “local manufacture obligation” for patent
holders that was originally provided under Brazilian law. As this requirement could have been
challenged as incompatible with Article 27(1) of the TRIPS Agreement, the 1996 Law abolished the
rule. Yet, Article 68(1), under the rubric “Compulsory Licensing,” provides that the following can
grant a decision of issuing compulsory licensing: “I. failure to work the subject matter of a patent on
the territory of Brazil, failure to manufacture or incomplete manufacture of the product or failure to
completely use a patented process, except for failure to work due to lack of economic viability, in
which case importing shall be admitted. Brazilian IP Law, supra note 112, at art. 68(1).
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consent.”115 As reported, legislative debates found this solution necessary “to
provide a balance between the . . . right holders and . . . the citizens”116 Argentina
also adopts international exhaustion, according to Article 36(c) of Law No. 24.481
(consolidated text, 1996) on Patents and Utility Models and subsequent amendments
“The right conferred by a patent shall not have any effect against: (c) Anyone
acquiring, using, importing or in any way marketing the patented product or the
product obtained by means of the patented process, after said product has been
lawfully placed on the market in any country.”117
The four members of the Andean Community—Bolivia, Ecuador, Colombia, and
Peru—also practice international exhaustion.118 Article 54 of Decision 486 of the
Commission of the Andean Community establishes that the patent shall not confer
the right “to proceed against a third party making commercial use of a product
protected by a patent once that product has been introduced into the commerce of
any country by the owner or another person authorized by the right holder or with
economic ties to that patent owner.”119 Notwithstanding, the imports of these
products can be further restricted by national laws providing for the import autho-
rizations and other formalities.
3.4 European Union and Switzerland
Free movement of goods, including of pharmaceuticals, is allowed in the EU/EEA
under the rule of regional exhaustion. Articles 34 and 36 of the Treaty on the
Functioning of the European Union (TFEU)—originally then the Treaty
Establishing the European Economic Community (EEC Treaty)—are the applicable
provisions to the exhaustion of patented goods within the EU. Notably, the distri-
bution of a patented good by the consent of the patent owner into the market of any
EU Member State exhausts the rights of distribution within the EU.120 Exhaustion
does not apply, however, if the product is a patented pharmaceutical manufactured
115Law No. 19.039 on Industrial Property of 1991, art. 49(5) (Chile). This provision has not been
modified in the various amendment and updates of Law 19.039 that have been adopted since 1991.
116World Intellectual Property Organization, Standard Committee on Patents Electronic Forum,
Questionnaire on Exceptions and Limitations of Patent Rights, Chile, Exhaustion of Rights, https://
www.wipo.int/scp/en/exceptions/replies/chile.html#Q8.
117Law No. 24.481, Oct. 23, 1995, art. 36(c), [LV-C] A.D.L.A. 2948 (as amended by Law
No. 24.572 [LV-E] A.D.L.A. 5892 (Arg.) [hereinafter Argentine Patent Law]. See also Correa
and Correa (2016), p. 202.
118Decision No. 486 Establishing the Common Industrial Property Regime, Sept. 14, 2000, art.
54, WIPO CAN012, https://wipolex.wipo.int/en/text/223717 (Andean Community).
119Id.
120See Stothers (2007); Case15/74, Centrafarm v. Sterling Drugs, [1974] E.C.R. 1147; Case
187/80, Merck & Co. v. Stephar, [1981] E.C.R. 2063.
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for the purpose of marketing approval rather than for commercialization.121 Articles
34 and 36 also apply regardless of possible contractual limitations against further
distribution of patented products. In particular, these limitations may be in conflict
with Article 34 if they restrict or prevent importation into and distribution in another
Member State.
An additional exception to the principle of free movement is found in the Act of
Accession 2003122 of new members from Eastern Europe, which provides that IP
holders can rely on the “Specific Mechanism” and prevent the import and marketing
of pharmaceuticals from new EU Member States into other EU Members States in
which they have protection.123 The reason for this exception was because patent
protection and supplementary protection certificate (SPC) for pharmaceuticals was
implemented later in time in these countries and at the time of accessions, several
drugs were patented in the Western EU Member States but could no longer be
patented in these countries. The “Specific Mechanism” additionally provides
importers should demonstrate to the authorities in charge of issuing the permission
to import they have notified the patent or SPC holder no less than a month earlier.124
In 2005, the “Specific Mechanism”was later extended to Bulgaria and Romania, and
in 2012 to Croatia.125
The only case in this area, Merck v. Sigma,126 confirmed nonetheless a
pro-exhaustion stance by the CJEU’s interpretation of the provision. In particular,
even though the Court accepted the Specific Mechanism provides for a specific
derogation to the principle of free movement, it also stated that importers do not have
“an obligation to obtain the express prior consent” from the rights holders.127
Instead, rights holders have one month to oppose the imports and if they do not
“take advantage of that period,” importers “may legitimately apply to the competent
authorities for authorisation to import the product and, where appropriate, import
121Case C-316/95, Generics v. Smith Kline & French Laboratories, [1997] E.C.R. I-3929.
122Act of Accession of Cyprus, the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta,
Poland, Slovenia and Slovakia, Apr. 16, 2003, 2003 O.J. (L236) 33 [hereinafter Specific Mecha-
nism]. See Heath (2014b), p. 399; Stothers (2016), pp. 169, 178.
123Specific Mechanism, supra note 122.
124Id. Critically, in general, over this type of differentiated systems, see Jerome Reichman, Ruth
Okediji, Ioannis Lianos, Robin Jacob, Christopher Stothers, The WTO Compatibility of a Differ-
entiated International Exhaustion Regime Proposed by the Eurasian Economic Community, A
Consultancy Report, Research Paper Series, Skolkovo-HSE International Laboratory for Law &
Development (on file with author).
125Act of Accession of Bulgaria and Romania, 2005 O.J. (L157) 203, Annex V.1; Act of Accession
of Croatia 2012 O.J. (L112) 21, Annex IV.1.
126Case C-539/13, Merck Canada Inc. v. Sigma Pharmaceuticals plc, [2015] R.P.C. 30. The
importer provided advanced notification to Merck of its intention to import pharmaceuticals from
Poland, where protection did not apply. Merck did not respond and the products were imported into
the U.K. Merck objected and parallel imports were blocked. When Merck also sought damages, the
issue was referred to the CJEU. See Stothers (2016), at 179.
127Case C-539/13, Merck Canada, ¶ 28.
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and market it.”128 This should not be read as the rights holders have “forfeited the
right to rely on the Specific Mechanism.”129 They simply cannot “obtain compen-
sation for the loss” due to the imports “which he failed to oppose” in time,130 but
remain “free to oppose future importation and marketing of the pharmaceutical
product protected by the patent or SPC.”131
Not an EU Member State, Switzerland’s example is worth noting as part of the
European region. Until 2008, Swiss law applied national exhaustion to patents. The
rule was then changed in favour of regional patent exhaustion and Switzerland now
practices regional exhaustion with the countries members of the EU/EEA.132 How-
ever, pharmaceuticals are still subject to national patent exhaustion in Switzerland,
and parallel imports of pharmaceuticals first put into the market in a foreign country,
including in the EU/EEA, cannot enter into the country. To be precise, Article 9
(a) paragraph 5 indicates that the principle of regional exhaustion does not apply and
the consent of the holder of the patent of a product “is reserved” in the instances in
which the price the product “in Switzerland or in the country in which they are
placed” has been “fixed by the state.”133 This principle applies directly to prescrip-
tion pharmaceuticals and all the medicines that are subjected to price control by
national government. However, in the law, this principle is not directly referred to
pharmaceuticals, but to all patented products that could be subject to price control.
3.5 Selected Jurisdictions in Africa
Access to medicines is a priority for most countries in Africa, the continent with the
largest number of LDCs worldwide,134 all of which are users of pharmaceuticals
coming from foreign countries.135 National practice on patent exhaustion varies
128Id. at ¶ 31.
129Id. at ¶ 32.
130Id.
131Id.
132Federal Act on Patents for Inventions (SR 232.14 LBI) art. 9a (inserted by No I of the Federal
Act of June 22, 2007 (AS 2551 (2009); BBl 1 (2006)), as amended by No I of the Federal Act of
Dec. 19, 2008, in force since July 1, 2009 (AS 2615 (2009); BBl 303 (2008)) (Switz.).
133Id. at art. 9a, ¶ 5 LBI (“Irrespective of the provisions of paragraphs 1–4, the consent of the
proprietor of the patent for the placing on the market of patent-protected goods is reserved if their
price in Switzerland or in the country in which they are placed on the market is fixed by the state.”).
See also Kyle (2009), p. 339, 345 (noting that, on the other side, “Switzerland treats copyrights and
trademarks as internationally exhausted.”).
134See United Nations, Committee for Development, List of Least Developed Countries, https://
www.un.org/development/desa/dpad/wp-content/uploads/sites/45/publication/ldc_list.pdf (listing
the 47 countries currently categorized as LDCs).
135Vawda and Shozi (2020); dos Santos and Lowé Gnintedem (2018), pp. 592, 593–594; Ncube
(2016), p. 110.
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across countries in the continent, however, with some countries practicing interna-
tional exhaustion, while others national or regional exhaustion. The laws of several
countries also remain silent on the issue.136
For example, the following countries do not seem to have a clear position on the
issue as of today: Congo, Egypt, Nigeria, Swaziland, Angola, Lesotho, and
Malawi.137 South Africa’s position is also unclear, even though several commenta-
tors support it following international exhaustion. In the late 1990s, South Africa
implemented regulations authorizing parallel importation of medicines protected by
patents and trademarks,138 but the South African Patents Act remains unclear as to
whether the doctrine of exhaustion of rights applies nationally or internationally.139
Well-known by experts in this area, South Africa wanted to authorize parallel
importation of retroviral pharmaceuticals for AIDS in the 1990s.140 It was precisely
in this occasion that patent holders argued that international exhaustion was pre-
cluded by Article 28 of the TRIPS Agreement.141 The case was eventually dropped,
but the ensuing criticism led to the adoption of the Doha Declaration.142
International patent exhaustion is instead directly adopted in the law of several
countries in Africa. These countries include Ghana, which changed its previous
regime of national patent exhaustion with the revision of the Patent Act in 2003,
whose Section 11(4)(a) now states that “[t]he rights conferred under the patent shall
not extend to acts in respect of articles which have been put on the market in any
country by the owner of the patent or with the owner's consent.”143 Similarly, Article
43(1) of the 2012 Industrial Property Act of Namibia provides that “[t]he following
acts do not constitute an infringement of the rights under a patent, namely: a) acts of
importation of patented inventions which have been put on the market in any
territory or country by the owner of the patent or with his or her authorization.”144
Kenya also explicitly permits the parallel imports of patented pharmaceuticals under
the Industrial Property Act 2001, replacing the Industrial Property Act 1989, which
prohibited parallel imports. Notably, Article 58(2) now recites, “[t]he rights under
the patent shall not extend to acts in respect of articles which have been put on the
market in Kenya or in any other country or imported into Kenya.”145 Additional
136Id. at 31–32. In general, see also McKeith (2013), p. 287.
137SeeWIPO, Questionnaire on Patent Exceptions (in which the respective countries may indicated
that there is no clear national position of the issue).
138Abbott (2016), pp. 146–147.
139Id.
140See (Tayler 2004, p. 117).
141See supra Section 1.2.
142Id.
143Patents Act No. 657 (2003), § 11(4)(a) (Ghana). Vawda and Shozi (2020), p. 32.
144Industrial Property Act No. 1 (2012), § 42(1)(a) (Namibia). Vawda and Shozi (2020), p. 32.
145Industrial Property Act No. 3 (2001), § 58(2), as amended up to Act No. 11 (2017) (Kenya).
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countries that explicitly follow international patent exhaustion are: Botswana,146
Burundi,147 Liberia,148 Seychelles,149 Sierra Leone,150 Zambia,151 Zanzibar,152 and
Zimbabwe.153
To the contrary, the following countries provide for national exhaustion: Mada-
gascar, Mozambique, Rwanda, Sao Tome and Principe, South Sudan, and
Uganda.154 This choice is, at best, puzzling as all the countries in this list are
LDCs.155 Even though these countries may not protect pharmaceuticals with patents
at this time because of the TRIPS Council’s waiver—thus the impact of a national
exhaustion regime ultimately does not affect imports of pharmaceuticals—this
system can affect parallel imports of other products currently patented in these
countries. Moreover, a system of national exhaustion may protect the business
interests of the foreign patent holders more than the national interests, as most
patents are filed by foreigners in the countries in question.156 Another country
practicing national exhaustion is Morocco under Article 55(d) of the Patent Law
of 2000.157 The provision was repeated in the US-Morocco FTA in 2004,158 in
which both the U.S. and Morocco subscribed to this position. As the U.S. later
changed its national rule to international patent exhaustion,159 Morocco could also
consider a change in policy for public health reasons.
Finally, regional exhaustion is the system practiced by the seventeen members of
the Organisation Africaine de la Propriété Intellectuelle (OAPI): Benin, Burkina
Faso, Cameroon, Central African Republic, Chad, Comoros, Congo, Côte d’Ivoire,
Gabon, Guinea, Equatorial Guinea, Mali, Mauritania, Niger, Guinea Bissau, Sene-
gal, and Togo. Its seat is in Yaoundé, Cameroon. In particular, OAPI operates a
146Industrial Property Act No. 8 (2010), § 25(1)(a) 2010 (Botswana). Vawda and Shozi (2020),
p. 32 (recounting that Botswana utilized this flexibility when it declared HIV/AIDS a national
emergency in 2000 and began importing cheaper ARV drugs).
147Industrial Property Law No. 1 (2009), art. 57 (Burundi).
148Liberia Intellectual Property Act, § 13.11(b) (2016) (Liberia).
149The Patents and Industrial Design Act, § 19 (2012) (Seychelles).
150Patents and Industrial Design Act, § 23(1)(a) (2012) (Sierra Leone).
151Patents Act No. 40 (2016) § 76 (Zam).
152Industrial Property Act No. 4 (2008) § 11(4)(a)(i) (Zanzibar).
153Patents Act [Chapter 26:03], § 24A (amended by Act 9 of 2002) (Zimbabwe).
154Vawda and Shozi (2020), p. 32.
155See United Nations, supra note 134.
156See Graff and Pardey (2019) (for a survey of patent filing by foreigner and local inventors in
Africa).
157Law No. 17-97 on the Protection of Industrial Property, art. 55 (Morocco).
158United States-Morocco Free Trade Agreement, 15 June 2004, 44 I.L.M. 544, art. 15.9 (“4. Each
Party shall provide that the exclusive right of the patent owner to prevent importation of a patented
product, or a product that results from patented process, without the consent of the patent owner
shall not be limited by the sale or distribution of that product outside its territory”).
159Impression Prods., Inc. v. Lexmark Int’l, Inc., 581 U.S. 1523 (2017). See Ghosh and Calboli
(2018), pp. 88–102.
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unitary system for patents and OAPI member states do not have individual national
laws. The Revised Bangui Agreement of February 1999 is the applicable patent law
for all member states.160 Article 8(1)(a) of Annex I provides that “The rights deriving
from the patent shall not extend: (a) to acts in relation to subject matter brought on to
the market on the territory of a member State by the owner of the patent or with his
consent.”161 It should be noted, however, that even though thirteen of OAPI
members states (excluding Cameroon, Congo, Côte d’Ivoire, and Gabon) are
LDCs, the rights granted under the Bangui Agreement include pharmaceutical
patents (as per Article 27 of the TRIPS Agreement).162 Accordingly, LDCs in
OAPI are de facto excluded from taking advantage of the existing TRIPS Council’s
waiver for patent protection for pharmaceuticals.163 Moreover, these countries are
bound by a system of regional exhaustion and not international exhaustion, whereas
international exhaustion could likely a more favorable approach for all OAPI
member states.164
4 Overlapping Intellectual Property Rights and Parallel
Trade of Pharmaceuticals
In addition to patents, other IP rights can affect parallel trade, even when countries
practice international patent exhaustion. This situation can arise when countries
practice national exhaustion for trademark, copyright, or design rights.165 In general,
overlapping IP rights can apply to a product in its entirety or to different parts or
features of it.166 An example of the former is the overlapping trademark and
copyright protection that can apply to the shape of a perfume bottle, the décor of a
store, or the pictorial logo affixed to the packaging of consumer products, including
pharmaceuticals.167 An example of the latter is the cumulation of patent, trademark,
and copyright protection that can cumulate on a pharmaceutical, the first protecting
the compound/product and/or process of making the compound, the second
protecting the shape and/or color of the pill made with the patented compound and
160Bangui Agreement, supra note 23.
161Id. at Art. 8(1)(a). See also Kongolo (2000), p. 717.
162Bangui Agreement, supra note 23, art. 2.
163Deere (2008), p. 240.
164Vawda and Shozi (2020), pp. 32–33. In addition, the same regime of regional exhaustion applies
to trademarks, which may result in blocking, as possible trademark infringement, also trademarked
generic medicines from foreign countries. See Calboli and Visser (2020), p. 102.
165See Calboli, Avoidable Effects, supra note 3; Ginsburg and Calboli (2020), p. 434. In this
chapter, I do not focus on design rights, which nonetheless may remain a relevant area of
investigation, even this overlap may be less relevant, in practice, due to the limited duration of
design rights, which is generally comparable, or shorter in time than patents rights.
166Ginsburg and Calboli (2020), p. 434; Derclaye and Leistner (2011); Moffat (2004), p. 1473.
167Ginsburg and Calboli (2020), p. 434.
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through the patented process, and the third being the written instructions accompa-
nying the medicines’ packaging, or the decoration of the packaging itself.168 The
problematic effects of these overlaps and their application to parallel imports is
addressed in this Section.
4.1 Overview of Overlapping Rights and Enforcement
of Copyright to Parallel Imports
Overlapping IP protection can apply simultaneously or sequentially. In the first case,
two or more rights protect the same product at the same time. For example, a
pictorial logo or the shape or color of a product—be this product a chocolate, liquor,
or a pharmaceutical—can simultaneously enjoy trademark protection as distinctive
signs and possibly copyright protection as independent artistic works, in addition to
the protection the product may enjoy under patent or design law.169 Likewise, the
labels, instructions, and other literary parts of a products could be protected under
copyright in addition to the protection that the products enjoys under patent law.
Instead, in the second case, two or more types of protection apply to the same
product at different times. For instance, the patent or design granted on a product, or
copyright protection on its shape or logo, are set to be limited in time. Instead,
trademark protection on a product’s logo and possibly shape or color can continue
without time limits.170 Whether they are used simultaneously or sequentially,
overlapping rights can prolog and/or enhance the scope of protection of the inter-
ested products.
In the context of pharmaceuticals, overlapping protection is often sought for
different parts of the medicines or their packaging during or after patent protection.
For example, in addition to protecting the names of the pharmaceuticals as marks,
trademark registrations are often granted for the shape, colors, and other distinctive
features of the medicines.171 Similarly, logos and decorative or distinctive elements
168Id.
169Id. For a detailed list of examples, see Calboli (2014b), p. 52 [hereinafter Calboli, Overlapping
Rights]. For examples of overlapping protection between trademarks and patents, in particular
applied to pharmaceuticals, see the cases cited infra in Part IV.B. See also Calboli (2020),
p. [hereinafter Calboli, Trademark Protection for Medicines]. See also the contributions in
Overlapping Intellectual Property Rights (Neil Wilkof & Shamnad Basheer eds., 2012.
170Ginsburg and Calboli (2020), p. 434. For famous cases in the U.S., see Frederick Warne &
Co. v. Book Sales, Inc., 481 F. Supp. 1191, 1196 (S.D.N.Y. 1979); Walt Disney Prods. v. Air
Pirates, 581 F.2d 751 (9th Cir. 1978) (finding that both copyright and trademark permissible on
Disney comic book characters); Universal City Studios v. J.A.R. Sales, Inc., 216 U.S.P.Q. 679
(C.D. Cal. 1982) (discussing the protection of the “E.T.” motion picture character).
171For several relevant examples in the U.S., see U.S. Trademark Registration Nos. 2,593,407
(Pfizer Inc.; Viagra pill; diamond shape and color blue); 2,625,335 (Glaxo Group; Flovent HFA
inhaler; tethered cap, mouthpiece covering shape, edge shapes); 2,679,181 (Gilead Sciences, Inc.;
Viread pill; almond shape and color blue); 3,812,561 (Glaxo Group; Advair diskus inhaler; unique
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applied to the packaging, or the labels, product instructions, or similar features of the
pharmaceuticals could be protected as copyrighted works.172
The justification for overlapping IP rights rests on several elements: the broad
definition of protectable subject matter (the item to be protected and the individual
scope of protection of the type of products or individual product features); the lack of
a comprehensive normative system prohibiting the possibility to cumulate separate
types of IP protection in the same product, or different features of the same product;
and the lack of a comprehensive system prohibiting, as misuse or abuse of rights, the
enforcement of IP protection outside the traditional scope of protection.173 Even
though national variations subsist regarding the treatment of overlapping rights in
individual nations, overlapping IP protection is generally accepted.174 Some exclu-
sions apply regarding the protection of the functional elements and additional
protection under trademarks or copyright.175 Still, in most countries, there are no
round design, color purple, color white, and wave patterns); 5,018,105 (Gilead Sciences, Inc.;
Harvoni pill; diamond shape, light-orange color, and identification number); 5,018,106 (Gilead
Sciences, Inc.; Sovaldi pill; oval shape, light-yellow color, and identification number); 5,030,567
(Gilead Sciences, Inc.; Truvada pill: oblong shape, color blue, word engraving); 5,298,494 (Eli
Lilly and Co.; Olumiant pill; color light pink, oval/oblong shape, and word engraving); 5,435,196
(Teva Respiratory; AirDuo RespiClick inhaler; colors yellow and white); 5,614,245 (Glaxo Group;
Seretide evohaler; color purple Pantone Matching System 2587). See also Calboli, Trademark
Protection for Medicines, supra note 170.
172In the U.S., for example, the following are registered: U.S. Copyright Registration Nos.
TX0004141715 (Pfizer, Inc.; Zyrtec (certirizine Hydrochloride) tablets for oral use; copyright
registration for the product label); TX0004065039 (Abbott Laboratories; Advera, Specialized,
complete nutrition, clinically proven effective nutritional management; copyright registration for
the product label); TX0004068652 (Abbott Laboratories: Pedialyte oral electrolyte maintenance
solution; copyright registration for the product label); TX0004862188 (Novartis Crop Protection,
Inc.: AAtrex 4L herbicide : CGA 7L38BB 052 : 2/12 gallons, US standard measure: copyright
registration for the directions for use and conditions of sale and warranty); TX0001650844 (Merck
& Company, Inc.: Clinoril (selindac/ M S D:), copyright registration for the product information
summary); TX0001135773 (Merck & Company, Inc.: Cosmegen (dactinomycin, M S D),
actinomycin D, injection; copyright registration for the product label).
173See Calboli (2014b), p. 58.
174For example, in 2013, the United Kingdom eliminated the prohibition of cumulating copyright
and design protection. The Enterprise and Regulatory Reforms Act 2013 extended copyright
protection also to artistic works that have been reproduced more than 50 times. See Enterprise
and Regulatory Reforms Act 2013, § 74 (U.K.) http://www.legislation.gov.uk/ukpga/2013/24/
section/74/enacted.
175In the U.S., see TrafFix Devices v. Mktg. Displays, 532 U.S. 23, 32 (2001); see also McKenna
(2012), pp. 823, 824 (advocating for a broader application of the doctrine of functionality and
prohibiting overlaps). In the EU, see Case C-299/99, Philips v. Remington, 2002 E.C.R. I-05475,
ECLI:EU:C:2002:377; Case C-48/09, Lego Juris v. OHIM, 2010 E.C.R. I-08403, ECLI:EU:
C:2010:516; Case C-30/15, Simba Toys v. European Union Intellectual Property Office
(EUIPO), 2016 EUR-Lex-62014TJ0687, ECLI:EU:C:2016:849. See also the contributions in The
Protection of Non-Traditional Trademarks: Critical Perspectives (Irene Calboli &Martin Senftleben
eds., 2018).
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bright line rules also in this respect and the decision frequently falls with the
courts.176
To date, several national decision related to overlapping rights in the context of
parallel imports have focused on the mutual overlap between copyright or trademark
rights, the use of copyright for incidental product features,177 and the overlap
between patent and trademark rights.178 In the reminder of this section, I address
the overlap between copyright and trademarks and the use of copyright on incidental
feature, including the use copyright protection against generic pharmaceuticals. The
use of copyright in this context is particularly pernicious. Copyright protection
applies without the need of registration or other formalities across all members of
the Berne Convention for the Protection of Literary and Artistic Works, which
makes its enforcement with respect to pharmaceuticals both inexpensive and appli-
cable worldwide without the need to market the product in the countries where
protection is sought. Trademark protection is also useful, but is based on national
registration and/or national use. Moreover, marks are deemed abandoned after a few
years of non-use. Still, trademark protection’s primary advantage remains the poten-
tial for perpetual protection as trademarks can be renewed for an unlimited number
of times while copyright also expires.179
The overlap between trademark and copyright protection came to the attention of
the courts first in Australia, a country practicing international trademark exhaustion
but national copyright exhaustion.180 In 1986, however, this strategy went too far
when the parallel imports of liqueur bottles were stopped based on infringement of
the copyright in the labels affixed to the bottles.181 Considerable criticism followed
this decision, and in turn the Australian Parliament deliberated to introduce
Section 44C into the Copyright Act to prevent similar situations in the future. The
new provision specifically prohibits against invoking copyright protection (and
national copyright exhaustion) in the context of parallel imports. The provision
reads that “[t]he copyright in a work a copy of which is, or is on, or embodied in,
a non-infringing accessory to an article is not infringed by importing the accessory
with the article”182—“accessory” being defined as: labels, packaging, containers,
176Australia, Singapore, and other parts of the Commonwealth practice a demarcation between
copyright and design protection regarding artistic works that are reproduced in series. In particular,
creators generally lose copyright protection in artistic works when the works are industrially applied
(more than 50 copies of the work are made) or when the work is registered, or could be registered, as
a design (the owner must then rely on the Designs Act). See, e.g., Copyright Act 1968 (Cth) §§
75, 77, and 77A (Austl.); Singapore Copyright Act of 1987, §§ 69, 70, and 74 (2006) (Sing.).
177See Calboli (2014b).
178See infra discussion and cases cited in Part IV.B.
179Ginsburg and Calboli (2020), p. 434.
180See, e.g., Calboli and LaFrance (2013), p. 1.
181R A & A Bailey & Co. Ltd. v. Boccaccio Pty. Ltd. (1986) 6 IPR 279.
182Copyright Amendment Act (No. 1) 1998 (Cth.) [Austl.] (amending § 10(1) and adding
ss. 44C, 112C).
Intellectual Property Exhaustion and Parallel Imports of Pharmaceuticals:. . . 57
instructions, warranties, “or other information,” as well as instructional sound
recording or films, “provided with the article.”183
IP holders played a similar game in the U.S. and Canada, until the respective
Supreme Courts called it off. In the U.S., the 2013 decision in Kirtsaeng v. Wiley and
Sons184 clarified that the Copyright Act provides for a system of international
exhaustion. Previously, however, the majority of courts supported that the combined
reading of Section 109(a) and Section 602(a)(1) of the Copyright Act prescribed
national copyright exhaustion.185 Before Kirtsaeng, IP holders used copyright
protection to block parallel imports of otherwise legitimate products—famous
examples were shampoos bottles186 and sports watches.187 Similarly, Canada prac-
tices international trademark exhaustion and national copyright exhaustion.188 In
Euro-Excellence, Inc. v. Kraft Canada, Kraft sued an importer for copyright
infringement for the importation of chocolate bars.189 The Supreme Court found
the imports to be lawful, however, even though it reached its decision “on contrac-
tual grounds.”190 In 2013, Professor Mary LaFrance and I191 proposed a legislative
provision be implemented in the U.S. similar to the amendment approved in
Australia in order to prohibit the enforcement of a claim for copyright infringement
on “accessory copyright.”192 A revision of copyright law to this extent would
prevent misuses of copyright law to block the parallel imports of otherwise legiti-
mate products, in particular when the claim for copyright infringement refers to
accessories or nonessential parts of the products.193 Even though the US currently
applies international exhaustion both for patents and copyrights, a similar
183Id. In 2003, the Australian legislature expanded this list, and added that a “computer program,”
“electronic literary or music item,” or “sound recording” that is part of or combined with imported
articles are also “accessories. Copyright Amendment (Parallel Importation) Act 2003 (Cth.)
[Austl.]. See Polo/Lauren Co. LP v. Ziliani Holdings Pty. Ltd. [2008] 75 I.P.R. 143 (F.C.A.)
(applying the provisions and finding that parallel imports of polo shirts were not infringing). See
Ghosh and Calboli (2018), pp. 148–152.
184Kirtsaeng v. John Wiley & Sons, Inc., 133 S. Ct. 1351, 1358 (2013).
185For a detailed reconstruction of doctrine of copyright exhaustion in the U.S., see Calboli (2014c),
p. 75; Ghosh and Calboli (2018), p. 116.
186Quality King Distribs., Inc. v. L’Anza Research Int’l, Inc., 523 U.S. 135 (1998).
187Costco Wholesale Corp. v. Omega, S.A., 131 S. Ct. 565 (2010).
188See Ghosh and Calboli (2018), p. 122.
189Euro-Excellence Inc. v. Kraft Canada Inc., [2007] 3 S.C.R. 20, 2007 SCC 37.
190Id.
191Calboli and LaFrance (2013), p. 1.
192Id. at 266-72 (referring also to the relevant case law in Australia).
193See supra note 172 listing examples of copyright registration for medicines in the U.S. For an
example of attempt to enforce copyright against a generic pharmaceuticals producer, see
SmithKline Beecham Consumer Healthcare, L.P. v. Watson Pharms., Inc. 211 F.3d 21 (2d Cir.
2000) (holding that copyright liability does not attach to the use by the seller of a generic medicine
of the label of the same medicine by the originator company, the Nicorette gum, after the generic
seller had obtained FDA approval to sell the medicine).
58 I. Calboli
amendment would prevent the opportunity for future strategic overlaps, should the
law again be amended toward a system of national exhaustion.
Attempts by the pharmaceutical industry to use copyright law have been
acknowledged in the U.S. and Australia, for example, even though this use was
not with respect to parallel imports of genuine products but to block the introduction
to market of generics nationwide. In 2000, the U.S., an originator company
attempted to block the distribution of a generic claiming copyright infringement
on the FDA-approved labelling that the generic manufactured used. This claim was
rejected by the court based on the fact that the Hatch-Waxman Act requires the use of
the “same” labelling and accordingly this requirement trumps the possibility to claim
copyright infringement on pharmaceutical labels. Still, the court stated that copyright
protection could be used, not regarding labels, but other materials such as advertis-
ing.194 Similarly, in Australia, in 2008, an originator company claimed copyright
infringement against a generic producer because of the reproduction of the legally
required product information of the medicine. This claim was eventually also
rejected and led to adoption of another amendment in Australia: the Therapeutic
Goods Legislation Amendment (Copyright) Bill 2011, which was passed in 2001
and introduced Section 44BA to the Copyright Act.195
In Norway, however, the pharmaceutical industry attempted to claim copyright
infringement against parallel imports within the EU/EEA. This attempt was also
rejected.196 Notably, the Norwegian Medicines Control Agency had provided notice
to the industry that it would allow parallel importers to use the official Summaries of
Product Characteristic (SPCs) given by originator companies for the purpose of
seeking the importing authorization for intra EEA parallel imports. Astra Norge sued
the Norwegian government on the claim that this infringed its copyright in the SPCs.
The court of first instance ruled in favor of Astra Norge, but the court of appeal
referred asked to the EFTA court if this decision would violate the EU Directive on
marketing authorizations.197 In conclusion, the EFTA Court ruled that indeed a
finding of copyright infringement would represent a measure having equivalent
194SmithKline Beecham, 211 F.3d 21. See Tsien (2014), p. 334, 366.
195Therapeutic Goods Legislation Amendment (Copyright) Bill 2011 (Cth) [Austl.] (adding
s. 44BA). According to the new provision the copyright infringement cannot be invoked: “2 . . .:
(a) supplying, in Australia, some or all of any product information that is approved. . . in relation to
medicine; (b) reproducing, in Australia, [this] information . . .; (c) publishing, in Australia, [this]
information . . .; (d) communicating, in Australia, [this] information . . .; (e) adapting, in Australia,
[this] information . . .; to the extent that the supply, reproduction, publication, communication or
adaptation is for a purpose related to the safe and effective use of the medicine referred to in
paragraph (a).” Moreover, “3. An act done in Australia that is ancillary or incidental to a supply,
reproduction, publication, communication or adaptation referred to in subsection (2) is not an
infringement of any copyright . . .” I am grateful to Luigi Palombi for pointing me to this specific
amendment.
196This is reported by Stothers (2007), p. 426 (citing the decision Case E-1/98 Norway v. Astra
Norge [1998] EFTA Court Reports 140).
197Id.
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effect to a quantitative restriction and a disguised restriction to EU/EEA trade.198
Once again, the principle of free movement in the EEA prevailed over the attempt to
use copyright (or other IP rights) to block intra EU/EEA parallel trade. Ultimately
these various attempts demonstrate that IP holder always try to use multiple avenues
to pursue their interests, the enforcement of copyright to features of the packaging or
information annexed to the medicines being also one of these avenues.
4.2 Enforcement of Trademark Rights to Parallel Imports
of Pharmaceuticals
In addition to (attempting to) enforce copyright protection, an additional avenue to
attempt to block the parallel imports of pharmaceuticals, and products in general, is
the enforcement of trademark protection for products that may still be protected by
patents or whose patent protection has expired.
The advantage of this overlap is obvious when the country of importation
practices international exhaustion for patents but national exhaustion for trademarks,
as the imports can then be blocked as a trademark infringement. For example,
amongst the countries analyzed in Part III, several of the countries practicing
international patent exhaustion have no clear policy in the area and apply instead
national trademark exhaustion.199 This is the case, for example in LDCs in ASEAN,
Cambodia and Lao PDR,200 which block parallel imports under trademark law. Also
in Thailand, which does not have an express position on trademark exhaustion in
general, it has been noted that trademark law can be invoked to block the imports of
pharmaceuticals not imported directly by the trademark holders.201 Another country
practicing national trademark exhaustion is Brazil, with the exception of the instance
where the trademark holder has not restricted in licensing agreements against parallel
imports into Brazil or does not have a licensee in Brazil.202 Unfortunately,
198Id.
199Ghosh and Calboli (2018), p. 65. See also Grigoriadis (2014).
200See Law Concerning Marks, Trade Names and Acts of Unfair Competition of the Kingdom of
Cambodia, Art. 11(c) (Cambodia); Lao PDR Law, supra note 81, at art. 57(3) lit. 1.
201See Lifescience Asia-Pacific Network, A Comparative Overview of Distribution and Marketing
of Drugs in Asia-Pacific:, p. 49. https://corrs.com.au/site-uploads/images/PDFs/Insights/article-IP-
comparative-overview-of-distribution-and-marketing-of-drugs-across-asia-pacific.pdf (noting that,
in Thailand, “parallel imports are not permitted in the pharmaceutical sector because it is mandatory
for a company to preliminarily obtain an import license and product registration locally” and that
“the FDA will not accept an application for a product with a trademark that is identical to other
products in the Thai market, unless this product has the same manufacturer and the manufacturer
has given its authorization to use and sell the product.”).
202Brazilian IP Law, supra note 112, Art. 132 (III). See also Grigoriadis (2014), pp. 457–458
(highlighting that Brazil practices national trademark exhaustion even though it is a Member State
of Mercosur, which establishes the principle of international exhaustion under Article 13 of the
60 I. Calboli
information is not readily available at this time regarding the position several African
countries, in particular LDCs, adopt on trademark exhaustion. Still, there are no
doubts the effect of the limitations invoked under a system of national exhaustion are
very relevant, as they can contribute to effectively blocking medicines from entering
the countries allowing these imports under patent law.
IP holders have invoked trademark law to block the parallel imports also within
regions that practice regional exhaustion, notably in the EU. However, the CJEU
resisted the IP overlaps game and, in most instances, ruled in favor of parallel
imports. As mentioned above, free movement of goods is one of the fundamental
freedoms of the EU, and the CJEU long made it clear that the exercise of IP rights
cannot trump free movement. Moreover, the CJEU designed the principle “mutual
recognition” according to which Member States should accept “the sale in [their]
territory of a product lawfully produced and marketed in another Member” even
when the “technical or quality requirements . . . differ from those imposed on [their]
domestic products.”203 In other words, genuine products of materially different
quality cannot be blocked within the EU/EEA as long as they comply with national
standards, which today have largely been replaced with EU standards. However, in
the EU cases in question, parallel importers repackaged the pharmaceuticals—thus,
the products carried differences in quality not because the trademark holder had
produced them as such, but because the importers had altered the quality of the
packaging. Yet, the CJEU still allowed the imports.204
In particular, the CJEU supported trademark rights could not be enforced against
repackaged parallel imported medicines when “the repackaging did not adversely
affect the original condition of the product” and that “the trade mark owner receives
prior notice of the marketing of the repackaged product.”205 In Bristol-Myers Squibb
v. Paranova,206 the Court created a specific list of conditions for the repackaging and
stated that: (1) it should be necessary to market the product in the country of
importation; (2) does not affect the original condition of the product inside the
packaging; (3) clearly states who repackaged the product and the name of the
manufacturer; (4) does not damage the reputation of the trademark or of its holder;
and (5) the importer gives notice to the trademark holder before the repackaged
Protocol on Harmonization of Norms on Intellectual Property in Mercosur in Matters of Trade-
marks, Indications of Source and Appellations of Origin adopted in 1995).
203Commission Communication No. C 256/2, Communication from the Commission concerning
the consequences of the judgment given by the Court of Justice on 20 Feb. 1979 in Case 120/78,
1980 O.J. (C 256) 2, 2–3 (EC). The CJEU developed the principle of “mutual recognition” in Case
120/78, Rewe-Zentral AG v. Bundesmonopolverwaltung fur Branntwein, 1979 E.C.R. 649 (Cassis
de Dijon).
204See Stothers (2016), pp. 171–175.
205Hoffmann-La Roche v Centrafarm, 1978 E.C.R at 1166. See Stothers (2016), pp. 171–172.
206Joined Cases 427, 429 & 436/93, Bristol-Myers Squibb v. Paranova 1996 E.C.R. I-3457. See
Stothers (2016), pp. 172–173.
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product is put for sale, and, on demand, supplies her with a specimen.207 In addition,
the CJEU ruled that even changing the mark on the packaging (with the mark used
by trademark holders in the country of importation) was not grounds to prohibit
parallel imports if the trademark holders deliberately used different marks in differ-
ent EU countries.208 This constituted, according to the Court, a “disguised restriction
on trade between Member States” under the rule of Article 36 of the Treaty209 as
long as210 the mark’s replacement is “objectively necessary”211 and not only for “the
parallel importer . . . to secure a commercial advantage.”212 Still, despite these
supportive rulings regarding parallel imports of pharmaceuticals, the CJEU also
ruled a decade ago the unauthorized repackaging and relabeling of genuine products
may constitute “legitimate reasons” against parallel trade within the EU/EEA when
this may lead to consumer confusion or provoke unfair detriment to a mark’s
reputation.213
Using trademark protection can prove useful to block parallel imports not only
when a country practices national exhaustion but also when it follows a system of
international trademark exhaustion.214 Notably, under the rule of several national
trademark laws—the U.S., Canada, India, China, Korea, Singapore, amongst
others—IP holders can oppose parallel imports under a regime of international
exhaustion when the quality of the imported products is different of those sold
nationally, even if the products are genuine and were first marketed by IP holders
in foreign markets.215 This principle is based on the idea trademarks indicate to
207Several cases followed from these “BMS conditions,”which frequently were resolved in favor of
parallel importers. See Stothers (2016), p. 172 (citing C-143/00, Boehinger Ingelheim
v. Swingward, 2002 E.C.R. I-3759; Case C-348/04, Boehinger Ingelheim v. Swingward, 2002
E.C.R. I-3759, as applied by the English Court of Appeal in [2008] EWCA (Civ) 83; Joined Cases
C-400/09 and C-207/10, Orifarm v. Merck Sharp & Dohme, 2011 E.C.R. I-7063). As we have seen
in Section III regarding the Specific Mechanism, the requirement to notify the originator of the
pharmaceuticals remains, however, an important condition to fulfil by parallel importers. Courts
have rules that failure to notify will result in finding of infringement. See Id. at 173 (citing Hollister
v. Medik Ostomy Supplies, [2012] EWCA (Civ) 1419, [2012] W.L.R 327 (Eng.)).
208Case 3/78, Centrafarm BV v. American Home Prods. Co., 1978 E.C.R. 1823.
209Id. at 1841–1842.
210Case C-379/97, Pharmacia & Upjohn v. Paranova, 1999 E.C.R. I-6927.
211Id. at I – 6967–6969.
212Id. See Stothers (2016), pp. 174–175 (citing Specialty Euro. Pharm. v. Doncaster Pharms. Ltd.,
[2015] EWCA (Civ) 54, [69], [2015] W.L.R.).
213Case C-59/08, Copad, SA v. Christian Dior Couture SA, 2009 E.C.R I- 03421 (stating that a
trademark owner may oppose the unauthorized sale of luxury goods to discount stores by a licensee
if the sale could damage the reputation of the mark). See Calboli, Reviewing Trademark Exhaustion,
supra note 10, at 261–262.
214See, e.g., Calboli (2011), p. 1241; LaFrance (2013), p. 45.
215Ghosh and Calboli (2018), p. 65; Grigoriadis (2014).
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consumers origin and consistent quality.216 Accordingly, consumers could be con-
fused when they rely on the mark affixed to the paralleled imported products, but
these products are “materially different” in quality.217 Small quality differences
often apply to products marketed in different countries because of national standards
or producers’ choices (or marketing partitioning strategy by IP holders).218 In some
countries, like the U.S. and Singapore, this rule is mitigated by the use of dis-
claimers—in other words, the products can still be lawfully imported as long as the
importers properly labels the products indicating their origin and quality dispelling
the risk of consumer confusion.219 Yet, in an action for infringement, it is up to
national courts to decide the extent they could find these disclaimers weigh against a
likelihood of consumer confusion. Courts in the U.S., for example, have interpreted
the concept of “material differences” broadly, to include a large set of product
features and accessories and have blocked parallel imports accordingly.220
In summary, it is not surprising that the pharmaceutical industry considers
trademark protection as an important avenue to block parallel imports even though
the courts have frequently denied their claims. Considering the expansion of trade-
mark protection, that can protect today the packaging but also the color and shape of
several pharmaceuticals, and the length that this protection grants due to the possi-
bility to renew the protection indefinitely, we will certainly continue to see more
activity in this respect.
216See Landes and Posner (1987), pp. 265–266 (“[T]rademark law . . . can best be explained on the
hypothesis that the law is trying to promote economic efficiency.”); see also Economides (1988),
p. 523, 526; Kratzke (1991), pp. 199, 205.
217See Schechter (1927), p. 813, 818 (“The true functions of the trademark are, then, to identify a
product as satisfactory and thereby to stimulate further purchases by the consuming public.”);
Sanders and Maniatis (1993), p. 406.
218Calboli (2011), p. 1271.
219Tariff Act, 19 U.S.C. § 1307 (1930). “This product is not a product authorized by the United
States trademark owner for importation and is physically and materially different from the autho-
rized product.” The disclaimer must be “designed to remain on the product until the first point of
sale to a retail customer in the United States.” 19 C.F.R. § 133.23(b).
220In the US, for example, see Societe Des Produits Nestle S.A. v. Casa Helvetia, Inc., 982 F.2d
633, 639 n.7 (1st Cir. 1992) ; Lever Bros. Co. v. U.S., 877 F.2d 101, 103, 108 (D.C. Cir. 1989);Dial
Corp. v. Encina Corp., 643 F. Supp. 951, 952 (S.D. Fla. 1986); Ferrero U.S.A., Inc. v. Ozak
Trading, Inc., 753 F. Supp. 1240, 1243, 1247 (D.N.J.), aff’d, 935 F.2d. 1281 (3rd Cir. 1991); El
Greco Leather Prods. Co. v. Shoe World, Inc., 806 F.2d 392 (2d Cir. 1986).
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5 Conclusion: A Call for a Wider Application
of the Flexibility of Article 6 of the TRIPS Agreement
in Developing and Least Developed Countries
In the light of the above, what conclusions could be derived from the comparative
review offered by this chapter regarding domestic policies on patents exhaustion and
the application of overlapping IP right to the parallel imports of pharmaceuticals?
At the outset, the analysis elaborated in this chapter confirms that the national
treatment of the principle of IP exhaustion remains a highly complex legal question
across different jurisdictions. This is even more true regarding pharmaceuticals
considering how many countries apply differentiated rules or have recently changed
their national laws to address these imports. As I anticipated in the Introduction, this
review also confirms that the principle of IP exhaustion remains a relevant tool for
countries’ international trade policies, including for trade in pharmaceuticals. In turn,
it is still important to engage in scholarly discussions on this area, even though other
factors—from marketing approvals, to import authorizations, or contractual restric-
tions—can affect the admissibility of these imports into national markets. For
example, domestic policies providing for national exhaustion can become the
ultimate barrier against parallel imports of pharmaceuticals in the instances in
which national governments do grant the necessary regulatory approvals
(or recognize specific foreign approvals) to these products. To the contrary, domestic
policies on international exhaustion would become the decisive factor to permit
these imports into national markets. In addition to patent exhaustion, domestic
policies on trademark or copyright exhaustion can also be used as effective barrier
to the parallel imports of pharmaceuticals, including generics.
More specifically, the comparative review presented in this chapter highlights
that, twenty-five years after the adoption of the TRIPS Agreement, a number of
national governments are using more actively the flexibility offered by Article 6 of
the TRIPS Agreements in order to frame national solutions on the application of the
principle of IP exhaustion in ways that best fit their international and domestic trade-
related interest. Several countries, developing and developed countries, have under-
gone specific revisions of their national laws in this respect, and the interpretation of
the principle of exhaustion has been debated at large by national courts in the past
several decades. In general, both national legislators and judges seem to have
acquired a better understanding of the possible applications of this principle.
National and international economic studies have also been prepared to assist policy
makers in determining the economic implications of legislative choices in this area.
Interestingly, several developed countries, including the US and Canada, have
changed their national policies from national to international patent exhaustion—
even though parallel imports may still be blocked in several countries through
(enforceable) contractual restrictions and, with respect to pharmaceuticals, by the
mentioned regulatory requirements.
To the contrary, legislative or judicial reforms in favour of more liberal policies
on IP exhaustion are still not the case for several developing countries and LDCs.
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Instead, as noted in this chapter, several of these countries continue to follow a
system of national patent exhaustion. For example, this position is followed by
several LDCs in Africa. Several developing countries and LDCs even allow for the
enforcement of overlapping IP rights in their jurisdictions. As noted in this chapter,
the LDCs countries members of OAPI follow a system of regional exhaustion, which
remains more restrictive than international exhaustion. These findings, and the
limited use of the flexibility of Article 6 of the TRIPS Agreement in these countries,
are the most problematic conclusions from the comparative review in this chapter.
The reasons for these choices are difficult to identify as the legislative history of
these laws cannot be easily reconstructed, but most likely range from the lack of
expertise of national legislators, to the lack of economic studies regarding these
countries, or the absence of, or low quality technical assistance, or the pressure of
foreign governments and business interests, including trade-offs accepted as part of
trade agreements or foreign direct investments. Regardless of the reasons, these
national policies are problematic as they undermine the possibility, for these coun-
tries, to import less costly products, including pharmaceuticals. In the case of
pharmaceuticals, these national policies could essentially amount to block these
countries from accessing life saving medicines for their citizens.
Simply put, it is almost paradoxical, and quite problematic, that several developed
countries currently apply less restrictive IP exhaustion policies than a number of
developing countries and LDCs, whereas the former have larger economic capabil-
ities and access to products than the latter.
The last conclusion that can be derived from the comparative review in this
chapter is the relevance of IP overlaps in this debate, in particular when countries
practice different type of exhaustion—national instead of international. In particular,
it is clear that only when countries practice international exhaustion for all IP rights
overlapping IP protection cannot interfere with the general admissibility of parallel
imports in that country—at least from the perspective of the enforcement of IP rights.
As a result, pharmaceutical companies have attempted to invoke copyright and
trademark rights to block the further circulation of their products or to block the
introduction to market of generics. In the EU, in particular, companies have invoked
both copyrights, and most frequently trademark protection to try to block the parallel
trade of their products within the EU since the late 1970s. As mentioned in this
chapter, copyright could be used to protect the packaging, the logos, and the
instructions of the medicine. Likewise, trademark rights are granted today not just
for the marks affixed to the pharmaceutical packaging, but also on the pills, the
devices necessary to inhale the medicines, etc.
This finding, certainly not new but not frequently raised in the debate of scholars,
which are experts on patents and pharmaceuticals, is also problematic. In particular,
the enforcement of these additional rights can easily nullify the effects of domestic
policies on international patent exhaustion, should countries practice national trade-
mark or copyright exhaustion. The same applies, as this chapter illustrates, when IP
holders can invoke differences in the quality of the products, even in the case of
domestic policies providing for international exhaustion. Again, calling upon these
rights may become a last resort for the pharmaceutical industries—which still
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heavily relies on regulatory schemes to control the international distribution of
pharmaceuticals—and courts seem to have rarely supported these claims. Yet,
these disputes may not be representative of the number of claims actually used in
cease and desists letters to parallel importers and distributors of these products
nationally. As it is known, very few disputes reach the courts, due to the time and
legal fees involved. Instead, most disputes are settles in highly secretive and
nontransparent out-court proceedings where dubious claims and weak rights—
such as copyright and trademark protection for pharmaceuticals—can be validated
by the parties in the settlements. Ultimately, this large numbers of rights simply
offers more arrows that IP holders to throw against parallel imports, and we can be
sure that, should the occasion arise, the arrows will be used with full force.
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Compulsory Licenses and Government Use:
Challenges and Opportunities
Yousuf A. Vawda
Abstract The compulsory licensing and government use flexibility is potentially
the most powerful tool available under the TRIPS Agreement, as amplified by the
Doha Declaration, to advance public health objectives. Yet, many lower and middle
income countries have shown an apparent reluctance to both incorporate them into
their national legislation and then utilise them—except in a relatively small number
of cases. This contribution analyses the circumstances surrounding this phenome-
non. It outlines the context, historical roots of compulsory licensing and its inclusion
on the TRIPS Agreement, recent examples of its utility including in two sub-Saharan
countries affected by HIV/AIDS, and offers some recommendations. Among the
propositions advanced are that the use of such flexibilities is not an insurmountable
problem (as the case of Zimbabwe illustrates) and that in the longer term, public
health objectives are best advanced by, among others, amending the TRIPS Agree-
ment to exempt health technologies from the ambit of intellectual property protec-
tion, and new, alternative models for rewarding innovation in this field of technology
being introduced.
1 Introduction
This paper is a contribution to the debate on the role of compulsory licensing and
government use to promote access to medicines, and is situated within the context of
the universally accepted right of access to health care and medicines.1 These are two
types of authorisation issued to either third parties or the government itself to make
use of a patented invention without the consent of the patent holder, under defined
circumstances.
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1For present purposes, the term ‘medicines’ includes pharmaceutical and biologic products, vac-
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Despite the fact that international law unequivocally establishes access to
healthcare as a fundamental right,2 this right has achieved recognition mostly in
theory. The consistent prioritisation by states and multinational corporations of
enforcement of intellectual property (IP) rights over promoting access to medicines,
has resulted in health technologies becoming increasingly inaccessible. This is
largely because of the monopoly pricing of many life-saving medicines—which
has rendered them unaffordable and endangered public goods.3 Such an indictment
has been met by the proponents of strong IP protection with the counterclaim that
certain provisions in international instruments secure IP protection as a human right.
They often cite, in support, the recognition in the ICESCR of the right to the
‘protection of the moral and material interests resulting from any scientific, literary
or artistic production of which he is author’.4 However, this sub-article must not be
read in isolation, and is counterbalanced by another, which recognises everyone’s
right ‘to enjoy the benefits of scientific progress and its applications’5 which, it is
argued, must trump any IP claims.
This tension between IP protection and access to health has been the subject of a
number of international commissions and, most recently, the UN Secretary-Gen-
eral’s High Level Panel on Access to Medicines in 2016.6 One of the Panel’s key
recommendations directly references the need for adoption and use of compulsory
licensing legislation:
Governments should adopt and implement legislation that facilitates the issuance of com-
pulsory licenses. Such legislation must be designed to effectuate quick, fair, predictable and
implementable compulsory licenses for legitimate public health needs, and particularly with
regards to essential medicines. The use of compulsory licensing must be based on the
provisions found in the Doha Declaration and the grounds for the issuance of compulsory
licenses left to the discretion of governments.7
It is in this context that compulsory licences and government use provisions in IP
law are advanced as both important safeguards against abusive practices by IP rights
holders, and enablers of the public’s right to access medicines at affordable prices.
In theory, the compulsory licence and government use flexibility is one of the
most powerful tools available under the 1994 WTO Agreement on Trade Related
2For example, in the Universal Declaration of Human Rights https://www.ohchr.org/EN/UDHR/
Documents/UDHR_Translations/eng.pdf (UDHR), the International Covenant on Economic Social
and Cultural Rights https://www.ohchr.org/Documents/ProfessionalInterest/cescr.pdf (ICESCR),
and a host of other international and regional instruments.
3Vawda and Baker (2013). http://www.scielo.org.za/scielo.php?script¼sci_arttext&pid¼S1996-
20962013000100004#top119.
4UDHR, art 27(2) and ICESCR art 15(1)(c).
5ICESCR, art 15(1)(b).
6United Nations (2016), http://www.unsgaccessmeds.org/final-report.
7United Nations (2016), recommendation 2.6.1 (b). In addition, recommendation 2.6.1 (c) urges the
revision and adoption of the paragraph 6 decision.
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Aspects of Intellectual Property Rights (TRIPS Agreement)8 (as amplified by the
Doha Declaration9) to advance public health objectives. This is because is removes
the patent holder’s exclusive right to work the patent. Despite these options having
been recognised internationally since as far back as the Paris Convention in 188310
(as elaborated below), and more recently in Article 31 of the TRIPS Agreement, and
with increasing use particularly in the wake of the HIV/AIDS pandemic, many lower
and middle income countries (LMICs) have shown an apparent reluctance to fully
engage with these mechanisms. They have firstly, not universally incorporated these
and other flexibilities into their national legislation and, secondly, where they are
available in their legislation, failed or refused to utilise them—except in a relatively
small number of cases.11
“The lack of appropriate national legislation for the full implementation of such
flexibilities remains one of the greatest difficulties for some developing countries. At
the international level, there is a need to improve the legal and technical assistance
offered to these countries with respect to intellectual property and public health. In
the 16 years since the Doha Declaration, technical assistance has been insufficient or
inappropriate.”12 This comment highlights the twin problems of the failure to
incorporate the flexibilities in national legislation, and the lack of sufficient and,
importantly, appropriate technical assistance.
There are of course multiple other difficulties to be surmounted. They include:
political and economic pressures by countries which house IP-rich industries not to
use the flexibilities;13 the lack of political will by the governments of LMICs, as well
as of some regional IP organisations;14 the lack of technical, legal and regulatory
capacity to process such applications; and the legal and judicial culture existent in
8Trade-Related Aspects of Intellectual Property Rights [WTO] https://www.wto.org/english/docs_
e/legal_e/27-trips_03_e.htm.
9Declaration on the TRIPS agreement and public health [WTO] https://www.wto.org/english/
thewto_e/minist_e/min01_e/mindecl_trips_e.htm.
10As elaborated below in Sect. 2.
11See, for example, Ellen ‘t Hoen, The Global Politics of Pharmaceutical Monopoly Power. Drug
patents, access, innovation and the application of the WTO Doha Declaration on TRIPS and Public
Health (2009) https://www.msfaccess.org/sites/default/files/MSF_assets/Access/Docs/ACCESS_
book_GlobalPolitics_tHoen_ENG_2009.pdf.
12Correa and Velasquez (2019) South Centre Research Papers 85 https://www.southcentre.int/wp-
content/uploads/2019/04/RP85_Access-to-Medicines-Experiences-with-Compulsory-Licenses-
and-Government-Use-The-Case-of-Hepatitis-C_EN.pdf.
13This problem was most recently highlighted in the case of Colombia’s attempts to issue a
compulsory licence on imatinib, as indicated by its Minister of Health to a meeting of the World
Health Assembly. See WIPO (2017) WIPO Standing Committee on the Law of Patents https://
www.wipo.int/edocs/mdocs/scp/en/scp_27/scp_27_6.pdf, 3.
14Sangeeta Shashikant, “The African Regional Intellectual Property Organization (ARIPO) Proto-
col on Patents: Implications for Access to Medicines” [2014] South Centre Research Paper No
56, 6.
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many countries whose intellectual property law has its genesis in the period of
colonialism.15
This paper’s sights are more modest. It reviews the distinct responses of two
countries caught in the epicentre of the HIV/AIDS pandemic in sub-Saharan Africa
(namely Zimbabwe and South Africa), to understand their respective approaches to
the use of compulsory licensing and government use and the barriers that need to be
confronted, and to explore some future directions for policy and legal reform in this
thematic area.
2 Historical and Conceptual Roots
A compulsory licence is an authorisation granted by a government allowing third
parties to produce a patented product or to utilise a patented process without the
consent of the patent holder, and which use will not amount to an infringement of the
patent. The grant of a compulsory licence constitutes a proactive governmental
intervention when market forces result in a disequilibrium between the objectives
of rewarding innovation and ensuring social and economic welfare.16 They ‘ensure
an efficient operation of innovation markets by avoiding the risk that patents
themselves become barriers to invention and innovation . . . (and) . . . (a)s policy
tools, compulsory licences help to ensure that patent protection remains properly
balanced with other socio-economic interests.’17
The first iteration of the term ‘compulsory licence’ in an international instrument
is to be found in the Paris Convention of 188318 which, although it does not itself
define the term, provides for its grant ‘to prevent the abuses which might result from
the exercise of the exclusive rights conferred by the patent, for example, failure to
work.’19 The earliest recorded references to compulsory licences are found in the
Venice Patent Law of 1474.20 This was followed by the UK Statute of Monopolies
of 1623 and has, over the past few centuries, been received into the national laws of
many jurisdictions.21 In similar vein, ‘government use’ or ‘crown use’ is a grant by
15Vawda (2018) South Centre Research Papers 90, 16–18.
16For a history of the evolution of intellectual property, compulsory licences and related issues, see
May and Sell (2006).
17Max Planck Institute (2014), p. 9 https://www.mpg.de/8133454/Patent-Declaration1.pdf.
18Paris Convention for the Protection of Industrial Property of March 20, 1883 https://www.wipo.
int/edocs/lexdocs/treaties/en/paris/trt_paris_001en.pdf.
19Paris Convention for the Protection of Industrial Property of March 20, 1883, art 5A(2).
20See Editorial (2012) http://thailawforum.com/articles/Trips-and-access-to-medicines-India-
and-Thailand-2.html.
21Correa (1999) Trade-Related Agenda, Development and Equity, Working Papers https://www.
iatp.org/sites/default/files/Intellectual_Property_Rights_and_the_Use_of_Co.pdf. accessed
26 January 2020. For a background of the use of compulsory licensing in other jurisdictions, see
Ellen ‘t Hoen, The Global Politics of Pharmaceutical Monopoly Power. Drug patents, access,
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the government, to itself or other entities or contractees acting on behalf of govern-
ment, to make use of a patented product or process without the consent of the patent
holder. Its origin is frequently attributed to UK law.22 In both instances of compul-
sory licences and government use, a royalty is required to be paid to the patent
holder.23 In the case of compulsory licences, prior negotiation for a voluntary licence
on reasonable commercial terms and within a reasonable period of time is also a
requirement.24 This requirement is waived in cases of national emergency or other
circumstances of extreme urgency, or in cases of public non-commercial use (gov-
ernment use)25 or to remedy a practice that has been determined after a judicial or
administrative process to be anti-competitive.26
The availability and use of compulsory licensing in the pharmaceutical sector was
apparently limited during the early twentieth century, as many countries excluded
such products from patentability.27 Nonetheless, there are examples of its use in
industrialised countries, for example, early instances of use in Canada28 resulted in
some of the lowest prices for medicines, while in the UK29 the ‘crown use’ pro-
visions have been effectively deployed to secure generic medicines for the National
Health Service. The US,30 too, has a long history of government use licences under
28 U.S.C. section 1498, especially for federal programmes involving defence equip-
ment as well as medicines. In terms of this expeditious provision, the government
was able to procure cheaper generic drugs in the 1960s at less than 1% of their list
price together with a reasonable royalty.31 And recently, during the 2001 anthrax
innovation and the application of the WTO Doha Declaration on TRIPS and Public Health (2009),
41–44.
22Patents, Designs, and Trade Marks Act of 1883, s 27(2) https://archive.org/stream /
patentsdesignsa01britgoog/patentsdesignsa01britgoog_djvu.txt.
23Trade-Related Aspects of Intellectual Property Rights [WTO], art 31(h) requires the payment of
‘adequate remuneration’.
24Trade-Related Aspects of Intellectual Property Rights [WTO], art 31(b).
25Trade-Related Aspects of Intellectual Property Rights [WTO], art 31(b).
26Trade-Related Aspects of Intellectual Property Rights [WTO], art 31(k).
27Ellen ‘t Hoen, The Global Politics of Pharmaceutical Monopoly Power. Drug patents, access,
innovation and the application of the WTO Doha Declaration on TRIPS and Public Health
(2009), 40.
28Ellen ‘t Hoen, The Global Politics of Pharmaceutical Monopoly Power. Drug patents, access,
innovation and the application of the WTO Doha Declaration on TRIPS and Public Health
(2009), 41.
29Ellen ‘t Hoen, The Global Politics of Pharmaceutical Monopoly Power. Drug patents, access,
innovation and the application of the WTO Doha Declaration on TRIPS and Public Health
(2009), 42.
30Ellen ‘t Hoen, The Global Politics of Pharmaceutical Monopoly Power. Drug patents, access,
innovation and the application of the WTO Doha Declaration on TRIPS and Public Health
(2009), 43.
31Brennan et al. (2016) “A Prescription for Excessive Drug Pricing: Leveraging Government Patent
Use for Health (2016), p. 275 https://yjolt.org/sites/default/files/kapczynski_18yjolt275_gk_0_0.
pdf.
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scare, Canada and the US were willing to consider invoking this flexibility, as has
Italy on a number of occasions on anti-trust grounds.32
3 The TRIPS Framework
Article 31 (a) to (l) of the TRIPS Agreement provides for the grant of compulsory
licences provided certain conditions are satisfied and procedures followed. These
are:
• Each case must be considered on its individual merits;
• The proposed user must have made a prior attempt to obtain a voluntary licence
from the right holder on reasonable commercial terms, which attempt has not
been successful within a reasonable period of time. This requirement is waived
(1 ) in the cases of national emergency or other circumstances of extreme
urgency, or in cases of public non-commercial use, although the right holder
must be notified; and (2) where a compulsory licence has been granted to remedy
anti-competitive practices;
• The scope and duration of use is limited to the purpose for which the use was
authorised and such authorisation shall be terminated if and when the circum-
stances which led to the use cease to exist and are unlikely to recur, subject to the
legitimate interests of the licensee being protected;
• The use is non-exclusive, and is non-assignable except with that part of the
enterprise or goodwill which enjoys such use;
• The use is to be predominantly for the supply of the domestic market, except
when the compulsory licence is issued to remedy anti-competitive practices.
(There is now an additional exception for countries with little or no manufactur-
ing capacity under Article 31bis);
• The patent holder must be paid adequate remuneration for such use taking into
account the economic value of the authorisation, but compensation may be
adjusted downwards when a compulsory licence is issued to remedy anti-
competitive practices;
• The legal validity of any decision relating to the authorisation of the use, as well
as the amount of remuneration, is subject to judicial or other independent review
by a “distinct higher authority” in that country; and
• The right holder of a second patent that cannot be exploited without infringing the
first patent may receive a licence if the second invention involves an important
technical advance of considerable economic significance in relation to the first
invention. In such instances, the owner of the first patent shall be entitled to a
cross-licence to the second invention on reasonable terms, and the use authorised
32Ellen ‘t Hoen, The Global Politics of Pharmaceutical Monopoly Power. Drug patents, access,
innovation and the application of the WTO Doha Declaration on TRIPS and Public Health (2009),
41–42.
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in the licence on the first invention shall not be assigned without assignment of
the second patent.
Article 31 of the TRIPS Agreement does not specify or otherwise limit the
grounds upon which licences can be granted. This clarification was one of the key
outcomes of the Doha Declaration, namely that each country has the right to grant
compulsory licences, to determine the grounds on which to grant them, and to
determine what constitutes an emergency or other circumstances of extreme
urgency, notably public health crises with no restrictions as to disease coverage or
frequency of use.33 In addition, the TRIPS Council was mandated to find a solution
to the problem encountered by countries with insufficient or no manufacturing
capacity in their potential use of the compulsory licensing provisions of Article
31.34 Finally, the Declaration reiterated the freedom of countries to adopt the
exhaustion regime of their choice (in order to facilitate parallel importation).35
In the wake of the HIV/AIDS pandemic, and buoyed by the Doha Declaration’s
pro-public health interpretation of the TRIPS Agreement, a significant number
of developing countries and LDCs afflicted by this crisis issued a combination of
compulsory licences and government use orders to facilitate the acquisition of
antiretroviral medicines (ARVs) and, occasionally, medicines for other conditions.
Such countries include Brazil, Ecuador, Eritrea, Ghana, India, Indonesia, Malaysia,
Mozambique, Thailand, Zambia and Zimbabwe.36 Further discussion of such use is
undertaken below.
Compulsory licences are generally available on a variety of grounds, most
notably in relation to patents where the patentee is found to have abused its rights
in one manner or another, for example, by excessive pricing, refusals to license, or
failure to work, but also where the government wants to ensure alternate sources of
medicines supply, to facilitate co-formulations, or even to promote local production.
Countries might also consider including judicial licences as an alternative remedy to
interdicts in claims of infringement.37
33Doha Declaration paragraphs 4b and 4c.
34The solution proposed and now codified in Article 31bis entails onerous procedural requirements
on both importing and exporting countries, and has been used only once. See Correa (2019) South
Centre Policy Brief N0 57 https://www.southcentre.int/wp-content/uploads/2019/01/PB57_Will-
the-Amendment-to-the-TRIPS-Agreement-Enhance-Access-to-Medicines_EN-1.pdf.
35Doha Declaration paragraph 4d.
36See Khor (2014), p. 24.
37See, for example, United Nations Development Programme (2013), p. 39 https://www.undp.org/
content/dam/undp/library/hivaids/English/using_law_to_accelerate_treatment_access_in_south_
africa_undp_2013.pdf accessed 26 January 2020. This option is discussed in some detail below in
the section ‘The South Africa case’. (See also, further discussion on judicial licences below).
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4 A Scan of the Use of TRIPS Flexibilities
The most comprehensive data currently available on the use of flexibilities are those
compiled by Medicines Law and Policy.38 It records some 155 instances of the use
of various TRIPS flexibilities since 2001 in 82 countries across the spectrum of
WTO classification (least developed countries, developing countries, high-income
countries).
In terms of the relevant flexibility invoked, the majority (105) were in respect of
compulsory licensing and government use, followed by the LDC pharmaceutical
transition period provision (46), which provides a total waiver from recognizing or
enforcing pharmaceutical patents and data protections (Table 1).
A recent update by the South Centre records further uses of compulsory licensing
in Russia, in 2019, and Israel, in 2020, the latter in the wake of the COVID-19
pandemic.39
It is evident that the compulsory licensing and government use flexibility is most
favoured by countries seeking to enhance access to medicines, with some of them
invoking a public health emergency as the basis for their decision.40
Thailand and Ecuador feature as the countries which have made the most frequent
use of TRIPS flexibilities, in some 11 instances each. Thailand’s example of
government use licences is instructive for the manner in which it marshalled the
synergies among evidence-based research and analysis, public mobilisation by civil
society, and leadership by politicians and policy makers to ‘move the mountain’.41
The effects of the licences issued between 2006 and 2007 on the prices of various
medicines have been substantial. The price for the ARV efavirenz dropped by more
than 7 times, and lopinavir/ritonavir by 3 times; for the anti-platelet clopidogril by
50 times; and for the anti-cancer drugs docetaxel and letrazole by 24 and 70 times
Table 1 Use of flexibilities against type. Adapted from Medicines Law and Policy (note 38)
Flexibility utilised or intended Number of uses
TRIPS Art 31 (compulsory licensing, public non-commercial use) 105
Doha Declaration Para 7 (LDC pharmaceutical transition period provision) 46
TRIPS Art 30 (patent exception) 3
Doha Declaration Para 5(d) (parallel importation) 1
TOTAL 155
38Medicines Law and Policy, “The TRIPS Flexibilities Database” http://tripsflexibilities.
medicineslawandpolicy.org/.
39See South Centre, “Compulsory Licences and Government Use of Patented Medicines: Pre-
cedents Relevant to Address COVID-19” https://ipaccessmeds.southcentre.int/covid-19-pandemic/.
40See Khor (2014). Of the 12 countries surveyed Ghana, Mozambique, Eritrea and Zimbabwe
premised their licences on the emergency ground.
41Wibulpolprasert et al. (2011) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180369/.
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respectively.42 Indonesia is another country with multiple uses, having issued
compulsory licences for the supply of ARVs on 3 occasions.43
According to the TRIPS Flexibilities Database, 40 of the 46 instances of the use
of flexibilities by LDCs related to the LDC transition provision. With the exception
of Bangladesh44 there does not appear to be any instances of the use of this flexibility
prior to the Doha Declaration. It is therefore significant that there has been a surge in
the use of this flexibility post-Doha. Additionally, in terms of the most recent
extension of the waiver until 2033, the exemption relates not only to pharmaceutical
patents, but also to data protection, mailbox obligations and market exclusivity.45
Reference has been made to the lack of appropriate technical advice to countries,
when formulating their IP laws, in relation to their use of public health flexibilities.
In this regard, the situation of the African Regional Intellectual Property Organisa-
tion (ARIPO) is instructive. A 2014 study on the ARIPO Protocol on Patents46
revealed that the effective use of TRIPS flexibilities by countries in the East African
Community (EAC), for example, has been constrained by the workings of ARIPO,
which processes the majority of patent applications for that region. Further, that its
current modus operandi ‘does not facilitate the full use of TRIPS flexibilities and
instead erects patent barriers to the importation and local production of affordable
medicines.’47 A recent analysis by Baker of the ARIPO-commissioned ‘Compara-
tive Study of the Industrial Property Laws of ARIPO Member States’ (Comparative
Study) criticises it for ‘its failure to address the vast majority of TRIPS flexibilities’
that are available to its members.48 These include, among others: the lack of
substantive discussion on stringent patentability standards; on the full range of
allowable non-inventions and exclusions; on research and education, as well as
other exceptions permitted under TRIPS Article 30; on disclosure requirements;
on the prerogative of governments to define the grounds for compulsory licences;
and on the use of competition policy to address abuse of patents.
42Khor (2014), p. 13.
43Medicines Law and Policy, “The TRIPS Flexibilities Database”.
44See Gay (2018) https://www.researchgate.net/publication/325206579_Pharmaceutical_Dreams_
TRIPS_and_drugs_policy_in_Bangladesh.
45UN Committee for Development Policy (2015) https://www.un.org/ldcportal/wto-drugs-patent-
waiver-for-ldcs-extended-until-2033/.
46Shashikant (2014) South Centre Research Paper No 56 https://www.southcentre.int/wp-content/
uploads/2014/11/RP56_The-ARIPO-Protocol-on-Patents_ENl.pdf.
47Shashikant (2014) South Centre Research Paper No 56, 45.
48Baker (n.d.) “A Full description of WTO TRIPS Flexibilities Available to ARIPOMember States
and a Critique of ARIPO’s Comparative Study Analyzing and Making Recommendations
Concerning Those Flexibilities [2019] http://kelinkenya.org/wp-content/uploads/2019/05/ARIPO-
Member-States-obligations-and-flexibilities-under-the-WTO-TRIPS-Agreement-March-2019.pdf.
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5 A Tale of Two Countries
This section will focus on two case examples from Southern Africa, regarding
neighbouring countries heavily affected by the HIV/AIDS pandemic, and their
respective approaches to the use of compulsory licensing and government use for
access to medicines.
5.1 The Zimbabwean Case
Zimbabwe’s compulsory licensing regime presents an interesting legal framework.
The primary statute is the Patents Act,49 which has undergone three rounds of
amendments (in 2001, and twice in 2002) to make it TRIPS-compliant. The Act
contains, in addition to provisions for compulsory licensing and government use,
special provisions for government use during particular emergencies.
In addition, there is extensive resort to secondary legislation, such as statutory
letters or instruments, to support this framework. Statutory instruments are a form of
legislation which allow the provisions of an Act of Parliament to be subsequently
brought into force without Parliament having to pass a new Act. They are derived
from UK law, Zimbabwe having been a former British colony. The Statutory
Instrument or Government Notice is thus a form of delegated or subsidiary legisla-
tion.50 In Zimbabwe, an Act of Parliament may delegate power to a relevant Minister
to make statutory instruments51 within the scope, and for the purposes, of the
particular Act, provided they are consistent with that Act, as well as the Declaration
of Rights in Chapter 4 of the country’s Constitution.52
It should be noted that the range of flexibilities incorporated into the Patents Act
includes provisions for: compulsory licensing53 and government use;54 parallel
importation;55 early working exception (‘test batches’);56 pre-grant opposition to
49Patents (Amendment) Act, 1987 Chapter 26:03 (amended by Acts 26/1971, 39/1973 (ss. 39 and
52), 42/1976 (s. 15), 39/1979, 15/1981, 29/1981, 41/1983, 12/1986 (s. 13), 11/1991 (s. 17), 20/1994
(s. 7), 22/2001, 9/2002, 14/2002.)
50Statutory Instruments (2008), UK House of Commons Information Office Factsheet L7 Legisla-
tive Series https://www.parliament.uk/documents/commons-information-office/l07.pdf.
51Delegated or Subsidiary Legislation (undated) Zimbabwe Legal Information Institute https://
zimlii.org/content/delegated-or-subsidiary-legislation.
52Constitution of Zimbabwe Amendment (No 20) Act (2013). See also, Declaration of Rights
(2013), Zimbabwe Human Rights Commission. http://www.zhrc.org.zw/your-rights/.
53Patents (Amendment) Act, 1987 Chapter 26:03, ss 30A and 31.
54Patents (Amendment) Act, 1987 Chapter 26:03, ss 34 and 35.
55Patents (Amendment) Act, 1987 Chapter 26:03, s 24A.
56Patents (Amendment) Act, 1987 Chapter 26:03, s 24B.
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patents on a wide range of grounds;57 and revocation on substantially the same
grounds as those for opposition to the grant of a patent.58
Exemptions are granted from patenting of diagnostic, therapeutic or surgical
methods of treatment; plants, animals, micro-organisms, and essentially biological
processes for their production.59
The requirements of novelty, inventive step and industrial applicability for the
grant of a patent are included as grounds for pre-grant opposition should they not be
satisfied, but the Act does not address the patentability criteria in any detail, and does
not specifically exclude new uses, or new compounds, combinations or admixtures
of a known substance from patenting. Neither are there any exceptions for educa-
tional, research, experimental and other uses. A ‘relative novelty’ standard is
applicable, as the Act requires that the invention was ‘not known or used in
Zimbabwe.’60
5.1.1 Compulsory Licences
The grounds for compulsory licences are limited to: (1) dependent patents,61 and
(2) several grounds for ‘abuse of patent’, such as: non-working; failure to meet
demand on reasonable terms; refusal to license; and any anti-competitive abuse.62 In
the second set of instances, an applicant has to demonstrate that he or she has not
been able to obtain a licence on reasonable terms within 6 months of a request for a
voluntary licence, and on the ground that the reasonable requirements of the public
with respect to the invention have not been or will not be satisfied.63 The circum-
stances which will satisfy the latter criterion are deemed to have occurred if:
• the invention, though capable of being worked in Zimbabwe, is not being worked
on a commercial scale and there is no satisfactory reason for non-working;
• such working is being prevented by the importation of the patented article by the
patentee or associated persons, namely, persons claiming under him, or directly or
indirectly purchasing from him, or against whom he is not taking legal action for
infringement;
• the demand for the patented article in Zimbabwe is not being met to an adequate
extent and on reasonable terms;64
57Patents (Amendment) Act, 1987 Chapter 26:03, s 17.
58Patents (Amendment) Act, 1987 Chapter 26:03, s 45.
59Patents (Amendment) Act, 1987 Chapter 26:03, s 2A.
60Patents (Amendment) Act, 1987 Chapter 26:03, s 2(2)(a).
61Patents (Amendment) Act, 1987 Chapter 26:03, s 30A.
62Patents (Amendment) Act, 1987 Chapter 26:03, s 31.
63Patents (Amendment) Act, 1987 Chapter 26:03, s 31(1).
64See also footnote 84, and accompanying text. In this regard, it is submitted that the reference to
‘reasonable terms’ could well include ‘unreasonable pricing’ of a medicine, particularly in the
context of the socio-economic conditions in a particular country.
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• by the refusal to grant a licence on reasonable terms, trade or industry in
Zimbabwe, or that of any persons trading or the establishment of any new trade
or industry in Zimbabwe is being prejudiced, and it is in the public interest that
licence(s) be granted;
• trade, industry, or any person(s) engaged therein are being prejudiced by unfair
conditions attached by the patentee to the purchase, hire, license or use of the
patented article or use or working of the patented process;
• any restrictive condition (such as being in restraint of trade or contrary to public
policy) has been inserted into a licensing contract for the sale, lease or use of any
article or process protected by the patent; and
• a practice by the patent holder has been determined after a judicial or adminis-
trative process to be anti-competitive, in which case the requirement for prior
negotiation for a voluntary licence is waived.65
The procedure for the application for a compulsory licence is relatively workable.
It entails a fully motivated application to the Registrar of Patents in the manner
prescribed by the Act; permits the patentee or other person to oppose it; and after
consideration of all the submissions, the Registrar may grant the application on
appropriate terms, or refuse it.66 Decisions of the Registrar may be appealed before
the Intellectual Property Tribunal.67 This entails an essentially administrative pro-
cedure with recourse to appeal before a quasi-judicial Tribunal.
In addition, the Act apparently also permits a presumptive licence where a patent
is in force in respect of a substance capable of being used as food or medicine or in
their production.68 This ‘necessity’ premise is plausible where the invention is
a medicine or other public necessity that is not available to the general public or a
significant group of patients. The relevant tribunal shall on application, grant a
presumptive licence subject to payment of a reasonable and affordable royalty.
Other inventions falling into this category include the process for producing such
substances, inventions capable of being used as surgical or curative devices, or in the
protection of the environment, or those capable of substantially improving the
technological, social and economic development of the country.69
5.1.2 Government Use
By far the strongest flexibility in the Act relates to government use and the special
provisions as to State use during an emergency. The essence of this use provision is
that ‘any department of state or any person authorized in writing by the Minister
65Patents (Amendment) Act, 1987 Chapter 26:03, ss 31(1), 31(6) and 31(6a).
66Patents (Amendment) Act, 1987 Chapter 26:03, ss 31(1) to 31(5).
67Patents (Amendment) Act, 1987 Chapter 26:03, s 69.
68Patents (Amendment) Act, 1987 Chapter 26:03, s 32(1)(a).
69Patents (Amendment) Act, 1987 Chapter 26:03, s 32(1).
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(of Justice, Legal and Parliamentary Affairs) may make, use or exercise any inven-
tion disclosed in any specification lodged at the Patent Office for the service of the
State in accordance with this section.’70 Section 34(1) is TRIPS-plus to the extent it
requires agreement with the patent holder on the terms and conditions of the use,71
and appears to contradict section 34(5) (which requires that the patent holder need
only be informed). It elaborates that the authority may be given either before or after
the patent grant, or either before or after the acts for which the authority is given are
done, that is, the authority is retrospective in this regard, presumably with an
emergency in mind. Secondly, the authority may be given to any person, whether
or not he or she is authorised directly or indirectly by the patentee to make, use,
exercise or vend the invention.72 The patentee need only be informed timeously and
be furnished with any information required, unless it would be contrary to the public
interest to do so.73
The Act additionally includes ‘Special provisions as to State use during emer-
gency’74 in terms of which the State and authorised parties shall have the power to
make, use, exercise and vend the invention for purposes deemed by the Minister
necessary or expedient to achieve a number of identified public interest purposes. In
the case of access to pharmaceutical inventions, the relevant provisions relate to the
following needs: the maintenance, and securing a sufficiency, of supplies and
services essential to both the life and well-being of the community; promoting the
productivity of industry, commerce or agriculture; fostering and directing exports
and reducing imports of any classes, from all or any countries and for redressing the
balance of trade; or generally, ensuring that the whole resources of the community
are available for use, and are used, in a manner best calculated to serve the interests
of the community.75
Employing this framework, the Zimbabwean government issued what appears to
be the first government use licence on medicines in the post-Doha era.76 The licence
invokes the following legal provisions:
1. Section 34 of the Patents Act which is the enabling provision for the government
use licence (Use of patented inventions for service of the State).
70Patents (Amendment) Act, 1987 Chapter 26:03, s 34(1).
71Patents (Amendment) Act, 1987 Chapter 26:03, s 34(2). TRIPS Article 31(b) waives this
condition in cases of national emergency or other circumstances of extreme urgency, or of public
non-commercial use.
72Patents (Amendment) Act, 1987 Chapter 26:03, ss 34(4)(a) and (b).
73Patents (Amendment) Act, 1987 Chapter 26:03, s 34(5).
74Patents (Amendment) Act, 1987 Chapter 26:03, s 35.
75Patents (Amendment) Act, 1987 Chapter 26:03, ss 35(1)(b), (c), (d), (e) and (f).
76Cecilia (2006) Int. J Intellectual Property Management Vol 1 Nos 1/2, 22-36 https://www.
researchgate.net/publication/247835566_Compulsory_licences_Recent_experiences_in_develop
ing_countries.
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2. Section 35 of the Patents Act which enables the declaration of an emergency to
override, in this case, antiretroviral patents (Special provisions as to State use
during emergency).
3. General Notice 240 of 2002: Declaration of Period of Emergency for an initial
period of 6 months commencing 24 May 2002 (reproduced below).
4. Statutory Instrument 32 of 2003, extending the period of emergency for a further
5 years (from January 2003 to December 2008).
General Notice 240 of 2002
PATENTS ACT [CHAPTER 26:03]
Declaration of Period of Emergency (HIV/AIDS) Notice 2002
IT is hereby notified that the Minister of Justice, Legal and Parliamentary
Affairs has, in terms of section 34 as read with section 35 of the Patents Act
[Chapter 26:03] made the following notice:
1. This notice may be cited as the Declaration of Period of Emergency
(HIV/AIDS) Notice, 2002.
2. In view of the rapid spread of HIV/AIDS among the population of
Zimbabwe, the Minister hereby declares an emergency for a period of six
months, with effect from the date of promulgation of this notice, for the
purpose of enabling the State or a person authorised by the Minister under
section 34 of the Act
(a) to make or use any patented drug, including any antiretroviral drug, used
in the treatment of persons suffering from HIV/AIDS or HIV/AIDS related
conditions;
(b) to import any generic drug used in the treatment of persons suffering
from HIV/AIDS or HIV/AIDS-related conditions.
P. A. CHINAMASA Minister of Justice, Legal and Parliamentary Affairs.
24-5-002
Once the extended period of emergency had been proclaimed, several companies
applied for authorisation to supply antiretrovirals, with a locally-registered company
Varichem Pharmaceuticals [Pvt] Ltd being granted authority to ‘produce antiretro-
viral or HIV/AIDS-related drugs and supply three-quarters of its produced drugs to
State-owned health institutions’ at prices that ‘shall be fixed subject to price control
mechanisms to be determined by the Minister.’77 Subsequently, another local
company Datlabs, and a local agent Omahn, were authorised to import ARVs
from Indian companies Ranbaxy and Cipla, respectively. The authorisation did not
77As quoted in Cecilia (2006), p. 26.
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specify the rate of royalty payable, but it appears that the rate offered was 4% of the
value of the generic medicines actually delivered.78
5.1.3 Lessons
The provisions discussed above represent an expeditious mechanism to enable
access to medicines in the context of a declared public health emergency. A number
of important lessons may be drawn from this example.
Firstly the importance of effective enabling legislation, so that clear guidelines are
available in the law to institute the use of this flexibility, supplemented by detailed
mechanisms in the regulations.
Secondly, an expedient administrative rather than judicial procedure, both for the
issuance of a compulsory licence, as well as the operation of the government use
licence. It is vital that such a procedure is time-saving and cost-effective.
Thirdly, various other access-friendly considerations were tied in with this public
health flexibility, namely: advancing the industrial policy objective of promoting
local production; cost-saving measures such as the use of generic medicines; and the
employment of price controls to make the medicines affordable to the State.
However, medicines prices generally continue to be high in both the private and
public sectors in Zimbabwe, with one study showing that public sector prices were
higher than average prices for medicines in seven other African countries,79 although
subsequent public sector prices for essential medicines have declined.80 Since the
establishment of the Unitaid Medicines Patent Pool, and the inclusion in its coverage
of all WHO-recommended ARVs, all sub-Saharan African countries are included in
the category of eligible countries, rendering the use of flexibilities superfluous for
such medicines. However, as there are no such licensing arrangements for a range of
other highly-priced essential medicines, the need to utilise TRIPS flexibilities
continues to exist.81
78Ibid.
79See Gavaza et al. (2009), https://www.researchgate.net/publication/51704733_The_prices_
people_pay_for_medicines_in_Zimbabwe.
80Marume et al. (2018), https://www.ajol.info/index.php/cajm/article/view/164302.
81Hoen et al. (2018), https://joppp.biomedcentral.com/articles/10.1186/s40545-018-0157-7.
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5.2 The South African Case
5.2.1 Legal Framework
Despite the existence of relevant provisions in over a century of patent legislation,82
not a single compulsory licence has been granted on a pharmaceutical-related patent
in South Africa.83 The existing legislation provides for compulsory licences in cases
of (1) dependent patents,84 and (2) abuse of patents. In the latter case, the following
permissible grounds are enumerated:
• The patented invention is not being worked in the country on a commercial scale
or to an adequate extent;
• The demand for the patented article is not being met to an adequate extent and on
reasonable terms; (One proposed policy option available in this regard is that ‘a
price charged by the patent holder that bears no reasonable relation to the
marginal or average variable cost of manufacturing the item shall be deemed
unreasonable.’)85
• The refusal to license on reasonable terms prejudices trade, industry or agriculture
in the country, and it is in the public interest that a licence be granted; and
• The demand is being met by importation and the price charged is excessive in
relation to the price charged in countries of manufacture.86
The government use provision states that ‘a Minister of State may use an
invention for public purposes on such conditions as may be agreed upon with the
patentee, or in default of agreement on such conditions as are determined by the
commissioner (of patents) on application by or on behalf of such Minister and after
hearing the patentee.’87 The requirement of ‘on such conditions as may be agreed
upon with the patentee’ is, of course, TRIPS-plus in that TRIPS Article 31
(b) expressly waives this requirement in certain circumstances, in particular for
public non-commercial use.
For reasons that are explored more fully below, which include the problem of
AIDS denialism, pressure from the US government and the legal difficulties of
82Patents Act No 57 of 1978, s 56 provides a limited number of grounds for the issuance of
compulsory licences, and s 4 permits government use (albeit still requiring prior agreement on the
terms).
83See, for example: Vawda (2018), https://www.southcentre.int/wp-content/uploads/2018/12/
RP90_Compulsory-Licensing-Jurisprudence-in-South-Africa-Do-We-Have-Our-Priorities-Right_
EN-1.pdf; Yousuf A Vawda (2013), “Country Case Study: South Africa. In Correa (2013) https://
www.southcentre.int/wp-content/uploads/2016/05/Bk_2013_Pharmaceutical-innovation_EN.pdf.
84Patents Act 57 of 1978, s 55.
85See United Nations Development Programme (2013), p. 68.
86Patents Act 57 of 1978, ss 56(a), (c), (d) and (e) respectively.
87Patents Act, s 4.
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succeeding in compulsory licensing applications,88 advocates of access to medicines
have had to seek other flexibilities to advance their cause.
It has been said that the key to successful rights litigation is both the framing of
access issues as human rights claims, as well as having this framing embedded in
domestic law.89 Although South African treatment activists have been successful in
framing their access to health care and medicines campaigns in terms of human
rights norms, they have been less successful in having this paradigm inserted in IP
contests in the courts.90 Sometimes presented as the use of compulsory licensing in
South Africa,91 the most successful use of a TRIPS flexibility in the country was the
invocation of competition law and policy to challenge excessive prices and refusal to
licence key ARVs. In the first 2002 Hazel Tau case, after the Competition Commis-
sion found probable violations and prior to the Competition Tribunal considering the
Commission’s request to grant anti-competition compulsory licences, the patent
holders settled by granting licences to multiple generic companies allowing sales
throughout the region, thus increasing affordable access to medicines.92 The second
case, in 2007, involved a complaint against another company on the grounds of
refusal to licence.93 Here again, the company negotiated voluntary licences, with
similar results.94
In this instance, not only was the general framing in terms of human rights norms
evident, but the legislation in terms of which the complaint had been lodged was
expressly grounded in transformative and rights-based terms:
The people of South Africa recognise:
That apartheid and other discriminatory laws and practices of the past resulted in
excessive concentrations of ownership and control within the national economy, weak
enforcement of anti-competitive trade practices. and unjust restrictions on full and free
participation in the economy by all South Africans.
That the economy must be open to greater ownership by a greater number of
South Africans.
88See Sects. 5.2.2, 5.2.3 and 5.2.4 below.
89See, for example: Land (2013) https://www.academia.edu/10455316/Human_Rights_Frames_
in_IP_Contests?email_work_card¼view-paper; and Berger and Kapczynski (2009) Human Rights
Advocacy Stories https://papers.ssrn.com/sol3/papers.cfm?abstract_id¼1323522.
90See discussion below in respect of the approach of South African courts to employing a human
rights lens in IP disputes, despite having a strong Bill of Rights in its Constitution.
91See Medicines Law and Policy, “The TRIPS Flexibilities Database”.
92Hazel Tau and Others v GlaxoSmithKline and Boehringer Ingelheim (Competition Commission)
Case No 2002Sep226, in which patients and civil society organisations complained to the Compe-
tition Commission that the named pharmaceutical companies had abused their dominant position in
the ARV market, refused to license an essential facility, and engaged in excessive pricing. The
Commission found against the companies, and its request to the Competition Tribunal was to order
compulsory licences. As indicated, the dispute was settled prior to this hearing with the companies
agreeing to grant several voluntary licences for the medicines involved.
93Treatment Action Campaign v MSD (Pty) Ltd & Another (November 2007) Competition Com-
mission of South Africa.
94United Nations Development Programme (2013), pp. 93–95.
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That credible competition law, and effective structures to administer that law are
necessary for an efficient functioning economy.
That an efficient, competitive economic environment, balancing the interests of
workers, owners and consumers and focussed on development, will benefit all
South Africans.95
This legal text is significant in that it situates competition law in the context of
South Africa’s history, distorted by apartheid, and outlines a developmental path to
the application of competition law in the country.
5.2.2 AIDS Denialism
The unfortunate chapter of AIDS denialism in South Africa’s lack of response to the
pandemic and the resultant avoidable and unnecessary deaths has now been well
documented.96 In the context of the government’s questioning of the connection
between HIV and the resulting disease syndrome as well as the efficacy of ARVs and
other medicines having rendered the question of treatment highly controversial,
prospects for the use of compulsory licences were remote.
5.2.3 US Pressure
Early legal challenges and threats against South Africa, Brazil and Thailand on
proposed and purported use of compulsory licences have also been well
documented.97 In addition, over the past two decades, the US has threatened many
countries contemplating such use and routinely placed them on its Special
301 Reports under the US Trade Act of 1974. As commentators have noted, while
such threats are usually bluster, it has not stopped some countries (such as India and
Brazil) from backing down.98 No doubt, such threats have a chilling effect on
countries seeking to preserve their trade relations with the US.
The use of TRIPS flexibilities has increasingly come under attack in recent
bilateral and regional trade agreements involving the US. In particular, the US has
sought to constrain the use of compulsory licensing by, for example, limiting the
95Competition Act No 89 of 1998, Preamble. The emphasis here is on the final sentence.
96See, for example, Nattrass (2005) https://www.sahistory.org.za/sites/default/files/nattrass_
hivaids_policy.pdf; and Geffen and Cameron (2009) Centre for Social Science Research Aids
and Society Research Unit, CSSR Working Paper No 257 https://open.uct.ac.za/bitstream/item/
22585/Geffen_deadly_hand_denial_2009.pdf?sequence¼1.
97See, for example: Oxfam (2001), https://oxfamilibrary.openrepository.com/bitstream/handle/
10546/620381/bn-access-to-medicines-south-africa-010201-en.pdf?sequence¼1&isAllowed¼y;
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grounds to: remedying anti-competitive practices, or in cases of public
non-commercial use, or of national emergency or other circumstances of extreme
urgency (as in the Australia-US Free Trade Agreement).99 This strategy ‘has been
characterised by a progressive “ratcheting up” of IP protections for pharmaceuticals,
with provisions intended to prolong monopolies, support high prices and frustrate
market entry of generic medicines—all of which undermine access to affordable
medicines.’100
In South Africa, neither the government nor the judiciary appears to have had any
appetite for compulsory licences, despite the declarations of its representatives at
global fora.101
Previous calls by civil society and generic manufacturers on the government to
implement the provisions of the Patents Act to this end have gone unheeded.102
Currently, patient groups are again engaging the government to issue compulsory
licences in respect of newer ARVs, and drugs for use in the treatment of cancer and
tuberculosis.103
5.2.4 Judicial Deference
An analysis of compulsory licence applications on pharmaceutical and chemical
products before the Commissioner of Patents (High Court) or the Supreme Court of
Appeal of South Africa during the period 1978 - 2018 revealed that not a single
compulsory licence had been issued, nor has one been issued since the advent of
patent legislation in the country in the early twentieth century.104
In summary, the case analysis highlighted the following lines of reasoning
adopted by the courts in rejecting such applications:
• The failure on the part of the applicant to discharge the evidentiary burden that the
patent had been abused.105
• The concept of working a patent included exploitation, which was interpreted
widely enough to entail working by importation.106
99See Lopert and Gleeson (2013), pp. 199–223 http://onlinelibrary.wiley.com/doi/10.1111/jlme.
12014/abstract.
100Lopert and Gleeson (2013), p. 199.
101See, for example, WIPO (2016) https://www.wipo.int/edocs/mdocs/scp/en/scp_25/scp_25_6.
pdf.
102See, for example, Oxfam (2001), pp. 2–3.
103See Medicins Sans Frontieres (2015) https://www.msf.org/south-africa-should-override-patent-
key-hiv-medicine-after-widespread-stock-out-problem; and Fix the Patent Laws Campaign (2019)
https://www.fixthepatentlaws.org/.
104Vawda (2018), p. 90.
105Syntheta (Pty) Ltd v Janssen Pharmaceutica NV & Another 1999 (1) SA 85 SCA.
106Sanachem (Pty) Ltd v British Technology Group PLC 1992 BP 276 (CP).
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• With regard to the amount of remuneration, that it was not unreasonable to charge
a royalty which the trade would carry.107
• Regarding negotiating reasonable terms for a licence, the court required evidence
indicating, with reasonable precision, what reasonable terms are.108
• That a charge of unreasonable terms is not established merely on proof that the
compulsory licensing applicant can sell the same sort of article at a lower price.109
Absent from this formalistic reasoning were any considerations of the level of
development of the country, the socio-economic status of the majority of it popula-
tion, or the impact of the price of the medicines on access to health care.
Of significance is the manner in which the courts have approached the dispute
between the patent holder and patent challenger. Thus, in an application (Aventis)110
for, among others, a temporary interdict (injunction) based on an infringement claim
against a generic drug manufacturer, the court refused, despite being requested, to
consider the impact of the interdict on the supply of medicines and adjudicate the
case through the lens of the Constitution and its Bill of Rights.111 It further took a
rather narrow view on the question of awarding damages (royalties) as an alternative
to the interdict, holding that this would be tantamount to granting a compulsory
licence. Article 44.2 of the TRIPS Agreement permits this option and there is now
strong precedent for the granting of judicial, royalty-bearing licences instead of
injunctions from the US Supreme Court.112 Even though the court in Aventis
acknowledged that the issue of patent validity (which had been challenged) still
stood to be determined in revocation proceedings, it refused to accept this less
restrictive means of resolving an interim dispute, and appears to have disregarded
the social value of the alleged infringing product in its considerations.
There are several other instances of what appear to be deference towards the
interests of patent holders. One relates to the anomalous practice in infringement
proceedings that, even if it were found that the invention was not patentable, it would
remain valid absent a counterclaim for revocation.113 The effect of this approach is
that in infringement proceedings, even if the defence of invalidity is successful
thereby defeating an infringement claim, the patent remains on the register, and
the proprietor can sue others on the patent.
Another instance where the prerogatives of the patent holder are prioritised are
the so-called interlocutory applications for amendments to patent specifications,
where the court has relieved the applicant (the patent holder) of the burden of
107Sanachem (Pty) Ltd v British Technology Group PLC 1992 BP 276 (CP).
108Afitra (Pty) Ltd and Another V Carlton Paper of SA (Pty) Ltd 1992 BP 331 (CP).
109Afitra (Pty) Ltd and Another V Carlton Paper of SA (Pty) Ltd 1992 BP 331 (CP).
110Cipla Medpro v Aventis Pharma (139/12); Aventis Pharma SA v Cipla Life Sciences (138/12)
[2012] ZASCA 108 (26 July 2012).
111Constitution of the Republic of South Africa (1996).
112eBay Inc. v MercExchange, L.L.C. 547 U.S. 388 (2006). See also the Indian High Court decision
of Hoffman La Roche v. Cipla & Anr, IA No. 642/2008 in CS (OS) No, 89.2008.
113Strix Ltd v Nu-World Industries (Pty) Ltd 2016 (1) SA 387 (SCA).
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providing full reasons for the amendment.114 The Bateman judgment cites with
approval another decision (Kimberly-Clark),115 despite the fact that the latter deci-
sion in fact adopts the opposite approach. In addition, this court adopted the
approach that ‘it is in the public interest that patents should be rectified or validated
by way of amendment’116 without having regard to the impact of the continuing
validity of the patent on the broader public interest. Any appreciation of the notion of
‘access’ as a public interest in relation to an essential product, facility or service is
absent.
It is therefore contended that the very architecture of the patent landscape, the
rather limited grounds on which an application for a compulsory licence may be
brought, combined with the overly formal approach to judicial interpretation and
adjudication, including an apparent deference to patent holders over the general
public, may be responsible for the dearth of such applications, and hence the lack of
their grant. It must be noted in passing that generic manufacturers are unlikely to
apply for compulsory licences unless there are sufficient commercial prospects,
given that the South African pharmaceuticals market is relatively small. And, as
regards those medicines covered by the Medicines Patent Pool, South Africa is
already benefiting from this initiative.117
5.2.5 New IP Policy Phase I
In 2018 after a protracted civil society-led campaign,118 the South African Cabinet
approved a new IP policy, premised on public health,119 in recognition of the abject
failure of the present system to adequately meet the need of the general public to
access affordable medicines. The IP Policy draws its inspiration from the Constitu-
tion of South Africa, and recognises that ‘there is a need for a comprehensive IP
Policy that will promote a holistic, balanced and coordinated approach to IP that is
mindful of the many obligations mandated under the South African Constitution.’
The policy expressly recognises the need to reform the regime as it relates to
compulsory licences, both in terms of their scope and procedure for application, as
well as for the establishment of guidelines for expedited government use.120
114Bateman Equipment Ltd and Another v The Wren Group (Pty) Ltd 2000 (1) SA 649 (SCA).
115Kimberly-Clark of South Africa (Pty) Ltd formerly Carlton Paper of South Africa (Pty) Ltd v
Proctor & Gamble (Pty) Ltd (A488/96) [1998] ZASCA 39.
116Bateman Equipment Ltd and Another v The Wren Group (Pty) Ltd 2000 (1) SA 649 (SCA).
117See footnote 80 and accompanying text.
118Baker (2015-16), pp. 309–343 documents the origins of such a campaign.
119Republic of South Africa (2018) https://www.thedti.gov.za/news2018/IP_Policy2018-Phase_I.
pdf.
120Republic of South Africa (2018), p. 28.
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6 Compulsory Licensing Options Under TRIPS
As indicated,121 the TRIPS Agreement does not limit the grounds upon which
licences can be granted. The robust discourse over the last two decades around the
use of TRIPS flexibilities and, in particular compulsory licensing, had provided
policy-makers, legislators and advocacy groups with a panoply of options to con-
sider122 in relation to various aspects of this flexibility: broad grounds, easy-to-use
procedures, and royalty guidelines and rates that are not so onerous that they
frustrate generic competition and hence access to affordable medicines.
6.1 Expanded Grounds for Compulsory Licences
The expanded grounds for the issuance of compulsory licences that may be consid-
ered are:
• The patent is not worked or not fully worked in the country by the patent holder
including that the invention is not available to the public at a reasonably afford-
able price; or that it has not been worked locally other than by importation and the
patent holder fails to demonstrate that it is not economically or technologically
feasible to manufacture it in whole or in part in the country;
• The patent is worked by the patent holder or licensee in a form and by means that
are harmful to or abusive of the public interest;
• The price charged by the patent holder bears no reasonable relation to the
marginal or average variable cost of manufacturing the item and is deemed to
be unreasonable;
• The patent can be worked locally on a feasible economy of scale and may benefit
the general public; or through a licence granted for importation where it is
considered advantageous to do so;
• There is an emergency or other urgent matter of national interest, in which case
prior negotiation for a licence on reasonable commercial terms is not required;
• There is a risk of supply interruptions of essential products such as medicines;
• There is a need to promote local production and technology transfer;
• There is any other public interest or public health need;
• The patent holder has been found to have engaged in an anti-competitive practice;
• Where the invention, being a medicine or other public necessity, is not available
to the general public or a significant group of patients, the relevant tribunal is
121See Sect. 3 above.
122These options are drawn primarily from United Nations Development Programme (2013),
pp. 57–71; Baker and Vawda (2017), pp. 40–60 https://www.fixthepatentlaws.org/submission-by-
university-of-kwazulu-natal-affiliated-academics-on-sa-draft-intellectual-property-policy/.
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enabled to grant, on application, a presumptive licence subject to a reasonable and
affordable royalty;
• Where the country lacks sufficient capacity to produce a medicine patented in that
country, a compulsory licence may be issued for the importation of the product;
and conversely for a compulsory licence to be issued in the manufacturing
country where that medicine is under patent, for the purpose of supplying a
country with insufficient manufacturing capacity, in terms of a streamlined,
easy-to-use procedure. Alternatively, to adopt Article 31bis of the TRIPS Agree-
ment and the Annex to it;
• The grant of a judicial licence in cases alleging infringement, as a satisfactory and
less restrictive alternative to the grant of an interdict or injunction;
• Where it is not possible to execute the licence granted on any of the foregoing
grounds based on patent disclosures alone, a compulsory licence may be granted
on otherwise confidential manufacturing know-how, subject to prior negotiation,
payment of reasonable royalty, and non-exclusivity and non-assignability; and
• Where a product is already on the market while the patent application regarding a
needed invention (such as a medicine to respond to an epidemic) is still pending, a
provisional compulsory licence may be granted to take effect when the relevant
patent/s are granted.
6.2 Government Use
With regard to government use licences, these need to be expeditious and easy to
implement. The following formulation has been proposed:123
• Any properly designated public official or government contractor, domestic or
foreign, receiving the authorisation or consent of the government of a country,
may make public, non-commercial use of a patent.
• No prior negotiation with the patent holder is required, it being necessary only to
promptly notify the holder of such use.
• For the purposes of this provision, the use or manufacture of an invention
described in and covered by a patent granted in the country by a contractor,
sub-contractor, or any person, firm or corporation for the government and with
the authorisation or consent of the government, shall be construed as use for that
country.
123Baker and Vawda (2017), pp. 47–49.
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6.3 Adequate Remuneration
As regards remuneration of the right holder, TRIPS Article 31(f) requires adequate
remuneration based on the economic value of the licence in the country issuing
it. The following formulation has been proposed:124
• Remuneration Guidelines shall specify a normal royalty of 4% of wholesale cost,
with an upward adjustment of no more than 2% based on disclosed, extraordinary
research and development costs or therapeutic breakthrough in the case of
pharmaceuticals. The rate could be adjusted downwards by the same margin
based on the use of public funds in the research, or if the holder has already
recovered significantly more than its research and development costs as adjusted
for risk and opportunity costs.
6.4 Procedures for Compulsory Licensing Applications
As indicated, procedures for compulsory licensing should be expeditious and easy-
to-use. Expedited administrative procedures, rather than judicial processes, which
are both more time-consuming and expensive, should be used. The TRIPS Agree-
ment requires judicial process only in relation to independent administrative review
in respect of the legal validity of a licence and the amount of remuneration.125 The
following formulation has been proposed:126
• Examination of an application for a compulsory licence shall be conducted by the
relevant authority or tribunal.
• The relevant authority or tribunal shall by notice summon the patent holder and
applicant to hear their evidence and opinions, and shall stipulate time periods for
the submission of evidence, opinions and other matter.
• Should the patent holder not respond to the notice within 2 months, the patent
holder will be presumed to have no objection to the issuance of the compulsory
licence.
6.5 Collaboration and Cooperation in the Issuance of CLs
Finally, there are significant benefits to cooperation between countries on the
issuance of compulsory licences. Groups of developing countries could, for exam-
ple, pool their procurement needs and coordinate the proposed use of compulsory
124Baker and Vawda, “Submission by University of KwaZulu-Natal-Affiliated Academics”, 56–58.
125TRIPS Agreement, art 31(i) and (j).
126Baker and Vawda (2017), pp. 58–60.
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licences for selected medicines, thereby generating sufficient economies of scale to
make it viable for generic manufacturers to enter those markets.127
An interesting variant of this approach is that permitted by Article 31bis of
TRIPS:
With a view to harnessing economies of scale for the purposes of enhancing purchasing
power for, and facilitating the local production of, pharmaceutical products: where a
developing or least developed country WTOMember is a party to a regional trade agreement
. . . at least half of the current membership of which is made up of countries presently on the
United Nations list of least developed countries, the obligation of that Member under Article
31(f) shall not apply to the extent necessary to enable a pharmaceutical product produced or
imported under a compulsory licence in that Member to be exported to the markets of those
other developing or least developed country parties to the regional trade agreement that share
the health problem in question. It is understood that this will not prejudice the territorial
nature of the patent rights in question.128
Thus, for example, all member states of the Southern African Development
Community can benefit from this collaborative and pooled procurement mechanism,
as 9 of the 15 members are LDCs,129 or those of the East African Community as
well, with 4 of its 5 WTO-member states being LDCs.
A strong case has been made that, for African countries to make optimal use of
compulsory licensing, they must develop strong manufacturing capacity in the
pharmaceutical sector. This is imperative because, as the emerging economies in
Asia have begun ‘to implement a more protectionist intellectual property framework,
Africa is ill-advised to continue relying on generic manufacturers in Asia for access
to affordable pharmaceuticals.’130 The African Union’s Pharmaceutical Manufactur-
ing Plan for Africa131 has increasingly been promoting national and regional col-
laboration in order to achieve greater self-sufficiency and a sustainable supply of
pharmaceuticals for the continent.
6.6 A Compulsory Licensing Facility
Another novel proposal to address the inadequate and uncoordinated use of com-
pulsory licensing is that of the establishment of a compulsory licensing facility or
consortium (CL Facility).132 In a submission to the UN Secretary-General’s High
127See Reichman (2009), pp. 247–263.
128TRIPS Agreement, art 31bis 3.
129Hoen et al. (2018).
130Owoeye (2014), pp. 92, 217 http://www9.who.int/bulletin/volumes/92/3/13-128413/en/.
131African Union (2012), https://apps.who.int/medicinedocs/documents/s20186en/s20186en.pdf.
132See Baker (2016a) http://www.unsgaccessmeds.org/inbox/2016/2/27/brook-baker?rq¼brook%
20baker; Baker (2016b) http://www.unsgaccessmeds.org/inbox/2016/2/26/z73kpodxk4jw96mhqe
2tivq0sd1g3v.
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Level Panel on Access to Medicines, the aims of the proposed CL Facility are stated
as being to:
• undertake a series of analyses on all possible options for compulsory licences, the
conditions and circumstances of their use, and their implications for access to
medicines;
• develop and support the implementation of model legislation effectuating the
optimal use of compulsory licences and government use orders; provide technical
and advocacy assistance for their adoption and use both nationally and regionally
(to enable aggregated markets to sustain production and access to medicines).
7 Conclusion
Developing countries and LDCs, particularly, face many challenges with both the
domestication and also the implementation of TRIPS flexibilities, including com-
pulsory licences and government use. Many of these are not insurmountable, such as
the need for political will, the ability to resist trade and political pressures, and the
engagement of appropriate technical assistance. In some instances, such as in
South Africa, there is the additional reluctance of the judicial system to apply
access-friendly interpretations of IP law in line with its Constitution and Bill of
Rights.
In the two case studies presented here, the prospects for the use of compulsory
licensing and government use are not encouraging. Although Zimbabwe used this
flexibility in the instances cited more than 10 years ago, it has not done so since then.
In South Africa, it has never been used despite many compelling circumstances and
strong appeals. There is great expectation that the new IP Policy, once legislated,
ought to clear the path for easy use of these forms of licensing. Thereafter it will be
entirely up to the political will of government to act on the legislation.
The current COVID-19 pandemic has brought into sharp relief the inequality that
exists both among countries of the world, and within them. Access to any vaccines
and other therapies that may be developed cannot be guaranteed, because they are
likely to be protected by various forms of intellectual property rights, and hence only
be available at a high cost. In this context, compulsory licensing and government use
remain an important option for, particularly, developing and least developed coun-
tries to ensure access to such health technologies.
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Access to CRISPR Genome Editing
Technologies: Patents, Human Rights
and the Public Interest
Duncan Matthews
Abstract While detailed debates are underway about the scientific and ethical
implications of genome editing, this chapter argues that greater attention should be
paid to the patent policy issues that these technologies raise. The chapter argues that
WTO Members need to consider urgently the implications of patenting genome
editing inventions for human rights and the public interest, taking into account
Article 27.2 of the TRIPS Agreement, which provides that Members may exclude
from patentability inventions, the prevention within their territory of the commercial
exploitation of which is necessary to protect ordre public or morality. Furthermore,
while genome editing has great potential to transform healthcare and the wellbeing in
society across a broad range of scientific fields, the granting of patent rights for these
technologies will have profound implications for affordability and access, particu-
larly for people living with chronic lifelong illnesses and for future generations not
yet born who are at risk of inheriting preventable medical conditions from their
parents. The chapter argues that WTO Members need to consider carefully the
impact of granting of genome editing patents, balancing the need to reward
inventorship while at the same time having regard to implications for affordability,
access and the enjoyment of fundamental human rights.
1 Introduction
Genome editing technologies hold great potential for scientific research and society.
They provide fast, efficient, precise and relatively inexpensive tools to modify the
cells of any living organism. Using genome editing techniques, cells of the body
(somatic cells) can be modified, potentially curing patients of chronic, lifelong
illnesses. Editing the genome of human embryos can also modify the germline
identity of human beings, eradicating hereditary diseases in new-born babies and
creating resistance to life-threatening conditions for future generations. There is also
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great potential for non-human uses of genome editing technologies. New varieties of
plants can be developed that are disease resistant or have a higher crop yield, while
new breeds of farmed animals or marine life can be introduced into the food system
in order to offer a broader range of options to consumers and to contribute positively
to food security.
The great potential of genome editing is due to the fact that it offers a relatively
simple tool to change any organism’s deoxyribonucleic acid (DNA). This allows
genetic material to be added, removed or altered in particular locations in the
genome. Genome editing technologies can be divided into four types: zinc finger
nucleases (ZFNs), transcription activator-like effector nucleases (TALENs),
meganucleuses and CRISPR (Clustered Regularly Interspaced Short Palindromic
Repeats). All four work by inducing a natural cellular repair mechanism designed to
repair breakages in DNA but the first three are considered more difficult, less precise
and more time-consuming process than CRISPR.
Since 2012, CRISPR has been used in combination with Cas9 (CRISPR associ-
ated protein number 9, which plays a vital role in the natural immunological defence
system of the body) to guide and cut DNA, and therefore alter, a cell’s genome. It
does not fundamentally differ from the previously known genome editing technol-
ogies but the additional advantages of the CRISPR-Cas9 system lie in its ability to
provide a faster, cheaper, more accurate and more efficient method than other
previously known genome editing techniques.1 For instance, if there is a mutation
in the genome, CRISPR-Cas9 makes it possible to search, delete and even replace
it.2 A simple analogy would be with a word processor document, whereby the author
can search for, delete and replace a typographical error.3
Yet genome editing raises new challenges in terms of how governance systems
regulate technologies and involves key public policy imperatives, particularly those
of human rights, fair and equitable access to the benefits of this new technologies’
use, and how governance systems can act in the public interest.
In the patent policy debate on genome editing technologies thus far, preliminary
studies have already been undertaken into the patentability of CRISPR-Cas9 inven-
tions under United States (U.S.) law,4 while claims have been made that patent law
in Europe is already fit for purpose.5 Elsewhere, various studies have examined the
extent that licensing practices can enable or impede research,6 how patent-holding
1See also National Institutes of Health (NIH), U.S. National Library of Medicine, Your Guide to
Understanding Genetic Conditions: What Are Genome Editing and CRISPR-Cas9? https://ghr.nlm.
nih.gov/primer/genomicresearch/genomeediting
2The human genome is about 300 billion letters long and, so far, scientists have identified
approximately 6000 mutations.
3This analogy with word processing was used, for example, in the presentation by Feng Zhang
(Broad Institute) at the Program on Science, Technology and Society Workshop on Editorial
Aspirations: Human Integrity at the Frontiers of Biology, 26–28 April 2017, Harvard University.
4Deborah (2017), p. 408; Hannah Mosby (2018), p. 579.
5All European Academies (ALLEA) (2016).
6Sherkow (2017a), p. 565; McMahon (2020) op. cit. n 6.
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universities grant exclusive licences to private companies which stand in as surro-
gates for the institutions themselves,7 and how ethical licensing can be used as a tool
of privately driven governance,8 with evidence that the private governance function
of patents is often overlooked.9 Other studies have advocated using international law
to facilitate agreement on the governing principles,10 particularly to identify appro-
priate limitations to the CRISPR toolkit.11 Elsewhere research exemptions have been
advocated as mechanisms to guarantee freedom to operate alongside patent pools,
clearing houses and compulsory licences in order to help to facilitate access to
patented genome editing technologies.12
Rather less attention has been paid to the extent that patents for genome editing
technologies can be considered barriers to affordable healthcare that infringe the
fundamental rights, particularly the right to health.13 Greater attention needs to be
paid to the extent that the patent issues that CRISPR-based therapies raise can have
adverse implications for public health.14
Fair and equitable access to healthcare in the context of the right to health is
underpinned by the fundamental principle that everyone should have access to the
health services they need, when and where they need them, without suffering
financial hardship.15 This principle takes as its legal basis Article 25.1 of the
Universal Declaration of Human Rights, 1948, which states explicitly that “([E]
veryone has the right to a standard of living adequate for the health and well-being of
himself and his family, including food, clothing, housing and medical care. . .” and
by Article 12.1 of the United Nations International Covenant on Economic, Social
and Cultural Rights, which states that “[T]he States parties to the present Covenant
recognize the right of everyone to the enjoyment of the highest attainable standard of
physical and mental health”.16
This chapter will argue that, in debates about the inter-relationship between
patents, fair and equitable access to human genome editing, greater attention needs
to be paid to human rights approaches, taking into account the public interest. As
such the patent system needs to be considered carefully from a human rights
perspective when the governance of genome editing is scrutinised. This human
7Contreras and Sherkow (2017), p. 698.
8Guerrini et al. (2017), p. 22.
9McMahon (2020), p. 161.
10Tsung-Ling (2019), p. 1.
11Sadie (2019), p. 1.
12Van Overwalle et al. (2006), p. 143.
13For a general discussion see on the relationship between patents, access to healthcare and the right
to health see Matthews (2015), pp. 496–512.
14For a preliminary study see Sherkow (2017b), p. 667.
15Health is a fundamental human right. Statement by Dr Tedros Adhanom Ghebreyesus, WHO
Director-General, 10 December 2017: https://www.who.int/mediacentre/news/statements/funda
mental-human-right/en/.
16For further discussion see Matthews (2010), pp. 118–139.
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rights approach to the study of patents for genome editing technologies is under-
developed and, the chapter will argue, must take place if governance institutions are
to understand fully the impact of granting of genome editing patents, balancing the
need to reward inventorship with affordability, access and the enjoyment of funda-
mental human rights.
In order to address these issues, the chapter will first provide an explanation of the
human genome and how CRISPR-Cas9 genome editing works, highlighting the
huge potential genome editing of the germline identity of humans for individuals and
for society. The chapter will then turn attention to recent patenting controversies,
highlighting the genome editing patent disputes that have already taken place in the
U.S. and Europe.
Observed through the lens of recent patent disputes in the U.S. and Europe, the
chapter will argue that World Trade Organisation (WTO) Members need to pay
greater consideration of the patent policy implications of genome editing. Such
consideration is imperative in order to ensure that the granting of private rights
can be accommodated on an equitable basis, balanced alongside the need to avoid
unnecessary risk (including ordre public and morality exceptions under patent law),
taking into account human rights principles, meeting public expectations, ensuring
fair and equitable access, and acting in the public interest with regard to these
potentially transformational healthcare technologies.
By way of limitation, it should be stated from the outset that this chapter is
concerned primarily with editing the human germline, given that this specific
application of genome editing technologies accords most closely with (and has
most immediacy for) concerns about the patent policy implications in terms of the
impacts on society outlined above. While it should be acknowledged that many of
the issues considered in this chapter apply equally to somatic therapeutic uses (the
cells of the body that are not involved in reproduction) and to agricultural or fisheries
food production, germline applications will remain the chapter’s primary focus.
2 The Human Genome
The human genome is contained in 23 pairs of chromosomes (22 autosomes and
1 pair of sex chromosomes) in a sequence of paired chemical bases that are held
together in the long molecules of DNA that are present in almost all the cells of the
body. The genome is the complete set of genes—regions of the DNA molecule of
varying length that usually encode proteins that perform distinct biological func-
tions—together with interspersed non-coding regions that regulate when the genes
are expressed.17
17Nuffield Council on Bioethics, Genome Editing and Human Reproduction: Social and Ethical
Issues (2018), p. 7.
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Although all people have similar sets of genes, no two people have exactly the
same genome. Even the genomes of “identical” (monozygotic) twins may differ
owing to errors in DNA replication and somatic mutations, as well as acquired
differences in their epigenomes.18 Some of the genomic differences between people
produce differences in their appearance or in their physiology (known as their
“phenotype”), while others have no observable effects. Although genomic differ-
ences can be highly significant for the expression of disease-related and other
characteristics, many of the differences between people that are observable or
medically significant arise from the combined effects of genetic, environmental
and biographical factors. The Nuffield Council on Bioethics, for instance, has
pointed out that environmental factors can cause changes in genes that may increase
susceptibility to cancers.19
From time to time, inherited genomic variations result in disease or confer a
predisposition to disease. This usually comes about due to small changes in the
genome, which may be transmitted to future generations. These changes can affect
the production of proteins in cells, as well as the regulatory regions of genes or genes
that encode a ribonucleic acid (RNA) product. Inherited genetic conditions include
life-limiting conditions such as Duchenne muscular dystrophy and cystic fibrosis.
Genetic conditions are also significant causes of infertility, pregnancy loss and
neonatal death.20 Additionally, even the same genetic mutation can differ signifi-
cantly in terms of the way it is manifested in the people affected (their “phenotype”)
and the consequences that this may have for the length or quality of their lives. This
is because the function of some genes can be modified by other genes, as well as by
environmental factors. In the case of single gene disorders, such as Huntingdon’s
Disease, it is therefore possible that multiple variants in the same genome affect the
associated phenotype. These are sometimes referred to as “modifier genes”.21
Thus far, over 10,000 single gene disorders have been identified which are
associated with an alteration in a region of a single gene that affects the biological
function of that gene product. Individually, single gene disorders are usually rare, but
collectively they affect at least one in every hundred people born worldwide. Since
they can be inherited and because of the way humans have evolved, migrated and
18The epigenome is a multitude of chemical compounds that can tell the genome what to do. The
human genome is the complete assembly of DNA (deoxyribonucleic acid)-about 3 billion base
pairs—that makes each individual unique. DNA holds the instructions for building the proteins that
carry out a variety of functions in a cell. The epigenome is made up of chemical compounds and
proteins that can attach to DNA and direct such actions as turning genes on or off, controlling the
production of proteins in particular cells. When epigenomic compounds attach to DNA and modify
its function, they are said to have “marked” the genome. These marks do not change the sequence of
the DNA. Rather, they change the way cells use the DNA’s instructions. The marks are sometimes
passed on from cell to cell as cells divide. They also can be passed down from one generation to the
next. Source: National Human Genome Research Institute, Epigenomics Fact Sheet: https://www.
genome.gov/about-genomics/fact-sheets/Epigenomics-Fact-Sheet.
19Nuffield Council on Bioethics (2018), op. cit. n 17, 7.
20Zorrilla and Yatsenko (2013), p. 1; Hyde and Schust (2015), p. 5; Wojcik et al. (2018), p. 20.
21Nuffield Council on Bioethics (2018), op. cit. n 17, 8.
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mixed or, in some cases, become geographically isolated, some genetic disorders
tend to be associated with particular ethnic groups.
An example is the blood disorder beta thalassaemia, which occurs more com-
monly among people of Mediterranean origin; another is sickle cell disease, which is
more prevalent in Afro-Caribbean groups. In Europe, one of the most widely known
single gene disorders is cystic fibrosis, which arises in children of parents who each
have an altered copy of the cystic fibrosis transmembrane conductance regulator
gene when the child inherits both mutated alleles. While many genetic disorders are
now well understood, many rare genetic disorders have not yet been defined in terms
of the genetic mutation responsible.22
The Nuffield Council on Bioethics has highlighted the practical consequences of
the diffusion of genomics. On the one hand, there will be increasing emphasis in
health care on prevention and public health and, on the other, the development of
increasingly ‘personalised’ (and therefore differentiated) medicine. This suggests
that, as greater awareness of individuals’ susceptibility to illness becomes known
through the diffusion of genomics, new obligations will arise for public authorities to
provide improved societal conditions (for example, higher-quality environmental
standards, such as improved air quality, and equitably provided healthcare). Impor-
tantly, knowledge about genomics also raises the question of responsibility on
individuals not only for adapting their own behaviour and choosing a suitable
lifestyle and a suitable material and social environment, but also, potentially, for
selecting a genotype that will be expressed in their future children.23
Debates about “designer babies” resulting from genetic interventions into
pre-implantation embryos in an attempt to influence the traits that resulting children
will have are not new.24 However, these debates have been brought more sharply
into focus by the relative ease with which CRISPR genome editing techniques can
alter the germline identity of human beings. The National Academies of Sciences,
Engineering and Medicine 2017 Report on Human Genome Editing, for instance,
draws the distinction between restorative intervention that can alleviate suffering
caused by genetically inherited diseases on the one hand, and interventions that
improve bodily condition or function beyond what is needed to restore or sustain
health, such as enhanced sports prowess, on the other hand.25
22Nuffield Council on Bioethics (2018), op. cit. n 17, 8.
23Nuffield Council on Bioethics (2018), op. cit. n 17, 13.
24See, for instance, Bonnie Steinbock, Designer babies: choosing our children’s genes, The Lancet
(11 October 2008); Jonietz (2003).
25The National Academies of Sciences, Engineering and Medicine, Human Genome Editing:
Science, Ethics and Governance, 2017, Consensus Study Report, 145.
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3 The CRISPR-Cas9 Genome Editing Technique
The transformative potential of CRISPR-Cas9 first came to public attention in 2012
following the publication of a seminal paper published in Science by Jennifer
Doudna of University of California Berkeley, Emmanuelle Charpentier, at that
time based at Umeå University in Sweden, and their collaborators.26 The Science
paper demonstrated that CRISPR-Cas9 can be used to cut and (possibly) edit DNA
in vitro. Doudna and Charpentier, and also Feng Zhang and George Church at the
Broad Institute (an independent research institute that evolved from a decade of
research collaborations among scientists at Harvard University and the Massachu-
setts Institute of Technology), became the names most closely associated with
CRISPR-Cas9, while the parallel work of Virginijus Šikšnys was also recognised
along with that of Doudna and Charpentier with their joint award of the Kavli Prize
in Nanoscience in 2018.
CRISPR-Cas9 was adapted from a naturally occurring genome editing in the
bacterial immune system. The bacterial immune system captures snippets of DNA
from invading viruses and uses them to create DNA segments known as CRISPR
arrays.27 The CRISPR arrays allow the bacteria to remember the viruses and, if the
viruses attack again, the bacteria produce RNA segments from the CRISPR arrays to
target virus DNA. The bacteria then use Cas9 or a similar enzyme to cut the DNA
apart, which disables the virus.28
In the context of CRISPR-Cas9 gene editing in the laboratory, bio-scientists are
able to create a small piece of RNA with a short “guide” sequence that attaches
(binds) to a specific target sequence of DNA in a genome. The RNA also binds to the
Cas9 enzyme and guides it to the targeted location. The Cas9 enzyme then cuts the
DNA at the targeted location so that the genome editing can take place.29 As such,
CRISPR-Cas9 has enabled precisely targeted alterations to be performed on DNA
sequences in living cells. Working like genetic scissors, the Cas9 nuclease opens
both strands of the targeted sequence of DNA to introduce the modification to
knock-out the mutation. In this way, genome editing is in effect the ability to develop
one-shot genome editing medical treatments.30 It is being explored in research on a
wide variety of diseases, including single-gene disorders such as cystic fibrosis,
haemophilia, Huntingdon’s disease and sickle cell anaemia, with possible
26Jinek et al. (2012), p. 816.
27National Institutes of Health (NIH), op. cit. 1.
28National Institutes of Health (NIH), op. cit. 1.
29The underlying mechanism of CRISPR had also been described previously in Archaea by
Francisco Mojica in 1993, who is later said to have coined the term ‘CRISPR’ in correspondence
with a colleague (see: Mojica et al. 1993, pp. 613–621; Davies and Mojica 2018, p. 5) and earlier in
bacteria by Ishino and colleagues (see: Ishino et al. 1987, pp. 5429–5433), while the conjunction of
CRISPR and CRISPR associate nucleases (CRISPR-Cas) was identified as a proto-immune system
from 2007 (see: Barrangou et al. 2007, pp. 1709–1712).
30Feng Zhang (Broad Institute), op. cit. n 3.
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applications including plant, microbial, animal and human genetic interventions.31
Genome editing also holds promise for the treatment and prevention of complex
diseases such as cancer, heart disease, mental illness and human immunodeficiency
virus (HIV) infection.32
In order to allow access to embryos for the purpose of editing them, these would
be created in a laboratory using a method of in vitro fertilisation (IVF). Perhaps the
most plausible application for this would be cases in which the variant predisposed
whoever had it to a clinically recognised disease. In this case, it would be necessary
to know before the embryo was created that there was a likelihood of it inheriting the
disease-causing variant, such as by screening the prospective parents. For instance,
individuals might have been alerted to the possible presence of the variant through
having an affected relative and through screening.
However, it is important to recognise the uncertainty that continues to exist about
the technical efficacy of the procedures currently available. Of particular concern in
this regard is whether CRISPR-Cas9 systems faithfully cleave their intended geno-
mic target without uncontrolled cutting of other sequences (“off-target events”) in
ways that would make them unsafe for clinical use. The Nuffield Council on
Bioethics has also pointed to uncertainty over whether the HDR pathway can be
recruited to produce the desired genome change at sufficiently high frequencies for
effective clinical use or, if so, how.33
There are widespread concerns that CRISPR-based genome editing may result in
unintended effects in terms of both off-target effects and mutations of human
embryos and of incidental editing.34 Kosicki, Tomberg and Bradley, for example,
found DNA damage that included deletions of thousands of DNA bases, including at
spots far from the edit.35 In some instances deletions can silence genes that should be
active and, in other instances, activate genes that should be silent, including cancer-
causing genes.36
31See also Nordberg et al. (2018), pp. 36–83: 37.
32National Institutes of Health (NIH), op. cit., n 1.
33Nuffield Council on Bioethics (2018), op. cit. n 17, 36. Homology directed repair (HDR) is a
naturally occurring nucleic acid repair system that can be used to modify genomes in many
organisms, including humans. HDR is initiated by the presence of double strand breaks (DSBs)
in DNA.
34For the US Food and Drug Administration (FDA), off-target effects would usually be assessed in
relation to toxicity of a drug. How the off-target effects of gene editing can be assessed is less clear,
given that mutations will perhaps occur two or three generations later.
35Kosicki et al. (2018), p. 765.
36Sharon Begley, ‘Potential DNA damage from CRISPR has been “seriously underestimated”
study finds’, 16 July 2018, STAT News: https://www.statnews.com/2018/07/16/crispr-potential-
dna-damage-underestimated/.
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4 Lulu and Nana: The Chinese Genome-Edited Twins
“Immune from HIV”
Widespread public awareness of the possible negative implications and controver-
sies associated with the use of genome editing to edit the human germline identity
became the focus of global attention in November 2018 when a Chinese researcher
at the Southern University of Science and Technology of China in Shenzhen, Dr. He
Jiankui, revealed at the Second International Summit on Human Genome Editing in
Hong Kong that, as a result of his research, he had implanted into a female patient
embryos that had been edited to disable the genetic pathway HIV uses to infect cells
and twins had been born whose embryonic genomes had been edited.37 Dr. He
claimed to have disabled a gene called CCR5, which encodes a protein that allows
HIV to enter cells. Dr. He was seeking to mimic a mutation that is present in about
6–8% of the population and which helps to protect them from HIV infection.
Concerns were raised in the scientific community that Dr. He might have inad-
vertently caused mutations in other parts of the genome, which could have
unpredictable health consequences.38 If the gene has been disabled, the twin girls
born with CCR5 disabled could be vulnerable to other diseases. CCR5, for instance,
is already thought to help people fight off, for example, the effects of West Nile
virus.39
Dr. He was widely condemned by the global scientific community for violating
long-standing scientific principles and ethical norms through the application of his
research. Subsequently, on 21 January 2019, the Southern University of Science and
Technology in Shenzhen announced that Dr. He had been dismissed from his post
following an investigation by the Guangdong Health Ministry.40 By the end of 2019
a court in Shenzhen had found He and two collaborators guilty of conducting illegal
medical practices when they had forged ethical review documents and misled
doctors into unknowlingly implanting gene-edited embryos into two women.41
37Cyranoski and Ledford (2018), pp. 607–608, https://www.nature.com/articles/d41586-018-
07545-0.
38Most recently, see Antonio Regalado, MIT Technology Review, December 3, 2019: https://www.
technologyreview.com/s/614764/chinas-crispr-babies-read-exclusive-excerpts-he-jiankui-paper/.
39Cyranoski and Ledford (2018) op. cit. 37.
40Cyranoski and Ledford (2018) op. cit. 37.
41Normile (2019).
Access to CRISPR Genome Editing Technologies: Patents, Human Rights and. . . 113
5 Patenting the CRISPR-Cas9 Genome Editing
Breakthrough
Doudna, Charpentier and their collaborators were named as co-inventors for
U.S. Patent Application No. 13/842,859, filed by the University of California, the
University of Vienna and Charpentier on 15 March 2013, with a priority date of
25 May 2012 when the original provisional application was filed at the US Patent
and Trademark Office (USPTO). The patent application was particularly broad in
scope, listing 155 claims to the general CRISPR technology.42
Zhang and Church’s Broad Institute patent application to the USPTO, US Patent
No. 8,697,359, was filed later with a priority date of 12 December 2012, seven
months after the Doudna, Charpentier and collaborators’ priority date. The Broad
Institute patent was nevertheless deemed eligible for a special accelerated examina-
tion track and the patent was issued by the USPTO on 15 April 2014.43
The USPTO granted the key patent over the foundational CRISPR technology to
the Broad Institute following interference proceedings with the University of
California.
The outcome of the USPTO Patent Trial and Appeal Board (PTAB), rendering
judgment that there was no interference-in-fact between the claims in interference
between the University of California and the Broad Institute.44 Broad persuaded the
PTAB that the parties claim patentably distinct subject matter, rebutting the pre-
sumption of interference. Broad convinced the PTAB that its claims, which were all
limited to CRISPR-Cas9 systems in a eukaryotic environment, are not drawn to the
same invention as the University of California’s, the latter which were all directed to
CRISPR-Cas9 systems not restricted to any environment.
Specifically, the evidence showed the PTAB that the invention of such systems in
eukaryotic cells would not have been obvious over the invention of CRISPR-Cas9
systems in any environment, including in prokaryotic cells or in vitro, because the
ordinary skill in the art would not have reasonably expected a CRISPR-Cas9 system
to be successful in a eukaryotic environment.45
The PTAB terminated interference proceedings upon accepting Broad’s argu-
ment that its claims pertaining to eukaryotic cells are sufficiently distinct from the
University of California’s claims for use in any environment, meaning there was no
“interference in fact,” a threshold requirement rooted in 37 C.F.R. § 41.203(a).
42See also Feldman (2016), p. p. 401.
43See also Jacob S. Sherkow, The CRISPR Patent Interference Showdown Is on: How Did We Get
Here and What Comes Next? Stanford Law School Law and Biosciences Blog: https://law.stanford.
edu/2015/12/29/the-crispr-patent-interference-showdown-is-on-how-did-we-get-here-and-what-
comes-next/.
44USPTO Patent Interference No. 106,048. Decisions on Motions 37 C.F.R. § 41.125(a).
45Cyranoski and Ledford (2018) op. cit. 37, 2. See also Kevin Noonan, ‘CRISPR Interference
Parties Propose Motions’, Patent Docs Patent Law Blog, 1 August 2019: https://www.patentdocs.
org/2019/08/crispr-interference-parties-propose-motions.html.
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The University of California’s claims had been based on inventions made by
Doudna, Charpentier and their collaborators. As discussed above, their breakthrough
research in 2012 had demonstrated that CRISPR-Cas9 can be used to cut and
(possibly) edit DNA in vitro. However, the USPTO decided that this did not extend
to editing genomes in advanced, or eurkaryotic cells, and as such the Broad
Institute’s invention was not obvious having regard to the prior art.
Though the PTAB did not cancel or finally refuse any claims when terminating
the interference, its decision triggered speculation that UC might eventually take
U.S. rights to use in prokaryotes, with Broad taking them in eukaryotes.
The equivalent application by the Broad Institute for European patent was filed at
the European Patent Office (EPO) but, on 23 March 2018, the EPO Opposition
Division (OD) found that the priority claim is not valid and revoked the patent for
lack of novelty. The case was then referred to the EPO Board of Appeal (BoA),
which issued its preliminary comments in preparation for Oral Proceedings on
4 November 2019 (T 0844/18).
The key issues for the Oral Proceedings were whether the priority claim of the
Broad Institute patent EP2771468 was valid and whether the EPO had the power to
decide on entitlement to priority. The patentees appealed the OD Decision and the
Oral Proceedings before EPO Board of Appeal 3.3.08 on this critical issue com-
menced on 13 January 2020.
The opponents to the Broad Institute argued successfully that the EPO is com-
petent to priority and bound to do so by Article 87 of the European Patent Conven-
tion (EPC), and that the OD decision was in line with the large body of EPO case law
on priority. The EPO case law provides that the right to claim priority from an earlier
application according, as set out in Article 87 EPC which itself is derived from
Article 4 of the Paris Convention on the Protection of Industrial Property (1967), is
afforded to the applicant of the earlier application and to no other party. As such, the
applicant (or applicants) must be the same as the original filing. The Broad Institute's
European patent EP2771468 was based on a Patent Cooperation Treaty (PCT) filing
(WO2014204729) claiming priority from a number of US provisional applications.
One of the US provisionals named an inventor-applicant who was not named on the
PCT application.
The two earliest priority documents that the Broad Institute was seeking to rely on
at the EPO from 12 December 2012 and 2 January 2013 named Luciano Marraffini
of Rockefeller University as an inventor-applicant. Marraffini was not an applicant
on the later patent and had not assigned priority rights to the Broad Institute. In fact,
until mid-2017 the Broad Institute and Rockefeller University were in an
inventorship dispute over a number of early CRISPR patents.46 The ‘468 patent
was thus revoked in view of an invalid priority claim.
46Allen & Overy, Broad Institute CRISPR-Cas9 Patent Revoked in Europe, https://www.
allenovery.com/en-gb/global/news-and-insights/publications/broad-institute-crispr-cas9-patent-
revoked-in-europe.
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Of particular note in this case, was the impressive array of prominent experts who
provided expert opinions on behalf of the Broad Institute, including former UK
Supreme Court President The Rt. Hon. Lord Neuberger, former UK Lord of Appeal
in Ordinary judge The Rt. Hon. Lord Hoffmann, Matrix Chambers barrister Philippe
Sands, Emeritus Scientific Member of the Max-Planck-Institute for Innovation and
Competition Prof. Dr. Joseph Straus, former chair of an EPO Board of Appeal
Dr. Ursula Kinkeldey and Swiss Federal Patent Court Judge Dr. Tobias Bremi.47
This list of experts attests to the significance that the Broad Institute placed on the
value of the patent at stake and the significance of the legal issue in question.
Despite expectations that the Board of Appeal would refer questions on priority
arising in the case to the EPO Enlarged Board of Appeal, in fact the Board of Appeal
decided it could sufficiently answer all questions on priority and, as such, upheld the
findings of the Opposition Division and dismissed the case on grounds that there was
already substantial and consistent body of EPO case law on the matter of priority
under Article 87 EPC. Broad will also face further oppositions to EP3009511, which
is directed to CRISPR-Cpf1 (now called Cas12a) systems.48
At the time of writing, the EPO has so far granted three European patents, all to
the University of California, the University of Vienna and Emmanuelle Charpentier,
and related to “Methods and compositions for RNA-directed target DNA modifica-
tion and for RNA-directed modulation of transcription”.
The first European patent granted to the Regents of the University of California,
the University of Vienna and Emmanuelle Charpentier (EP2800811), concerning the
basic CRISPR method, was granted on 7 April 2017.49 It claims a DNA-targeting
RNA that comprises a targeting sequence and, together with a modifying polypep-
tide, provides for site-specific modification of a target DNA and/or a polypeptide
associated with the target DNA. Opposition Proceedings at the EPO were filed
subsequently by seven parties, with oral proceedings taking place on 5–7 February
2020. The outcome of the EPO Opposition Proceedings was, taking account of the
amendments made by the patent proprietor during the opposition proceedings, the
patent and the invention to which it relates were found to meet the requirements of
the EPC.50
47Amy Sandys, EPO Revokes Broad Institute Patent – But it’s just the beginning for CRISPR-cas,
JUVE Patent, 17 January 2020.





50Art. 53(c) and Rule 28 objection raised by only one of several opponents against EP2800811. The
Opposition Division’s provisional opinion was fairly dismissive of the Article 53(c) and Rule
28 objections.
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The second European patent, with claims that are directed to compositions and
uses of a chimeric version of the Cas9 protein, most often associated with use in
regulation of gene expression as opposed to direct editing of the genetic code itself,
was granted on 26 January 2018.51 Opposition proceedings against the grant of the
second European patent have been initiated by four parties, while the most recent
European patent for a CRISPR-related invention, which claims methods and com-
positions of using CRISPR-Cas9 to modify DNA and regulate gene activity in
eukaryotic cells, including kits to carry out such work, was granted on 1 March
2019, with the first opponent filing an EPO Opposition almost immediately on
1 April 2019.52 At the time of writing, the date for oral proceedings relating to the
second and third European patents granted to the Regents of the University of
California et al has yet to be set and, overall, this is likely to be a lengthy process.
6 Excluding Genome Editing Technologies from
Patentability
What is surprising about the cases related to CRISPR-Cas9 genome editing that have
been considered thus far at the USPTO and EPO is the lack of consideration of the
necessity test in decisions to grant patents on these foundational technologies. The
Agreement on Trade-Related Aspects of Intellectual Property (the TRIPS Agree-
ment) introduces a “necessity test” to assess whether protection of an overriding
social interest is justified.53 Specifically, Article 27.2 permits World Trade Organi-
sation (WTO) Members to “exclude from patentability inventions, the prevention
within their territory of the commercial exploitation of which is necessary to protect
ordre public or morality, including to protect human, animal or plant life or health or
to avoid serious prejudice to the environment, provided that such exclusion is not
made merely because the exploitation is prohibited by their law”.
As is often stressed, a patent is a grant of exclusive rights but not in itself an
authorisation to exploit the patented invention. The latter can be regulated by
separate legislation provided this is consistent with Article 27.2, including on
grounds that it is necessary to protect human, animal or plant life or health or to
avoid serious prejudice to the environment.54 The flexibility of WTO Members to
exclude patents, for example on inventions related to genome editing technologies,
therefore is provided for explicitly in the TRIPS Agreement.
The TRIPS flexibilities contained in Article 27.2 reflect the “necessity test” under
the evolving jurisprudence of the WTO whereby the national regulatory autonomy
constitutes a core principle for WTO Members which are entitled to pursue their
51EP3241902: https://register.epo.org/application?number¼EP17163434&tab¼main.
52EP3401400: https://register.epo.org/application?number¼EP18152360.
53See also UNCTAD-ICTSD Project on IPRs and Sustainable Development (2005), p. 378.
54Ibid., page 382–383.
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domestic policy objectives and choose the means for their fulfilment, provided they
do not entail protectionist ends.55 The necessity test also underpins the principles set
out in Article 8.1 of the TRIPS Agreement, whereby “Members may, in formulating
or amending their laws and regulations, adopt measures necessary to protect public
health and nutrition, and to promote the public interest in sectors of vital importance
to their socio-economic and technological development, provided that such mea-
sures are consistent with the provisions of this Agreement.”
The scope of Article 8.1 was elaborated on by the WTO Dispute Settlement Panel
Report in Canada—Patent Protection of Pharmaceutical Products, whereby the
prohibition on discrimination as to the field of technology contained in Article 27.1
of TRIPS “does not limit the ability to target certain products in dealing with certain
of the important national policies referred to [in Article 8.1].”56 The Panel therefore
confirmed that there is considerable scope for WTO Members to include in national
legislation exclusions based on measures necessary to protect health and to promote
the public interest as set out in the permissible ordre public or morality exceptions
set out in Article 27.2 of TRIPS.
With regard to the application of the TRIPS flexibilities available under Articles
8.1 and 27.2 of TRIPS in the U.S., it is widely understood that there are no
restrictions on patentable subject matter under Section 101 of the U.S.C., and
hence no immediate grounds for the USPTO to refuse CRISPR-Cas9 genome editing
patents using Article 27.2 type ordre public or morality exceptions to patentability.
This legal position was subject to confirmatory judgment by the U.S. Supreme Court
in Diamond v. Chakrabarty, with the seminal conclusion that statutory subject matter
under 101 includes “everything under the sun that is made by man”.57
The situation differs in Europe, where the patentability of inventions related to the
editing of germline genomes is already restricted in EPC countries, exceptions to
patents being directly linked and based on the logic of inserting public policy
mechanisms in patent law.58 When these public policy mechanisms are applied to
the grant of patents in the field of the life sciences, and particularly in reproductive
medicine and genetic engineering, the debate has been controversial for decades.59
Article 53(a) of the EPC sets out a general ordre public and morality exception
whereby “European patents shall not be granted in respect of . . . inventions the
publication or exploitation of which would be contrary to ‘ordre public’ or morality,
provided that the exploitation shall not be deemed to be contrary merely because it is
prohibited by law or regulation in some or all of the Contracting States”.
The meaning of ordre public in the context of Article 53(a) EPC has since been
elaborated by the EPO Technical Board of Appeal in the T356/93 decision as
55Kapterian (2010), pp. 89–127; Salinas Alcaraz (2015), pp. 77–99.
56Canada – Patent Protection of Pharmaceutical Products, Report of the Panel, WT/DS114/R,
17 March 2000, paragraph 7.92.
57Diamond v. Chakrabarty 447 U.S. 303 (1980).
58Nordberg et al. (2018) op. cit. n 31, 40.
59For a wider discussion see Ingrid SchneiderLL (2019), pp. 263–287.
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follows: “It is generally accepted that the concept of ‘ordre public’ covers the
protection of public security and the physical integrity of individuals as part of
society. This concept encompasses also the protection of the environment. Accord-
ingly, under Article 53(a) EPC, inventions the exploitation of which is likely to
breach public peace or social order (for example, through acts of terrorism) or to
seriously prejudice the environment are to be excluded from patentability as being
contrary to ‘ordre public’.”60
In the same T 356/93 decision, the EPO Technical Board of Appeal elaborated on
the meaning of “morality” under Article 53(a) EPC as follows: “The concept of
morality is related to the belief that some behaviour is right and acceptable whereas
other behaviour is wrong, this belief being founded on the totality of the accepted
norms which are deeply rooted in a particular culture. For the purposes of the EPC
the culture in question is the culture inherent in European society and civilisation.
Accordingly, under Article 53(a) EPC, inventions the exploitation of which is not in
conformity with the conventionally accepted standards of conduct pertaining to this
culture are to be excluded from patentability as being contrary to morality.”
The EPO Guidelines for Examination on Article 53(a) EPC also elaborate on how
the test should be applied: “Any invention the commercial exploitation of which
would be contrary to ‘ordre public’ or morality is specifically excluded from
patentability. The purpose of this is to deny protection to inventions likely to induce
riot or public disorder, or to lead to criminal or other generally offensive behaviour
. . . Anti-personnel mines are an obvious example. This provision is likely to be
invoked only in rare and extreme cases. A fair test to apply is to consider whether it is
probable that the public in general would regard the invention as so abhorrent that
the grant of patent rights would be inconceivable. If it is clear that this is the case,
objection should be raised under Art. 53(a); otherwise not. . .”.61
In the EU law context there are explicit links with the ordre public and morality
exceptions of Article 53(a) EPC by means of the 1998 Biotechnology Directive.62
The Directive includes, in Articles 5 and 6, provisions which can be interpreted as
having the aim of preserving European fundamental values and human rights norms
in patent law.63
Article 5 of the Biotechnology Directive focuses on the human body which, at
various stages of its formation and development, and the simple discovery of one of
its elements, including the sequence or partial sequence of a gene, cannot constitute
patentable inventions. Nevertheless, Article 5 goes on to state that an element
isolated from the human body or otherwise produced by means of a technical
process, including the sequence or partial sequence of a gene, may constitute a
60EPO Technical Board of Appeal in Plant Genetic Systems/Glutamine synthetase inhibitors T356/
93 [1995] EPOR 357.
61Guidelines for Examination in the EPO C-IV, 4.1.
62Directive 98/44 of the European Parliament and of the Council of 6 July 1998 on the Legal
Protection of Biotechnological Inventions.
63Schneider, op. cit. n 58.
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patentable invention, even if the structure of that element is identical to a natural
element, provided that the industrial application of a sequence or a partial sequence
of a gene is disclosed in the patent application.
The sixteenth recital to the Biotechnology Directive indicates that the logic of
Article 5 is “respect for the fundamental principles safeguarding the dignity and
integrity of the person”, asserting that “it is important to assert the principle that the
human body, at any stage in its formation or development, including germ cells and
the simple discovery of one of its elements or one of its products, including the
sequence or partial sequence of the human gene, cannot be patented”.64
Article 6(1) of the Biotechnology Directive then goes on to require that “inven-
tions shall be considered unpatentable where their commercial exploitation would be
contrary to ordre public or morality”, while Article 6(2) sets out a non-exhaustive list
of examples of biotechnological inventions that are excluded from patentability on
moral grounds, including (a) “processes for cloning human beings”, (b) “processes
for modifying the germ line genetic identity of human beings”, and (c) “uses of
human embryos for industrial or commercial purposes”.
Nevertheless, Article 6(1) of the Biotechnology Directive should be read in
conjunction with Recital 42, which states that “. . . in any case such exclusion does
not affect inventions for therapeutic or diagnostic purposes which are applied to the
human embryo and are useful to it”. Whether genome editing techniques comprising
processes for modifying the germline genetic identity of human beings constitute
inventions for “therapeutic” purposes within the meaning of Recital 42 therefore
remains uncertain and is yet to be clarified by the EPO or its Boards of Appeal.
In this regard, it should be noted that although the EPO, as an organisation
constituted by the EPC, is not subject to the treaties and legislation of the EU, the
EPO Administrative Council adopted all the articles of the Biotechnology Directive
into its own legal order via the implementing rules of the EPC, with Articles 5 and
6 of the Biotechnology Directive comprising Rules 28 and 29 of the EPC.65
Consequently, Rule 28 of the Implementing Regulations to the EPC imports the
Article 6(2)(b) provision of the Biotechnology Directive into EPO examination
practice whereby “Under Article 53(a) EPC European patents shall not be granted
in respect of biotechnological inventions which, in particular, concern: . . .
(b) processes for modifying the germ line genetic identity of human beings. . .”.
The possibility that Recital 42 of the Biotechnology Directive could over-ride the
exception to the patentability of genome editing technologies for processes related to
modifying the germline genetic identity of human beings therefore remains remote
before the EPO.
64See also Schellekens and Vantsiouri (2013), p. 190: https://www.tandfonline.com/doi/abs/10.
5235/17579961.5.2.190, who elaborate on the concept of human dignity and refer to Marco
Olivetti’s commentary on Article 1 of the EU Charter of Fundamental Rights, in which he ‘discerns
human beings becoming mere objects in medical or biological practices as an example of an affront
to dignity’ (Olivetti 2010, p. 7).
65See also Schneider, op. cit., n 58, 264.
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Rule 29 of the Implementing Regulations is also directly relevant to genome
editing technologies relating to the human germline given that it states, in Rule 29.1,
that “[t]he human body, at the various stages of its formation and development, and
the simple discovery of one of its elements, including the sequence or partial
sequence of a gene, cannot constitute patentable inventions”.
Nevertheless, the debate remains ongoing as to whether the exclusions to patent-
ability encompassed in Articles 5 and 6 of the Biotechnology Directive and, by
association, Rules 28 and 29 of the Implementing Regulations to the EPC embody
the precautionary principle as enshrined in Article 191 of the Treaty on the Func-
tioning of the European Union (TFEU) which aims at ensuring a higher level of
environmental protection through preventative decision-taking in the case of risk. In
practice, the scope of the principle is far wider and covers also consumer policy, as
well as EU legislation concerning food and human, animal and plant health.66
Whether the precautionary principle should (or could) also be taken into account
by patent granting authorities when determining whether a European patent should
be issued remains, as yet, unresolved.67
As demonstrated by the foregoing discussion, the European patent system there-
fore comprises a fairly comprehensive toolkit to enable patent examiners to assess
what types of inventions should be excluded from patentability on grounds that they
are considered socially undesirable and/or violate human dignity.68 This has a
perceptible impact on the drafting of CRISPR-related patent applications to the
EPO, with disclaimers such as “non-human’, “human germline not modified” or
“wherein the cells are not germ cells”.69
Specifically, although European patent claims to the “composition” or “vector
system” (that is to say a DNA molecule used as a vehicle to artificially carry foreign
genetic material into another cell) are regularly being granted by the EPO, on
grounds that they are considered to fall outside the Rule 28(b) exception, there is
significant evidence of amendments to the claims in genome editing European patent
applications which explicitly exclude use of a process for modifying the germline
genetic identity of human beings.70
66European Commission, Communication (COM(2000) 1 final) on the Precautionary Principle:
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri¼LEGISSUM%3Al32042.
67See, for instance, Reynolds (2013), p. 95; Nordberg et al. (2018), op. cit. 31, 49–50, noting that in
its most simple formulation the Precautionary Principle may seem to ignore the costs of not
continuing a line of research and development and finding that, while a broadly precautionary
approach to regulation of gene editing is justified, it is important that it is interpreted in a way that
avoids a disproportionate (and potentially incoherent) focus on possible harm. Nordberg et al.
(2018) op. cit. n 31, sum up that CRISPR-Cas9 and the future of gene-editing technology can
potentially produce enormous benefits to humans, but the uncertainty about possible harm that may
result from large-scale gene editing means that a precautionary approach is advisable to policy
decisions that respect a proportionality constraint on acceptable precautions.
68See also Schneider, op. cit. n 58, 267.
69See also Schneider, op. cit. n 58, 283.
70Sherkow and Thomas Scott (2019), p. 97 North Carolina Law Review 1497, discusses the
strategy of keeping some of the most significant information about vectors secret while patenting
only certain aspects.
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A practical example of limitations to claim language introduced by the EPO
Examining Division is the aforementioned Broad Institute European patent
EP2771468, which was subject to Oral Proceedings at the EPO in January 2020.
The Broad Institute patent contained amended claim language relating to “Use of the
composition of claim 1, or the vector system of claim 2 or any claim dependent
thereon for genome engineering, provided that said use is not a method for treatment
of the human or animal body by surgery or therapy, and provided that said use is not
a process for modifying the germline genetic identity of human beings” [emphasis
added]. This amended claim language is, of course, consistent with both Rule 28 of
the Implementing Regulations to the EPC and Article 6(2)(b) the Biotechnology
Directive.
Indications that limiting claim language into European patents for CRISPR
technologies is being established as office practice at the EPO is supported by closer
examination of the Regents of the University of California, University of Vienna,
Emmanuelle Charpentier European patent EP2800811. The University of California
et al patent contains similar amended language to the Broad Institute ‘468 patent.
Specifically, the ‘811 patent at claims 20 and 21 states: “provided that said method is
not a method of modifying the germ line identity of a human being” [emphasis
added], this wording being upheld during EPO Oral Proceedings on 5-7
February 2020.
It is certainly significant that the limiting claim language to the ‘468 and ‘811
patents are very similar, indicating a practice for the EPO Examining Division to
insert Rule 28 type language in all such cases. The approach taken in the ‘468 and
‘811 patents is also consistent with findings of the All European Academies
(ALLEA) Statement on Patent-Related Aspects of CRISPR-Cas Technology
which, in 2016, considered the principles enshrined in the EU Biotechnology
Directive and the Implementing Regulations of the EPC, as applied in the patent
grant practice of the EPO to inventions related to CRISPR technology, fit for purpose
and flexible enough to take account of future regulatory developments.
Such limitations on patent claims (or refusal to grant a patent based on morality
exceptions) have raised concerns that such a policy may result in a chain reaction of
overall reduction in the various types of incentives to innovate and invest in the areas
of research concerned.71 No doubt such concerns will continue to be raised and
limitations to claim language for European patents related to genome editing tech-
nologies will remain under close scrutiny in the future.
71See, for instance, Nordberg et al. (2018), op. cit. n 31, 51.
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7 International Human Rights Law and Genome Editing
We now turn in this chapter to the implications of granting patents relating to
genome editing in terms of the enjoyment of internationally binding human rights.
The applicable international and legally binding instrument dealing specifically with
the protection of human rights in the biomedical field is the Oviedo Convention.72
The Oviedo Convention draws on the principles established by Article 1 of the
Universal Declaration on Human Rights (UDHR) of 1948, which affirms that “[a]ll
human beings are born free and equal in dignity and rights.”
As the Nuffield Council on Bioethics has acknowledged, dignity is an important
concept that links human beings to the possession of a human genome and, at the
same time, elevates the being of individual humans above the given.73 Dignity also
plays a restraining role. For example, the UNESCO Declaration on Science and the
Use of Scientific Knowledge affirms specifically that both “scientific research and
the use of scientific knowledge should respect human rights and the dignity of
human beings.”74
The Oviedo Convention aims to protect the dignity and identity of all human
beings and guarantee everyone, without discrimination, respect for their integrity
and other rights and fundamental freedoms with regard to the application of biology
and medicine. It set out fundamental principles applicable to daily medical practice
and is regarded as establishing basic patient’s rights. It also deals with biomedical
research, genetics and transplantation of organ and tissues.75
Specifically, Article 13 of the Oviedo Convention (entitled ‘Interventions on the
human genome’) prohibits germline modification: “An intervention seeking to
modify the human genome may only be undertaken for preventive, diagnostic or
therapeutic purposes and only if its aim is not to introduce any modification in the
genome of any descendants.”
Article 13 therefore establishes two key principles. First, that any genome
modification (in research or in treatment) should have as its aim a benefit for
human health. It does not permit genome modifications that are for other purposes.
For example, it does not permit attempts to enhance human characteristics beyond
normal functioning or for welfare purposes not related to health. For those states in
which the Oviedo Convention is in force, Article 13 therefore limits, but does not
prohibit, genome editing involving human embryos for research purposes. Second,
72Convention for the Protection of Human Rights and Dignity of the Human Being with regard to
the Application of Biology and Medicine: Convention on Human Rights and Biomedicine (ETS No
164).
73Nuffield Council on Bioethics (2018), op. cit. n 17, 124.
74UNESCO Declaration on Science and the Use of Scientific Knowledge (1999), Preamble, para.
19. The UNESCO Declaration on Bioethics and Human Rights asserts that the “ethical issues raised
by the rapid advances in science and their technological applications should be examined with due
respect to the dignity of the human person. . .”.
75Oviedo Convention and its Protocols, Council of Europe, opened for signature on 4 April 1997,
Oviedo, Spain: https://www.coe.int/en/web/bioethics/oviedo-convention.
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the aim must not be to introduce changes that can be passed on to future generations;
that is, interventions that lead to the birth of children with a modified genome.76
On the face of it, Article 13 of the Oviedo Convention appears to prohibit
heritable genome editing interventions although, according to the Nuffield Council
on Bioethics, not without some ambiguity.77 However, it has been argued persua-
sively that the Convention does not veto genetic editing for basic research purposes,
but only its clinical application on human embryos to be transferred into the womb.78
This argument is supported by the strict textual interpretation of the Convention,
given that Article 13 states explicitly that “An intervention seeking to modify the
human genome may only be undertaken for preventive, diagnostic or therapeutic
purposes and only if its aim is not to introduce any modification in the genome of any
descendants” [emphasis added].
The prohibition introduced by Article 13 of the Oviedo Convention therefore
appears limited to interventions seeking to modify the human genome only where
this introduces modifications into the genome of descendants. As such, the wording
of Article 13 can be interpreted as giving sufficient room for basic research into
preventive, diagnostic or therapeutic purposes.79 Nevertheless, it should also be
borne in mind that the explanatory report to the Convention refers explicitly to the
need to “protect the dignity and identity of all human beings”,80 underpinned by the
guiding principle of the primacy of the human being.81
Although the Oviedo Convention is the only international legal instrument that
explicitly addresses heritable genetic modification, even those countries that have
not signed or ratified the Convention, including the UK and Germany, have taken it
into account in framing their domestic provisions in many areas of biomedicine such
as patient rights, consent and privacy, the protection of biomedical research partic-
ipants or living donors and in relation to applications of biomedicine such as
genetics.82
76See also Nuffield Council on Bioethics (2018), op. cit. n 17, 117.
77Nuffield Council on Bioethics (2018), op. cit. 17, 124.
78de Mignuel Beriain et al. (2019), p. 226.
79Ibid, 229.
80‘In every case, any intervention which aims to modify the human genome must be carried out for
preventive, diagnostic or therapeutic purposes. Interventions aimed at modifying genetic charac-
teristics not related to a disease or to ailment are prohibited. As long as somatic cell gene therapy is
currently at the research stage, its application can be allowed only if it complies with the standards
of protection provided for in Article 15 and the following Articles’. Paragraph 90, Explanatory
Report to the Convention for the Protection of Human Rights and Dignity of the Human Being with
regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedi-
cine’, Oviedo, 4.IV.1997, European Treaty Series No. 164, Council of Europe: https://rm.coe.int/
16800ccde5. See also Nordberg (2018), pp. 54–92: 77.
81The whole Convention, the aim of which is to protect human rights and dignity, is inspired by the
principle of the primacy of the human being, and all its articles must be interpreted in this light’.
Paragraph 22, Explanatory Report to the Convention, ibid.
82See also Nuffield Council on Bioethics (2018) op. cit. n 17, 116.
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Elsewhere, in the scientific community, the wider debate on whether there should
be a complete ban on gene editing technologies continues and remains largely
polarised.83 Central to this wider debate are arguments that the Oviedo Convention,
as currently worded, prioritises human rights and human dignity over the interests of
scientific endeavour and technological needs.84 This emphasis on human rights and
human dignity is consistent with Article 3 of the EU Charter of Fundamental Rights,
which protects the right to respect for a person’s physical and mental integrity.85
Paragraph 1 of the Charter asserts that “everyone has the right to respect for his or her
physical and mental integrity”, while paragraph 2 sets out a not exhaustive list of acts
that must be respected in particular in the fields of medicine and biology, namely:
(a) the free and informed consent of the person concerned, according to the pro-
cedures laid down by law; (b) the prohibition of eugenic practices, in particular those
aiming at the selection of persons; (c) the prohibition on making the human body and
its parts as such a source of financial gain; and (d) the prohibition of the reproductive
cloning of human beings.
8 International Initiatives on the Regulation
and Governance of Gene Editing
International initiatives lead by the scientific community have also played an
important role to play in framing the debate on access to gene editing technologies
and allaying fears of a eugenic future.86 Persistent calls have been made for an
international moratorium on gene editing.87 In March 2015, many of the eminent
scientists working at the cutting-edge of CRISPR research co-authored a statement
published in Science magazine calling for a moratorium on germline cell editing.88
Elsewhere, the US National Academies of Science and National Academy of
Medicine Human Gene-Editing initiative, designed to inform decision-making
related to recent advances in human genome-editing research, has been a particularly
83See, for example, the counter arguments in Sykora and Caplan (2017), pp. 1871–1872, who argue
that the debate cannot occur while scientists and clinicians forge ahead with germline modifications
and disregard the views, interests and concerns of the many communities to whom germline
modification matters; and Baylis and Ikemoto (2017), pp. 2084–2085.
84Baylis and Ikemoto (2017) ibid 2084.
85Charter of Fundamental Rights of the European Union (2010/ C 83/389: https://eur-lex.europa.eu/
LexUriServ/LexUriServ.do?uri¼OJ:C:2010:083:0389:0403:en:PDF.
86Nordberg et al. (2018), op. cit. n 31, 39.
87See, for example, Schneider, above, n 58, 281, citing Baltimore et al. (2015a), pp. 36–38;
Lanphier et al. (2015), pp. 410–411; Leopoldina Nationale Akademie der Wissenschaften, The
Opportunities and Limits of Genome Editing (2015): https://www.leopoldina.org/en/publications/
detailview/publication/chancen-und-grenzen-des-genome-editing-2015/; Reich et al. (2015).
88Baltimore et al. (2015b), pp. 365–338: https://www.ncbi.nlm.nih.gov/pmc/articles/
PMC4394183/.
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valuable venue for international dialogue.89 The First International Summit on Gene
Editing took place in Washington DC on 1-3 December 2015, hosted by the National
Academy of Sciences and the National Academy of Medicine and co-hosted by the
Chinese Academy of Sciences and the UK Royal Society. The Summit convened
experts from around the world to discuss the scientific, ethical, and governance
issues associated with human gene-editing research. A Second International Summit
on Human Genome Editing took place in Hong Kong on 27–29 November 2018,
hosted by the Academy of Sciences of Hong Kong in collaboration with the UK
Royal Society, the US National Academy of Sciences and the US Academy of
Medicine.
Subsequently, on 13 August 2019, the first public meeting on the International
Commission on the Clinical Use of Human Germline Genome Editing took place in
Washington DC, hosted by the National Academy of Sciences, with the second
meeting of the Commission taking place in London on 14–15 November 2019 and
hosted by the Royal Society.
The World Health Organization (WHO) is also playing an increasing active role
in coordinating global policy responses to CRISPR genome editing worldwide. On
14 December 2018 the WHO announced the establishment of an 18-member multi-
disciplinary Expert Advisory Committee on the Governance and Oversight of
Human Genome Editing to examine the scientific, ethical, social and legal chal-
lenges associated with human genome editing (both somatic and germ cell).90 The
committee sought to identify regulatory and governance gaps, concerns about
inappropriate use of human genome editing technologies and concerns regarding
rogue clinics exploiting regulatory gaps in some parts of the world. On 29 August
2019 the WHO expert advisory committee announced that it had approved the first
phase of a new global registry to track research on human genome editing, using the
International Clinical Trials Registry Platform (ICTRP), a WHO entity.91
On 12 July 2021 the WHO Expert Advisory Committee on the Governance and
Oversight of Human Genome Editing published its final reports entitled Human
Genome Editing: A Framework for Governance and Recommendations. The Com-
mittee’s Framework for Governance elaborates why a governance role for patents
can be significant, acknowledging that patent holders may find themselves with a
reasonable amount of influence over how a technology develops. Likewise, the
Committee's Recommendations recognise the practical considerations in terms of
relevant patent holders perhaps being unwilling to limit the use of their inventions,
and the unequal geographic distribution of patent holders given the location of
current patent applications relevant to human genome editing. To implement these
89National Academies of Sciences Human Genome Editing Initiative: https://nationalacademies.
org/gene-editing/index.htm.
90Global health ethics: Human Genome editing, World Health Organization: https://www.who.int/
ethics/topics/human-genome-editing/en/.
91WHO Launches Global Registry on Human Genome Editing, World Health Organization,
29 August 2019: https://www.who.int/news-room/detail/29-08-2019-who-launches-global-regis
try-on-human-genome-editing.
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actions, the specific Recommendations of the Committee are: first, in collaboration
with other international institutions, such as the World Intellectual Property Orga-
nization (WIPO), the WTO and its TRIPS Agreement, that the WHO should
encourage relevant patent holders to help ensure equitable access to human genome
editing interventions; second, that the WHO should encourage industry to work with
resource-constrained countries to build capacity to take advantage of human genome
interventions; and, third, that the WHO should convene a meeting of those holding
or applying for patents relevant to human genome editing, industry bodies, interna-
tional organisations such as WIPO and the WTO, and those involved in establishing
or running relevant patent pools to explore the potential for the adoption of appro-
priate ethical licensing requirements.
WHO Expert Advisory Committee’s Recommendations on intellectual property
comprise one of eight core themes on the governance of human genome editing and
have been subject to careful analysis by patent scholars (including the author of this
chapter). This patent scholars’ analysis builds upon and elaborates the Committee’s
work, in particular by calling for wider public debate about the role of “ordre public”
or morality exceptions to patentability in the area of genome editing or considering
promoting post-grant governance through the use of research exceptions or compul-
sory licences.92
The WHO has also called for a moratorium, emphasising that countries should
not allow any further work on human germline genome editing in human clinical
applications until the technical and ethical implications have been properly consid-
ered.93 Such further work is considered, at this time, to be inconsistent with the
principle of responsible stewardship of science.94
9 Concluding Remarks
CRISPR genome editing interventions have great potential to edit the germline
human identity in a manner which will eliminate diseases, improve public health
and contribute positively to welfare in society. Yet genome editing also poses unique
and unprecedented challenges: scientific, regulatory and ethical. The potential uses
of these technologies to alter the human germline raise a number of fundamental
issues for society. Editing of the human genome will influence the characteristics of
92Matthews et al. (2021).
93WHO Launches Global Registry on Human Genome Editing, World Health Organization,
29 August 2019: https://www.who.int/news-room/detail/29-08-2019-who-launches-global-regis
try-on-human-genome-editing.
94Presentation by Robin Lovell Badge (Francis Crick Institute, UK), member of the WHO expert
advisory committee on developing global standards for governance and oversight of Human
Genome editing at the Second Meeting of the International Commission on the Clinical Use of
Human Germline Genome Editing, London, 14 November 2019. Available at: https://royalsociety.
org/topics-policy/projects/genetic-technologies/international-commission/.
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future generations in ways that may well be considered ethically unacceptable given
the unknown risks of off-target effects. Ensuring that institutions are appropriately
equipped to accommodate this new technology is essential for the future governance
and regulation of gene editing technologies, of which the patent system forms a
crucial component part.
The risks, benefits and ethical reasoning for exclusions to patentability need to be
considered carefully by the policy community, based on inputs from all stake-
holders, including patient groups, the scientific community and also those engaged
in patent law and policy. As has been argued convincingly, it is only through public
policy engaging multiple stakeholders and the interdisciplinary academic commu-
nity that dialog proceeds in a manner that is conducive to the future development of
this ground-breaking technology.95 This imperative applies to the patent system as
much as it does to other levers of governance and regulation.
In this context, WTO Members should pay careful attention to the patent policy
implications of genome editing technologies, particularly for inventions relating to
altering the germline identity of human beings. Strong arguments can be made in
favour of encouraging such inventions in terms of eradicating hereditary diseases in
new-born babies and creating resistance to life-threatening conditions for future
generations. Such uses of genome editing technologies may well be considered
consistent with fundamental human rights, particularly the right to dignity, of future
generations under Article 13 of the Oviedo Convention.
Nonetheless, WTO Members must balance decisions about permitting the
patenting of this transformational technology and the possibilities of eradicating,
for example certain hereditary diseases from society, with the possibilities of nega-
tive impacts when deciding to permit patents on altering the germline identity of
human beings. The extent of off-target effects for future generations, effects that are
ancillary to the intended genome alteration, are not yet known or fully understood.
The shadow of eugenics experiments conducted in Europe during the middle of the
last century remains strong. Human rights, particularly those enshrined in Article
13 of the Oviedo Convention, must be given primacy at all costs.
The patent system can, and should, play an important role in this process. As we
have seen in this chapter, Article 27.2 of the TRIPS Agreement establishes a
“necessity test” and encompasses the TRIPS flexibility that WTO Members may
exclude from patentability within their territory inventions, the commercial exploi-
tation of which could be considered contrary to ordre public and morality, including
to protect human animal or plant life or to avoid serious prejudice to the environ-
ment, provided that such exclusion is not made merely because the exploitation is
prohibited by their law.
The approach now being taken by the EPO is instructive in this respect. By
eschewing an approach based on rejecting CRISPR-based patent applications out-
right in favour of a more nuanced approach when considering the European patent
claim language of genome editing technologies with the potential to alter the
95Nordberg et al. (2018) op. cit. n 31, 46.
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germline identity of human beings, the EPO has retained limits on patentability
within the established EPC norms on exclusions to patentability. This chapter has set
out how the European patent tradition of exclusions to patentability based on ordre
public and morality is well-established by virtue of Article 53(a) EPC, Articles 5 and
6 of the Biotechnology Directive and Rule 28 of the Implementing Regulations to
the EPC. The chapter has also demonstrated how the EPO is now paying due regard
to these provisions by requiring amended claim language for European Patents
relating to genome editing technologies. Other WTO Members should take note of
this approach and, it is suggested by this chapter, follow suit. This is imperative in
order to ensure that the granting of private patent rights can be accommodated on an
equitable basis, balanced alongside the need to avoid unnecessary risk (including the
morality exception under patent law), take account of human rights, meet public
expectations, and act in the public interest with regard to this potentially transfor-
mational healthcare technology.
This chapter has set out some of the risks, advantages, ownership issues, ethics
and access problems related to genome editing. We saw in this chapter that the right
to health carries with it the expectation that everyone should have access to the
health services they need, when and where they need them, without suffering
financial hardship. This is particularly pertinent given the global context in which
access to health care technologies needs to be evaluated. Different IP regimes and the
national legislation of different countries express different ethical values.96 The
world is now only at the beginning of this new healthcare debate and patent systems
will be central to how we conceptualise and resolve these public policy problems.
Without doubt, given the rapid pace of genome editing science and its wide
applications, greater consideration of these crucial issues within the global patent
policy community is urgently required if governance institutions are to adequately
take into account the impact of granting of genome editing patents, balancing the
need to reward inventorship with affordability, access and the enjoyment of funda-
mental human rights in the public interest.
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Bolar Exception
Viviana Munoz Tellez
Abstract This chapter discusses the exemption from liability of patent infringement
for activities related to regulatory approval for medicines, also known as the
“regulatory review” or “Bolar” exception. The Bolar exception supports the market
entry of generics by allowing the use of a patented invention by a third party without
the consent of the patent holder for the sole purpose of obtaining regulatory
approval. This constitutes an important defense for generic manufacturers when
undertaking activities such as studies and trials to provide the information required
by regulatory agencies. In this regard, the Bolar exception can respond to a public
policy objective of facilitating market entry of generics to support competition and
exerting downward pressure on prices for medicines. The Bolar exception is
included in many country patent laws and is compatible with international legal
instruments regarding patent law.
1 Exceptions to Patent Rights
A patent grants the patent holder the exclusive right to exclude others from making,
using, importing, and selling the patented innovation for a limited period of time.1
Most, if not all, patent laws exclude certain matter from patentability, and also limit
the rights of patent holders by way of exceptions.2 These have the important function
V. Munoz Tellez (*)
South Centre, Geneva, Switzerland
e-mail: Munoz@southcentre.int
1The TRIPS Agreement states that the available term of protection must expire no earlier than
20 years from the date of filing the patent application. In some jurisdictions the term may be
extended, for example in the United States through Patent Term Adjustment (PTA) and Patent Term
Extension (PTE). The extended exclusivity delays generic competition that can negatively affect
access to medical products in the trading partners, and pressures patent offices to examine patent
applications more expediously. Patent term extensions are often requirements in regional trade
agreements involving the United States and European Union. See Correa (2017).
2Bently (2011), pp. 315–347.
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of defining spaces of freedom of action, wherein obtaining permission from patent
right holders is not required.
International patent law as regulated by the World Trade Organization (WTO)
Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS)3
contains an overall obligation for members of the WTO to grant patents for inven-
tions that meet the criteria of patentability4 in all fields of technology. Nonetheless,
certain exclusions from patentable inventions are permitted.5
Exceptions allow activities that would otherwise be considered patent infringe-
ment. They may remove liability for infringing patent rights, by deeming certain acts
as non-infringing (as is the case of the Bolar exception analysed in this chapter).
WTO members have greater freedom to introduce exceptions to the rights of patent
holders in their legal systems, as compared to exclusions from patentable subject
matter. Rather than defining the exceptions, the TRIPS Agreement allows Members
to develop limited exceptions so long as these comply with certain conditions.6
Exceptions that can be found in many jurisdictions are exceptions for private,
non-commercial use, or to promote research or experimentation.7 Generally, the
Bolar exception can be considered to be a specific type of experimental use
exception.
Members have discretion to decide what exceptions to establish, consistent with
the TRIPS Agreement. This has the advantage of allowing countries to determine
what exceptions are most relevant to their evolving domestic priorities and various
policy considerations. These may include, to confine the patent right for the subject
matter that it was intended, and for protecting third party rights and the public
interest.8 Exceptions to patent rights may be stipulated in legislation or judicially
created—developed through case law. Domestic exceptions can however be chal-
lenged under the WTO Dispute Settlement Understanding (DSU). There has so far
been a single instance of a challenge to exceptions that limit patent rights, in the
3Agreement on Trade-related Aspects of Intellectual Property Rights of 1994; being Annexe 1C to
the Agreement Establishing the World Trade Organization, April 15, 1994 (hereafter “TRIPS
Agreement”).
4TRIPS Article 27.1 states that “. . .patents shall be available for any inventions. . .in all fields of
technology, provided that they are new, involve an inventive step and are capable of industrial
application.” The TRIPS Agreement does not define “invention” and “technology” and does not
determine how patentability requirements should be applied. This is an important area of policy
space for WTO members to define the appropriate contours of their patent laws in accordance to
meeting the objectives of the patent system and against other objectives such as public health policy.
See Correa (2014).
5The permissible exclusions are defined in the TRIPS Article 27.2 and Article 27.3.
6TRIPS Article 30 states that “Members may provide limited exceptions to the exclusive rights
conferred by a patent, provided that such exceptions do not unreasonably conflict with a normal
exploitation of the patent and do not unreasonably prejudice the legitimate interests of the patent
owner, taking account of the legitimate interests of third parties.”
7See Correa (2005).
8Dreyfuss (2018), p. 8.
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panel Canada-Pharmaceutical Patents case.9 The panel decision is not a binding
precedent for Members in developing their exceptions that are compatible with the
TRIPS Agreement. Moreover, given that the decision was not appealed, the Appel-
late Body did not provide its own interpretation.10
2 Rationale for the Bolar Exception
When the patent monopoly expires, the patent ceases be a legal obstacle for a
competitor to produce and commercialize the protected product or use the protected
process. However, other market barriers may remain. Pharmaceutical products must
meet regulatory requirements for authorization to be placed on the market. The
patent status of the originator product can impede the competitor from being able to
start work to meet regulatory requirements in order to be able to place the product on
the market once the originator patent expires. Unless such work is permitted during
the patent term, by an exception. Without the Bolar exception, or a broad experi-
mental use exception that includes acts to provide information for regulatory
approval, the competitor will not be able to prepare for regulatory approval until
the patent expiry. This means that, as obtaining the marketing approval for a
generic11 medicine takes time, the patent monopoly for the originator is practically
extended further in time than originally conceived. In recognition of this problem-
atic, the Bolar exception is present in many national jurisdictions.
A review of the process of market authorization for medical products is presented
below, prior to discussing in more detail examples of how the Bolar exception is
crafted in various jurisdictions.
9World Trade Organization (2000)
10Mercurio and Tyagi note that the Appellate Body has supported a broad interpretation of
exceptions based on the Appellate Body Report, European Communities—Measures Concerning
Meat and Meat Products (Hormones), ¶ 104, WT/DS26/AB/R, WT/DS48/AB/R (Jan. 16, 1998),
(“[M]erely characterizing a treaty provision as an ‘exception’ does not by itself justify a ‘stricter’ or
‘narrower’ interpretation of that provision than would be warranted by examination of the ordinary
meaning of the actual treaty words, viewed in context and in the light of the treaty’s object and
purpose, or, in other words, by applying the normal rules of treaty interpretation.”). Mercurio and
Tyagi (2010), 262, footnote 68.
11In this chapter the term generics is used to describe chemical, small molecule medicinal products
that are structurally and therapeutically equivalent to an originator product. Generics are inter-
changeable with an originator product.
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2.1 Marketing Authorization of Medical Products
Governments have an important role in formulating laws and regulations to define
and control the national market in medical products in the interest of public health.12
The national medicine regulatory authority aims to protect public health by ensuring
that a product is safe, efficacious and of good quality before it reaches a patient.
Thus, national medicine regulatory authorities around the world subject pharmaceu-
tical products to premarketing evaluation and marketing authorization to ensure that
they conform to required standards.13 The marketing approval system is applied in
accordance to national law. All medicines have to be authorized before they can be
marketed. The manufacturers of any medicine, whether it is a brand-name originator
or a generic,14 need to comply with the requirements. A granted marketing autho-
rization is valid in the geographical territory in which it is applied for.15
The specific regulatory requirements for a medical product to be marketed may
vary. For chemically synthesized pharmaceuticals, regulatory authorities generally
require that generic products demonstrate the same bioavailability and often bio-
equivalence of the generic medicine to a reference product. Producing a full dossier,
including showing the results of pre-clinical tests and clinical trials to show safety
and efficacy of the product, can require significant investment and time. In the case
of requests for approval for local production of medicines or import of medicines
already marketed and approved in third countries, requirements of local clinical trials
may be waived. Hence, if a medical product is a generic of a reference medical
product, it may receive an abridged process for compliance with the premarketing
evaluation and marketing authorization.
Marketing approval or licensure of biologics—referring to medical products that
are made from living organisms-, and biosimilars16 may be subject to specific and
more stringent requirements. There is significant divergence on approaches being
12See World Health Organization (1999).
13See World Health Organization (2011).
14A generic medicine is an equal substitute for an already marketed brand-name drug and is not
protected by a patent in force. Generics are generally commercialized under a non-proprietary
name. Pharmaceutical substances and active pharmaceutical ingredients are given unique,
non-proprietary, generic International Nonproprietary Names (INN). A generic may also be
marketed under its own brand name.
15However, many national regulatory authorities have entered into harmonization initiatives or
mutual recognition agreements. For example, in the European Union there are different authoriza-
tion routes and some medicines go through a centralised marketing authorisation valid in all EU
member States.
16Another term used for example by the WHO is “similar biotherapeutic products”, to refer to a
biological product which is similar in terms of quality, safety and efficacy to an already licensed
reference biotherapeutic product.
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taken by regulatory agencies in this area and debate are ongoing on the current
guidance by the World Health Organization (WHO) on the matter.17
2.2 Relationship of Patent Protection, Marketing
Authorization and Supplementary Legal Protection
The relationship between patent protection and marketing authorization of medical
products at first would appear to be very weak. All medical products are subject to
regulatory requirements, regardless of their patent status. Moreover, in accordance to
patent law, once patent protection expires, competitors should have free entry.
However, in practice, questions of marketing authorization and patent protection
for medical products have become more intertwined, as policy makers juggle in
balancing between innovation and competition incentives, under pressure from a
wide range of stakeholders.
In principle, the patent status of the originator medical product should be irrele-
vant for purposes of the regulatory requirements for approval of generics or
biosimilars. However, some countries have adopted a patent linkage regime to link
the grant of marketing approval by a regulatory authority with the patent status of an
originator medical product.18 This system poses the additional burden on the regu-
latory authority to review whether there may be a patent infringement before it will
issue marketing approval for a new product and creates new restrictions for the
registration of generic and biosimilar products.
In addition, patent term extensions may be available in some jurisdictions under
the rationale of compensating for delays in examination or simply because the
product is subject to regulatory review. These provisions, generally incorporated
in free trade agreements entered into by the USA and the European Union,19 result in
further delays of generic and biosimilar market entry.
The increased laxity in the criteria applied in patent examination in some juris-
dictions also enables the pharmaceutical industry to employ strategic patenting
tactics such as “evergreening” to artificially extend the patent term for profitable
medical products.20 Moreover, in some jurisdictions, the patent incentive for inno-
vation is now supplemented with other legal exclusivities that support the originator
17See Velásquez (2018). See also on challenges on advancing biosimilars, Vaca and Gómez (2020),
Kang et al. (2020).
18Patent linkage is not an international obligation, but often requested by the United States in free
trade agreement negotiations and as part of unilateral trade pressures. See Mercurio (2017),
pp. 97–122, and Correa (2020).
19See Daniel Opoku Acquah, Revisiting the Question of Extending the Limits of Protection of
Pharmaceutical Patents and Data Outside the EU – The Need to Rebalance, Research Paper
127, December 2020, South Centre, https://www.southcentre.int/wp-content/uploads/2020/12/RP-
127.pdf.
20See Ducimetière (2019). Gurgula (2019). I-Mak (2018).
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in delaying entry of generics or biosimilars after the patent term expiry, including
data and market exclusivity21 and supplementary protection certificates.22
On the other hand, in order to promote competition, regulatory authorities may
provide abbreviated pathways for the approval of generics and more recently, for
biosimilars. The policy rationale of the Bolar exception, where available in national
patent laws, also aims to lower product development costs, expedite regulatory
approval and ease market entry.
In this sense, the balance between innovation and competition no longer rests
solely on the design and implementation of the patent system—but on the myriad of
other related instruments that are crafted to respond to the variety of interests
involved and overall complex ecosystem of medical product development, procure-
ment and supply.
2.3 Role of Generic and Biosimilar Competition in Promoting
Access
Medicine prices decrease significantly after patent expiry.23 The increased use of
generic medicines is an important measure for cost-containment in pharmaceutical
procurement. Generics increase competition and lower prices for medicines that
improve access and lower medicine purchase expenditures for governments, to
sustain their healthcare systems. This is of particular relevance today in the context
of rising drug spending, affected by high prices for some medicines, in particular of
biologics such as monoclonal antibodies, notably in low and middle income coun-
tries where in addition to limited government budgets for public procurement, out-
of-pocket purchases are high.
In the United States, the top twelve grossing medicines, mostly biologicals, have
increased by 68% from 2012 to 2018 and cost $96 billion to health insurers,
government payers, and consumers in 2017 alone.24 A recent US FDA report from
December 2019 compared medicines that had initial generic entry between 2015 and
2017 and found that the median price of generics relative to brands is 40%.25 In
Europe, pioneer in biosimilar registration and the largest market for global biosimilar
21See Correa (2013), pp. 16-/173.
22The experience with these new exclusivities or sui generis IPRs for regulated products has also
led to the adoption of new exceptions. See Seuba (2019), pp. 876–886, https://doi.org/10.1093/
jiplp/jpz108.
23Vondeling et al. (2018), pp. 653–660. https://doi.org/10.1007/s40258-018-0406-6
pmid:30019138.
24I-Mak Report, Overpatented, Overpriced: how excessive pharmaceutical patenting is extending
monopolies and driving up drug prices, 2018. http://www.i-mak.org/wp-content/uploads/2018/08/
I-MAK-Overpatented-Overpriced-Report.pdf.
25The calculations use average manufacturer prices. Conrad and Lutter (2019).
140 V. Munoz Tellez
sales, biosimilar competition has significantly reduced prices for biologicals.26
Nonetheless, the overall market penetration of biosimilars remains low, though
expiration of patent and exclusivities of the originator biologics is increasing oppor-
tunities for further savings.27 Currently 61 biosimilars have been approved in Europe
since the establishment of the regulatory framework for registration of biosimilars in
2005.28 India is the largest provider of generic medicines globally, occupying a 20%
share in global supply by volume, and with increasing capacity for production of
biosimilars.29
The extent of the cost-saving potential from switching from originators to generic
products may nonetheless vary among countries depending on, among other factors,
differences in the timing of patent expiries, the type of generic medicine pricing
policies they apply,30 dispensing practices, the market share of generic medicines.
Expanding biosimilar uptake presents additional challenges, including the extensive
litigation actions by biopharmaceutical manufacturers, the need for greater accep-
tance by physicians and patients of biosimilars as safe and effective alternatives to
reference-biologic products.
On a more global level, the role of generics in increasing access is evident in
relation the HIV/AIDS pandemic. The decline in mortality rates between the mid
1990s to early 200s is attributable in large part to the expanded access to generic
antiretrovirals (ARVs), mostly produced in India, that greatly reduced prices and
allowed for treatment expansion. In Brazil, with the production of local generic
ARVs, the prices fell by more than 70% in four years. By 2000, AIDS mortality rate
in Brazil had been halved and HIV-related hospital admissions had fallen by 80%.31
3 History of the Bolar Exception
Patents and other exclusivities constitute barriers to market access for generics and
biosimilars. The Bolar exception is a tool within patent law that supports market
entry of generics and biosimilars, by allowing manufacturers to prepare these
products in advance of the expiration of the originators’ patents.
The history of the Bolar Exception is well documented. It stems from US
Congress reaction to the US Court of Appeals Federal Circuit 1984 decision in
26Gabi Journal Editor Biosimilars Markets (2020), pp. 90–92. https://doi.org/10.5639/gabij.2020.
0902.015.
27OECD/European Union (2018), https://doi.org/10.1787/health_glance_eur-2018-en.
28European Medicines Agency, https://www.ema.europa.eu/en/medicines/.
29https://www.investindia.gov.in/sector/pharmaceuticals.
30The various policies include free-pricing systems (i.e. US) versus price-regulated systems
(i.e. EU), reference pricing, price competition and discounts, and tendering procedures. Reimburse-
ment policies may also affect final generic price.
31UNAIDS (2008), p. 113.
Bolar Exception 141
Roche Products v Bolar Pharmaceutical Co. where it was held that the experimental
use doctrine did not protect the “limited use of a patented drug for testing and
investigation strictly related to US Food and Drug Administration (FDA) drug
approval requirements” and found that Bolar’s experimental use in this case had
definite, cognizable, and not insubstantial commercial purposes.32 The Generic
Pharmaceutical Industry Association (GPIA) had shown in its amicus curiae that
various generics had been tested prior to patent expiry, and argued that the decision
essentially allowed originator manufacturers to retain market exclusivity for their
products beyond the duration of the patent terms because generic manufacturers
could not even start developing and seeking approval for competing generic prod-
ucts until after the originator patent expired.33 Soon after, the US Congress passed
the Drug Price Competition and Patent Term Restoration Act of 1984, better known
as the Hatch-Waxman Act, 35 U.S.C. § 271(e) (2003). The Hatch-Waxman Act
made significant changes to US patent law with the aim to encourage innovation in
the pharmaceutical industry while facilitating the speedy introduction of lower-cost
generic medicines, thereby attempting to get a compromise between the interests of
the research based and generic segments of the industry. Among the changes
introduced, was the Bolar exception codified as 35 U.S.C. § 271(e)(1) that reversed
Roche v Bolar court of appeals decision:
It shall not be an act of infringement to make, use or sell a patented invention . . . solely for
uses reasonably related to the development and submission of information under a Federal
law which regulates the manufacture, use, or sale of drugs or veterinary biological products.
Judicial interpretations of 271(e)(1) have given a broad reading of the subject
matter (i.e. originators, biologics, generics, biosimilars, medical devices) and per-
mitted the coverage of a range of activities under the exemption.34
Many countries have subsequently introduced a similar regulatory review excep-
tion in their patent laws, as will be discussed further in section 5 below.
4 Consistency with Article 30 of the TRIPS Agreement
A WTO dispute settlement panel examined the regulatory review provision of the
Patent Act of Canada in the Canada–Pharmaceuticals Patent case35 and confirmed
that it conforms with the TRIPS Agreement. The panel found that there was no
conflict with a normal exploitation of the patent (Article 28.1 of the TRIPS
32Roche Products v Bolar Pharmaceutical Co., 733 F.2d.858 (Fed.Cir.1984) at 863.
33Krulwich (1985), pp. 519–525. Retrieved December 20, 2020, from http://www.jstor.org/stable/
26658803.
34See Noonan (2015), p. a020800. Published 2015 Mar 16. https://doi.org/10.1101/cshperspect.
a020800.
35Ibid, at 9.
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Agreement) and that it was justified under Article 30 of the TRIPS Agreement
(exceptions).
The Canada Patent Act, Section 55.2(1) reads: “It is not an infringement of a
patent for any person to make, construct, use or sell the patented invention solely for
uses reasonably related to the development and submission of information required
under any law of Canada, a province or a country other than Canada that regulates
the manufacture, construction, use or sale of any product.”
The panel held that the provision was justified under Article 30 by meeting all of
the three cumulative criteria: it is a “limited” exception, not unreasonably interfering
with the normal exploitation of the patent, and not unreasonably prejudicing the
rights of the patent holder, taking into account the legitimate interests of third
parties.36
In the WTO Council for Trade Related Aspects of Intellectual Property Rights
(TRIPS Council)37 and at the World Intellectual Property Organization,38 countries
have continued to exchange on the rationale for inclusion of the exception in their
laws as a mean to balance the private interests of patent right holders and public
interest, and experiences in its use.
5 Crafting National Legal Frameworks for the Bolar
Exception
The Bolar Exemption is recognized in various national patent laws, generally with
the aim to support entry of competitor products upon patent expiry of the originator
product. A WIPO study from 2018 indicates that at least 65 countries and two
regional instruments provide for a Bolar exception.39 While the objective of the
Bolar exception is the same—to avoid delays in market entry for competitor
products—there can be significant divergences among national approaches, includ-
ing on scope and implementation.
In fact, for the design of a Bolar exception, there can be numerous alternative
approaches. Professor Correa has advanced that “the broader the formulation of the
exception in terms of covered products, sources of samples, type of trials allowed,
36The panel found that the stockpiling provision in the Canadian Patent Act is inconsistent with
TRIPS Agreement Article 28.1, as it did not satisfy the first condition of TRIPS Agreement Article
30 because it is not a “limited exception.”
37WTO document IP/C/M/88/Add.1, Minutes of the TRIPS Council, 12 April 2018, Agenda item
12: Intellectual Property and Public Interest, Regulatory Review exception, https://docs.wto.org/
dol2fe/Pages/SS/directdoc.aspx?filename¼q:/IP/C/M88A1.pdf&Open¼True.
38WIPO draft reference document on the exception regarding acts for obtaining regulatory approval
from authorities (second draft), document SCP/28/3, https://www.wipo.int/edocs/mdocs/scp/en/




time to undertake them, and geographical scope, the more competitive environment
is ensured that will benefit consumers, health providers and other public agencies.”40
The policy choice for designing a broader Bolar exception is more favourable to the
objective of promoting competition.
Several countries, such as the United Kingdom and Ireland, have in recent years
amended their patent laws to broaden the scope of the Bolar exception. The
extension of the Bolar exception has also been under consideration in the EU41
given the divergences in current implementation throughout the member States and
in the context of how a future Unified Patent Court (UPC) may apply the Bolar
exception.42 A study by the Max Planck Institute for Innovation and Competition
prepared for the European Commission recommended that the EU member States
adopt a broader than the minimum standard currently provided for under Art. 27
(d) UPCA, in following the national Bolar exceptions in Germany, Ireland, Italy,
France, among other EU member States.43 The economic impacts of extending the
Bolar exception in the EU to cover any medicines (not limited to products following
an abridged marketing authorisation only), have been estimated as cost savings from
patent screening of up to €23-€34.2 million per year.44
In order to well define the Bolar exception, it may be preferable to design it as a
specific exception, as opposed to inclusion as part of a general research or experi-
mental exception.
The Bolar exception can be crafted to cover all regulated products, including but
not limited to health-related products for human use, such as medicines and medical
devices. Other regulated products covered in some Bolar exceptions include veter-
inary medicines and plant protection products.
The scope of the activities should be clearly defined. These should relate to
obtaining marketing approval for generics and biosimilars, but may also extend for
acts relating to medical devices (as provided for in the US) and innovative medicines
(for example to carry out health technology assessments as in the Bolar exception in
the UK Patents Act).
It is not necessary to restrict the user of the Bolar exception to the party that would
be requesting the marketing authorization. It can also include acts by third parties
involved in supplying materials to a company to run tests and trials related to
obtaining marketing authorization for a generic or biosimilar.
40Correa (2016).
41The Bolar exception was introduced in Article 10(6) of the Directive 2004/27/EC of 31 March
2004, https://eur-lex.europa.eu/legal-content/EN/TXT/?uri¼CELEX:32004L0027.
42The establishment of the unitary patent system and UPC may follow if the Agreement on a
Unified Patent Court (UPCA) enters into force. The UPCA Article 27(d) contains the Bolar
Exception: “The rights conferred by a patent shall not extend to . . .the acts allowed pursuant to
Article 13(6) of Directive 2001/82/EC or Article 10(6) of Directive 2001/83/EC in respect of any
patent covering the product within the meaning of either of those Directives”.
43Max Planck Institute for Innovation and Competition, Study on the legal aspects of supplemen-
tary protection certificates in the EU, European Union, 2018, pp. 338–361.
44Charles River Associates (2016).
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A clear definition of the scope of the permitted acts is one of the critical aspects of
a Bolar exception so as to provide legal certainty of the safeguards it provides against
patent infringement and to the rights of patent holders. Acts that are related to
obtaining marketing approval that should be covered include studies, trials and
experiments required for obtaining marketing approval in the country, as well as
for obtaining marketing approval in other countries. As noted earlier, third party
activity for the company seeking marketing approval, such as delivery of an Active
Pharmaceutical Ingredient (API) to carry out tests or trials when the company is
unable to produce the API in-house, can also be included.45
6 India Bolar Exception: Recent Developments
The design and implementation of the Bolar exception is of particular relevance in
countries that have domestic production capacity for generics and biosimilars. The
Bolar exception in Indian legislation is of special interest, as India, as noted, is a
global leader in the global supply of affordable generic and biosimilar products. The
Bolar exception contributes to a favorable environment for the generic and
biosimilar industry in India to develop and expand.
The Indian patent act in Section 107A includes a broad Bolar exception. It reads:
“any act of making, using, selling or importing a patented invention solely for uses
reasonably related to the development and submission of information required under
any law in India, or in a country other than India, shall not be considered as
infringement of patent rights.”46
The exception applies to any regulated sector, and extends to acts done for
submission of information not only in India but in any other country. The scope of
acts covered can include the manufacture of the patented protected product, export of
an API or finished formulation by a generic company, conduct of clinical trials, or
import of the API or formulation by a third party to support relevant regulatory
approvals in India or other countries.
While the Section. 107A is clearly worded, there has been significant litigation
with respect to this provision, and, accordingly the Indian judiciary has provided
important interpretation of its scope. A recent case tested in particular the definition
of “selling” and determined that it allows export of a patented product for generation
or submission of information for seeking regulatory approval in India or other
countries, without such export constituting an act of patent infringement. A Division
Bench of the Delhi High Court held that export for the purpose of conducting
development/clinical studies and trials is within the ambit of the Indian Bolar
45The Dusseldorf Court of Appeal in 2013 (docket no. I-2 U 68/12, Astellas v Polharma) referred a
preliminary ruling on this question to the European Court of Justice (ECJ), but the ECJ did not issue
a judicial pronouncement as Astellas withdrew action against Polpharma.
46https://indiankanoon.org/doc/151051886/.
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exception.47 The Court established an indicative list of factors to determine whether
the export is ‘reasonably related’ to the research purpose or not.
The court also clarified that section 107A is not to be treated as an exception to
section 48 of Indian Patent Act: “Its history of interpretation by TRIPS, the discus-
sion in the Parliamentary Joint Committee Report, all clearly point to its being a
special provision that deals with the rights of the patented invention for research
purposes.”48
The relationship of the Bolar exception with the terms of a compulsory license
was also considered by the court. As noted by Indian delegation to the WTO, “Bolar
exceptions have an important link with compulsory licensing. The absence of the
Bolar exceptions can severely affect the ability of a country to effectively utilize
compulsory license provisions when considered necessary.”49
In Bayer Corporation and Ors. v. Union of India and Ors., Bayer had filed a suit
for infringement of Patent against Natco, a generic producer. During the pendency of
the suit, Natco obtained a compulsory license for the same patent for the territory of
India. Bayer filed a writ petition in the High Court of Delhi seeking a direction to the
Custom Authorities to seize the consignments for export of the products covered by
the compulsory license (CL) manufactured by Natco, on grounds that the export
violated the terms of the CL. The Court passed an interim order to restrain Natco
from the export. In parallel, Natco requested and obtained permission to export 1 kg
of API to China to conduct clinical studies and trials for regulatory purposes. Bayer
considered that the API sale was an infringement of the patent in violation of the CL
terms. Natco argued that it was covered by the Bolar exemption as the export was for
regulatory purposes.50 In its decision the Court noted that “it is..of the opinion that
Natco’s status as compulsory licensee did not place it under any additional statutory
bar from exporting the product, as long as the underlying condition in Section 107A
was satisfied”.51
7 Conclusions
Policy makers can apply different approaches to address the competing interests of
promoting innovation and the discovery of new medicines while at the same time
fostering competition through the development and market entry of lower cost
47Delhi High Court decision pronounced on 22 April 2019 on Bayer Corporation vs Union Of India
& Ors. and Bayer Intellectual Property GMBH & Anr. v. Alembic Pharmaceuticals Ltd.RFA(OS)
(COMM) 6/2017, https://indiankanoon.org/doc/85364944/.
48Ibid, para 89.
49Ibid at 35, para 435, page 53.
50For further analysis of the arguments made by Bayer and Natco, see Rathod (2017), available at
https://doi.org/10.2139/ssrn.2971521.
51Ibid at 45, para 94.
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generic and biosimilar products. The policy approach should be in line with public
health policies, i.e. to support access to medicines for all, and informed by the
domestic context of the pharmaceutical industry.
Without the regulatory review or “Bolar” exception, competitive products such as
generics and biosimilars would not be able to enter the market for prolonged periods
following patent expiry of originator products. The safeguard against patent
infringement for acts covered by the Bolar exception supports the regulatory
approvals for generics and biosimilars without delay. Policy choices to expand the
term of patent protection, introduce test data exclusivity or patent linkage can have
the effect of increasing barriers for generic and biosimilar market entry.
A broad and well-defined Bolar exception, as described in this chapter, is suited to
the objective of promoting timely regulatory approval for generics and biosimilars to
lower costs for health systems and improve access to medicines.
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Patent Oppositions in India
Sandeep Kanak Rathod
Abstract Pre-grant and post-grant oppositions filed in India by civil society and
generic companies have been instrumental in visibly increasing access of drugs to the
public—both in terms of earlier generic entry and also cheaper prices due to such
generic competition. This paper looks at the significant pharmaceutical patent oppo-
sitions in India during the last 15 years. It focuses on some unique aspects connected
to each of these oppositions and tracks how these oppositions helped in securing
earlier access to generic drugs. The last part of the paper analyses patent opposition
pendency statistics and notes that increasing pendency numbers, over the last few
years, is a matter of deep concern as it could impact access to drugs, in future.
1 Introduction
Patent oppositions by civil society organisations and generic pharmaceutical com-
panies have been instrumental in increasing access of drugs to the public—by
preventing patent evergreening and bringing in earlier generic drug entry as well
as increasing competition in the pharmaceutical sector leading to cheaper prices due
to such generic entry. Over the years, various commentators have written on Indian
patent oppositions—from different legal and policy perspectives.1
In this paper, the author analyses key pharmaceutical patent oppositions in the last
one and half decade and shares certain lesser discussed angles of these oppositions.
The paper is divided in two parts. The first part discusses important pharmaceutical
patent oppositions pertaining to drugs across disease categories and looks at how
legal arguments have progressed moving beyond the simplistic statutory arguments
as well as how certain strategies that are beyond the opposition framework can lead
to successful results even when an opposition is not filed.
S. K. Rathod (*)
Mumbai, India
1Below are some papers that have looked at patent oppositions in India from different perspectives:
Amin (2010); Ho (2011); Ali (2016); Serrano and Burri (2019), pp. 275–294.
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The second part of the paper looks at the current opposition pendency statistics
and what these statistics mean for oppositions for the times to come. Before
proceeding further, it is important to note that India, like many developing countries,
has a healthcare system where individuals pay a very large proportion of healthcare
expenses from their pocket.2 This reality combined with a large population, means
that the drug access mechanism becomes that much more strained and every attempt
at increasing drug access needs to be seen not only in the limited framework of
intellectual property (IP) but in the broader framework of living in a resource
constrained country.
India has a long history of patent law, going back to the 1850s.3 The present
patents regime in India is enshrined within the Patents Act, 19704 (‘the 1970 Act’)
that was enacted after repealing the Indian Patents and Designs Act 1911. After
independence in 1947, India set up committees to look at the 1911 Act and these
committees noted the stage of economic development in India, the relevance of
patents to a country that was then not an industrially developed nation and what
possible changes could be made to the 1911 Act. The Ayyangar Committee Report5
also noted the disparities resulting from the 1911 Act and how certain steps were
necessary to completely rewrite the statute. Importantly, this Report recommended
moving to a ‘process claims’ only regime for certain sectors6 and was the foundation
for the 1970 Act.
The 1970 Act allowed only process patents within the drug/pharmaceuticals and
food domain, until 2005. Changes were made in stages to the 1970 Act in 1999, 2002
and 2005 as a part of India’s commitments to the Trade Related Aspects of
Intellectual Property Agreement (TRIPs Agreement) and India restarted issuing
product patents for pharmaceuticals and allied sectors from 2005.
2As per the National Health Accounts (NHA) estimate for 2014–15, Out-of-Pocket Expenditure




The World Bank data also gives a similar figure (of 62.4% as OPE—latest data pertained to year
2017): <https://data.worldbank.org/indicator/SH.XPD.OOPC.CH.ZS?end¼2017&locations¼IN&
start¼2000&view¼chart>.
3The ‘background’ section has been adopted from author’s earlier article: Compulsory licences on
pharmaceutical patents in India: A short article. Journal of Generic Medicine, 13(3), 108–113.
doi:10.1177/1741134317691804.
4A copy of the statute is available at the Indian Patent Office’ website: <http://www.ipindia.nic.in/
acts-patents.htm>.
5‘Report on the revision of the patents law’ by Justice N. Rajagopala Ayyangar; released in
September 1959 and available at <http://www.ipindia.nic.in/writereaddata/Portal/Images/pdf/
1959-_Justice_N_R_Ayyangar_committee_report.pdf>.
6The Report discussed the background and rationale for moving from product claims to a process
claims only regime for certain sectors, extensively—Refer Paragraphs 56 through 102 of the
Report.
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Originally, oppositions came in the prosecution framework only once—i.e. after a
patent application had already been examined and accepted by the Patent Office
i.e. India allowed filing oppositions against ‘applications accepted for grant’. India
modified its patent opposition system in 2005 and created provisions for two types of
oppositions—pre-grant opposition against a published application and post-grant
opposition against a granted patent. In the earlier system, oppositions came in the
prosecution framework only once—i.e. after a patent application had already been
examined and accepted by the Patent Office. The modification thus allowed an
opposition to be filed at an earlier stage of the prosecution framework as well as
after the grant of patent.
Accordingly, a patent application can now be opposed under section 25(1) by
filing a representation with the Patent Office. This is also normally called as a ‘pre-
grant opposition’. A granted patent can be opposed under section 25(2) by filing an
opposition. This is normally called as a ‘post-grant opposition’. It needs to be filed
within 12 months from the date of publication of such grant. A patent can also be
sought to be revoked under section 64 and the Government can revoke patents on
policy considerations under section 66.
There are four main players within the patent opposition framework as applied to
pharmaceutical inventions:
• The Government—Ministry of Commerce & Industry, Government of India
(which is ultimately responsible for the functioning of the Patent Office and
grant of patents), the Ministry of Health and Family Welfare (responsible for
health framework) and the Ministry of Chemicals and Fertilizers (that houses the
Department of Pharmaceuticals);
• Innovator companies filing patents for their products (Applicants);
• Generic companies seeking to launch drugs as soon as possible (Opponents); and
• Civil society/Non-governmental organisations (also termed as ‘NGOs’) working
at the grassroots on access to medicines and patient rights and who oppose patent
applications/patents for ensuring drug access (hence, also Opponents).
Each of these players are important stakeholders and have different priorities/
goals within the patent system but each of them must play their roles with integrity
and efficiency to create a system that balances drug access and health with encour-
aging an intellectual property (IP) rights framework to reward innovators.
The paper discusses 14 oppositions (both pre-grant and post-grant) that relate to
important drugs that are needed by a large patient population. Oppositions for niche
drugs are excluded. In most of the cases, companies had launched a generic version
of the product, while the opposition proceedings were on-going and hence if the
oppositions would have failed, it would have negatively impacted generic drug
access.
As we trace these pharmaceutical oppositions, we note that many of the early
oppositions filed in 2005–2015 were centered mainly around the statutory arguments
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from S.37 (which excludes from patentability certain inventions and is titled ‘What
are not inventions’) and mostly around S.3(d) of the Patents Act (that bars grant of
patents to new form of known substances or mere use of known processes).
Opponents have, over the years, moved beyond basing their case on S.3(d) alone
and have gone to draft and win oppositions based on more complex arguments like
lack of inventive step, obvious to try, anticipatory disclosures from markush claim8
filings etc. Just like the opposition arguments moved beyond 3(d), so have the patent
examiners, for examination of pharmaceutical claims.
Published empirical research9 covering patent applications having priority dates
between 2000 and 2012 advises that while examiners are invoking S. 3(d) more over
time, but when they do so, it still tends to be in conjunction with novelty and
inventive step objections. But effective use of S.3 and its implementation is an
open question. A later paper10 covering pharmaceutical patents granted between
2009 and 2016 argues that the Examiners at the Patent Office have not been
implementing S.3 framework to its fullest and that more than 70% of such patents
were in contravention of the anti-evergreening framework of S.3.
Hence, while one can try and imagine what would have happened in these
13 cases in absence of these oppositions; the undeniable fact is these pharmaceutical
oppositions have expanded drug access for multiple important drugs—not just for
Indian patients but also for patients from other countries that are dependent on Indian
generic drugs.
Within this scenario, increasing pendency statistics for oppositions, over the last
few years, is a matter of deep concern as it could negatively impact drug access.
2 Patent Oppositions in India
2.1 Gleevec Opposition
Any paper on Indian patent oppositions can move forward only by starting from the
Imatinib Mesylate Beta polymorph form opposition. Imatinib (brand name Gleevec)
7Section 3 of the Patents Act, 1970, is titled—‘What are not inventions’. Section 3 is a ‘deeming’
fiction—it prohibits grant of patents to certain categories of inventions and is part of the chapter
titled ‘Inventions not patentable’. Thus, these inventions, in absence of this section would have been
patentable. Text of S.3 is available at https://indiankanoon.org/doc/874310/. Within S.3, S. 3(d), 3
(e) and 3(i) have special importance as they relate to pharmaceutical inventions.
8A ‘Markush’ claim recites a list of alternatively useable members and can cover millions of
compounds in a single claim. This can, at times, go much beyond actual embodiments exemplified
in the patent specification. For a general discussion on what are markush claims, please refer https://
www.uspto.gov/web/offices/pac/mpep/s2117.html.
9Sampat and Shadlen (2018), p. e0194714.
10Ali et al. (2018).
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is a Novartis drug used in treatment of certain cancers (such as acute lymphoblastic
leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors etc.).
This opposition battle went all the way up to the Supreme Court of India11 where
besides looking at the S.3(d) interpretation, the Court also made way for some very
interesting case-law on inventive step, rejecting Novartis’ arguments on disclosure
v/s claim scope.
Filing details in Table 1:
The Indian Imatinib opposition saga starts after the grant of an exclusive market-
ing right (EMR) in December 2003 by the Patent Office to Novartis on its application
for Beta polymorph of Imatinib Mesylate.
EMRs12 were the predecessors of ‘pharmaceutical product patent claims’. EMRs
were brought into the statute book in 1999 as an interim mechanism to afford product
patent type protection, after the United States’ filed an action against India at the
World Trade Organisation’s Dispute Settlement Body in 1997.13 These EMRs could
be granted only upon satisfying certain criteria and were to cease upon grant of
product patent to the EMR holder, in due course.
The drug ‘Imatinib’, including its salts forms was invented at Novartis in 1993
and patents were filed for it in many countries. This patent was not filed in India
since India did not allow product patent status for pharmaceutical products, in 1993.
Table 1 Imatinib opposition
Drug: Imatinib
Therapeutic area: Anti-cancer/Oncology
Nature of patent filing in India: Beta crystalline polymorph of drug—Imatinib Mesylate
Application # 1602/MAS/1998







Expiry, if patent would have been
granted:
17/July/2018
Opponent(s): Cancer Patients Aid Association (CPAA)
Companies: Hetero, Cipla, Natco
Unique points: Evidence submission, obviousness, disclosure versus claim
scope and S.3(d)
11Novartis AG v. Union of India & Ors. [2013] INSC 369. https://www.globalhealthrights.org/wp-
content/uploads/2013/04/SC-2013-Novartis-AG-v.-Union-of-India.pdf.
12EMRs were bought in via the 1999 amendment and covered in Chapter IVA (Sections 24A
through F) of the Patents Act. The EMR chapter was removed in the 2005 amendment that
reintroduced product patents for pharmaceuticals.
13Refer Nupur Maithani and Priyanka Vyas, ‘India: Exclusive Marketing Rights Revisited in India’
available at https://www.mondaq.com/india/patent/73894/exclusive-marketing-rights-revisited-in-
india.
Patent Oppositions in India 155
Novartis’ own experiments in 1996 had shown that there was no difference in
efficacy between Imatinib and Imatinib Mesylate salt. It filed the Indian patent
application for the Beta crystalline polymorph of Imatinib Mesylate in July 1998
and sought an EMR for the same from the Indian Patent Office, in March 2002. This
1998 patent filing was two steps away from the original 1993 invention—a move
from Imatinib base to Imatinib Mesylate and then a move from Imatinib Mesylate to
making a Beta crystalline polymorph of the same.
Meanwhile, Novartis had launched the drug in United States in 2001 and in India
in April 2002. It got the EMR in December 2003. Some generic companies also
launched the drug in India after Novartis’ launch, but before the grant of EMR. There
was a huge difference between Novartis’ price and the price charged by generic
companies.
Based on this EMR, in early 2004, Novartis went ahead with filing of infringe-
ment suits at two Courts—the Madras High Court (seven cases) and the Bombay
High Court (three cases). The Madras High Court granted injunction(s) in favour of
Novartis against such generic launches but the Bombay High Court did not grant
injunctions. Multiple generic companies and civil society groups filed pre-grant
oppositions against the pending application.
While journal articles have discussed nuances of the later court battles that came
after the pre-grant opposition—including the Madras High Court14 decision(s), the
Intellectual Property Appellate Board decision15 (IPAB) and the Supreme Court’s
decision,16 but there is very little written material on the actual pre-grant decision.
While the Opponents raised multiple grounds, two key questions raised were
related to (i) S.3(d) and (ii) assessment of obviousness. S.3(d) brings in an additional
question of examination when claims relate to new forms of known substances—in
this case, claimed ‘beta polymorph of imatinib mesylate’ was a new form of known
substance—Imatinib and its salts and would be eligible for patent only if the beta
polymorph passed the framework of S.3(d) i.e. a patent could be granted only if the
beta polymorph differed significantly in properties with regard to efficacy when
compared to Imatinib or its known salts. The obviousness assessment for these
claims was focused on the question of how making polymorphs of a known drug
or its salt forms could be considered obvious to a person skilled in the art.
There is a notion that the opposition proceeding was superficial and did not give
Novartis a fair chance to adduce evidence/data that it could not have put in the
original patent specification. This notion is not based on facts. Actually, the Patent
Controller (Mr. Rengaswamy), at first instance, had afforded an opportunity to
Novartis to show the merits of the beta polymorphic form. Novartis could only
show that there was a 30% improvement in bioavailability—i.e. the relative
14Basheer and Reddy (2008), pp. 131–155.
15The IPAB’s decision was analysed here: https://spicyip.com/2009/07/breaking-news-novartis-
loses-glivec.html.
16The Supreme Court decision has been discussed below: (i) Ragavan (2013). http://works.bepress.
com/srividhya_ragavan/156/. (ii) Attaran (2014), pp. 477–479. (iii) Grebe and Low (2017).
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bioavailability of Imatinib Mesylate in the beta crystalline form versus Imatinib free
base (and not Imatinib Mesylate salt)—but could not show any specific therapeutic
advantage of the beta crystalline form over Imatinib Mesylate itself. A salt form of a
drug (regardless of its polymorphic form) would normally have increased bioavail-
ability over a drug in its base form.
Importantly, in his decision, the Controller noted that ‘. . . also the difference in
bioavailability may be due to the difference in their solubility in water’ and he held:
. . . As regards efficacy, the specification itself states that wherever ß-crystals are used the
imatinib free base or other salts can be used. The present patent specification does not bring
out any improvement in the efficacy of the ß-crystal form over the known substances rather it
states the base can be used equally in the treatment of diseases or in the preparation of
pharmacological agents wherever the ß-crystal is used. Even the affidavit submitted on
behalf of the Applicant does not prove any significant enhancement of known efficacy. It is
found that this patent application claims only a new form of a known substance without
having any significant improvement in efficacy. Hence I conclude that the subject matter of
this application is not patentable. . .
Had these oppositions not been filed and Controller Rengaswamy not considered
these key questions viz. (i) S.3(d) framework for assessing patentability arguments
for new forms of a known substance and (ii) the law of obviousness for pharmaceu-
tical inventions—then theoretically, the EMR and subsequent product patent would
have sustained and possibly blocked generic launch until July 2018. While this
opposition used S.3(d) extensively, the jurisprudence that developed from the Patent
Office all the way up to the Supreme Court went a lot beyond the plain S.3
(d) argument.
Let’s focus on some things that had their genesis from this set of pre-grant
opposition(s). The filing of the pre-grant oppositions became the foundation for
the later battles that led to the following important consequences:
• Securing earlier and consistent availability of generic version—from 2003
onwards and much before July 2018 (which would have been the expiry for the
granted patent—thus earlier generic availability by a margin of 15 years);
• Bringing in a framework for examining obviousness while assessing pharmaceu-
tical inventions;
• Creating jurisprudence on the concept of efficacy in pharmaceutical inventions
and the difference between bioavailability and therapeutic efficacy (S.3(d));
• Laid the foundation for the Supreme Court to note that there cannot be a
difference between what is disclosed in the patent specification versus what is
claimed in the patent’ claims.
This last point will again be in focus in the coming years—as Markush disclo-
sures versus specific compound patent claim invalidation litigations are now pend-
ing the Indian Courts.
As noted earlier, literature has discussed extensively about the later high court,
IPAB and Supreme Court battles of Imatinib. However, it is Controller Rengaswamy
who was the first adjudicator/judge and made an important contribution that later
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became the cornerstone for India’s pharmaceutical patent opposition/drug
access saga.
2.2 Valcyte Opposition
Ganciclovir was approved as a drug in 1988. Roche later filed a patent application
for a modification of Ganciclovir—i.e. it claimed the L-valinate ester of Ganciclovir
(Valganciclovir, brand name: Valcyte). This drug is used in the treatment of adults in
preventing infection with cytomegalovirus (CMV) that may occur after an organ
transplant (heart, kidney, or pancreas). It is also used to treat CMV infection of the
eye in adults with acquired immunodeficiency syndrome (AIDS). See Table 2.
This application saw the opposition fight in multiple rounds at the pre-grant stage
and then a strongly contested post-grant opposition stage as well. And in the midst of
this, there were rounds to the Madras High Court and the Supreme Court too.
In the first round, only a single short pre-grant opposition was filed by civil
society groups (NGOs) in July 2006. The Controller rejected this opposition in
November 2007 summarily and proceeded to process the grant of the patent. The
civil society groups then moved the Madras High Court (HC) challenging this patent
arguing that their pre-grant opposition was not heard by the patent controller. In
December 2008, the HC asked the Patent Office to review its decision.
Roche decided to move the Supreme Court contesting the HC order17 which then
directed the Patent Controller to consider the pre-grant opposition and dispose the
case by 31/Jan/2009. The Patent Controller heard the matter again and through his
decision dated 30/Jan/2009, rejected the NGOs’ pre-grant opposition. Accordingly,
the first set of pre-grant oppositions (in 2 rounds) did not succeed and a patent was
granted to Roche.
Table 2 Valganciclovir opposition
Drug: Valganciclovir
Therapeutic area: Anti-viral
Nature of patent filing in India: Compound (L-valinate ester of Ganciclovir)
Patent/Application # IN207232 (from 959/MAS/1995)
Dates of decision(s): 2nd Pre-grant: 30/Jan/2009
Post-grant: 30/April/2010 and again on 01/July/2015
Expiry, if patent remained granted: 27/July/2015
Opponent(s): Indian Network of People Living with HIV/AIDS (INP+);
Companies: Matrix; Ranbaxy; Cipla and Bakul Pharma.
Unique points: Ambit of ‘Person interested’ to file post-grant opposition,
Obvious to try and S.3(d).
17https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sc-asks-chen
nai-patent-office-to-hear-roche/printarticle/4213952.cms.
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Meanwhile, Cipla had launched a generic version of the product in September
2008 and Roche filed a patent infringement suit. Subsequently, NGOs and multiple
generic companies filed post-grant oppositions.
While the post-grant opposition was fought on multiple grounds including (a) S.3
(d) barred patenting of ‘new’ ester form of a known substance ‘ganciclovir’, in
absence of enhanced efficacy and (b) an important obviousness argument was also
bought in by a generic company (Matrix) which argued that making a valinate ester
of a drug like Ganciclovir was obvious when seen from prior art construct of making
a valinate ester of a drug like Aciclovir (an ‘obvious to try’ framework!Acicyclovir
to its valinate ester—Valacyclovir approach would prompt a person to attempt to
make the valinate ester—Valganciclovir—from Ganciclovir since these are similar
drugs chemically and the underlying problem to be solved was similar)—this
obviousness argument was eventually accepted by the Controller.
Apart from the science aspects noted above, a lesser known but key aspect in the
post-grant stage was whether civil society groups had a ‘standing’ (‘locus’) to file a
post-grant opposition as the Patents Act states that only a ‘person interested’ could
file a post-grant opposition. Hence whether a non-manufacturing entity (like a civil
society group) could come within the scope of ‘person interested’, thus having
‘locus-standi’ to file a post-grant opposition was, till then, an open question. To
this question, the Controller specifically ruled that civil society groups came within
the ambit of ‘person interested’. This ruling expanded the scope of entities that could
file a post-grant opposition and consequently civil society groups were now free to
file post-grant oppositions.
The Controller, in the final Valcyte decision, not only revoked the granted patent
and secured generic production, but also helped in expanding the ambit of the term
‘person interested’ and demonstrated how an ‘obvious to try’ argument could be
effectively implemented for assessing patentability of alternative forms of known
substances.
Roche appealed the post-grant rejection from the Patent Office to the IPAB,
which remanded the matter back to the Controller. In July 2015, the Controller
revoked this patent a second time,18 which reconfirmed the earlier decision, includ-
ing ‘obvious to try’ framework and the standing of civil society organisations to file
post-grant oppositions as ‘person interested’.
2.3 Herceptin Opposition
Trastuzumab (brand name: Herceptin) is a biologic drug (a monoclonal antibody)
from Roche/Genentech, used primarily in the treatment of breast cancer. Roche had
one Indian patent that covered a particular formulation of this drug. Roche had—
over the years—filed multiple divisional applications from this original filing,
18https://spicyip.com/2015/07/valganciclovir-patent-revoked.html.
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creating a series of pending divisional filings—each of which would have normally
required filing separate oppositions, to secure launch of any generic product. Each of
the three divisional filings suffered from individual procedural defects which meant
that these were incorrect filings and should have not been allowed to remain in the
system, in the first place.
A generic company (Glenmark) had filed a post-grant opposition against the
granted patent, but that opposition never saw any traction at the Patent Office.
Glenmark had also filed a pre-grant opposition against the first divisional application
(1638), but this opposition too never reached the stage of a formal hearing.
Since late 2012, an NGO (‘Campaign for Affordable Trastuzumab’) had been
working to increase access to Trastuzumab and was talking to the Government for
the same.19 In March 2013, the Health Ministry had even recommended issuance of
a compulsory license against the formulation patent20 but no compulsory license was
issued on this patent.
In February 2013, a generic company had (Mylan Laboratories) bought the issue
of all three divisional filings being incorrect in law, to the notice of the Patent Office
by means of detailed letters. Consequently, the Patent Office invited Roche to
explain its divisional filings. Roche did not attend the meetings in July 2013 and
subsequently the Patent Office rejected the divisional filings.21 Roche had kept all of
above Indian filings, active, from 2000 through July 2013.
In August 2013, Roche also abandoned its main patent22 (by opting to not pay
renewal fee), but not before asserting23 that “This decision takes into account the
strength of the particular rights and the IP (intellectual property) environment in
India in general.” Roche statement excluded any mention about Roche’s rationale
for originally filing and then abandoning these divisional filings or why it suddenly
abandoned its main granted patent, for no specific reason.
Global media reports around the matter—led the Indian Patent Office to do
something that it had never done (and has not done since). The Patent Office put
out a press release (noted in Table 3) which systematically mentioned the defects in
each of the Roche’ divisional filings.
Roche’s decision to originally prosecute and later abandon the Indian formulation
patent as well as file and later abandon the multiple divisional applications (all of
which it had kept alive for many years)—must be also seen in a broader context of
corresponding filings outside India. While the above actions were going in India
during 2012–13, Roche had been fighting an intense battle with Hospira (a generic
company) first at the EPO (since 2006) and later also at the UK Courts for
19http://www.pharmabiz.com/NewsDetails.aspx?aid¼77303&sid¼1.
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counterpart of this formulation patent. In October 2010, the EPO, in a first instance
ruling, ruled this formulation patent (EP1308455), invalid. As of 2013, when Roche
abandoned the Indian patent, its appeal against the invalidity decision, was pending
at the EPO. In April 2014,24 the UK Patents Court, ruled the UK counterpart of the
formulation patent as being invalid.
The author submits that while these abandonment/rejection results were achieved
outside of the standard ‘oppositions’ framework, it must be noted that ‘out of the
box’ actions/petitions can also achieve path-breaking results, even before/without
filing an opposition. The Patent Office’s decision of removing these incorrect
divisional application filings and Roche’ abandonment of the sole granted patent
removed the need for filing multiple oppositions to the applications as well as the
granted patent and thus cleared the way for launch of the world’s first biosimilar
Trastuzumab, in India in early 2014.25
2.4 Zykadia Opposition
Ceritinib (brand name: Zykadia) is a Novartis drug used for treatment of lung cancer.
This relatively recent post-grant opposition decision against Ceritinib compound
patent is a short and interesting decision. See Table 4.
Natco had launched an ‘at risk’ generic version of Ceritinib in India, prior to this
opposition decision. Novartis also has a patent infringement suit pending against
Table 3 Trastuzumab opposition
Drug: Trastuzumab
Therapeutic area: Oncology (Breast cancer)
Nature of patent filing in
India:
Formulation for Trastuzumab
Patent/Application # 1. Original: IN/PCT/2000/391/KOL (matured into a patent
IN205534)
2. 1638/KOLNP/2005—first divisional application (child);
3. 3272/KOLNP/2008—second divisional application (i.e. first
grandchild);
4. 3273/KOLNP/2008—third divisional application (i.e. second
grandchild)
Date & Link: Government Press Release dated 05/Aug/2013 (Krishnan 2013)
Expiry date, for the
granted patent:
03/May/2019
Unique points: Filing of multiple divisional applications; Patent Office dismissed the
applications on procedural grounds
24[2014] EWHC 1094 (Pat), https://www.bailii.org/ew/cases/EWHC/Patents/2014/1094.html.
25https://www.thehindubusinessline.com/companies/mylan-launches-first-trastuzumab-biosimilar-
in-india/article23122107.ece.
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Natco at the Delhi High Court. The opposition decision allowed Natco to continue to
be present in market, but with the risk of payment of damages in future.
For the opposition, Natco used 3 main arguments—lack of novelty (anticipation),
lack of inventive step and not an invention u/s 3(d).
For anticipation, Natco argued that two separate prior document(s): IN232653
(application # 2241/CHENP/2005, coming from WO2004080980) and IN240560
(application # 553/CHENP/2006, coming from WO2005016894)—both disclosed
Markush26 group of compounds which individually destroyed novelty for Ceritinib
molecule i.e. one would get/find the Ceritinib molecule in either of these documents,
if one used the right substitutions. WO2005016894 had been cited in the original
prosecution but the Controller, at that time, had allowed the claims during
examination.
The Opponent also used these 2 documents and additionally 4999/KOLNP/2007
(coming from WO2007006926) to argue that the Ceritinib molecule lacked an
inventive step.
Finally, the Opponent also argued that the Patentee did not provide any in vivo
efficacy data for Ceritinib in comparison to compounds disclosed in these 2 docu-
ments and hence it failed the threshold of S.3(d) as Ceritinib would be a new form of
known compounds in either of these filings.
The Controller’s approval of the Markush filing destroying the novelty of later
specific compounds in his decision is very interesting to this author since there are
many other compound patent filings which fall in this template of an earlier Markush
patent disclosing a large number of compounds and a later specific patent filing for
the compound. This decision could potentially imply that the earlier broad Markush
patent disclosures can be used to invalidate later specific compound patent filings.
Note: The Patentee filed an appeal against the Controller’s revocation decision, at
the IPAB. In July 2020, the IPAB has issued a ‘stay’ on the Controller’s revocation
order27 as an interim order in the appeal proceedings.
Table 4 Ceritinib opposition
Drug: Ceritinib
Therapeutic area: Oncology
Patent/Application # IN276026 (from 3951/DELNP/2009)
Opponent: Natco Pharma
Dates of decision(s): 16/Aug/2019
Expiry, if patent remains
standing:
08/Dec/2026
Unique points: Anticipation—Markush disclosure versus specific compound; Lack
of inventive step and S.3(d)
26Refer earlier note for definition of ‘Markush’ claims.
27A copy of the IPAB Order is available at https://ipab.gov.in/ipab_orders/delhi/MP.NO.8.2019-
OA.20.2019.PT.DEL.pdf.
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2.5 The Viread Oppositions
Tenofovir Disoproxil Fumarate (brand name: Viread) is used in treatment of AIDS
and Hepatitis B. Gilead had filed a bunch of patent applications related to its Viread
IP portfolio for—Tenofovir Disoproxil (ester) and the final product—Tenofovir
Disoproxil Fumarate (salt form of the ester). Tenofovir had been invented years
earlier by a Czech scientist28 and later Gilead + UC San Francisco carried out
additional work. Finally, Gilead developed the salt form that finally became the
block-buster HIV drug.
Some interesting facets to the Gilead Viread Indian patent portfolio:
• Gilead filed a large number of divisional filings from the 2 original filings—
eventually turning into multiple ‘children’/‘grandchildren’ filings.
• Multiple companies, civil society and patient groups filed pre-grant oppositions in
2006 and onwards against most of these filings, over the years, including the
divisional filings.
• Gilead secured a process patent in 2004 (IN190780 from the 1998 Fumarate
filing) and later went on to complete a series of bilateral licenses with multiple
Indian generic companies for making and supplying Tenofovir and its combina-
tion products for HIV for multiple countries, including India.
While many Indian companies went ahead with the royalty bearing license
agreements around 2007, companies like Cipla did not take the license and contin-
ued with the opposition. It is worth nothing that except the original process grant,
Gilead lost out in the compound oppositions—on both the ester and salt patent
application series. Gilead also modified the license structure when it was argued that
the original bilateral license template covered language that would stop companies
from opposing Gilead’ patents—a position that was specifically barred in Indian
patent law. Table 5 summarizes the tenofovir opposition.
Over the years, Gilead has transformed its TDF licensing program from bilateral
licenses to eventually moving onto the Medicine Patent Pool (MPP) multi-lateral
license platform. The number of countries has also modified over the years with
some critics arguing that the licenses exclude important middle income countries
from the license ambit.29
It must always be remembered that Gilead’ first interaction in India was the
genesis of many later developments—mass pharmaceutical patent licensing, market
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expanding license program for later drugs to gain market acceptance (Gilead loaded
a lot of its later drugs onto the TDF license).
Observers opine that the Gilead licensing program is a fairly successful program
for most stakeholders. The MPP platform’s30 status today as the major licensing
platform covering HIV, Hepatitis and other drugs—is arguably due to Gilead’s early
move to that platform. The MPP platform has now become a template for most of
later HIV drug licenses and Gilead and many other companies extensively license
their IP across multiple drug categories, mostly for developing and least developed
countries.
2.6 Kaletra Opposition
We now look at another opposition worth noting—this too was not a routine
opposition against compounds, salts or polymorphs. This was an opposition against
Abbotts’ (now Abbvie) application covering its formulation technology platform to
make heat stable tablets of various HIV drugs (see Table 6). Abbott’s product (brand
name Kaletra) was originally a soft gelatin capsule containing a fixed-dose of
2 drugs—Lopinavir and Ropinavir, used in the treatment of HIV. The new platform
made it possible to make solid oral tablet formulation, instead of the earlier soft
gelatin capsules. The earlier capsule had some limitations in terms of storage/
handling etc.
This opposition is extremely significant from a drug access perspective since the
underlying technology platform is the basis for supply of heat stable formulations of
Table 5 Tenofovir opposition
Drug: Tenofovir
Therapeutic area: HIV
Nature of patent filings
in India:
Prodrug of Tenofovir &
Salt of above prodrug
Patent/Application # (a) Tenofovir Disoproxil—an ester prodrug of tenofovir (2076/DEL/
1997)
(b) Tenofovir Disoproxil Fumarate (TDF)—a salt form of Tenofovir
Disoproxil (896/DEL/2002—this itself came as a divisional applica-
tion from 2174/DEL/1998)
Opponents: Indian Network of People Living with HIV/AIDS (INP+)
Delhi Network of People Living with HIV/AIDS (DNP+)
Cipla Ltd.
Expiry, if granted: 25/July/2017 for the ester form and
24/July/2018 for the salt form
Unique points: Filing of multiple divisional applications, S.3(d)
30For list of available drug patent licenses on the MPP platform, visit: https://medicinespatentpool.
org/what-we-do/global-licence-overview/licences-in-the-mpp/.
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various HIV drugs—which is how multiple drugs can be given in tablet form across
many high temperature countries (especially as the African countries have a very
high presence of HIV-AIDS). This technology platform allowed making heat stable
tablets of the drug Ritonavir (and additional drugs) dissolved within a polymer
versus the earlier generation soft gelatin capsules that were not heat stable and
hence, had this application been granted in India, it would have given Abbott/Abbvie
a monopoly on the entire heat stable platform which today covers all Ritonavir based
combinations—e.g., Ritonavir + Lopinavir, Ritonavir + Atazanavir etc. Abbvie also
uses this platform today for its Hepatitis drug tablets.
Companies had launched generic versions of combination tablet in India and
other countries during the time the opposition was going on. So, the opposition
paved the way for securing continued marketing of multiple heat stable drug
formulations in India and other developing countries.
There were multiple arguments used including anticipation (including Abbott’s
own poster presentations and previous patent filings as anticipating the claimed
tablet invention). While the opponents lost out arguments under S.3(d), S.3
(e) [admixture of known substances] and insufficient description, the Patent Office
went ahead and rejected the application on the grounds of anticipation and lacking an
inventive step, in late 2010.
One key fact that is not well known publicly is that the Applicant also filed
multiple divisionals during the prosecution—including on the day of the parent
application’s opposition hearing. Interestingly, the Applicant filed not one divisional
but two divisionals—at two different branches of the Patent Office in two different
cities. Eventually, these divisionals were abandoned but not before the fact of the
divisional filings in different cities was highlighted to the Controller.31
Table 6 Ritonavir and Lopinavir opposition
Drug: Ritonavir and Lopinavir
Brand: Kaletra
Therapeutic area: Anti HIV
Nature of filings in India: Formulation platform to make heat stable tablets of various drugs
Application # 1. 339/MUMNP/2006 and its 2 divisionals:
2. 726/MUMNP/2009 and
3. 2474/DELNP/2009.
Date of decision: 30/Dec/2010
Opponents: Matrix Laboratories Limited, I-MAK, Cipla Ltd. and Okasa Pvt. Ltd.
Expiry, if granted: 23/Aug/2024
Unique points: Filing of multiple divisional applications, obviousness.
31For more information on the various divisional filings, refer:“Ever-greening: A status check in
selected countries” (Journal of Generic Medicines (2010) 7, 227–242. DOI: 10.1057/jgm.2010.14).
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2.7 Reyataz Opposition
The next opposition is worth noting against a Bristol Myers’ patent application for a
commercially relevant process to make the Sulphate salt of Atazanavir. Bristol
Myers’ sells an oral formulation of Atazanavir Sulphate under the brand name:
Reyataz.
This decision is important because it highlights the position that generic compa-
nies keep a keen watch on not only the product/salt applications but also track and
file detailed and strong oppositions against commercially sensitive process invention
claims. Indian companies had launched generic version of this drug much before the
opposition was finally adjudicated.
Apart from the standard approach for arguing obviousness (i.e. the process to
make unique crystals of Atazanavir Sulphate from Atazanavir) based on prior art of
Atazanavir and state of art, an interesting obviousness argument used here was that a
process to make the Sulphate salt of an anti-coagulant drug (Clopidogrel to
Clopidogrel Bisulphate) could lead to claims for making the Sulphate salt of
Atazanavir, as lacking an inventive step. This was another ‘obvious to try’ argument
by bringing in analogous prior art related to a different drug, but from overall field of
developing synthetic processes for crystals of drugs. This ‘obvious to try’ argument,
along with the other arguments, succeeded at the Patent Office. See Table 7.
2.8 Combivir Opposition
Combivir is Glaxo’s brand product for an oral fixed-dose combination of
Lamivudine and Zidovudine, used in the treatment of HIV infection. NGOs had
filed a pre-grant opposition (see Table 8) this filing in March 200632 at the Kolkata
Patent Office, stating the drug was not a new invention.
Table 7 Atazanavir Sulphate opposition
Drug: Atazanavir Sulphate
Therapeutic area: Anti HIV
Nature of filing in India: Process to make the Sulphate salt/crystals from Atazanavir
Application # 6425/DELNP/2006
Date of decision 20/Dec/2010
Expiry, if granted: 03/May/2015
Opponents: Matrix Laboratories, Cipla Ltd.
Unique points: Obvious to try, insufficiency of disclosure and S.3(d)
32https://www.msf.org/patent-application-aids-drug-opposed-first-time-india.
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After this opposition, Glaxo withdrew its patent application in Aug 200633 in
India and Thailand34 and this removed the threat of a patent infringement suit against
generic companies, in these 2 countries. The withdrawal meant that further opposi-
tions were not required. Combivir was not the only Glaxo HIV/AIDS medical
product that was opposed and this later resulted in more patent application(s) being
abandoned by Glaxo.
2.9 Trizivir Opposition
Trizivir is an oral fixed-dose combination of 3 drugs—Lamivudine, Zidovudine and
Abacavir Sulphate by Glaxo, used for the treatment of HIV infection. In October
2007, Glaxo withdrew its Indian application for Trizivir, after an opposition (see
Table 9) was filed. Glaxo stated35 that “the company’s move is in public interest and
is part of its policy of routine review of patent applications.”
2.10 Ziagen Opposition
Ziagen is a Glaxo product for the treatment of HIV, consisting Abacavir Sulphate.
Glaxo abandoned its patent application for the Hemisulphate salt of Abacavir, after
an opposition (see Table 10) was filed.
Per the author’s checks, Indian companies had launched generic version of the
above 3 Glaxo’ medicines even before the abandonment actions by Glaxo.
Table 8 Combivir opposition









Opponents: Indian Network for People Living with HIV/AIDS and the Manipur Network of
Positive People
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2.11 Isentress Opposition
Merck had filed a patent application for the Potassium salt of Raltegravir. Merck
sells this product under the brand ‘Isentress’.
Cipla has been selling a generic version of Raltegravir in India, for the last few
years. Three separate pre-grant oppositions (see Table 11) were filed against this
application. The first opposition was filed in 2011 and the last one in late 2018. The
oppositions did not see any traction for many years. When the Patent Office finally
called all parties for a hearing in Aug 2020, Applicant (Merck) sent a letter—less
than a week before hearing date—stating that they were not interested in pursuing
the application, any further.
2.12 Sanofi TB Drugs Oppositions
Sanofi had filed two patent applications in India pertaining to anti-tuberculosis drug
formulations for therapies known as 3HP and 3RH. The two applications covered
two different formulations of known TB 2 drugs (Isoniazid and Rifapentine). One
application covered a film coated formulation and the other application covered a
dispersible (pediatric) formulation of the 2 drugs.
Civil society groups have been advocating to Sanofi on these patents. They filed
oppositions (see Tables 12 and 13) in November 2019—first in India and then in
Table 9 Trizivir opposition
Drug: Combination of 3 drugs: Lamivudine, Zidovudine and Abacavir Sulphate
Therapeutic area: Anti-HIV
Application # IN/PCT/00/00521
Expiry, if granted: 26/April/2019
Opponent: Cipla Ltd.
Unique point: Applicant abandoned after pre-grant opposition




Opponent: Indian Network of People Living with HIV/AIDS (INP+)
Expiry, if granted: 14/May/2018
Copy of decision: Image, here.
Unique point: Applicant abandoned after civil society opposition
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Thailand36 and have also written letters asking Sanofi to abandon the patent families.
After the oppositions were filed, Sanofi withdrew both application families in many
countries. The application families were first withdrawn at the EPO, then Indonesia37
and later in India38 (February 2020). In August 2020, Sanofi formally confirmed that
it was abandoning all patent filings relating to these 2 applications.39
As noted in the multiple instances above, many patent applicants, especially from
the HIV domain, abandon their secondary patent applications (i.e. those related to
process, salt or crystal forms) once they face pre-grant oppositions or once civil
society groups start a public action on such drugs. It can be argued that the such later
Table 11 Raltegravir Potassium opposition
Drug: Raltegravir Potassium
Therapeutic area: Anti HIV
Nature of filing in India: Potassium salt of Raltegravir; crystals of the salt
Application # 4187/DELNP/2007
Expiry, if granted: 02/Dec/2025
Opponents: Indian Network for People Living with HIV/AIDS,
Delhi Network of Positive People and
Mylan Laboratories Limited
Unique point: Applicant abandoned after civil society opposition
Table 12 Isoniazid and Rifapentine opposition
Drug: Dispersible combination formulation of Isoniazid and Rifapentine
Therapeutic area: Anti-Tuberculosis
Application # IN201637002758
Expiry, if granted: 22/July/2034
Opponent: Delhi Network of People Living with HIV/AIDS (DNP+)
Table 13 Isoniazid and Rifapentine opposition (different formulation)
Drug: Film coated combination formulation of Isoniazid and Rifapentine
Therapeutic area: Anti-Tuberculosis
Application # IN201637002757
Expiry, if granted: 22/July/2034





38Refer information tweeted at: <https://twitter.com/achayansz/status/1245229743521370112>.
39Refer Sanofi’s letter dated 04/August/2020, to Treatment Action Group, available at: <https://
www.treatmentactiongroup.org/wp-content/uploads/2020/08/tag_otmeds_sanofi_patent_with
drawals_RESPONSE.pdf>.
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abandonment action is due to the patent applicant assessing the strength of its filing
versus the legal arguments put forth by the pre-grant opponents [e.g. obviousness
and S.3(d)] and the potential negative press related to drug access issues.
2.13 Veklury Opposition
The CoVid-19 pandemic has bought many drugs and issues surrounding drug access
and patents, in the public limelight, at a scale, hitherto unseen. Gilead has at least
4 patents/patent applications pertaining to Remdesivir (Gilead brand: Veklury), in
India. Amidst the global medical crisis, in April 2020, the Cancer Patients Aid
Association (‘CPAA’) and later Third World Network (both being civil society
organizations) asked the Government of India to revoke Gilead’s granted Indian
patent(s).
A post-grant opposition under section 25(2) was filed by a not-for-profit civil
society organisation—LowCost Standard Therapeutics—on the patent (IN332280)
in June 2020 (see Table 14). The petitions/letters did not opt for filing the standard
post-grant opposition(s) under S.25(2) but sought revocation of the patent(s) under
S.66 (‘Revocation of patent in public interest’40).
CPAA filed the request for revoking one patent (IN332280) with the Ministry of
Chemicals and Fertilizers as well as the Health Secretary for the Government of
India.
Table 14 Remdesivir opposition
Drug: Remdesivir
Therapeutic area: CoVid-19
Patents # IN275967 (from 7068/DELNP/2010)
IN332280 (from IN201727012821)
Petitioner(s) (i) Cancer Patients Aid Association (CPAA)
(ii) Campaign for Access to Affordable Medicines, Diagnostics and
Devices, India (CAMeD-India) + Third World Network (India)
Opponent: (iii) LowCost Standard Therapeutics
Copy of request
letter:
Copy of the Request letter dated 09/April/2020 is available at the CPAA
website
Copy of the Third World Network letter dated 13/May/2020 is available at
their website.
40Text of S.66 is available at <https://indiankanoon.org/doc/441313/>. It states:
66 Revocation of patent in public interest. –
Where the Central Government is of opinion that a patent or the mode in which it is
exercised is mischievous to the State or generally prejudicial to the public, it may, after
giving the patentee an opportunity to be heard, make a declaration to that effect in the
Official Gazette and thereupon the patent shall be deemed to be revoked.
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The Campaign for Access to Affordable Medicines, Diagnostics and Devices,
India (CAMD-India) and Third World Network (India) jointly wrote a separate
request calling for revocation of two patents (IN275967 and IN332280) with the
Department of Promotion of Industry and Internal Trade (DPIIT) (within the Min-
istry of Commerce & Industry, Government of India).
The DPIIT supervises the functioning of the Patent Office. None of the Govern-
ment ministries/departments have made any public statement on these letters as of
end July, 2020. In July 2020, the Patent Office asked Gilead to respond to the
LowCost Standard’ opposition. Gilead filed its reply in Oct 2020. A final hearing on
the Opposition has not yet been scheduled.
Starting May 2020, Gilead has signed voluntary licenses for manufacture and sale
of Remdesivir in 127 countries (including India), with multiple companies (nine
companies as of end July 202041) on a ‘zero royalty’ basis, until the disease remains
a pandemic. These bilateral licenses are a change in Gilead’s strategy from the HIV
multi-lateral licenses on the MPP platform. The Remdesivir license text is not
available in the public domain.
3 Pendency of Oppositions in the Indian Patent Office
Oppositions can only help in increasing access if they are adjudicated in a timely and
transparent fashion. So, while in the earlier section, we saw the monumental impact
that pre-grant and post-grant oppositions had on drug access, it would be remiss if
we do not look at some current ground realities.
The Government has over the last few years, multiple times, shown that it is
focused towards higher number of patent grants42 but the author believes that
adjudication of oppositions has been very slow at the Indian Patent Office, over
the years.
We have two sources for numbers—the first are the annual reports published by
the Patent Office. The Report for year ending March 2020 is not available on IPO site
as of end December 2020. The CIPAM website43 is the second source for some of
the numbers. A few years ago, Prashant Reddy (an Indian IP lawyer) tried to find
out44 the exact number of oppositions pending at the Indian Patent Office, using the
information request pathway, but the exercise did not yield relevant results. The
2020 Numbers are courtsey SpicyIP website.





44For a detailed article on his exercise, do read his note at the SpicyIP blog, available here:<https://
spicyip.com/2017/12/rtis-reveal-tardy-record-keeping-practices-at-the-ipo-no-records-of-pending-
patent-oppositions-113857-trademark-oppositions-pending-5533-rectifications.html>.
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The Patent Office has done a commendable job in terms of increasing the size of
the Examiner cadre, increasing the number of applications examined, reducing the
pendency of period taken to examine and grant a patent, but a deeper check reveals
the potential opposition pendency numbers and that presents an alarming picture.
As will noted, the data is not complete. And even for items where the IPO releases
numbers, there are internal inconsistencies.
3.1 Pre-grant Oppositions
• Post 2008–09, specific data for cumulative pre-grant oppositions pending at end
of every year is not given in the Patent Office’ Annual Reports. Hence, we do not
know the number pre-grant oppositions pending on a cumulative basis, as per
the IPO.
• For the latest 12-year period (FY 2007–8 through FY 2019–20), cumulatively
~3600 pre-grant oppositions have been filed while the cumulative disposal
number is ~950 oppositions. This means, potentially, 64% pre-grant oppositions
are, as yet, undecided as per my calculations (see Fig. 1).
• The number of ‘new’ pre-grant oppositions filed annually for last few years has
been below 300 (with a sudden upward spike from FY 2018–19: 426 and going to
a massive 800 in FY 2019–20). This trend, when considered with the larger
increase in number of patent applications filed each year, would still imply that on
a percentage basis, a lesser number of applications are now being opposed,
each year.
• The annual pre-grant opposition disposal rate has not kept pace with trend of












Fig. 1 Pre-grant opposition data 2007–2020
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it matched the pace of increase in new opposition filings. The disposal rate for
year 2018–19 shows a sudden, huge upward unexplained spike: 399 and then a
fall back to 67. This fall is in line with earlier trend of close to 100 or less
pre-grant disposals annually. The one-time surprise figure of 399 pre-grant dis-
posals in FY 2018–9 is an unexplainable mystery.
• For the same period, upon adding the numbers for pre-grant oppositions filed and
reducing the annual pre-grant oppositions disposed (3607 less 947 equals 2660)
and assuming that at least some of the pre-grant oppositions are duplicates against
a single patent application or some oppositions may have been withdrawn, I
believe that at least 1300+ unique pre-grant total oppositions are still pending.
3.2 Post-grant Oppositions
• As at end of FY 2019–20, per the IPO, only 99 post-grant oppositions are pending
on a cumulative basis. This differs drastically from my calculation (184)—which
is based on simple addition/subtraction.
• For the latest 12 year period (FY 2007–8 through FY 2019–20), based on my
calculation, cumulatively 310 post-grant oppositions have been filed while the
cumulative disposal number is 126 oppositions (see Fig. 2).
• Around 10 post-grant oppositions are being disposed, annually for the last few
years.
• The number of ‘new’ post-grant oppositions filed annually for last few years has
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Post-grant opposition data
Pendency information as per Annual Reports
(This number differs from mathematical difference)
Pendency at year end:
cumulative filed less cumulative disposed)
Number of Post-grant Oppositions disposed in period
Number of Post-grant Oppositions filed in period
Fig. 2 Post-grant opposition data 2007–2020
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2 years)—which when considered with the large increase in number of patents
granted, would again imply that on a percentage basis, comparatively lesser
number of post-grant oppositions are now being filed every year.
• As per IPO annual report data, annual post-grant opposition pendency figure was
below 170 for last few years. This high pendency number is also a cause of
concern. However, the IPO data for pending post-grant opposition at year end is
not completely understanding. For instance, for FY 2019-18: 193 pending and
then for 2019–20 only 99 pending, but the IPO did not dispose 100 odd post-grant
oppositions in FY 2019–20—so there is some confusion as to how the 193 pen-
dency figure went down to only 99.
• The difference in the calculated pending cumulative post-grant oppositions 184 at
end of FY 2019–20 versus the pending cumulative post-grant oppositions as per
IPO (99)—cannot be easily explained but could possibly be due to some cases of
multiple oppositions to a single patent or expiry of some patents before disposal,
where no disposal decision was issued.
The number of patents granted has moved to approx. 25,000 grants for year ending
March 2020 while the number of applications examined moved impressively by
approx. 7 times (from ~11,700 to ~80,000+), with an approx. 3 times increase in the
Examiner cadre (163 to 449). Within these numbers, the contentious proceedings
disposal pendency as mentioned by IPO (from 23 in 2007–8 (17 pre-grants + 6 post-
grants) to ~74 in 2019–20 (67 pre-grants + 7 post-grants) continues to remain a cause
of concern.
3.3 Pendency at the Intellectual Property Appellate Board
(IPAB)
Appeals from IPO (for most items) needed to be filed at the IPAB. As of mid-2019,
approx. 617 Patent cases were pending with IPAB.45 Even after starting various
advertising initiatives on the importance of IP, it is glaring that the Government was
consistently not able to keep the requisite bench strength at the IPAB, including the
chairperson or the technical member (patents) at the IPAB.
As per a calculation done on SpicyIP, an Indian IP blog, ‘in its 17 years of
existence, the IPAB has not had a Chairperson for a cumulative total of 1130 days’.46
The position of the Chairperson of the IPAB (i.e. the judicial member) was vacant
for quite a long time and so the Supreme Court granted a fresh term in December
45Year wise pendency data is not available for the IPAB. These numbers have come from a court
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2019 to the already retired judicial member.47 In a similar pattern, the position of the
technical member (patents) was vacant since May 2016 and so, in July 2019, the
Delhi High Court had then asked the technical member (plant variety protection) to
look at the patent responsibilities.48
These judicial interventions show that recruitment of the senior-most IPAB
functionaries was not done in time even when the government was aware of the
normal tenure of such functionaries. Note: A new technical member (patents) was
finally appointed in July 2020 and the process of recruiting a new chairperson
(judicial member) to replace the current chairperson’s whose extended term was to
end in September 2020, had started.49
3.4 Impact of Pendency
The pendency number and dismal disposal for each component—pre-grant opposi-
tions, post-grant oppositions and IPAB cases—is very worrying. The adjudication of
pending oppositions (both pre-grant oppositions and post-grant oppositions) is a
continuing challenge for the Patent Office. The rise in pre-grant disposals for
2018–19 needs to be understood and expanded upon. While the number of exam-
iners at the Patent Office has trebled in the 3-year period, the numbers of controllers
becoming Assistant or Deputy Controllers has not jumped by that percentage. It is
the Controller who is at the center of managing the pre-grant and post-grant
opposition process and finally adjudicating on the opposition and this could also
be a reason for slower disposal.
The IPAB pendency position, for both proceedings and personnel, brings in a
bigger question on the Government’s willingness to work towards a quick and
efficient IP dispute disposal system. Undecided oppositions/IPAB revocations
mean that generic companies may not have the confidence to undertake at risk
launches, due to the threat of damages. Likewise, delay in clearing pre-grant
oppositions also hurts patent applicants as it chips away at the term of any future
patent available to the applicant and at same time, keeps a sword hanging on
opponents for years. The IPO’s leadership must examine the pendency and should
incentivize examiners and Controllers for faster adjudication of contentious pro-
ceedings. Examiners and Controllers today are assessed based on examinations and
grants and if opposition adjudication can be kept as an independent performance
target which can lead to faster professional growth inside the IPO, it could act as an




49Refer SpicyIP post: https://spicyip.com/2020/08/breaking-news-controller-generals-office-
agrees-with-our-petition-for-scrapping-the-intellectual-property-appellate-board.html.
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Clearly, the present system for managing and adjudicating oppositions/IPAB
matters, including timely recruitment, needs a major overhaul with time-bound
proceedings and decision issuance being implemented for faster adjudication of
oppositions. Urgent and immediate actions need to be undertaken by the Govern-
ment to bring in requisite personnel, reduce pendency and increase disposal of
oppositions and IPAB matters.
4 Conclusion
The pre-grant and post-grant oppositions filed by civil society organisations and
generic companies—over the years have been instrumental in earlier launch of
drugs, thereby increasing access of drugs not only for the Indian population—but
also allowed export of drugs to other countries.
The filing (and winning) of these oppositions have been the pivot for earlier
generic entry of many life-saving drugs. Oppositions have been instrumental in
competitively priced generics. These oppositions not only led to generic products
in India but also in a whole host of developing and least developed countries.
As we saw, the Indian oppositions have moved beyond the simple arguments of
S.3(d) to more complex arguments and have seen fair bit of success.
Finally, the increasing pendency of oppositions over the last few years is a matter
of deep concern and the current trend seems to imply that unless the Government
strengthens the system by bringing in requisite number of personnel, the pendency
numbers will not come down, substantially, in the near term.
Author’s Note
The Indian opposition saga has been one of achieving path-breaking results
through sheer advocacy and fighting spirit of the civil society organisations
(NGOs). The massive efforts undertaken by these NGOs over the years in
litigating against corporates with huge budgets must to be applauded, for the
results achieved.
The author is deeply indebted to friends from the civil society and generic
companies who willingly shared anecdotes and facts from these opposition
battles. Most of them chose to remain anonymous for the purposes of this
paper. The author thanks (in alphabetical order)—Swaraj Barooah, (Late)
Shamnad Basheer, Adv. Julie George, Adv. Rajeshwari Hariharan, Adv.
Feroz Ali Khader, Ms. Leena Menghaney, Adv. Guruswamy Nataraj and
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Prof. Bhaven Sampat for discussions over the years and friends who have
reviewed draft versions of this paper.
The present paper is based on a talk given by the author at the invitation of
the South Centre and the Max Planck Institute for Innovation and Competition
at the ‘Global Forum on Intellectual Property, Access to Medicines and
Innovation’ held at Munich in Dec 2019. The author thanks the South Centre
(and its wonderful team—Dr. Carlos Correa, Dr. German Velasquez,
Dr. Viviana Munoz and Mr. Nirmalya Syam) and Professor Dr. Reto
M. Hilty at the Max Planck Institute for Innovation and Competition, for the
opportunity.
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Protection of Clinical Test Data and Public
Health: A Proposal to End the Stronghold
of Data Exclusivity
Ellen ‘t Hoen
Abstract Test data demonstrating the efficacy, safety and quality of a medicine is
required by drug regulatory agencies before a new treatment obtains marketing
approval and can be made available to patients. Because test data can be costly
and time-consuming to produce, certain countries have ‘data exclusivity’ regimes
that restrict use of test data to the originator company for a period of time. Generic
and biosimilar companies rely on originator test data to obtain marketing approval
for generic products, so data exclusivity periods can delay entry of lower-cost
treatments to the market. While data exclusivity is not required by the World
Trade Organization, countries such as the United States and the European Union
often push their stronger data exclusivity provisions on other countries through free
trade agreements (FTAs). While a small number of countries have waivers to data
exclusivity for cases of emergency or other public health need, most do not. This can
hamper the timely and affordable availability of needed medicines. Waivers to data
exclusivity should be included in legislation to protect public health, and other ways
to protect test data against unfair commercial use should be explored.
1 Introduction: Test Data and Efficacy, Safety and Quality
of Medicines
Assuring the efficacy, safety and quality of medicines—be it of originator products
or generic medicines—is an important public function meant to protect the health of
consumers and patients. This function is performed by national or regional medi-
cines regulatory agencies, such as the US Food and Drug Administration (FDA) and
the European Medicines Agency (EMA), using the data that is submitted to the
agency by companies that seek to obtain a marketing authorisation for a medicinal
product. For new medicines, medicines regulatory agencies require drug companies
to submit test data that demonstrates efficacy, safety and quality of the medicine
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before granting marketing authorisation. Generating such data can be time-
consuming and costly, particularly when it involves a new chemical entity or a
new biologic medicine. As a result, test data is often protected against use by others.
The TRIPS Agreement (Article 39.3) requires the protection of certain kinds of test
data against unfair commercial use but does not require to provide exclusive rights to
such data. In certain jurisdictions the protection of test data takes the form of data
exclusivity; data exclusivity means that the use of the test data is exclusive to the
originator company for a certain period of time. In practical terms, this means that
during the data exclusivity period a generic version of the product cannot be
registered by the regulatory agency.
2 Generic and Biosimilar Medicine Marketing Approval
and the Use of Test Data
A generic company applying for marketing authorisation for a generic product has to
demonstrate that its product is bioequivalent to the originator product. Importantly,
the generic applicant is not required to generate its own clinical efficacy and safety
data. The generic applicant can rely on the clinical test data that was submitted by the
original applicant, and which is on file with the regulatory agency. Applicants for
biosimilar medicines (generic biologic medicines) have to demonstrate biosimilarity
(analogue to bioequivalence for biologic medicines) and can also rely on the safety
and efficacy experience gained with the reference medicine.1 This avoids unneces-
sary repetition of clinical trials already carried out with the reference medicine.
Data exclusivity regimes delay the use of existing test data by generic and
biosimilar companies in seeking marketing approval for their medicines for as
long as the data exclusivity period holds.2
Data exclusivity does not prohibit the generic or biosimilar company from
generating its own clinical efficacy data, but this is costly and, in most cases,
would raise serious ethical issues. Such tests would involve carrying out randomised
controlled clinical trials in which an already proven effective treatment is withheld
from part of the study participants who receive the comparator or placebo product. In
reality, generic companies do not carry out such trials. Therefore, a data exclusivity
regime creates strong monopolies that are automatically granted, quietly enforced by
the medicines regulatory system and often without exceptions or limitations.
1European Medicines Agency and the European Commission, Biosimilars in the EU: Information
guide for healthcare professionals (European Medicines Agency, 2019) https://www.ema.europa.
eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf.
2Technopolis (15 June 2018a). https://www.technopolis-group.com/report/effects-of-supplemen
tary-protection-mechanisms-for-pharmaceutical-products/.
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3 Rationale for Data Exclusivity
The notion behind data exclusivity is that the production of clinical test data—by
running, for example, clinical trials—requires significant investments. Protecting
such test data against use by generic and biosimilar companies is thus seen as a
means to encourage medical research and development (R&D). The rationale behind
data exclusivity is similar to the rationale behind patents and other pharmaceutical
market exclusivities: the assumption that the protection of the research and devel-
opment investments that companies make by providing exclusive rights is needed
and sufficient to stimulate innovation.
3.1 Data Exclusivity and Patents
There are important differences between data exclusivity regimes and patents. Data
exclusivity is granted automatically and enforced through the regulatory system; the
holders of the rights, mostly drug companies, do not have to apply or provide
evidence of eligibility. Patent applications, by contrast, are examined before market
exclusivities are granted; rights holders must demonstrate their product meets
patentability criteria such as novelty, usefulness and inventive step. Most medicines
laws that provide for data exclusivity do not provide for a waiver of it should it be
necessary for public interest grounds to suspend the exclusivity. For patents, com-
pulsory licences and other measures to circumvent exclusivity can be sought when
there is a public health need (see also Sect. 6).
Data exclusivity rights exist independently of patents, can overlap with patents
and can also exist where patents do not. Data exclusivity is also different from
patents in that there is no international obligation to provide data exclusivity.
3.2 Data Exclusivity’s Effectiveness in Stimulating
Innovation
Whether data exclusivity is an effective or necessary measure to stimulate innovation
is questionable at best. A publication by Dutch research group Technopolis, pre-
pared upon request of the Dutch government that looked at pharmaceutical exclu-
sivity incentives available to industry in the EU3 concluded “this study cannot
provide any evidence on whether, or to what extent, the impacts of these exclusiv-
ities and protections align with the intended objectives.” In 2009, the US Federal
Trade Commission (FTC) concluded that a lengthy exclusivity period of
3Technopolis (May 2018b) http://www.technopolis-group.com/wp-content/uploads/2018/06/2718-
Technopolis-report-on-supplementary-protection-mechanisms.pdf.
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12–14 years is unnecessary to promote innovation by biologic drug manufacturers.
The FTC considered existing incentives (patents and market-based pricing) to be
sufficient to support biologic innovation.4 In 2016, the EU Council decided to carry
out an assessment of the various pharmaceutical incentive mechanisms contained in
EU regulations with a view “to strengthen the balance in the pharmaceutical systems
in de EU and its Member States.” This review is ongoing but preliminary reports
indicate that evidence is ambiguous at best.5,6,7
4 History of Data Exclusivity
4.1 Data Exclusivity in the United States
Data exclusivity was first introduced in the US in 1984 when the “Drug Price
Competition and Patent Term Restoration Act of 1984,” also known as the
“Hatch-Waxman Amendments” was adopted. The act provided several types of
exclusivities to innovators, in addition to patents, as a trade-off for provisions to
make market entry of generics easier and quicker.8 The US provides 5 years of data
exclusivity for small molecule new chemical entities; 3 years for a new indication of
a previously approved medicine; and 4 years for biologics, complemented by a
parallel 12-year market exclusivity.9
4.2 Data Exclusivity in the European Union
The EU introduced data exclusivity in 1987. Directive 87/21/EEC initially provided
for 6 years of data exclusivity for most medicines, and 10 years for biotechnology
products, both measured from the date of first marketing approval. Member states
4Federal Trade Commission (June 2009) https://www.ftc.gov/sites/default/files/documents/reports/
emerging-health-care-issues-follow-biologic-drug-competition-federal-trade-commission-report/
p083901biologicsreport.pdf.
5Council of the EU, ‘Council conclusions on strengthening the balance in the pharmaceutical
systems in the EU and its Member States’ (17 June 2016) https://www.consilium.europa.eu/en/
press/press-releases/2016/06/17/epsco-conclusions-balance-pharmaceutical-system/.
6Copenhagen Economics, Study on the economic impact of supplementary protection certificates,
pharmaceutical incentives and rewards in Europe (European Commission, May 2018) https://ec.
europa.eu/health/sites/health/files/human-use/docs/pharmaceuticals_incentives_study_en.pdf.
7https://medicineslawandpolicy.org/useful-resources/briefs/.
8Lietzan (2016), p. 91 https://pdfs.semanticscholar.org/2fdb/0784f6fb314cf99063933cb6bfbfae6a7091.
pdf.
9U.S. Federal Trade Commission (FTC, June 2009). https://www.ftc.gov/reports/emerging-health-
care-issues-follow-biologic-drug-competition-federal-trade-commission-report.
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could extend data exclusivity to 10 years if they considered this was “in the interest
of public health.” Member states had different views as to when an extension to
10 years was justified, which led to a variation in exclusivity periods throughout the
EU. In 2004, the EU data exclusivity rules were further harmonised and extended to
8 years of data exclusivity, plus two additional years of market exclusivity during
which generic companies can prepare and apply for their marketing approval using
test data but not market the product. An additional 1 year of market exclusivity can
be obtained by the originator company for a new indication with significant added
clinical benefit.10 The new EU exclusivity regime became known as the 8+2+1 rule.
The EU data exclusivity regime is the most generous in the world.
4.3 Protection of Test Data and the Rules of the World Trade
Organization
During the Uruguay Round negotiations on intellectual property, the option of
making data exclusivity an explicit obligation under the Agreement on Trade-
Related Aspects of Intellectual Property Rights (TRIPS Agreement)11 was
discussed, but the TRIPS negotiators explicitly rejected language that would have
required granting exclusive rights to test data, opting for the more general text of
Article 39.3,12 which reads as follows:
Members, when requiring, as a condition of approving the marketing of pharmaceutical or of
agricultural chemical products which utilize new chemical entities, the submission of
undisclosed test or other data, the origination of which involves a considerable effort,
shall protect such data against unfair commercial use. In addition, Members shall protect
such data against disclosure, except where necessary to protect the public, or unless steps are
taken to ensure that the data are protected against unfair commercial use.
The WTO TRIPS Agreement contains an obligation of WTO members to protect
certain kinds of test data against unfair commercial use, but does not create an
obligation to provide data exclusivity. TRIPS data protection against unfair com-
mercial use is required only where that data is related to a new chemical entity and
required as a condition of marketing approval, was previously undisclosed, and
required considerable effort to generate. Importantly, TRIPS does not stipulate a
time period for this protection. This is further evidence of the absence of a data
exclusivity obligation.
10Directive 2004/27/EC on the Community code relating to medicinal products for human use
[2004] OJ L136/34.
11Agreement on Trade-Related Aspects of Intellectual Property Rights (Apr. 15, 1994) (hereinafter
TRIPS Agreement).
12The World Health Organization (WHO), the World Intellectual Property Organization (WIPO)
and the World Trade Organization (WTO), WHO (2012), p. 64. https://www.wipo.int/policy/en/
global_health/trilateral_cooperation.html.
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TRIPS also does not preclude the use of test data for the regulatory approval of a
competing product, which, as some have argued, does not fall within the definition
of ‘unfair commercial use’.13,14,15 This position was reiterated by the developing
country members of the WTO in 2001 at the Doha Ministerial Conference, where
they stated that article 39.3 of TRIPS “does not require granting ‘exclusive rights’ to
the owner of the data” and that it “does permit a national competent authority to rely
on data in its possession to assess a second and further applications, relating to the
same drug, since this would not imply any ‘unfair commercial use’.”16 TRIPS also
does not require WTO members to extend protection to data that is in the public
domain.17
The obligation to protect test data against ‘unfair commercial use’ does not yet
apply to least developed country members (LDCs) of the WTO, who do not need to
implement pharmaceutical-related aspects of the TRIPS agreement until 2033 or
until they cease to be LDCs.18
Today, most WTO members, outside the EU or the United States, do not provide
data exclusivity. A survey of MedsPaL,19 a database of select medicines patent and
exclusivity status, shows that only around 16 middle-income countries provide data
exclusivity. Data exclusivity regimes often find their origin in trade agreements with
the EU or the US that were negotiated outside of the WTO (see Sect. 5).
In conclusion, the TRIPS Agreement gives countries considerable latitude as to
how they want to implement test data protection.
13Reichman (2009), p. 17.
14Timmermans (2007), p. e2.
15Commission on Intellectual Property Rights, Innovation and Public Health, Public Health,
Innovation and Intellectual Property Rights (World Health Organization, 2006).
16‘TRIPS Council Discussion on Access to Medicines: Developing Country Group’s Paper’ (World




18The Council for Trips Extension of the Transition Period Under Article 66.1 of the Trips
Agreement for Least Developed Country Members for Certain Obligations with Respect to Phar-
maceutical Products (6 November 2015), World Trade Organization IP/C/73.
19‘MedsPaL: The Medicines Patents and Licences Database’. https://www.medspal.org.
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5 Data Exclusivity in Free Trade Agreements (FTAs)
The obligation to grant data exclusivity to the originator company in the US and the
EU goes beyond the requirement of the TRIPS Agreement20 for the protection of
undisclosed test data against unfair commercial use. Both the US and the EU seek to
globalise their data exclusivity norms through trade agreements, including in WTO
accession agreements with other countries or in bilateral agreements or trading blocs,
by demanding from their trading partners that they introduce or expand data
exclusivity.
In recent FTAs there has been some roll back of the demands related to data
exclusivity. In 2018, after the withdrawal of the US, the 11 remaining parties to the
Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP,
formerly the TPP) suspended the IP chapter, including its various market exclusivity
obligations. The US-Mexico-Canada Agreement (USMCA) initially contained a
provision that bound parties to 5-year exclusivity for small molecules, 3 years for
new clinical information (new use of a known medicine), and 10-years for biologics.
In 2019, driven by the debate on high drug prices in the US, the provision for 10-year
exclusivity for biologics was removed from the USMCA.
6 Data Exclusivity and TRIPS Flexibilities
The TRIPS Agreement includes a number of flexibilities that are relevant for public
health. Data exclusivity can form a serious barrier to the effective use of such
flexibilities for the purpose of accessing lower priced medicines. In particular, the
effectiveness of compulsory licensing—a mechanism whereby a government grants
third parties or itself the right to use a patented innovation without the consent of the
patent holder—may be muted by data exclusivity.
6.1 Compulsory Licensing and Government Use in Drug
Procurement
When a government grants itself the right to make use of a patented innovation
through a compulsory licence, this is often called ‘government use’, or ‘public
non-commercial use’.21 Such compulsory licences can be particularly useful in
20During the Uruguay Round negotiations, the option of making data exclusivity an explicit
obligation under the TRIPS Agreement was discussed, but negotiators instead adopted the general
wording of the current Article 39.3. See: WTO, WIPO, and the WHO (n 10).
21This chapter will further use the term ‘compulsory licence’ to refer to both compulsory licences
and government use or public non-commercial use of a patent.
Protection of Clinical Test Data and Public Health: A Proposal to End the. . . 189
public procurement of medicines to access lower-priced medicines from generic
competitors.
The government is free to determine the grounds for granting a compulsory
licence. Some countries’ domestic laws include specific provisions such as ‘high
prices’ of medicines, or a ‘lack of access to medicines’. For example, French patent
law authorises government use upon request by the minister of health when medi-
cines are ‘only available to the public in insufficient quantity or quality or at
abnormally high prices.’22
In 2001 the WTO Doha Declaration on the TRIPS agreement and Public Health23
provided a welcome clarification of the flexibilities24 contained in the TRIPS
Agreement for the purpose of public health and specifically ‘to promote access to
medicines for all’.25 Against the background of trade pressure on low- and middle-
income countries that contemplated the use of compulsory licensing and other
TRIPS-flexibilities, the Doha Declaration took away any doubts about the legality
of such measures. Subsequently, low- and middle-income countries have used
TRIPS flexibilities on a large scale in particular but not exclusively to facilitate the
supply of low-cost generic medicines used for the treatment of HIV.26
6.2 Data Exclusivity and Compulsory Licensing
Countries that have a data exclusivity regime may find providing more affordable
access to a patent-protected medicine through a compulsory licence is hindered if the
originator company’s product benefits from data exclusivity. While a compulsory
licence may open the possibility of providing generic versions of a medicine that is
still patent protected, data exclusivity may prevent the registration of such generic
medicines and therefore still block their entry into the market.
22Code de la propriété intellectuelle (version consolidée au 9 octobre 2016) Article L613-16.
23Declaration on the TRIPS agreement and public health (14 November 2001) WT/MIN(01)/DEC/
2. https://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm (hereinafter
Doha Declaration).
24The term ‘flexibilities’ is used to describe limitations and exceptions to exclusive rights that
countries can deploy for reasons of public interest. See also: WIPO, ‘Meaning of Flexibilities’.
http://www.wipo.int/ip-development/en/agenda/flexibilities/meaning_of_flexibilities.html.
25Doha Declaration (n 22).
26Hoen (2016).
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6.3 Remedies to Data Exclusivity Barriers and Compulsory
Licensing
Some countries have introduced waivers to data exclusivity, which can be invoked to
ensure that the regulatory authority can proceed with the registration of a generic
product produced or imported under a compulsory licence. Countries that have such
data exclusivity waivers include Malaysia, Chili and Colombia.27
Section 5 of theMalaysia 2011 Directive of Data Exclusivity,28 entitled Non-Application of
Data Exclusivity, provides that Nothing in the Data Exclusivity shall:
(i) apply to situations where compulsory licenses have been issued or the implementation
of any other measures consistent with the need to protect public health and ensure
access for all; or
(ii) prevent the Government from taking any necessary action to protect public health,
national security, non-commercial public use, national emergency, public health crisis
or other extremely urgent circumstances declared by the Government.
In Chile, Article 91 of Law 19.996, as amended in 2012,29 provides that test data
exclusivity shall not be applied:
(b) Where, for reasons of public health, national security, public non-commercial use,
national emergency or other circumstances of extreme urgency declared by the compe-
tent authority, it is justified to terminate the protection referred in Article 89’ [on test data
exclusivity].
(c) The pharmaceutical or agrochemical product is the subject of a compulsory license in
conformity with the provisions of this law.
In Colombia, Article 4 of Decree 2085 of 2002 on data exclusivity provides that, ‘The
protection referred to in this Decree does not apply in the following cases [. . .] c) where
necessary to protect the public, as qualified by the Ministry of Health’.
In the absence of such a waiver, countries have found it difficult to make effective
use of compulsory licensing. See Box 1.
Box 1: Case of Romania and Malaysia
In 2015 the World Health Organization (WHO) set the target of eliminating
hepatitis C (HCV) as a public health threat by 2030. To reach this goal,
prevention and treatment are necessary. People infected with HCV need a
12-week course of antiviral treatment. In countries that cannot access generic
supply of HCV medicines, the price of the originator product may be a barrier
to reaching the elimination target.
In 2016, the government of Romania contemplated use of a compulsory
licence for sofosbuvir, an essential medicine for the treatment of HCV.
(continued)
27Hoen et al. (2017). https://joppp.biomedcentral.com/articles/10.1186/s40545-017-0107-9.
28https://npra.gov.my/images/reg-info/DataEx/Directive_on_DE.pdf.
29http://www.wipo.int/edocs/lexdocs/laws/en/cl/cl042en.pdf.
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Box 1 (continued)
Sofosbuvir was only available from the originator company at a price of
around 50,000 euro for a 12-week treatment.30 However, EU data exclusivity
for the product will not expire before 2022. This means that, even with a
compulsory licence, the registration of a generic version of sofosbuvir would
be prohibited until that date.31 Further, the EU market exclusivity for
sofosbuvir expires at the earliest in 2024. Romania, like any other EUMember
State, cannot give effect to a compulsory licence during the data and market
exclusivity terms.
In contrast, when Malaysia issued a compulsory licence for sofosbuvir in
201732 it was not hampered to register the generic product due to its legal
waiver to data exclusivity (see Sect. 6.3).
6.4 Data Exclusivity Waivers in FTAs
The US does not have an explicit exception to data exclusivity for medical products.
However, the consequence of data exclusivity for the effective use of TRIPS
flexibilities was recognised in 2007 when the New Trade Policy in the US explicitly
authorised a public health exception to data/market exclusivity in the event of a
compulsory licence or other public health need. This flexibility in implementing data
exclusivity was included in several US developing-country FTAs, including with
Colombia, Panama, and Peru. This implementation flexibility reads:
For pharmaceutical products, Article 16.10.2(e)(i) provides an exception to the data exclu-
sivity obligations for measures to protect public health in accordance with the Declaration on
the TRIPS Agreement and Public Health (WT/MIN(01)/DEC/2) (the ‘Doha Declaration’).
Thus, where a Party issues a compulsory licence in accordance with Article 31 of the TRIPS
Agreement and the Doha Declaration, the data exclusivity obligations in Chapter Sixteen
will not prevent the adoption or implementation of such a public health measure. In addition,
in a case in which there is no patent on the pharmaceutical product, and, therefore, no need to
issue a compulsory licence, the data exclusivity obligations in Chapter Sixteen will not
prevent the adoption or implementation of such a measure.33
Certain trade agreements the EU is a party to establish that, in regard to test data,
parties may provide exceptions to exclusivity for reasons of public interest and for
30Paun (2016) http://www.politico.eu/pro/high-drug-prices-romania-changes-patents-hepatitis/.
31European Medicines Agency, ‘Marketing authorization’ Europa http://www.ema.europa.eu/ema/




33Office of the U.S. Trade Representative, Statement of Administration Action (2007) https://ustr.
gov/archive/assets/Trade_Agreements/Bilateral/Peru_TPA/PTPA_Implementing_Legislation_
Supporting_Documentation/asset_upload_file194_15341.pdf.
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emergency situations. An example is the EU–Peru Agreement. Article 231 (4) pro-
vides that ‘[t]he Parties may regulate exceptions for reasons of public interest,
situations of national emergency or extreme urgency, when it is necessary to allow
access to those data to third parties.’34 The implication of this is that the EU and
Peru, both party to this agreement, may provide and use data exclusivity waivers to
ensure effective use of compulsory licence. The waiver may also be relevant for
non-patented products that still have a monopoly in the market because of data
exclusivity. To take advantage of this provision, the party countries would need to
provide for a data exclusivity waiver in their regulations.
6.5 EU Medicines Regulation and Compulsory Licensing
EU law does not yet provide a safety valve to data exclusivity to allow registration of
a competitor product in the EU. This became apparent during the h5n1 virus (avian
influenza) outbreak in 2006, when the threat of a shortage of the antiviral oseltamivir
(Tamiflu) signalled the need for an emergency compulsory licence in countries that
wanted to ensure sufficient stockpile of the antiviral medicine. The European
Generic Association had inquired as to the options under EU law to provide generic
oseltamivir for epidemic preparedness purposes, but the European Commission
informed them that:35
National emergency provisions in an EU Member State may allow the granting of a
compulsory patent licence which would allow a generic or other company to use the patented
product in the Member State in question.
However, the Community pharmaceutical acquis does not currently contain any provi-
sion allowing the waiver of the rules on data exclusivity and marketing protection periods
described above in the case of a national or an EU-wide emergency.
Before expiry of the data exclusivity and marketing protection periods provided for by
the European pharmaceutical legislation, applicants for a generic marketing authorisation
have to either (1) provide the relevant authority with the required documentation on pre-
clinical tests and clinical trials or (2) confirm that the marketing authorisation holder has
consented to the use of the required documentation by the applicant.
The Commission response confirms the lack of public health safeguards in
European pharmaceutical legislation. Even in cases of an urgent need or emergency
situations, no data exclusivity waiver exists that can be applied by EU member
states.
34Trade Agreement between the European Union and its Member States, of the one part, and
Colombia and Peru, of the other part [2012] L354/3.
35European Commission, ‘Letter from the European Commission to Mr. Greg Perry,
EGA-European Generic Medicines Association on the subject of Tamiflu application and data
exclusivity in an emergency compulsory license situation’ (Brussels, 2006) http://www.cptech.org/
ip/health/dataexcl/ec-de-tamiflu.pdf.
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6.6 EU Data Exclusivity Waiver and Compulsory Licence
for Export
The one waiver to data exclusivity in the EU is only foreseen in cases of compulsory
licensing for manufacturing a product for export outside the EU but not to enable
effective use of compulsory licensing or other measures to protect public health
within EU member states.36,37 Article 18 of the EU Regulation addresses the
situation in which the applicant for a compulsory licence to manufacture medicines
in an EU Member State for export outside the EU may use the scientific opinion
procedure of the European Medicines Agency38,39 or any similar national procedures
intended exclusively for markets outside the EU. These scientific opinions provide a
benefit/risk analysis of a medicine, designed to facilitate registration in importing
countries.40 The procedure provides waivers to data exclusivity rules necessary to
obtain such opinions from the EMA or national authorities.41
6.7 Data Exclusivity Waivers in Voluntary Patent Licences
The need to provide data exclusivity waivers to ensure effective availability of
generic medicines is often recognised in voluntary licences. For example, all Med-
icines Patent Pool42 (MPP) licences include a data exclusivity waiver to facilitate
36Regulation 816/2006 on Compulsory Licensing of Patents Relating to the Manufacture of
Pharmaceutical Products for Export to Countries with Public Health Problems [2006] OJ L157/1.
37This regulation implements the WTO ‘August 30, 2003 decision’, which provided a waiver to the
TRIPS Article 31(f) requirement that production under a compulsory licence be predominantly for
the domestic market. This restriction hampered the use of compulsory licensing by countries that
were dependent on the importation of medicines. The 30 August 2003 waiver became a permanent
amendment of the TRIPS Agreement in 2017 (see: WTO, ‘WTO Members Welcome Entry Into
Force of Amendment to Ease Access to Medicines’ (30 January 2017) https://www.wto.org/
english/news_e/news17_e/heal_30jan17_e.htm.
38Article 58 of Regulation (EC) No 726/2004.
39Committee for Medicinal Products for Human Use (CHMP) (European Medicines Agency,
17 November 2005). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guide
line/2009/09/WC500003883.pdf.
40European Medicines Agency, ‘Medicines for use outside the European Union’. https://www.ema.
europa.eu/en/human-regulatory/marketing-authorisation/medicines-use-outside-european-union.
41Regulation (EC) No 816/2006 of the European Parliament and of the Council of 17 May 2006 on
compulsory licensing of patents relating to the manufacture of pharmaceutical products for export to
countries with public health problems. Article 18(2) reads: “If a request for any of the above
procedures concerns a product which is a generic of a reference medicinal product which is or has
been authorised under Article 6 of Directive 2001/83/EC, the protection periods set out in Article 14
(11) of Regulation (EC) No 726/2004 and in Articles 10(1) and 10(5) of Directive 2001/83/EC shall
not apply”.
42Medicines Patent Pool http://www.medicinespatentpool.org/.
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regulatory approval of generics manufactured by MPP licensees in the territories that
grant test data exclusivity. For instance, Guatemala is included in the territory of the
MPP licences with ViiV Healthcare for paediatric formulations of dolutegravir
(DTG) and for adult formulations of DTG and abacavir (ABC), both treatments
for HIV. The licences specifically state that:
ViiV shall provide any Sublicensee with NCE [New Chemical Entity] exclusivity or other
regulatory exclusivity waivers to the extent required by the applicable regulatory authorities
in order to manufacture or sell Product in the Territory in accordance with the terms of the
Sublicence. ViiV shall further provide to any Sublicensee such consents which it has the
legal capacity to give as are necessary to enable such Sublicensee to perform its
obligations.43
Box 2: Data Exclusivity Waiver in Voluntary Licences: The Case
of Guatemala
The HIV treatment formulations of DTG 50 mg and ABC/DTG/3TC 600/50/
300 mg are protected by test data exclusivity in Guatemala until 11 November
2020 and 29 November 2021 respectively.44 However, MPP licensees will be
able to register and market generic versions of these formulations in Guate-
mala before the expiration of these rights, based on the waiver included in the
MPP licence agreements.
Drug company Gilead has included the following waiver of data exclusivity
in its licence agreements for HCV treatment sofosbuvir:
Gilead agrees to provide Licensee with NCE Exclusivity, or other regulatory exclu-
sivity, waivers as may be required by the applicable regulatory authorities in order to
manufacture or sell Product in the Territory, provided such manufacture and sale by
Licensee is compliant with the terms and conditions of this Agreement. Licensee
agrees not to pursue or obtain regulatory exclusivity on any Product in any country
within the Territory.45
Even though Gilead obtained test data exclusivity for sofosbuvir 400 mg
until 14 July 2021 in Guatemala, for instance, Gilead licensees should not be
barred from registering and selling generic versions of sofosbuvir 400mg
during this data exclusivity period in Guatemala, which is included in the
license territory.
43Medicines Patent Pool, ‘Products Licensed: ViiV’ https://medicinespatentpool.org/what-we-do/
global-licence-overview/licences-in-the-mpp/?patent_holder¼2718 Link Does Not Work.
44Medicines Patent Pool, ‘MedsPaL The Medicines Patent and Licences Database’. https://www.
medspal.org.
45Gilead Sciences (15 September 2014) https://www.gilead.com/~/media/files/pdfs/other/2014_
original_hcv_licensing_agreement.pdf?la¼en.
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6.8 Public Health Measures, Data Exclusivity
and Competition Law
Some scholars have argued that the issuance of a compulsory licence for public
interest reasons creates the obligation for the patent holder to provide a waiver to
data exclusivity.46 A company holding a dominant position in the market that denies
access to the data held by the regulatory authority in the case of a compulsory licence
is likely to be viewed as abusive under competition law since national authorities
have already decided that the public interest requires an additional product on the
market. However, enforcing this position will likely lead to protracted legal pro-
cedures and delays in the availability of the medicine for which the compulsory
licence was requested.
6.9 EU Law Needs an Explicit Data Exclusivity Waiver
It would be desirable to introduce explicit data and market exclusivity waivers in
national legislation. This is particularly important in the EU, now that European
countries have indicated that they lack the negotiating power to obtain good results
in price negotiations with pharmaceutical companies concerning patented products
and several EU countries are exploring the use of compulsory licensing to strengthen
this position.47
The following amendment to the EU medicines regulation would introduce a
waiver to data exclusivity similar to the one contained in the Regulation on com-
pulsory licensing for export:48,49
The protection periods set out in article 14 (11) of Regulation 726/2004 shall not apply in
cases where it is necessary to allow access to and the use of pharmaceutical test data to
register a generic of a reference medicinal product, which is or has been authorised under
article 6 of Directive 2001/83/EC, for reasons of public interest including public health, in
case of compulsory licensing of patents, including for public non-commercial use, and in
situations of national emergency or extreme urgency.
46Junod (29 January 2019) https://www.publiceye.ch/fileadmin/doc/Medikamente/ValerieJunod_
Legal-Analysis-CL_20190129.pdf.
47Rumney (Public Finance International, 16 January 2017). https://www.publicfinancefocus.org/
news/2017/01/drug-manufacturers-have-too-much-power-price-negotiations-says-oecd.
48Regulation (EC) No 816/2006 of the European Parliament and of the Council of 17 May 2006 on
compulsory licensing of patents relating to the manufacture of pharmaceutical products for export to
countries with public health problems.
49Hoen et al. (2017).
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7 Conclusion and Recommendations
The TRIPS Agreement provides much flexibility for WTO members to design a test
data protection regimes conducive to public health.
Where possible, countries should refrain from implementing data exclusivity and
instead use the flexibility offered to them in the TRIPS agreement to provide data
protection for certain types of data only and without granting exclusive rights to the
originator of the data.
Safeguards need to be in place to ensure that data remains available for legitimate
public health functions including the assessment of efficacy and safety of needed
products. Countries that have a data exclusivity regime should have the option to use
waivers to data (and market) exclusivity for effective use of measures such as
compulsory licensing, to protect public health.
There are different ways in which undisclosed test data can be protected, includ-
ing: protecting it against dishonest commercial practices, but allowing its use to
register a generic product,50 permitting generic reliance on the test data but with
compensation to the entity that originally generated the data.51 Countries should
consider replacing data exclusivity regimes with data protection regimes that
acknowledge the investment made to generate data but do not allow the investor
to exclude others from using the data. Under a data compensation regime, the
registration of a generic medicine or biosimilar medicine is considered fair commer-
cial use. The originator company that made the investment that was needed to
generate the data will receive adequate remuneration for the use of the data but
cannot prevent its necessary use by the medicines agency to perform its public health
duties. The data compensation regime could be proposed as an alternative to data
exclusivity demands in trade negotiations.
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Courts and Pharmaceutical Patents: From
Formalist Positivism to the Emergence of a
Global Law
Calixto Salomão Filho and Vitor Henrique Pinto Ido
Abstract This article seeks to repurpose the relation between courts and IP law,
avoiding describing them as a purely neutral and unidimensional process whereby
‘courts apply IP law’. Based on two cases from Brazil (Trastuzumab and
Sofosbuvir), the article argues that the role of courts in implementing TRIPS
flexibilities is in itself a factor that determines or at least influences the behavior of
actors in the field. As such, courts are not arenas, but actors that influence compe-
tition and restructure markets. This pushes for the recognition that patent use and
patent abuse, including practices in patent filings such as evergreening and sham
litigation, are legal phenomena that ought to be regulated differently by law. Instead
of formalist positivism, law should be more thoughtful of socio-economic conse-
quences and of existing contexts. This aims at addressing economic structures rather
than reinforcing them in cases pertaining to pharmaceutical patents.
The article concludes by proposing an interpretation of IP law which is integrated
with competition law principles, both oriented towards, and based on, public interest
provisions. Overall, the article posits that this is a better framework than regarding IP
and competition law as ‘complementary’ and to address issues of how courts may be
misused by economic actors due to fragmentation of the two legal fields.
Furthermore, such endeavors are part of an emerging body of what some could
even call “global law”; in this case, it means a nod for the transnational implications
of national IP cases beyond its original realm.
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Courts are prominent actors in the implementation of intellectual property (IP) law. 1
Apart from being enforcers of the existing law, they also delineate the contours of IP
protection, including the definition of patentability criteria, scope of protection of
IPRs, exclusions of patentable subject and conditions for enactment of injunctions. 2
This is an intrinsic characteristic of how IP law is conceived and how it operates,
rather than a process of politicization of courts or an expansion of their role beyond
their competence. 3 By doing so, courts inevitably affect competition and play a
major role in the implementation of TRIPS in national jurisdictions, often with
transnational consequences.
Scholarship’s attention on the role of judicial and quasi-judicial courts in IP has
risen, 4 including advocates for courts to be the best suited for balancing IP policies 5
and ample discussions on specialized IP courts. 6 Judicial enforcement of IP has
become a common, yet very questionable, variable for assessing what is understood
as the level of IP protection in a given country. 7 It has also deserved emerging
1 While judges in some jurisdictions may be typically more prominent in such role—such as
common law systems, which give more importance on precedents—, the last decades saw an
unquestionable rise in the number of courts dealing with IP. This process has both a geographical
dimension and an institutional one. Geographically, there has been a “globalization” of jurisdictions
deciding upon IP and pharmaceutical cases. Institutionally, there has been a stark expansion of
actors deciding IP cases, such as quasi-judicial independent IP appellate bodies, competition
authorities’ decisions and IP specialized courts.
2 They are not the only relevant actors, as administrative border agents, police officers and others all
concretely decide on issues such as what is a counterfeit. Nonetheless, courts have a specifically
defining role as they provide the basis for the applicability of laws and regulations “on the ground”.
3 In this sense, when adjudicating IP cases, judges do not create, but rather apply, law. The issue is
that this process is by default not a mere formalistic endeavor, and the exact details of IP law
necessarily depend upon such interpretation. In many jurisdictions, where public considerations are
directly embedded into IP law, this adjudication cannot be dissociated from a broader spectrum of
public principles, including health and socio-economic development. Acknowledging this particu-
lar feature of IP law is not the same as advocating for courts to disregard precedents, decide against
the law or over-expanding their own competence. As this paper will point out in more detail, the
refusal to acknowledge such role, including when courts do not rule, is in itself a factor that impacts
competition, generates judicial uncertainty and compromises the whole IP system. Also please see
Sect. 2 of this article for a more comprehensive argument on the role of courts in IP.
4 For a comprehensive overview of developed countries, see Geiger et al. (2018).
5 Burk and Lemley (2013) (on the specific case of the USA, acknowledging its failures and
considering that courts are the most suitable for patent law reform by adopting different interpre-
tations according to different industries).
6 de Werra (2016). Published in: Specialised Intellectual Property Courts - Issues and Challenges,
Global Perspectives for the Intellectual Property System, Issue Number 2: CEIPI-ICTSD. 2016,
p. 15-41. Available at SSRN: https://ssrn.com/abstract¼2761209 (drawing positive and negative
arguments for their implementation, noting that they cannot be recommended in all circumstances).
7 In those cases, “judicial enforcement” simply means the enforcement of pro-IP holder interests,
without the inclusion of public interest provisions. As such, these rankings may wrongly give the
impression that enforcement of IP means exclusively the protection of private rights. It is not a
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importance by the WIPO, the South Centre and other international organizations as
key players in implementing IP norms, each with a distinct approach. 8
In particular, the consequences of court rulings to access to medicines is a
sensitive topic, particularly if decisions are taken prioritizing exclusively IP holder
interests. A single court ruling (or sometimes lack thereof) may have huge conse-
quences for public policies and the realization of rights, as IPRs may pose major
barriers to competition and access to essential products. As such, it makes sense to
craft a more comprehensive analysis of the role of courts in implementing or not the
in-built TRIPS flexibilities 9 across jurisdictions.
This article seeks to repurpose the relation between courts and IP law, avoiding
describing them as a purely neutral and unidimensional process whereby ‘courts
apply IP law’. According to this view, the main issue of concern would be how to
provide specific technical knowledge on IP for judges. Instead, this article aims at
exposing that jurisdictional practices are themselves an element to interpret TRIPS
flexibilities, as courts reshape markets and the extension of patent monopolies even
when they decide not to take action. In this sense, courts apply IP and by doing so
define markets; they are also mutually influenced by the market structures.
surprise that they are used as pressure tools for developing countries to adopt more stringent
standards of protection. In reality, the process of enforcement is supposed to be a balancing between
private and public interests and should be seen as an important policy space for countries to enact IP
policies that are coherent with other goals such as public health and industrial development (see Li
and Correa (2009). For the use of rankings, see, for instance, “create”, the U.S. Chamber Interna-
tional IP Index, which includes numerous indicators on enforcement. The 2018 edition included
new indicators, which “cover important evolving areas of IP rights, such as injunctive-style relief
through the disabling of infringing content online, as well as the practical operation of a given
national IP system. As the Index evolves, it is only natural that a greater focus be placed on the
operational aspects of a national IP system. The new indicators seek to measure national efforts at
coordinating IP rights enforcement”, among others (https://www.theglobalipcenter.com/wp-
content/uploads/2018/02/GIPC_IP_Index_2018.pdf). Similarly, the International Property Rights
Index (associated to the Property Rights Alliance, an explicitly pro-property organization) includes
indicators such as “judicial independence”, “rule of law”, “protection of intellectual property rights”
and “perception of IP protection” (https://www.internationalpropertyrightsindex.org/about). These
rankings also find a notable echo in older and criticizable views of the “Law and Finance literature”,
which evaluated jurisdictions according to their capacity to secure private rights (See La Porta et al.
(1998), pp. 1113–155).
8 The World Intellectual Property Organization (WIPO), for instance, has created its WIPO Judicial
Institute (https://www.wipo.int/about-wipo/en/activities_by_unit/index.jsp?id¼1022). Technical
assistance provided by many multilateral institutions, including the European Patent Office
(EPO), the European Commission, the United States Patent and Trademark Office (USPTO) and
the JPO (Japanese Patent Office) have reportedly increased attention to judges, offering trainings
that often mirror their understandings of IP law to other jurisdictions. An example is the interna-
tionalization of doctrines that are originally European, such as the “Swiss claims” or the need to
protect “Markush claims” for pharmaceuticals. Other institutions seek an alternative approach, such
as the South Centre, which focuses its activities on the full implementation of TRIPS flexibilities in
relation to IP law (https://ipaccessmeds.southcentre.int/).
9 For an overview of the notion of TRIPS flexibilities and their implementation, see Correa (2016);
see also Deere (2008).
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Furthermore, other actors play crucial roles, including civil society organizations and
lobbying economic pressures, 10 and dealing with them is another important dimen-
sion of the role of courts. In summary, it means a broader understanding of their role,
which is embedded in certain structures of thinking and socio-economic implications
and pressures. As we wish to propose, this framework allows a different legal
assessment of what in practice courts do and what economic consequences their
own behavior bear. For instance, when a court does not rule or takes too long to rule
an IP case, this in itself likely generates more judicial uncertainty than the content of
the decision. Despite differences in how this understanding reverberates in concrete
IP cases, a general takeaway is that this requires a different interpretation of IP law,
as per below.
The structure of the article is as follows: after this overview, it provides some
inputs for the reasons why courts, while implementing TRIPS flexibilities, can be
considered to be channels of “structural change”. This serves as a theoretical premise
to the analysis. It is followed by an assessment of the consequences of the legal
utilization—both directly and indirectly—of a narrative that treats intellectual prop-
erty protection as necessary for innovation. 11 This normative argument serves as a
de facto tool for impeding evidence-based discussions on the competitive implica-
tions of IP in concrete cases. In short, the threat of decreased innovation is used, even
if sometimes implicitly, to impede a more balanced and real consideration of rights
and interests involved in IP law.
It then exemplifies the overall argument above through the comparison of two
cases in Brazil. They share the similarity of dealing with access to medicines curbed
by high prices (due to, among other reasons, intellectual property rights), albeit with
different profiles, courts and arguments. In both, the role of courts is paramount, not
only as the ones defining the interpretation of legal principles and rules in IP law with
regards to demands of access to medicines, but also as setters of expectations for
competitors and society at large. Both medicines have been subject to patent disputes
in the country, in a way that IP is not necessarily the only issue to be considered, but
certainly a relevant one. The first case refers to a litigation that questioned prices on
the selling of cancer biological medicine Trastuzumab to Brazilian public entities,
particularly in light of a stark price discrimination between regular public purchases
10 The number of institutions, arenas and players engaging with the topic of IP has grown
immensely since the TRIPS Agreement was enacted. In the IP and public health field, key actors
include civil society organizations (such as Médécins sans Frontières—MSF Access Campaign)
and industry representatives (International Federation of Pharmaceutical Manufacturers & Associ-
ations—IFPMA). New organizations (such as the Medicines Patent Pool—MPP) have been created
and also shape and influence the very interpretation and implementation of IP. The existing
framework of global IP law and access to medicines is in many senses dependent on the work of
these organizations. See Hein and Moon (2013) and Matthews (2011).
11 While the specialized literature has a lot of divergence, the transplantation of this discussion into
a legal argument in IP cases tends to over-expand the scope of protection of patents in particular.
Therefore, by shedding light on the possibility of another kind of relation, that of innovation that
arises precisely from more access (to knowledge), and not from more monopolies (patents and other
IPRs), it is possible to reassess the role of IP in legal rulings.
204 C. S. Filho and V. H. P. Ido
and purchases to enforce judicial decisions. The second case deals with the procure-
ment of hepatitis C medicine Sofosbuvir and the price differentiation after a patent
was granted and later suspended, which is evidence for possible anti-competitive
excessive pricing and/or abuse of dominant position.
Finally, the text provides some theoretical conclusions on the relation between
courts and IP. It firstly proves that the role of courts in implementing TRIPS
flexibilities is in itself a factor that determines or at least influences the behavior of
actors in the field. As such, courts are not arenas, but actors that influence compe-
tition and restructure markets. This pushes for the recognition that patent use and
patent abuse, including practices in patent filings such as evergreening and sham
litigation, are legal phenomena that can be at least partly regulated differently by law.
In fact, by shedding light and putting all pieces of this interaction together, there is a
need for a different interpretation of IP law. Theoretically, it means a law that is more
thoughtful of socio-economic consequences and of existing contexts, which aims at
addressing economic structures rather than reinforcing them.
The article concludes by proposing an interpretation of IP law which is integrated
with competition law principles, both oriented towards, and based on, public interest
provisions. Overall, we argue that this is a better framework than regarding IP and
competition law as ‘complementary’ and to address issues of how courts may be
misused by economic actors due to fragmentation of the two legal fields. Moreover,
this interpretation is derived from international law, from the theoretical foundations
of IP and competition laws, and from the historical development of substantive
national provisions—and not a mere theoretical speculation. Furthermore, such
endeavors are part of an emerging body of what some could even call “global
law”; in this case, it means a nod for the transnational implications of national IP
cases beyond its original realm.
2 Assessing the Role of Courts in TRIPS Flexibilities As
Forms of Structural Change
In previous works, the authors have argued that the strong interplay between
economic power and law are so pervasive that structural interventions are needed
in order to prevent law from becoming a mere instrument of economic interests, and
to instead promote broader societal goals. 12 A “neo-structuralist” approach 13 means
that individual, moral(istic), and even institutional explanations are insufficient and
even sometimes misleading. Therefore, efforts to ensure the full implementation of
TRIPS flexibilities need to rely on a legal interpretation that is structural in the sense
of taking into account the role of economic structures of pharmaceutical monopolies
and ready to counter their negative consequences when needed. The approach
12 Salomão Filho (2013a) and Salomão Filho and Ido (2019).
13 Salomão Filho (2015).
Courts and Pharmaceutical Patents: From Formalist Positivism to the. . . 205
generally proposes that, willingly or not, legal interpretation will either be accepting
of the status quo (adopting compensatory mechanisms at most) or transformative in
a structural way. This analysis provides some inputs for a legal proposal for the role
of courts to be less formalistic—in its intimate, self-referred and negative connota-
tion—and more mindful about structural intervention through the application of
public values. Whether courts wish to acknowledge this role or not, adjudicators will
invariably perform it.
Specifically on the topic of TRIPS flexibilities, achieving broad access to med-
icines for all knowingly demands structural reforms in the current R&D model for
pharmaceuticals, a high-level policy commitment by governments to act boldly, and
a major rethinking in the behavior of companies. 14 None of this is primarily a task of
any courts around the world; none is exclusively a legal enterprise. Indeed, judges
and decision-makers should operate within the realm of existing laws and have, in
the majority of circumstances, a limited role for structural change. This is all true.
However, it should equally be stressed that structural change is a task that includes
courts and includes legal thinking. Legal interpreters need to rely, even if partly, on
philosophical foundations and legal theories for the interpretation of concrete cases.
Judges and adjudicators reflect certain viewpoints and distinct ideologies even if
they do not acknowledge so. 15
Both considerations seem particularly relevant to IP and access to medicines,
where notions of innovation, public interest and limits of monopolies are deeply
intertwined and even part of ordinary legal arguments on IP. 16 Considering how the
implementation of IP norms around the world since the TRIPS Agreement has been
the result of a push by developed countries and their industries, 17 courts that adopt a
formalist and limited approach will invariably reproduce the notion that IP needs to
be expanded at all costs. This disregards that TRIPS flexibilities, including a focus
on technological development and public health, are all primarily legal and legiti-
mate tools. As such, if courts would strictly “follow the law”, they should enforce the
14 For a critical overview of the current R&D model, see Velásquez (2020).
15 For a compelling general critique, see Kennedy (1997); for an example of how courts may
incorporate neoliberal values despite claims of impartiality, see Sanghera (2015), available at:
https://www.opendemocracy.net/en/odr/unmasking-central-asias-neoliberal-judges/; for how a
community of adjudicators and lawyers defines certain arguments in international arbitration and
assumes a central role for a transnational legal order, see Dezalay and Garth (1996).
16 Examples would include the interpretation of the common clause on exception of patentability
due to “public order”, dependent not only on an understanding of what “public order” means, but
also how it is applicable in an analysis of a patent application. For an overview, see Bently (2011),
pp. 315–347. Real cases show the need for courts to decide on multiple elements at once when faced
with concrete cases, from patentability of living organisms to the limits posed by religious and
morality laws to alleged obscene patent applications (see, for instance, Pankhuri and Shamnad
(2018), available at: https://spicyip.com/2018/08/the-morality-of-sexual-pleasure-patent-office-
training.html).
17 Sell (2003).
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validity of TRIPS flexibilities, and be particularly aware of the socio-consequences
to the public interest of patents and other intellectual property rights. 18 In other
words, courts have the potential of de facto limiting the policy space of a country,
and it is no surprise that so much effort is now given to the role of courts as part of the
international economic architecture. 19
In developing countries, these considerations are even more evident for two
reasons: on one hand, the material conditions of access to medicines are generally
worse; 20 on the other, the majority of such countries contain constitutional and legal
provisions that advocate for implementation of socio-economic rights (such as
health) and development goals, often in more directive and transformative ways
than the counterparts in industrialized economies. 21
Therefore, courts’ stance on TRIPS flexibilities is of utmost importance, such as
the position towards the validity of stringent patentability criteria for pharmaceuti-
cals and the use of competition law to address anti-competitive practices in IP and
health cases. Courts do not need to be “advocates” nor political actors to applying IP
18 This can be traced back to the very foundation of intellectual property law scholarship, such as
that of Italian Tulio Ascarelli, with profound repercussions to Brazilian commercial law, among
others. For Ascarelli (1970), p. 276.
19 Apart from intellectual property and TRIPS flexibilities, such considerations could be extended
to multiple realms, such as international investment law (particularly investor-state dispute settle-
ment—ISDS) and business and human rights litigation for environmental disasters, in which both
pro-private biases and formalist views on jurisdictions and conflict of laws effectively lead to
transnational economic deregulation. For notes on the impact of courts’ rulings in international
economic governance, see Muir-Watt et al. (2019) (for a compilation of cases that redefine the
boundaries of public and private, and highlight the increasing interdependence between national
and international jurisdictions); and for a more theoretical account, Muir-Watt (2016), pp. 347–428.
(“despite the contemporary juridification of international politics, private international law has
contributed very little to the global governance debate, remaining remarkably silent before the
increasingly unequal distribution of wealth and authority in the world. [...] According to the
genealogy of private international law depicted here, the discipline has developed, under the
aegis of the liberal divides between law and politics and between the public and the private spheres,
a form of epistemological tunnel-vision, actively providing immunity and impunity to abusers of
private sovereignty.); see also Zumbansen (2012), pp. 899–925.
20 See the final report of the United Nations Secretary-General High-Level Panel on Access to
Medicines (2016) for some considerations. The language agreed as part of the Sustainable Devel-
opment Goals (SDGs), especially SDG 3 on health, should also be stressed: “Target 3.b.Support the
research and development of vaccines and medicines for the communicable and non-communicable
diseases that primarily affect developing countries, provide access to affordable essential medicines
and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health,
which affirms the right of developing countries to use to the full the provisions in the Agreement on
Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health,
and, in particular, provide access to medicines for all.”. There is broad consensus on the need of
specific, and often bolder action, in the context of developing countries.
21 See, for instance, the constitutional provisions that have been deemed, among other terms,
“transformative” and “social”, including those of Brazil (1988), South Africa, (1996), Colombia
(1991), Bhutan (2008) and India (1950), just to name a few remarkable examples. See, for
theoretical discussions: Uprimny (2011); Bonilla Maldonado (2013); Mendes (2013), 272p; Iyer
(2019), pp. 359–385; Hailbronner (2017), pp. 527–565.
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law in a manner that is consistent with broader societal goals such as ensuring access
to medicines. However, they sometimes refrain from doing so on such grounds. As
we have noted before, the mere lack of decision is also a crucial feature in the lack of
their implementation. 22 In this context, advocates for judicial adjudication as a
purely neutral and technical process do not address the negative impact this very
stance has or might have on access to medicines.
3 Access and Innovation in Legal Discourse: From
Opposition to Coexistence
There is one economic narrative that has profoundly influenced the debate on IP and
access to medicines: the rhetoric whereby IP is an enabler of innovation, to the extent
which it provides incentives for inventors, and therefore is also a prerequisite for
access to future technologies. 23 In short, no access without IP. Importantly, this has
been often converted into a self-standing legal argument, either underpinned or
explicitly referred to, in multiple cases, without further consideration of historical
and empirical circumstances of the real markets they address.
The objective of this section is not to delve deeply into the broader debate on IP
and innovation, and how IP affects access to the outcomes of future and existing
22 The argument is also valid in the other direction: sometimes, measures taken by courts (such as
investigations) have an indirect effect that is sufficient for social results. For instance, in the Hazel
Tau case (2003), when the South African Competition Commission publicly announced that would
sanction pharmaceutical company Glaxo-Smith-Klein (GSK) for the abuse of the exercise of its
patent rights by charging excessive prices, a settlement was reached and no decision was taken. For
an overview, see Knowledge Ecology International (KEI). CPTech’s 2003 reports for the RSA
Competition Commission, in Hazel Tau et al. v GSK, Boehringer, et al. Available at: https://www.
keionline.org/competition/2003-hazel-tau-tac.
23 For example, the director-general of the International Federation of Pharmaceutical Manufac-
turers & Associations (IFPMA), Thomas Cueni, noted in a Financial times article on 17 May 2020
that “Patents, and IP more generally, are the main reason that there is such a strong innovation base
to work from to find solutions” (Cueni, Thomas. Intellectual property is not a hindrance but a help to
end Covid-19, Financial Times, available at: https://www.ft.com/content/e82dd07c-95c5-11ea-
899a-f62a20d54625). Another example of the utilization of this rhetoric is found in the official
stance of the United States Trade Representative (USTR)’s Special 301 report of April 2020 “To
promote affordable healthcare for American patients today and innovation to preserve access to the
cutting-edge treatments and cures that they deserve tomorrow, USTR has been engaging with
trading partners to ensure that U.S. owners of IP have a full and fair opportunity to use and profit
from their IP, including by promoting transparent and fair pricing and reimbursement systems”,
available at: https://ustr.gov/sites/default/files/2020_Special_301_Report.pdf. Similarly, in a publi-
cation by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), it
is noted that “A robust, time-limited system of patent protection is proven to facilitate development
of, and access to, innovative pharmaceutical products and processes. In particular, a well-
functioning patent protection system is a prerequisite for attracting finance for costly pharmaceu-
tical research, given its high failure rates, by ensuring that successful innovation is rewarded”.
Gawel (2016), pp. 45–53.
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innovation, but to note how the conversion of this narrative into a legal argument is
highly problematic. According to this view, less IP protection would necessarily lead
to less innovation and therefore less access. This means that protecting IP would
always be, according to this particular narrative, in the public interest. 24 Accord-
ingly, if IPRs are to be anyhow limited or restricted—even when they were wrong-
fully granted in the first place—this argument will consider that innovation will be
hampered and, as a final result, access will be compromised. 25
However, this assumption is remarkably questionable. For one, the role of IP in
fostering innovation is far from clear. 26 Some markets are innovative and creative
despite the lack of exclusivity rights, 27 and in many cases, IP is simply detrimental
to innovation. A number of evidence-based studies propose that the barriers created
24 In this sense, it performs the same functional role that theories on IP as natural rights once had.
Treating IP as a natural right tends to maximize its protection. Conversely, treating IP as a
temporary monopoly granted by the State requires a public interest justification based on the
incentives provided by it. The “IP as channel of innovation” argument leads to the same maximi-
zation of IP as natural rights without needing to give away the notion that IP only exist to provide
market incentives. It creates an overarching and somehow incontestable argument to consider that
IP should always be expanded (in order to “achieve innovation”). This leads to very pragmatic
consequences on the role of courts in IP law. When courts adopt fully this latter myth, the balancing
of private and public interests in IP becomes a de facto imbalance gearing towards the private
interest only. It becomes a tool for an adjudication that is incapable of properly taking into account
public needs in the protection of IP. For a comprehensive critical analysis of patent law and history,
which could include a reflection on the very adequacy of the “public and private balancing in IP”,
see Pottage and Sherman (2010).
25 One such example is found among opposers of compulsory licensing, despite their recognition as
a legal and legitimate tool under multiple international law instruments, including the WTO Doha
Declaration on Public Health (2001). For instance, in a preliminary ruling on a class action in Brazil
requesting the compulsory licensing of medicine Kaletra (lopinavir/ritonavir) due to high prices, the
judge considered that “issuing a compulsory license would trigger retaliation by the developed
world and possible shortages of the drug, while the very capacity of domestic industry to produce
the medicine in Brazil was also called into question”. See Costa et al. (2008). In a similar sense:
“Patents benefit society in a number of ways, and although their specific role in each industry is
unique, they are generally recognized for their ability to spur innovation. In the pharmaceutical
industry, for example, patents are essential to motivating and directing future innovation, which
generates new and better medicines for all. [. . .] The promise of immediate and improved access to
brand name HIV/AIDS drugs is definitely alluring, but issuing or threatening a compulsory license
has consequences. Compulsory licenses not only reduce foreign investment, they also impose costs
related to litigation, safety, and efficacy.” Borowski (2009). http://ir.law.fsu.edu/lr/vol36/iss2/6.
26 Boldrin and Levine have famously argued against patents: “The case against patents can be
summarized briefly: there is no empirical evidence that they serve to increase innovation and
productivity, unless productivity is identified with the number of patents awarded – which, as
evidence shows, has no correlation with measured productivity”. Boldrin and Levine (2013),
pp. 3–22. Moreover, the importance given to the number of patents as a measure of innovation
has been challenged not only as inaccurate, but also representative of a process of financial
speculation of patents as credits and even as financial assets. For such critique, see Kang (2020).
27 For an overview, see Darling and Perzanowski (2017). For a specific case, see Lemos and Castro
(2012), on the tecnobrega music style in Northern Brazil as an example of an open business model
which relies its success on the sharing of music without enforcement of copyrights.
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by IP serve not as catalysts, but hinderances, of innovation. 28 Notions of “patent
trolls” and “patent thickets”, where strategic patenting filing leads to an overlap of
multiple IP rights that unfairly block competition, have become a major issue for
contemporary markets. 29 As economist Joseph Stiglitz noted, following the US
Supreme Court Myriad Genetics case (2013), which defined that isolated genes
cannot be patented, “innovation has been accelerated, leading to better diagnostic
tests [. . .] at much lower costs.” 30 Accordingly, it is possible to argue that markets
without patents may be equally or even more innovative than those with IP protec-
tion and simultaneously also conducive to better access conditions.
Furthermore, for many accounts, IP has been historically an inefficient incentive
at best. 31 The development processes of the overwhelming majority of now indus-
trialized countries were based on copying strategies, national industrialization and
the creation of innovation ecosystems that include know-how and skilled profes-
sionals. In fact, IP has been deemed a limitation to development and innovation in
most cases. 32 The innovation landscapes of highly innovative countries in current
28 See Heller (2010); Heller et al. (1998), pp. 698–701. For some, this means an IP system that does
not deliver what it originally promises: “Intellectual Property rights are becoming increasingly
badly configured in the developed world, leading to a stifling of innovation, distortions in the
direction of innovation, and a reduction in the benefits which accrue from any innovation that
occurs. Many of these failures arise because there is, especially under currently prevalent IPR
regimes, no clear relationship between the social returns to innovation and the private returns. The
proliferation of me-too drugs, the increase in patent hold-ups and similar excesses buttress the
argument that the IPR system in the developed world is poorly configured.” Baker et al. (2017),
available at: http://ip-unit.org/wp-content/uploads/2017/07/IP-for-21st-Century-EN.pdf.
29 See Matthews and Gurgula (2016). Queen Mary School of Law Legal Studies Research Paper
No. 233/2016. Available at SSRN: https://ssrn.com/abstract¼2779014.
30 Stiglitz (2017), available at: https://www.theguardian.com/business/2017/oct/18/intellectual-
property-laws-demand-a-21st-century-solution.
31
“Both theory and the preponderance of historical evidence suggest that development, at least in
its initial stages, is best promoted by a weaker intellectual property regime than reflected in TRIPS,
or at the minimum a markedly different regime.” Baker et al. (2017), available at: http://ip-unit.org/
wp-content/uploads/2017/07/IP-for-21st-Century-EN.pdf.
32 See, for instance, the landmark book Schiff (1971). Irregular or protection exclusively for
nationals was also a feature in the United States, Germany and the United Kingdom. The studies
on the socio-economic transformation of Japan, and then the Asian Tigers and more recently China,
also prominently play a crucial role in a developmental State process that had little to do with the
protection of foreign IP, relying instead on imitation and adaptation processes, at least in its earlier
stages. For instance, Japan provided protection for national applicants but low protection for
foreigners in the decades after WW2—a strategy later emulated by other late industrializing regions
with high levels of innovation, such as South Korea and Taiwan. This is all relatively well-known
and increasingly defended as means to assess even current practices by the very same players that
actively put pressure in the international arena for developing countries to adopt higher standards of
IP protection against what they have done in the past and also what they continue on doing. See, for
instance, Chang (2002) and Amsden (2001).
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times are also not reliant on IP alone, 33 even if the extent of its impact is debatable.
In fact, even among its strong defenders, there is a general consensus that IP is not
necessarily conducive to innovation at all times, 34 and that in particular the effects of
patents differ between industrialized and developing countries. 35 An example of the
detrimental consequences to access without accruing any benefits of innovation is
the early implementation of the TRIPS Agreement in Brazil in 1996, which can be
contrasted with the relative positive experience of India. 36
33 Highly innovative countries do not adopt a laissez-faire approach and contain enormous funding
for basic research, different research grants and direct investments alike. Examples include massive
investments by DARPA and BARPA US agencies. For an assessment of the role of the State in
innovation and the economy more broadly, see Mazzucato (2013).
34 See, for instance, Fink and Raffo (2019).
35 IP may possibly serve as an incentivizing mechanism in industrialized countries with a robust
pharmaceutical industry already in place, with proper financial mechanisms, large public grants in
early stages of research and research institutions and universities with large capacity and expertise.
It will however not produce such an effect in countries with different profiles, and the historical
global evidence in developing countries seems very clear in that regard. In summary, the already
contested effects of IP towards innovation are even less compelling in the Global South, precisely
where issues of access have been the most pressing and negative. The fact that HIV treatments were
effectively rendered available in African countries around 10 years after they were available,
leading to the unnecessary death of literally millions of lives, is no overstatement. For some
broad considerations, see Cimoli et al. (2014). For a defense of the idea that prices should
necessarily be lower in developing countries, and dissociated from any notion of compensation
for investments, see Salomão Filho (2007), pp. 160–161.
36 Brazil and India are among the very few countries in the Global South which have developed
solid national generic industries (public and private). In both countries, the creation and consoli-
dation of national pharmaceutical industries took place in the absence of IP incentives in the
mid-twentieth century. In fact, similarly to the majority of the Global South, laws had been amended
as to remove pharmaceutical patents from its national laws, a clear industrial and developmental
policy measure. While the lack of IP was definitely not the only element that enabled the rise of
pharmaceutical industries, they were seen as a clear barrier to the development of emerging
industries. In Brazil, public laboratories such as Farmanguinhos and Butantã Institute play a crucial
role in ensuring manufacturing of vaccines and medicines at affordable prices, as well as world-
known R&D and public health research. India was able to consolidate the largest generic pharma-
ceutical market of the world and is still lauded as a prime example of success, deemed the
“pharmacy of the [developing] world”. Nonetheless, despite relatively comparable benchmarks,
the implementation of TRIPS led Brazil and India to remarkably different paths. While Brazil opted
to enact an Industrial Property Law in 1996, not fully enjoying the crucial TRIPS flexibility to only
recognize pharmaceutical patents in 2001, India used it fully until the latest possible deadline in its
case (2005). A major promise of the proponents of the Industrial Property Law of 1996 in Brazil
was the need to “modernize” the national system and “promote investments and innovation”. Yet,
the granting of pharmaceutical patents in Brazil is overwhelmingly composed of foreign applicants,
and combined with the lack of other policy incentives for the national industry, the result was a
major negative impact in terms of its industrial capacity. It also has no signs of innovation output
growth at all in the pharmaceutical sector. In fact, the new patent system created disincentives for
generic companies due to their legal risks: as almost all of those benefitting from patents were
foreign applicants, the investment in R&D in Brazil for pharmaceuticals actually declined and many
generic firms are said to have become particularly conservative in their business practices, delaying
competition even further. Even if the majority of the Indian companies are not lead innovators in the
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Finally, there are also particular issues with any direct association between IP and
innovation in legal thinking. The TRIPS Agreement and many national laws note
that IP requires a constant balancing between public and private, the public value
pertaining to access to medicines being one of paramount importance. 37 Patents are
granted taking into account the public interest related to the disclosure of the
invention and competition; they are an exceptional, limited and temporary legal
bundle of exclusivity rights granted by the State solely in, and to the extent which it
favors, the public interest. 38 As a consequence, the impediments created by IP as
barriers to access should always be taken into account in the interpretation of
concrete cases more prominently.
Indeed, the pharmaceutical sector is a particular and very sensitive case. On one
hand, R&D investments are higher than most other industries, and risks are larger,
with few successful products out of a much larger pipeline of candidates. On the
other, in this field, there is much more public investment in R&D (in many cases the
main investment is public not private) because its products are or at least should be
essential goods, as they directly relate to health, sometimes as a life or death
dilemma. Perhaps curiously, these arguments have been utilized to sustain opposite
views: both the need for less or no patents (prioritizing access) and for more patents
(prioritizing innovation). In light of the overview above, the problem with the debate
framed in such a way is that it reinforces a questionable direct relation between IP,
innovation and access.
Many have empirically exposed, for instance, that the enactment of compulsory
licensing has not had detrimental effects to foreign investment and has not
undermined innovation overall, 39 and successful cases have drastically reduced
prices and therefore enhanced access to medicines. Additionally, the global com-
munity increasingly acknowledges that a model based only on patent protection is
pharmaceutical field, they have proven remarkably successful in ensuring access to medicines
worldwide. Its economic importance to the country is also huge. See, for comparisons and analyses
of the political economy of such countries, Shadlen (2017) and Vanni (2020).
37 Articles 7 and 8, TRIPS Agreement: “Article 7 Objectives.The protection and enforcement of
intellectual property rights should contribute to the promotion of technological innovation and to
the transfer and dissemination of technology, to the mutual advantage of producers and users of
technological knowledge and in a manner conducive to social and economic welfare, and to a
balance of rights and obligations Article 8. Principles 1. Members may, in formulating or amending
their laws and regulations, adopt measures necessary to protect public health and nutrition, and to
promote the public interest in sectors of vital importance to their socio-economic and technological
development, provided that such measures are consistent with the provisions of this Agreement.
2. Appropriate measures, provided that they are consistent with the provisions of this Agreement,
may be needed to prevent the abuse of intellectual property rights by right holders or the resort to
practices which unreasonably restrain trade or adversely affect the international transfer of tech-
nology”. For the effective implications of this tension in various countries and situations, see
Dreyfuss and Rodríguez-Gavarito (2014).
38 In light of these considerations, it makes sense to conceive IP in terms of bundles of rights instead
of an absolute and unitary right.
39 For example, Inthira et al. (2011), p. 7:28.
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not the best incentive for innovation in the pharmaceutical sector, and alternatives
exist. 40 For example, Amy Kapczynski compellingly describes the open science
network of the Global Influenza Surveillance and Response System (GISRS), where
“a global influenza virus-sharing network that has for decades produced critically
important information goods, at significant expense, and in a loose-knit group—all
without recourse to IP”, 41 which both responds better to societal health needs and
does not treat innovation and access as a trade-off.
The global initiatives seeking the development and subsequent “equitable and
affordable” access to Covid-19 vaccines and treatment, treating them as “global
public goods” and as a “people’s vaccine”, 42 with support by key actors such as the
European Union and China, have highlighted the needs for collaborative efforts.
Unprecedented funding and multiple actions have been taken, including the creation
of the voluntary WHO Covid-19 Technology Access Pool on the basis of a proposal
by Costa Rica, 43 public international pledges for more resources, 44 as well as
private pledges for making IP-protected technologies related to Covid-19 free of
charge. 45 It highlights a possible new approach to global pharmaceutical R&D, not
based on competition, but rather on intense sharing of information, which may
produce faster and much more accessible outcomes in terms of health products.
40 It is not a surprise that calls for a renewed R&Dmodel for pharmaceuticals are a constant demand
in international discussions. See, for instance, Velásquez and Seuba (2011) (calling for a mandatory
international agreement on pharmaceutical R&D at the World Health Organizaation); Stiglitz and
Jayadev (2010), pp. 217–226 (“promoting prizes over patents; directing innovation toward socially
beneficial outputs by adopting some form of value-based pricing; publicly funding clinical trials to
reduce conflicts of interest while reducing costs; and actively managing frontier technologies to
maximize positive social spillovers”). Proposals on prizes are among the most common alternative,
at least in academia. See, for instance, the proposed Health Impact Fund—HIF (https://
healthimpactfund.org/). Nowadays, alternative R&Dmodels do exist for neglected diseases, such as
the successful non-profit organization Drugs for Neglected Diseases Initiative (DNDi), which has
already achieved approved medicines for neglected diseases under substantially lower R&D costs if
compared to large transnational pharmaceutical firms for most diseases (https://www.dndi.org/).
CEPI—Coalition for Epidemic Preparedness Innovation (https://cepi.net/), founded in 2017, may
also serve as an alternative model for financing future vaccines, including for Covid-19. It is
currently funded by industrialized countries and charities such as Bill and Melinda Gates Founda-
tion and the Wellcome Trust. Unlike DNDi, the exact access conditions in case of a successful
candidate are however yet unclear and subject to debates.
41 Kapczynski (2017) Available at: https://scholarship.law.cornell.edu/clr/vol102/iss6/3.
42 For an analysis of the debate and how it has been partly incorporated (albeit with major
limitations) into the 73rd World Health Assembly Resolution “Response to Covid-19” in 2020,
see Syam et al. (2020).
43 See WHO COVID-19 Technology Access Pool (C-TAP): https://www.who.int/emergencies/
diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/covid-19-tech
nology-access-pool.
44 See European Commission Press Release. “Coronavirus Global Response: €7.4 billion raised for
universal access to vaccines”. 4 May 2020, available at: https://ec.europa.eu/commission/
presscorner/detail/en/ip_20_797.
45 See Open Covid Pledge: https://opencovidpledge.org/.
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Again, in this sense, a more efficient approach that may achieve more innovation and
broader access. 46
Finally, a caveat to the association between IP and innovation refers to the real
costs of R&D, which are deeply non-transparent, and where, as noted before, the role
of public funding is pivotal. 47 It challenges once again the assumption of a necessary
trade-off, rendering explicit instead the possibility of achieving a coexistence
between access and innovation. More transparency on the pharmaceutical sector
could enable courts to rely not on the general, abstract notion that IP is conducive to
innovation, and instead make an empirical assessment of, for instance, how much
public funding the medical product received or not, how the final net pricing has
been fixed, and the exact socio-economic repercussions of a patent or other IP to the
market. This would mean a better balance between private and public interest in IP
and access to medicines.
In summary, this section aimed at presenting two important points for adjudica-
tors dealing with IP and access to medicines to consider:
1. arguments that entangle the protection of IP with innovation and access are an
improper interpretation legal technique, which disregards the socio-economic and
developmental implications of IP as much as it tends to limit the role of the public
interest in IP. 48
2. access and innovation are not a necessary trade-off: under many (and perhaps
most) circumstances, collaborative and deeply competitive markets are more
inventive and also provide better access conditions.
As a conclusion, adjudication in IP and access to medicines calls for an evidence-
based and thoughtful analysis of what is really at stake in a particular case. From a
legal point of view, the broader pharmaceutical sector regulation can be interpreted
46 For a proposal, see Mazzucato and Torreele (2020), available at: https://www.project-syndicate.
org/commentary/universal-free-covid19-vaccine-by-mariana-mazzucato-and-els-torreele-2020-04.
47 While pharmaceutical companies may insist some of this information is trade secret (therefore
legally protected), much of this data is actually not. A landmark Resolution at the 72nd World
Health Assembly (WHA/72.8) agreed on the need for more transparency in the pharmaceutical
industry, including net prices, but falling short of including specific commitments to the transpar-
ency of R&D costs. Moreover, much attention has been given to the role of public funding in
pharmaceutical innovation, particularly in earlier stages, which is neither recognized nor reflected in
safeguards in terms of affordability and accessibility for the very public that financed it in the first
place. For an overview of existing literature, see Vieira and Moon (2019), available at: https://www.
knowledgeportalia.org/public-funding-of-r-d; Vieira and Moon (2020), available at https://www.
knowledgeportalia.org/cost-of-r-d.
48 Rather than conclusive remarks on the relation between intellectual property and innovation—or
more precisely, the multiple relations between IP, access and innovation—, the crucial point to be
made is that courts have no clear evidence to decide based only on the premise that IP is a necessary
element to achieve innovation. However, this is exactly how many courts are inclined to argue; or,
at least, by exacerbating the role of IP in innovation without a proper balance with public interests
related to access, courts will also be inclined to maximize IP protection in the detriment of all other
stakeholders, patients included. Therefore, as a conclusion, it is necessary to disentangle IP and
innovation as separate categories, with a direct impact to legal interpretation.
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in a way that secures both access and innovation, and not as a trade-off as a departing
point. The following section attempts to exemplify how a legal rationale in that sense
could take place, and what may happen when this is not taken into account. By doing
so, it will also be possible to reflect on what role do courts have in TRIPS
flexibilities' implementation.
4 Trastuzumab High Price Litigation in Brazil
Trastuzumab (sold under brand name Herceptin) is a groundbreaking medicine for
the treatment of breast cancer, listed as essential medicines by the World Health
Organization (WHO). 49 Breast cancer is a disease that kills thousands of persons,
especially women, yearly around the world. In Brazil alone, 53.680 cases were
reported in 2013, and more than 56.000 in 2014. Trastuzumab was developed by
Genentech, a pharmaceutical company based in San Francisco, United States, which
later licensed to Swiss pharmaceutical 50 company F. Hoffmann-La Roche (hence-
forth Roche) for US$40 million upfront, later sharing royalties with Genentech. 51 In
practice, Roche is the owner of patents related to the drug and manages them.
According to a Forbes article on 28 August 2019, Trastuzumab “is the leader in
the breast cancer drugs space with annual sales of around $7 billion”, accounting for
about 15% of the overall profits of Roche yearly. 52
Given how essential the medicine is 53 and its very high prices overall, various
concerns about access to Trastuzumab have been highlighted in multiple jurisdic-
tions around the world by civil society organizations. The production cost of the
medicine is reported to be around US$240 for a 1-year supply. 54 Nonetheless, as
reported by Médécins sans Frontières in 2017, Trastuzumab’s annual prices were set
at around US$ 38 365 for the private sector and US$ 15 735 for the public sector in
49 World Health Organization (2019).
50 Grupo Direito e Pobreza (Law and Poverty Group) (2014).
51 Hu et al. (2020).
52 Forbes (2019), available at: https://www.forbes.com/sites/greatspeculations/2019/08/28/can-
roches-blockbuster-drug-herceptins-sales-grow/#62da696a42e5.
53 In fact, from a competition perspective, all cancer drugs are essential in terms of the demand side,
given the severity of the disease. As it is literally a matter of death or life, the equilibrium point
between offer and demand is drastically influenced by a hugely inelastic demand. This means that
structurally such drugs tend to be highly priced under purely market conditions, and therefore
particular attention to potential competitive abuses is necessary. In other words, this means a careful
assessment of pricing and how offer takes place.
54 See Hoen (2019) Strong call for transparency on medicine prices, cost of R&D at WHO Fair
Pricing Forum. Medicines Law and Policy https://medicineslawandpolicy.org/2019/04/strong-call-
for-transparency-on-medicine-prices-cost-of-rd-at-who-fair-pricing-forum/.
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South Africa, where patents will only expire in 2033. 55 Brazil, as we will expose in
more details, prices were also extremely high: unaffordable for patients and
unsustainable for the public budget. It is further relevant to note that the basic patent
of Trastuzumab has expired in many other countries, including the USA. In both
USA and Europe, there are already biosimilar versions available in the markets,
which contributes to reducing prices. In Brazil, due to the patent extension term for
cases of backlog of patent applications (provided for by Article 40, sole paragraph,
of the Industrial Property Law (Law 9279/1996) and currently pending constitution-
ality ruling at the Federal Supreme Court 56), the patent will not expire until 16 June
2028. 57
However, even the lack of patent is no guarantee of reduced prices per se. In
India, where patent oppositions had been filed, Roche withdrew patent applications
on Trastuzumab. Still, the company has relied on litigation against biosimilar pro-
ducers through India's drug regulatory body, which effectively enables Roche to be
the sole provider of the medicine in the country as well. 58 This has been taken to the
Indian Competition Commission as a possible abusive conduct for stalling the
approval of generic drugs. 59
These facts are important evidence to highlight that high prices of Trastuzumab
are not only caused by its uniqueness, as there are already biosimilar medicines
available in international markets, and that the balancing between profits and health
seem to be radically unaligned. The similarity of high prices around the world further
denotes a tendency of monopoly pricing and abuse of patent.
The medicine was registered by the Brazilian regulatory agency ANVISA as
early as 1999 and was incorporated as a treatment provided for by the public health
55 See MSF Global day of action against Roche’s inhumanity #RocheGreedKills. Press Release,
6 February 2017 https://msfaccess.org/global-day-action-against-roches-inhumanity-
rochegreedkills.
56 Direct Unconstitutionality Claim (ADIN 5529). The judgment is expected to scrutinize whether
the mentioned Article 40, Sole Paragraph of the Industrial Property Law is constitutional or not. It
provides an extension of patent terms due to patent backlog by establishing that a patent has a
minimum term of 10 years of protection. Since the general term is 20 years, any patent application
procedure that lasts longer than 10 years leads to an extension in the overall term of protection.
However, the competition effects of such extensions are dramatic. The strongest interpretation of
Brazilian constitutional legal system and the majority of commentators seems to note that such legal
provision is unconstitutional—similar to provisions on pipeline patents, also not yet judged by the
Brazilian STF. In this sense, it becomes clear how it is important to acknowledge how the lack of
action by the court—in such cases by refraining from deciding—is a central piece in the under-
standing of their role in the implementation of patents in Brazil, and how they negatively affect the
implementation of TRIPS flexibilities.
57 According to the analysis by the Law and Poverty Research Group, University of São Paulo, the
first known patent that refers to Trastuzumab was filed on 3 November 2008; its unionist priority
dates back to 16 June 2008. See Grupo Direito e Pobreza (Law and Poverty Group) (2014), p. 6.
58 See MSF Access Campaign Global day of action against Roche’s inhumanity #RocheGreedKills
(2017), https://msfaccess.org/global-day-action-against-roches-inhumanity-rochegreedkills.
59 Competition Commission of India. Case No. 68 of 2016—Roche—Mylan Biocon CCI Order
68 of 2016.
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system SUS in 2012. Cancer prevention, detection, treatment and control are all
covered by the public health system. Nonetheless, diminishing prices was a condi-
tion for effective access to take place after its incorporation as a registered medicine
paid by the SUS. During that occasion, and discounted taxes, prices of Trastuzumab
were 62% higher than international price average and 115% of the lowest reported
international price (surprisingly or not, in the United States). 60
Public procurement bids were conducted by the Ministry of Health in order to
generate economies of scale, later distributing to State Health Secretaries under
Brazilian federalist system. After direct negotiations with Roche, prices were
reduced from R$7.860,26 per dose, charged in 2007, to R$3.446,89 in 2012 (without
taxes, prices in Brazilian Real). However, State Health Secretaries have also been
obliged through individual health claims, to provide Trastuzumab. This is a conse-
quence of Brazil’s widespread “judicialization of health”, which enables individuals
to go to courts demanding specific medicines and treatments, also obliging public
entities to provide them regardless of costs in the majority of cases. 61 In practice,
this means that there were two main routes for access to Trastuzumab: via the general
60 Grupo Direito e Pobreza (Law and Poverty Group) (2014).
61 This is a direct translation from the Portuguese “judicialização da saúde”, or “judicialización” in
Spanish. Brazil's legal system is characterized by an ample recognition of the right to health,
including universal health system, the SUS, which are both constitutionally protected (Articles
6 and 196, Federal Constitution of Brazil, 1988). This has been interpreted as a direct constitutional
mandate which allows thousands of individual claims for medicines and treatments to reach courts,
which have been in general granted in almost all cases, even experimental treatments and no matter
the costs. The process has been also identified in other Latin American countries, particularly
Colombia, Argentina and Costa Rica. In common, public budgets are overwhelmed by such claims,
which are in certain cases a very large proportion of overall budgets. In 2019 and 2020, two
landmark rulings by the Supreme Federal Court (STF), the country’s highest judicial instance,
drastically reduced such claims as to avoid an overburden for health systems, in light of the
recognition that individual claims affected the social realization of health rights. For a critical
overview, see Kapczynski (2019), available at: http://humanityjournal.org/issue10-1/the-right-to-
medicines-in-an-age-of-neoliberalism/. She notes that “The budgetary impact of the right to med-
icines cases has unsurprisingly been significant. According to government figures, from
2010–2016, the federal government spent 4.4 billion reais ($1.4 billion) to comply with judicial
decisions, with most of this going to provide medicines.49 This sum has risen sharply over time,
along with the number of cases.50 In 2016 alone, the federal government spent 1.2 billion reais
($400 million) to satisfy judicial mandates.51 The bulk of suits for access to medicines arises at the
state level, where data are harder to come by. But analysis has found that states and municipalities
may be spending anywhere from 3 to 10 per cent of their health budgets to satisfy right to health
cases, and as much as 22 per cent of their medicines budgets to fulfill judgments mandating access
to medicines.”. She further notes the impact of patents as one of the main causes for such high costs:
“Why are the medicines involved, or more accurately, some of the medicines involved, so pro-
foundly expensive? It is common ground that the “exponential growth in costs” in Brazil “can be
explained by a high concentration of cases demanding expensive patented drugs.”81 Almost 80 per
cent of the total sum spent by the federal government to satisfy judgments for medicines in 2011 was
spent on just 20 medicines, for fewer than 0.05 per cent of litigants”. For a concern about the
possibly deceptive and anti-distributive character of such claims, see Wang (2015), p. 617; for a
defender of its counter-hegemonic potential as a grassroots instrument for the poor, despite its
shortcomings, see Biehl et al. (2016).
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universal public healthcare system and via individual court litigation. If this, on one
hand, may pressurize public entities to provide better healthcare services and avoid
individual claims, on the other hand, this dual system creates strong inequalities in
terms of who may access medicines and when (often with “shortcuts”). An often-
disregarded issue regarding this topic is how this system may also present an
opportunity for abusive pricing conducts and patent abuses. In the specific case of
Trastuzumab, Roche provided the medicine under a price agreed by the public bid,
but refused to sell Trastuzumab for the same price in individual healthcare litigation
cases, charging instead R$7.192,00—more than double the negotiated with the
Ministry of Health. Further evidence shows that similar higher pricing occurred
for all purchases not related to the centralized procurement, i.e., all individual
litigations (Table 1). 62
In light of this data, the Law and Poverty Research Group of the University of São
Paulo (USP) produced a comprehensive report on the prices charged by Roche on
Trastuzumab, reporting the figures above. It then filed in June 2014 a “representa-
tion” (i.e. a form of denunciation mechanism) for the Federal Public Ministry of
Brazil, the authority mandated with the protection of collective rights in the country
and general overseer of the public interest. 63
The research group noted that the price differentiation between markets is a case
of abuse of dominant position, a doctrine of competition law but applicable more
broadly to this case also, and further noting a case of excessive pricing given the





























R$ 4.728,98 R$ 4.832,21
aCMED is the acronym for “Câmara de Regulação do Mercado de Medicamentos” (Chamber of
Regulation of Medicine Market), the Brazilian federal regulatory agency responsible for monitoring
prices and establishing caps according to the prices of selected markets around the world, including
the United States
bPF is “Preço de Fábrica” (Manufacturer’s price)
cCAP is “Coeficiente de Aplicação de Preço” (Price Application Coefficient, in Portuguese) is a
mandatory minimum discount applied for medicine purchases by public administration entities,
such as the Ministry of Health
Recommendation Report by CONITEC/SUS—Trastuzumab for Treatment of Initiatial Stage Breast
Cancer—July 2012, p. 16
62 Grupo Direito e Pobreza (Law and Poverty Group) (2014).
63 Grupo Direito e Pobreza (Law and Poverty Group) (2014).
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existence of market power by Roche. The company in this case was apt to discrim-
inate between consumers without justification, leading to an overprice. 64 According
to the legal document, they are in violation of the constitutional economic order and
of a conduct of arbitrary profits (Articles 170 and 173, §§4 and 5 of Brazilian Federal
Constitution). In this sense, although some arguments are usually found only in
competition/antitrust law, the case dealt with civil torts.
Finally, the average price charged in Brazil above the international average was
utilized as grounds for another evidence of abusive conduct, according to Brazilian
law. This takes into account precisely the monopolistic power of Roche in an
international context, with discretion to charge higher prices in jurisdictions where,
at least in theory, prices should be lower. With these elements, the research group's
representation requested the launch of an investigation by the Federal Public Min-
istry, demanding damages in the benefit of the public, the compulsory licensing of
Trastuzumab, the immediate parallel import of biosimilars and for all conditions for
local manufacturing to be available.
Indeed, the Federal Public Ministry welcomed the document and later filed a
collective claim (“Inquérito Civil n. 1.16.000.000699/2015-87”, which proposed the
civil public action) against Roche in 2016, replicating the arguments above and
further considering that, while within the boundaries of the maximum regulated
prices by CMED, they were still abusive due to the stark differentiation. 65 Notably,
prices were much up to three times higher than those in the United States, and more
than double of the international average. The decision to pursue a judicial litigation
was rooted, among others, in the dissatisfaction with the laboratory’s formal
response. The Federal Public Ministry requested all purchases to be equated with
the centralized public procurement price, and requested a compulsory licensing to be
issued and the immediate authorization for parallel imports.
In August 2018, however, the Federal Court of the Federal District (Brasilia)
responsible for the case agreed with Roche that there was no demonstration of price
abuse nor illegal conduct, since Roche had brought justifications. 66 As a conclusion,
the whole situation described above remained unchanged. While there was an appeal
64 For a more thorough analysis of market power, and the use of the Lerner Index doctrine borrowed
from competition law, see Salomão Filho (2013b), p. 152.
65 The existence of a regulation on medicine prices does not remove it from the scope of potential
abusive practices regarding prices, an argument that was inaccurately explored by Roche. In reality,
the price regulation (not a direct price fixing) cannot be used to shield liability from abusive pricing.
It means that the Judiciary should acknowledge that there is potential abusive conduct in charging
excessive prices of medicines, even if they are regulated. Furthermore, CEMED’s methodology is
criticized for establishing excessively high price caps, which would also prove the point.
66 Among the arguments of the defendant, Roche argued that logistics costs are much higher when
destined to a specific litigation, unlike the larger public procurements. Indeed, the relatively more
complex molecule (being a biological drug) and specific needs for storages do pose difficulties
regarding its manufacturing and logistics. The weakness of the argument is demonstrated by the fact
that Roche sells other drugs in different places in Brazil with no such regional differences—
showing therefore that the difference in price is in effect due to market power and illegal price
discrimination.
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filed against such decision, taking the case to the Appeals' Federal Court and pending
final decision, some members within the Federal Public Ministry (claimant) opposed
the continuation of this litigation.
Meanwhile, Roche also joined a Partnership for Productive Development (PPD)
with the Ministry of Health, securing transfer of technology for national laboratories
Tecpar and Axis, while guaranteeing a market (following this agreement, 40% of all
purchases by SUS would come from Roche). In theory, PPDs would lower prices,
even if higher than direct competition. However, once again, prices went up, which
led to another proceeding in August 2019, this time by the Union Audits Court
(“Tribunal de Contas da União”), a quasi-judicial administrative court responsible
for auditing public expenses, for abusive pricing. 67 This case is still pending at the
conclusion of this paper.
From this description, a few preliminary comments can be made. In this particular
case, the existence of patent protection over Trastuzumab was the defining feature
that permitted Roche Brazil to charge monopolistic prices, putting the public health
sector in an extremely unequal position (having one sole provider of a product with
an extremely inelastic demand). If generics to Trastuzumab were available, individ-
ual litigations could also purchase from the alternative providers, and the bargaining
power of Roche towards the Brazilian public sector would be much more limited.
Moreover, it is possible to conceptualize this behavior in relation to public purchases
and court rulings as an abuse of patent rights under Brazilian competition law:
although often disregarded, the way market players may benefit economically
from legal uncertainty, multiple case filings and lack of competitors should be
under the scrutiny of competition and IP law alike, not only as background facts,
but as evidences. All in all, this is equally an important call for the inclusion of
responsibilities of companies in litigations of public interest such as those related to
access to medicines.
What is the direct result of this federal judicial ruling? The maintenance of the
status quo and an implicit legitimization of Roche’s pricing practices. Also, while the
new investigation at the Union Audits Court is unrelated to the previous one, it
allows other reflections, including what is the relation between them and what are the
possible legal impacts of one investigation in the other. The fact that this case has
been framed as a “non-patent” issue or which has perceived the market monopoly
power conferred by a patent as ancillary at best is the result of the limited under-
standing pointed out in the Introduction: failing to acknowledge the role of courts in
individual litigations to enhancing the power stemming from a patent in this partic-
ular web of details, the ultimate result does not properly apply the public interest
requirements of Brazilian IP and competition laws.
Finally, even though a preliminary analysis could possibly focus on the role of the
individuals involved in the litigation, this description highlights in fact that the
67 Junqueira (2019). Available at https://www1.folha.uol.com.br/cotidiano/2019/08/investigacao-
do-tcu-aponta-sobrepreco-em-remedio-para-cancer-e-leva-a-desabastecimento.shtml.
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functioning of the IP system is extremely reliant on the role of courts. 68 As stated
before, this is less about individual biographies of adjudicators/attorneys/business-
people and more about a judicial system based on silos and typically reluctant to
commit to applying law in a more comprehensive manner, even in light of such
socio-economic circumstances. This has been moreover a case where a hesitant and
absent role of the Judiciary to address IP and access to medicines issues has directly
impacted the possibility of implementing access to medicines policies, even if at first
glance this seems to not be a case on patents or competition. Importantly, the
argument of how price differentiation by Roche was only being possible due to
the complex web of various litigations had indeed been brought to courts, but the
decisions overall preferred to interpret the facts in a much more limited way.
5 The Sofosbuvir Case in Brazil
Sofosbuvir—sold under the brand name Sovaldi by pharmaceutical multinational
company Gilead Sciences—is a key medicine for the treatment of Hepatitis C, for
decades an incurable disease. It has been deemed a long-waited game changer for the
treatment of the disease. The utilization of direct-acting antivirals (DAAs) such as
Sofosbuvir, in combination with other drugs, 69 is able to provide a cure in a very
high percentage of cases (over 95%), and also contains a drastic reduction of
collateral effects in comparison with the most utilized treatment for decades until
then, based on inter-venous use of Interferon. Since its launch, Sofosbuvir has been a
major commercial success for Gilead around the world, with estimations of billions
of dollars in profits, largely superseding its overall investments in R&D by any
possible account. 70
The major global concern on Sofosbuvir has been the fact that it is extremely
costly in developed countries and in the majority of middle-income countries. It has
been reported that the 12-week treatment has cost up to US$84.000 in the United
States. In countries with generic offer, such as those coming from Egyptian generic
company Pharco Pharmaceuticals, the same treatment can be provided for as low as
US$300. 71 Importantly, Egypt did not grant the patent on Sofosbuvir, and Gilead
68 See Sect. 2 for some inputs on this topic.
69 Combinations include sofosbuvir with ledipasvir, velpatasvir, simeprevir and/or dataclasvir.
Dataclasvir is patented by Bristol Meyer Squibb (BMS), while ledipasvir and velpatasvir have
also been patented by Gilead. Other companies similarly have DAAs placed in markets and more
are in the pipeline of new drugs.
70 According to an estimation by Hep C Coalition, a patient's of hepatitis C advocacy group, in the
period 2013–2018 the drug generated a profit of around US$25.8 billion. Nonetheless, access to
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has offered a much lower price of US$900 per treatment, since Pharco Pharmaceu-
ticals was also able to produce it. 72 The real beneficiaries were consumers and the
public health sector of Egypt, which could have access to a full treatment at
substantially lower prices than the majority of countries in the world. Importantly,
the fact that prices are so dramatically different around the world is another evidence
that pricing is a process that is disentangled from innovation processes. 73
Gilead established a large international scheme of voluntary licenses for certain
Indian generic companies to produce and export Sofosbuvir at very low prices to
least developed countries (LDCs). 74 However, middle-income countries (including
Brazil) were not part of the scheme at all. Such agreements also prevent competition
with non-licensee generic producers, and also impede exports to territories not
covered by the licenses. Thus the majority of world population in need remained
excluded from this beneficial scheme. 75 For those countries, the medicine remained
an extremely pricy drug, and likely even more in countries with weaker health
systems. This led Sofosbuvir to be at the central stage of global efforts for reduction
of prices, campaigns for affordable and equitable access, and different attempts by
governments to reduce prices, including the issuance of a compulsory license in
Malaysia. 76 Patent oppositions have been filed in multiple countries, including
Argentina, Brazil, Morocco, Egypt, Ukraine, Malaysia, India, China, Russia, the
United States, Vietnam and in the European Patent Office (EPO), 77 some with
successful outcomes to have a patent claim rejected or limited.
With millions of hepatitis C patients, Brazil incorporated DAAs as part of the
universal public health system and opted in 2014 to negotiate prices of Sofosbuvir
72 Correa and Velásquez (2018).
73 While net prices do relate to numerous variables, including logistic costs, costs of APIs (active
pharmaceutical ingredient), taxation, volume of purchases, reimbursement schemes, and others,
these stark price differences between countries were mostly related to patents. The fact that Gilead
Sciences as a transnational corporation group (despite separate legal entities) had the monopolistic
power to discretionarily charge higher prices across jurisdictions shows this even more clearly.
Medicine prices covered by patents are ultimately influenced by patents (therefore, by a monopoly),
and not related to innovation. This is yet another caveat to the logic described in the previous
section, to which a patent and its exercise, including the economic benefits arising from it, would be
at least partly justifiable due to the innovation provided. What economic evidence shows, however,
is that if prices and patents were really related to innovation, prices should be at least somewhat
similar in the world, which does not happen at all. As such, this is a clear case of what antitrust law
considers to be a monopoly pricing.
74 Hill et al. (2016), pp. 28–31.
75 Gilead. Chronic Hepatitis C Treatment Expansion – Generic Manufacturing for Developing
Countries. Available at: https://www.gilead.com/-/media/files/pdfs/other/hcv-generic-agreement-
fast-facts-11-15-17.pdf.
76 Press Statement Minister of Health 20th September 2017 – Implementation of the Rights of
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with Gilead directly. While a positive initiative that prevented prices from being
even higher, Sofosbuvir sold for the public health system through public procure-
ment mechanisms was estimated to be up to 52 times more expensive than generic
versions available in other countries, according to GTPI, a Brazilian civil society
organization. 78 From the outset until the present moment, while lower than the
maximum charged in the United States, prices in Brazil were substantially higher
than countries with generic availability such as Egypt and Malaysia (following its
compulsory license).
Multiple patent applications had been filed by Gilead at INPI, the Brazilian IP
office. In February 2017, Fiocruz files a pre-grant opposition to the main patent
application (PI0809654-6). MSF Brazil, GTPI/REBRIP, and other organizations
would follow. From the very beginning, the patent applications were controversial:
in March 2017, ANVISA denied the prior approval (“anuência prévia”) to the
patent. 79 In March, the National Council of Health (“Conselho Nacional de
Saúde”) issued a technical-political recommendation against the patent and called
for attention to public health needs. However, in May 2017, a preliminary injunction
questioned ANVISA’s decision and it was therefore, according to the Brazilian legal
system, legally bound to grant its prior approval—with the possibility of this
decision to be upheld or overruled in later stages. In practice, the court ruled that
the prior approval should be granted.
In its pre-grant opposition on the same patent application, GTPI/REBRIP, argued
that it did not meet patentability criteria, but also further noted that the patent
application in question referred to an essential drug, and therefore its granting
would lead to violation of the right to health of Brazilian population. While this
explicit public interest argument was not utilized, the INPI released on 19 April 2018
a preliminary technical examination report against the patent. While not legally
binding, it signaled that the patent would not be granted. On 5 June 2018, ANVISA
gave the regulatory approval for the generic drug to be produced locally by a
Farmanguinhos-Fiocruz and Blanver (a generic company) partnership. It was largely
expected that the patent would not be granted at this point. In June 2018, daclatasvir,
dimeprevir and sofosbuvir were incorporated in the Brazilian SUS; they were
expected to be distributed freely and universally by December 2018.
On 18 September 2018, in an unexpected decision, INPI granted the patent on one
of the 126 substances filed, having denied 125 others and reversing its own
78 Grupo de Trabalho da Propriedade Intelectual (GTPI). Brazil is excluded from license authoriz-
ing production of generic medicine for hepatitis C. Available at: http://deolhonaspatentes.org/
media/file/GTPI_statement_Gilead_license_sofosbuvir.pdf.
79 The prior approval was an innovation of the Brazilian Patent system whereby the regulatory
agency ANVISA conducts an analysis of the patent application for pharmaceuticals, granting or not
its “prior approval” before the INPI analysis. The interaction between the two agencies and the
mandate of ANVISA have been hotly debated. In early times, ANVISA would conduct a full
patentability criteria analysis and its decision was binding; this was later replaced to be an analysis
of public health implications of the technology patent application, but no veto power per se is
recognized as of now.
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preliminary technical examination. The main compound was not patented, but still,
the decision was met with outcry and major discontent by civil society and patient
groups. Although in principle generics could be produced if they did not infringe this
limited patent, any generics reaching markets, in this case, would be subject to costly
and limiting litigation. This risk is substantially higher in Brazil for generic compa-
nies given the fact that damages for patent infringement are necessarily set at the
highest possible amount, which hinders competition. 80 Subsequently, the generic
medicine was legally and effectively blocked from entering the markets and Gilead
enjoyed a legal monopoly due to its new patent.
Shortly thereafter, on 20 September 2018, Marina Silva, a former environment
Minister and presidential candidate filed a federal lawsuit against the INPI decision
in order to annul the patent, based on arguments of public health and on the precarity
of the patent application, citing, among others, precedents in other countries. 81 The
federal judge in Brasilia accepted the arguments and issued a preliminary injunction
suspending the effects of the patent. 82 During this period, it can be said that there
was a competition period, whereby patents were not a barrier to competition and the
generic version was able to be commercialized and be part of public bids of
Sofosbuvir-based treatments. The price reached an all-time low of R$64,84 (also
see graphic below for the comparison).
In November 2018, combination medicines containing Sofosbuvir were procured
at an emergency procedure by the Ministry of Health. Gilead filed a claim to impede
its distribution due to patent infringement. In this context, a decision in favor of
Gilead is taken but later overruled. 83 In December 2018, the preliminary ruling in
Brasilia was overruled and the patent on Sofosbuvir is once again valid, leaving
Gilead to wait for its patent letter to start enforcing it. It is noteworthy to mention that
the decision by the Federal Court in Brasilia—1st Region was taken on procedural
grounds and was therefore not based on substantive patentability requirements. 84
Following the previous decision, a decision by a Rio de Janeiro Federal Court in
December 2018 suspends, under request of Gilead, PDP between Blanver and
80 See Articles 44, §1, 208 and 209 of the Brazilian Industrial Property Law. For an assessment of
how this maximalist set of norms impacts competition by greatly increasing the risks for generic
companies, see Gabriela et al. (2018), Fiocruz & Escola Nacional de Saúde Pública Sergio Arouca,
pp. 122–139.
81 Silva, Marina. Petição Inicial de Ação Popular (Statement of Claims of Popular Lawsuit).
82 Ação Popular n. 1019631-97.2018.4.01.3400. Judgement on 23 September 2018. (“acknowledge
that the INPI, by not facing explicitly the arguments that the patent application here questioned was
not in tune with the social, technological and economic interest of the country (from the point of
view of the Program to Combat Hepatitis C, maintained by the SUS), it disrespected its constitu-
tional obligation to preventively oversee national sovereignty and public interest, in the exact extent
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Fiocruz/Farmanguinhos for the production of generic Sofosbuvir until final decision
on patent is taken. 85 This effectively suspended the generic in Brazil. Also in
December 2018, Gilead commits to reducing prices in public procurement. 86 How-
ever, still much higher than the generic version. Gilead received its patent in
mid-January 2019. In February 2019, Gilead won major public procurements of
Sofosbuvir in Brazil.
This intricate description of events means temporally the occurrence of three
main phases:
1. a de factomonopoly, when there was only a patent application and Gilead was the
sole provider of Sofosbuvir; 87
2. a short competitive market period where the recently granted patent was
suspended due to a preliminary injunction based on public interest provisions,
and the generic version was able to enter the market;
3. a legal monopoly phase after the patent was reinstated, with only Gilead again in
the market. 88
It should also be highlighted the number of legal actions taken by all parties, but
in particular Gilead, which utilized various different legal tools, including infringe-
ment claims of its then suspended patent and attempts to nullify public procurement
bids that would have competition. Furthermore, while indeed the patent granted to
Sofosbuvir is not on its basic compound and some generics could theoretically still
be produced, in practice, some of the public bids are only available to Gilead. In
short, the current situation at the time of writing is of full legal and de facto
monopoly for the patent holder (Table 2).
The most decisive feature of this case, however, deals with the prices charged
after the patent was reinstated, as they were substantially higher than those from the
competition phase, but also from the original de facto monopoly situation.
According to another report by the Law and Poverty Research Group, there was a
spike of up to 1421.55% between the competition market period in mid (prices as
low as R$64,84 on average) and the later patented phase (R$986,57 on average),
85 Case n. 050277092320184025101, Federal Court of 2nd Region, Rio de Janeiro.
86 See SBAC (2019) http://www.sbac.org.br/blog/2018/11/28/dona-de-patente-que-barra-generico-
contra-hepatite-c-promete-desconto-a-governo/.
87 As noted in footnote 80, in Brazil, patent applications provide a very strong market power in
comparison to other countries. This is partly related to the legal provision that establishes damages
for patent infringement (including patent applications) at the maximum possible level in favor of the
patent holder (Articles 208 and 209, Industrial Property Law)—with retroactive effects (Article
44, §1 of the same Law), which greatly discourages competitors from entering markets. Brazilian
legal doctrine in patent law has also similarly sustained a view that patent applications are deserving
of an almost, if not equivalent, level of protection as granted patents. Due to this specificity, the
possibility for Gilead to charge a monopolistic price even before the granting of a patent is much
clearer than it would be in many other jurisdictions.
88 See Grupo Direito e Pobreza (2019).
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representing an overwhelming extra budget toll for the public sector. 89 Furthermore,
between the legal monopoly phase in 2019 (patented market) and the de facto
monopoly from 2015-2018, there is also a major difference in pricing. For instance,
in 2016, where a large number of Sofosbuvir units were purchased, the average unit
price was R$179,41, compared to R$986,57 charged in 2019 during the new patent
monopoly.
This complex intertwinement in the case calls for antitrust scrutiny. In light of the
situation, a group of nine different Brazilian civil society organizations, representing
both patient, consumer and human rights groups, as well as the Public Defenders of
Brazil, filed a joint formal notification to the competition authority (CADE 90) in
order to request the launch of an investigation for abusive anti-competitive practices
(both excessive pricing as abuse of dominant position and abuse of patents) and
asking for adequate remedies to be taken, including issuing a compulsory licensing
Table 2 (Extract from Law and Poverty Research Group report) Effect of Introduction of
Generic Sofosbuvir (Blanver/Farmanguinhos) in National Market
Effect of Introduction of Generic Sofosbuvir (Blanver/Farmanguinhos) in Brazilian Market
Sofosbuvir units sold by Gilead to the Brazilian State during the period





















89 Grupo Direito e Pobreza (2019). Importantly, Even though they refer to different public entities,
as noted in the case of Trastuzumab, from a competition perspective, this is the same relevant
market (public national health market, as essentially all procurements discussed here are made by
the public sector, even if sometimes via different entities—e.g. Ministry of Health and Health
Departments of States of Municipalities). The research also aggregated not only Sofosbuvir
(Sovaldi), but also a combination of medicines: Harvoni (Sofosbuvir + ledipasvir) and Epclusa
(sofosbuvir + velpatasvir).
90 CADE—Conselho Administrativo de Defesa Econômica (Brazilian Administrative Council for
Economic Defence).
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for Sofosbuvir on the grounds of an anti-competitive conduct (Article 31k of TRIPS
and Art. 38, IV, “a” of Brazilian Competition Law, Law 12.529/2011).
A preliminary administrative investigation was indeed launched by CADE, but
the case remains open. It might reach the Administrative Tribunal Council, which
decides upon antitrust cases in Brazil. At first impression, there seems to be more
space for a competition authority to address the case than judicial courts. 91 How-
ever, the relatively more flexible administrative procedure under competition law
and the stronger pressures on administrative bodies by government and interested
private companies (patent holders) make the results uncertain. This is especially the
case at a time in which pharmaceutical industries effectively threaten countries with
possible delays in the supply of Covid-19 related medicines (Gilead’s voluntary
licensing of Remdesivir, which excludes middle-income countries—including Bra-
zil—is an example 92). Despite the yet inconclusive outcome of this preliminary
investigation by CADE, the subsequent steps are largely dependent on how the
institution decides to perform or not such role.
6 Theoretical Conclusions on the Role of Courts in IP Based
on the Concrete Cases
The two cases reveal a number of issues on the interconnectedness between IP
protection and the role of courts. A different kind of interpretation on the role of the
Judiciary and other courts (including competition authorities’ adjudication bodies
and regulatory bodies, when applicable) with regards to patent protection may thus
be enabled. This section aims at presenting some theoretical conclusions drawn
partly from the cases discussed and examples presented.
a) Courts can reshape markets (and are also influenced by them). As such, patents
and patent use or abuse can be seen mainly as a legal phenomenon and their
scope depends on the enforcement given to the monopoly in different
jurisdictions.
91 For instance, given their broad mandate, their relative reduced number (if compared to judicial
courts), and the transnational characteristics of most cases (which impact and deal with conducts/
structures in multiple jurisdictions), most competition authorities are equipped for joint interna-
tional investigations, work through the sharing of information and to adopt a comparative approach
in terms of arguments and remedies deployed. In this sense, they are more accustomed to use case
law from other jurisdictions as direct and indirect basis for their own judgements. From an
international economic law perspective, it is also true that there is also more policy space for
competition authorities to pursue objectives than IP courts. Also, CADE has been one of the first
authorities to particularly address an abusive conduct case pertaining to IP, which is the sham
litigation case by pharmaceutical company Eli Lily (Administrative Proceeding N. 08012.011508/
2007-91, from June 2015).
92 Bermudez and Prabhala (2020). Gilead: o Brasil excluído no enfrentamento da pandemia.
Available at: http://www.cee.fiocruz.br/?q¼node/1176.
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Firstly, courts affect competition. Instead of purely arenas where legal arguments
meet in search of a ruling that clarifies the law, they are rather active actors that end
up determining the behavior of the parties involved in an IP dispute, even when
adjudicators refuse to recognize this role. In other words, judicial rulings and courts
are a factor that influences the economic behavior of patent holders, competitors and
governments.
As a consequence, they may in an intended or unintended manner expand the
patent monopoly’s effective scope. For instance, if companies are aware of the
extreme success rates of individual health litigation cases, such as it was the case
of Trastuzumab in Brazilian courts, and that there is no scrutiny for the prices
charged to the public sector in order to enforce judicial orders, this means that the
patent monopoly is enhanced exorbitantly. It becomes an implicit authorization to
charge any price, even if likely anti-competitive. Similarly, if companies know that
their litigation practices and their price discrimination (between different entities in a
same jurisdiction and/or across different countries) are to be considered lawful from
a competition law perspective, such as what has been argued in the ongoing
Sofosbuvir case before the competition authority (CADE), they also see their patent
monopoly reinforced, allowing them to pretty much shield themselves from antitrust
suits. The monopoly legally granted by a patent is not supposed to be so overarching
and comprehensive. However, it may become so due to courts. The conclusion is
that access to drugs is directly restrained.
In general, it is not possible to disregard the impact of courts; the absence of the
Judiciary decision is also often the main feature to expand patent monopolies. The
absence of rulings from the Brazilian Constitutional Court (STF) on patent matters
since the enactment of the 1988Constitution and the 1996 Industrial Property Law until
a May 2021 decision which ruled automatic patent term extensions unconstitutional
is a present and dangerous example of this absenteeism. Therefore, in short, courts can
reshape markets (and are also influenced by them). As such, patents and patent use or
abuse can be seen mainly as a legal phenomenon and their scope depends on the
enforcement given to patent rights and its flexibilities in different jurisdictions.
b) “IP as crucial to innovation” wrongly becomes a legal argument, which ham-
pers access
Secondly, rhetorical and economic narratives have direct legal consequences
when turned into arguments deployed or accepted by courts. By applying as a
given fact that maximal IP protection will lead to more innovation (therefore,
according to this view, IP protection per se is in the public interest), courts impede
an evidence-based assessment of concrete cases, preferring to rely on a pre-set
definition. Most laws themselves do not define the specific trade-off related to
patents, access and innovation, and invariably will require robust interpretation by
courts in practical terms.
This means that there will be no real balancing between, for instance, the effects
for competition or the impacts on prices and consequential increase in medicine
prices, and the protection of a certain patent claim. Furthermore, an analysis of even
“technical” aspects, such as patentability criteria, will tend to be informed and biased
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by a tendency towards the granting of a patent—similarly to the notion adopted by
some IP offices that patent applicants are “clients”, and not public offices working
for the public interest.
The economic narrative that equals IP with more innovation tends to overly
expand the scope of protection of IP from a temporary monopoly granted by the
State (quasi-public right, for some) to a naturalized and almost absolute right. 93
This, in a sense, is an effect of IP protection on the role of courts. This narrative has
been implicitly seen in the two cases analyzed, especially through the arguments
provided for by the law firms representing the pharmaceutical companies in Brazil.
This is the main conventional stream of argumentation in pharmaceutical patent
litigation and legislative debates around the world. 94
c) Anti-monopoly and IP law share public principles. As such, principles of
competition/anti-monopoly law should be directly applicable to patents (neither
as exemption nor complement)
Thirdly, apart from an IP interpretation that is more sensitive to the socio-
economic implications of IPRs, there is a case to be made about the applicability
of principles of anti-monopoly laws to patents. 95 This should not be seen as an
93 Oftentimes, the defense of TRIPS flexibilities mirrors the way the IP system is usually conceived:
a tension between public and private interest, the public being the interest of society at large to
benefit from more creations and inventions and access to them, and the private being the incentive/
recognition of the inventor/author to benefit, particularly economically, from it. The access to
medicines debate, in that sense, is normally portrayed as a defense of more public interest to the
relative detriment of the private interest of the IP holder. When put under those terms, the IP debate
is defined as a permanent imbalance and a constant pursue of the balance between public and
private. However, this should not necessarily be the case. The disaggregated framing of the question
allows for different considerations. An essential point often not referred to in the IP scholarship is
the impact of TRIPS flexibilities to the protection of IP. The flexibilities are neither an annulment
nor an attempt to impede the exercise of legitimate IPRs. When patents proliferate and are granted
under lax patentability criteria, it is well-established that this leads to the granting of numerous
patents to non-inventions (i.e. patent applications that do not fit the novelty or non-obviousness,
inventive step and industrial application requirements). Conceptually speaking, they should not be
granted in the first place. This means that, from the outset, patents are not synonyms of inventions.
However, if the patents granted to non-inventions are never subject to legal scrutiny—for instance,
through post-grant oppositions or through judicial rulings that invalidate patents—they will be
legally enforced.
94 Another good example of how this comes about is in the anxieties surrounding the likelihood of
international investment arbitration panels based on the measures taken by States with regards to
Covid-19 IP-protected technologies, which may cause hugely detrimental effects to certain coun-
tries, show how deeply engrained the “IP as innovation” approach is. Similarly, as noted by James
Love, “companies will be able to claim that anything that reduces the price reduces incentives to
invest in more rapid development, and litigate that issue.” See, Karlin-Smith (2020) https://www.
politico.com/news/2020/03/05/coronavirus-drug-industry-prices-122412.
95 See, for example, FTC v. Actavis US Supreme Court Case. In this case of a pay-for-delay
agreement, the court acknowledged that competition law should be applied to patents. This is
different from the previous US interpretation: before that, decision courts largely considered that a
behavior that falls within the subject matter of the patent would be lawful, even if it had a negative
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exception or as a complement to the legal discipline of patents and other IPRs, but as
an integral part of the meaning of IP: there is no IP without competition, even if it
may sound paradoxical at first.
In practice, in relation to the Trastuzumab civil federal case in Brazil, this would
lead to the recognition that the stark price differentiation between the price of public
procurement and the price charged resulting from a judicial ruling against the State is
so high that it should have been considered illegal. To do so, an application of
principles of competition law, in particular a discipline of abuse of dominant
position, would have been in our view sufficient to prove the case. The doctrine of
competition law abuse of dominant position should definitely be applicable to this
case, even if it was being ruled by an instance outside of the Brazilian competition
law system. This would be arguably also the case in other jurisdictions. Conversely,
for the Sofosbuvir competition case, the differences in the historical series of prices,
and between the de facto monopoly, the legal monopoly (patent protection) and the
competition situations (with generic drugs available in the market), highlight another
anti-competitive practice based on both excessive pricing (price demonstrated
through price discrimination) and abuse of patent power. 96 As noted before, this
case is still pending as of the conclusion of this paper.
While at first the difference in courts (federal judicial court and competition
authority) would seem to lead to completely different legal reasonings and rationale
of distinct bodies of law, in reality the similarity of cases denotes that the disciplines
of IP and competition law—and also in tune with public interest provisions and
fundamental rights—are or should be in fact in a path of merger. An IP court cannot
dismiss competition law as much as a competition body should not ignore IP
provisions; although they may have different organizing structures, and are usually
seen as targeting different goals, they have increasingly similar objectives and
intertwinements. Integrated principles and integrated disciplines does not mean
conflating all norms, arguing that IP and competition law are the same (they are
not), but it does mean passing from essentially private law spheres to a way of
interpreting law that should be based on public principles, particularly in light of the
demand that it should not reproduce socio-economic structures as natural entities,
but instead seek to regulate them for their economic power, as we have argued before
effect on the market and could be considered anti-competitive. This highlights that even in a country
so adamantly protective of patent rights, such as the United States, the possibility of applying patent
law to competition law exists.
96 There seems to be a proven argument in favor of an abuse of patent as an illicit anti-competitive
conduct. This is a clear recognition under Brazilian law, but it is also a hypothesis clearly delineated
by the TRIPS Agreement and therefore part of the national law of almost every jurisdiction around
the world. Furthermore, even though the majority of pharmaceutical IP-related cases in antitrust
bodies deals with “excessive pricing”, such doctrine is neither the only nor the sine qua non legal
argument to elicit the anti-competitive conduct. In other words, the illegality is not (only) in a price
deemed excessive, but in the utilization of a legal monopoly position (the patent) in an abusive
manner. Therefore the need to identify the two conducts.
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in different occasions. 97 Both are informed by and conceptualized under public
interest law more than bearers of private interests. This also means that the cases
described above would have required a different kind of interpretation that ade-
quately addresses competition impacts of IP protection both directly and indirectly—
including the role of courts as such. As many have argued in terms of the evolution
of both disciplines (IP and competition law), the trend towards a broader consider-
ation of interests, consequences and stakeholders denotes a process of
“publicization” of private law, rather than the opposite. 98
d) There is an emerging global (case) law of TRIPS flexibilities based on screening
and transparency. The role of courts is not dissociated from, but rather based on,
an interaction between academia, NGOs and other actors.
Finally, a few notes should be made on how an emerging body of decisions taken
by courts around the world has become a crucial feature for TRIPS flexibilities much
beyond their own initial scope. Courts are increasingly required to navigate distinct
“fields of law” and take into account other jurisdictions—both for the impact of their
decisions and as sources of legal arguments. 99 There is also a “screening” process
between courts. 100 Some national decisions have direct transnational repercussions,
such as a ruling on the legality of parallel exports, which will impact countries which
import or export medicines to that jurisdiction. An antitrust decision may deem
illegal a conduct based on abusive exercise of IPRs, and may impose restrictions and
sanctions that affect the outcomes of patent litigations in judicial courts.
97 See Sect. 2.
98 Salomão Filho (2015).
99 While IP law seems to be tightly related to national jurisdictions and international treaties only,
the increasing prominence of international licensing agreements in IP, the introduction of IP in
investment arbitration panels and the interplay between different actors discussed in this paper as
“pharmaceutical patent activism” highlight that courts need to navigate this much more complex
landscape, both public and private, both national and transnational at the same time. This is at least
partly applicable to this analysis. It also deals with other phenomena. For instance, in the field of
constitutional law and international human rights law, some have referred to this as “courts'
dialogue”, whereby interpretation of certain rights and case law of regional human rights bodies
such as the European Court of Human Rights and the American Court of Human Rights may
influence each other, as well as national constitutional courts. Even if the expression may not be
always accurate to describe constitutional practices, it does signal the possibility of cross-
referencing based on sharing of experiences and case law. This does not compromise the sover-
eignty or the independence of courts, as evidently all such arguments and data needs to be assessed
according to national laws and real cases. Instead, it provides more transparency and avenues for a
better coordination between different societal actors, which may have the positive effect of
increasing accountability.
100 Positive screening is an expression most commonly found in the investment world of stock
exchanges, whereby investors positively value companies with commitments such as
environmentally-sound operations and human rights protection, among others. Here, the notion
of “screening” is borrowed broadly from corporate governance in a critical way, where reputational
costs and examples set by peers in a given market are an increasingly important form of informal
governance.
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But in other cases, there are indirect consequences, which cannot be
underestimated either. Landmark rulings such as the USA Supreme Court Myriad
Genetics Case 101 and the Indian Supreme Court Novartis Case 102 have been
immensely discussed, read in law classrooms and utilized by courts around the
world that in theory would not be bound anyhow by such decisions. Others have
this emerging potential, such as the Kenyan High Court decision that, based on the
right to health, struck down a law with a concept of “counterfeit” which ended up
including safe and high-quality generic drugs. 103 In this sense, they are a real source
of law for other courts.
Similarly, pharmaceutical patent applications also have a transnational dimen-
sion. Pharmaceutical companies file patents around the world, sometimes translating
the content of application claims without proper adaption to national laws. 104 Civil
society groups and generic competitors counter applications of key medicines
through patent oppositions in one jurisdiction, such as India, which then become
the basis for subsequent oppositions in other countries. This can be deemed a form of
“patent activism”. 105 The cases of Trastuzumab and Sofosbuvir, as previously noted
in their respective descriptions, have both been subject to scrutiny and advocacy by
patients’ groups, and the dialogue between different actors and jurisdictions is a key
feature for understanding the conducts and strategies deployed in Brazil.
101 United States Supreme Court (2013), Assoc. for Molecular Pathology v. Myriad Genetics, Inc.,
569 U.S. 576 (2013) (on patentability of an isolated gene).
102 On constitutionality of Section 3(d) of the Indian Patent Act which establishes a robust inventive
step requirement. For instance, Siva Tambisetty notes that “The decision in Novartis v UOI heralds
a post-TRIPS coming of age for many jurisdictions like India, including Thailand, Brazil, Malaysia
and Indonesia. There is an urgent need to build up legitimate legal standards, tests and principles
around domestic patent legislation that do not replicate the predicament around patentability
standards that several jurisdictions face”. See Tambisetty, Siva. Novartis v. Union of India and
the Person Skilled in the Art: A Missed Opportunity. LSE Law, Society and Economy Working
Papers 2/2014. For Ahmed Abdel-Latif, the case was the first time a decision by a developing
country court was so intensely scrutinized, and could bear consequences to other countries, see
Abdel-Latif (2013), available at https://www.ip-watch.org/2013/04/15/the-novartis-decision-a-tale-
of-developing-countries-ip-and-the-role-of-the-judiciary/. Similarly, see Bennett (2014), p. 535 and
its possible impacts.
103 For a comment, see Kapczynski (2019).
104 As patents are territorial, patent applications also need to be filed in multiple jurisdictions.
Multiple streamlined and/or joint systems do exist, such as the WIPO-administered Patent Coop-
eration Treaty (PCT) system and regional patent systems such as the ones enabled by the European
Patent Office and the OAPI—Organisation Africaine de la Propriété Intellectuelle.
105 See, for instance, the work of Médécins sans Frontières—Access Campaign, ITPC—International
Treatment Patients Coalition, Third World Network (Malaysia), Lawyer’s Collective (India),
GTPI—Grupo de Trabalho da Propriedade Intelectual (Brazil, for only a few examples of organiza-
tions working specifically on this field. Furthermore, a database such as that of the Medicine Patent
Pool's Medspal, the compilation of TRIPS flexibilities by the Medicines Law & Policy, or the
compilation of compulsory licensing experiences such as that organized by the South Centre, are
good examples that may be utilized by any courts around the world. For a comparison between India,
Brazil and Nigeria (with a relative lack of “patent activism” in the latter), see Vanni (2020).
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Theoretically, these and other cases may be understood as part of global and
transnational law, 106 which may help to elucidate how specific courts are part of
global economic governance, even as national decisions. As such, adjudicators are
key actors in the consolidation of a global law of TRIPS flexibilities based on the
sharing of positive experiences, transnational advocacy, international solidarity and
in the benefit of developing countries. 107 It should include not only finalized cases,
but also legal proceedings initiated but not prosecuted, injunctions granted or not,
negotiations and settlements, and activists campaigns. Furthermore, developing
countries have an ever-growing importance in IP jurisprudence. 108 The current
Covid-19 pandemic and its multifaceted international reaction has a clear potential
to accelerate and foster this process.
7 Concluding Remarks
This article sought to repurpose the relation between courts and the implementation
of intellectual property. It argues for a shift from limited and uni-dimensional,
i.e. “courts apply IP law neutrally”, to broad and multi-dimensional, through
which courts define the contours of IP law and are also mutually influenced by IP
arguments, theories and stakeholders, all and each with specific socio-economic
impacts. Access to medicines is a field where these considerations become more
evident.
It proposed two main arguments. Firstly, that courts have an enormous impact on
the implementation of TRIPS flexibilities. While they are and should not be the only
variable in place, any efforts for advancing or curbing the flexibilities involves
courts. In particular, tribunals shape markets, even when—and maybe particularly
when—adjudicators decide to refrain from broader consideration of circumstances
106 Again, as examples, refer to Muir-Watt, Horatia, 2013; Zumbansen, Peer, 2011. Sometimes,
influences also come from non-state actors, such as arbitration panels, non-governmental entities
such as ISO, ICANN and FIFA, and transnational private contracts. In private international law,
notions of global law, transnational law and private ordering have been used to characterize a legal
political economy—both from a descriptive and a normative point of view—that is not exclusively
based on national and international law, but multiple normative setters.
107 The theoretical framework of a decentralized and collective construction of a global/transna-
tional law in IP means two things: on the normative side, that no single entity, no single individual
and no single country should define the effective norms and policies of the whole world; on a
descriptive point of view, that all players have an important role, and that this interplay between
academia, civil society organizations, international organizations and judicial/administrative
authorities is essential to construct a robust account of TRIPS flexibilities through example and
mutual screening.
108 Abbott, Drahos and Correa have argued that the world patent order was to be changed by the
innovation and development of IP in developing countries, with a particular nod to the role of
China, Brazil and India. This hypothesis can be now taken further to include the specific case law of
these and other jurisdictions alike. Abbott et al. (2012).
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and socio-economic impact of their own decisions. For this reason, the role of courts
itself (e.g. a ruling or a lack thereof) has competition impacts and should be taken
into account in legal interpretation.
Secondly, that a specific narrative which associates IP protection with fostering
innovation is misleading, as it establishes an incorrect trade-off between access to
health products and innovation. Since it is widely deployed by courts without further
consideration, this narrative turned into legal argument is particularly problematic
for over-expanding the effective protection of IP without a balance with the public
interest. Thus, it should not be accepted as a juridical category or narrative.
The description of the cases of Trastuzumab and Sofosbuvir in Brazil serve as
examples of how these different pieces come together, even if sometimes indirectly
and not explicitly. Many other rulings can and should be described under those
lenses. This article may present a framework for further analyses that include, rather
than ignore, the specific role of courts and their respective arguments on TRIPS
flexibilities.
A general conclusion is that this set of elements justifies a legal interpretation that
is mindful of structures such as patents, including their effects on societies and the
need for them to be reformed, rather than exclusively based on an allegedly formalist
interpretation of laws. Such laws, as described above, already enable the
restructuring of patent interpretation according to TRIPS flexibilities. This could
be deemed a “neo-structuralist” approach to patent law. 109 These cases also lead to
the recognition that IP and competition laws should be both interpreted jointly
according to integrated public interest principles. 110
Finally, the article posited that the increasing cross-referencing of courts and the
transnational characteristics of IP and competition laws may be described—both
descriptively and normatively—as an emerging global law of TRIPS flexibilities,
based on screening and transparency. The reaction to the Covid-19 pandemic has the
potential to accelerate this process. This is where other actors, including civil society
and governments, through for instance patent oppositions, transparency of R&D
costs and limitation of anti-competitive abuses, play a crucial role.
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Robust Patent Examination or Deep
Harmonization? Cooperation and Work
Sharing Between Patent Offices
Nirmalya Syam
Abstract Patent laws and regulations in many countries have utilized the flexibility
available under the WTO TRIPS Agreement to apply nationally appropriate stan-
dards to define the patentability criteria of novelty, inventive step and industrial
applicability, in order to ensure the grant of high-quality patents for genuine inven-
tions. Robust search and examination are crucial for the application of this flexibility
to ensure the grant of patents for genuine inventions, e.g., for secondary pharma-
ceutical patent applications which could lead to patent evergreening and adversely
impact access to medicines by restraining generic competition. However, limited
examination resources of patent offices have been stretched by the tremendous surge
in the number of patent applications to be processed, leading to delays and backlogs.
This has led patent offices to prioritize efficient and speedy processing of patent
applications with their limited resources by using the search and examination work
of other patent offices, sometimes to the extent of granting a patent on the basis of a
corresponding grant by another patent office. This chapter discusses how work
sharing has been driven by the major patent offices as part of a global patent
harmonization agenda, both within the WIPO Patent Cooperation Treaty and
through technical assistance and cooperation with other patent offices, and suggests
how patent offices in developing countries could best harness the advantages of
work sharing, particularly in a South-South cooperation framework, while
safeguarding the ability to apply in practice the patentability requirements under
their national laws through a robust search and examination of patent claims.
1 Introduction
Patent examination is one of the most critical tools available to a country to ensure
that patents are granted for genuine inventions that satisfy the patentability require-
ments under the law of a country. Patent examination practices adopted by a patent
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office plays a crucial role in the application of this important tool. Almost over the
past four decades, patent offices all over the world have entered into collaborative
relationships with each other that has effectively led to the creation of a global web
of collaboration networks between patent offices. These networks have evolved in
parallel to the pursuit of normative initiatives to harmonize substantive and proce-
dural aspects of patent law in multilateral forums such as the World Intellectual
Property Organization (WIPO) or in bilateral or regional trade agreements. While
the normative patent harmonization agenda has been resisted, the administrative
cooperation between patent offices has received relatively less attention. This chap-
ter examines how the various kinds of cooperative work sharing arrangements that
have evolved between patent offices can impact the ability of a patent office to
conduct robust search and examination in accordance with their applicable national
law and policy, and the opportunities and challenges that arise from the cooperation
between patent offices.
2 Patent Examination: A Critical TRIPS Flexibility
Rigorous examination of patent applications to determine whether they satisfy the
general patentability requirements of novelty, inventive step and industrial applica-
bility is the core function of patent offices in most countries. The decision by a patent
office to grant patents should be based on as thorough an examination of the patent
application as possible to ensure that only claims that fully meet the patentability
requirements under the national law are allowed. An erroneously granted patent
would remain valid unless it is successfully challenged before a judicial authority or
a tribunal.1 Thus, the patent offices are expected to act as gatekeepers of the patent
system and ensure that patents of questionable validity are not granted.2
Even while recognizing the possibility of grant of patents in all fields of technol-
ogy as required under the TRIPS Agreement, countries can have different thresholds
of novelty, inventive step and industrial applicability in relation to specific fields of
technology, such as pharmaceuticals. Thus, the outcome of a patent application can
vary from one country to another, depending on the standard of patentability
thresholds that are applied. The provisions of the World Trade Organization’s
(WTO) Agreement on Trade Related Aspects of Intellectual Property Rights
(TRIPS) provide the flexibility to WTO members to apply rigorous standards of
1Invalidation of a patent can take several years of litigation, during which period the patent can still
be enforced, and involve investment of substantial technical and financial resources which may be
difficult to access or afford, particularly in developing countries. Correa (2014a).
2Ibid, p. 2; the number of patent applications and grants have increased significantly in many
countries without a corresponding genuine increase in innovation due to the application of low
requirements of patentability.
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patent examination to ensure that only genuine inventions that meet high thresholds
of patentability criteria are granted a patent.3
Patent examination practices pursed by national or regional patent offices are
often based on the application of legal fictions.4 The adoption of some of these legal
fictions by a patent office in its approach to the examination of a patent claim may be
based on rules, regulations, bye-laws, guidelines or office practices. These may be
also influenced by the adoption of treaty obligations for patent cooperation, technical
assistance provided by influential patent offices, or administrative collaboration
arrangements between patent offices based on memoranda of understanding
(MOU) for such collaboration. Thus, even where the national law of a country
lays down very strict requirements of patentability, its application can be signifi-
cantly impacted by the practices followed by the patent office with regard to
examination of patent applications.5
This situation demonstrates the need for not only establishing appropriate thresh-
olds of patentability under the patent law, but also the important role that patent
examiners play in applying the law. Patent offices in developing countries face
challenges that impact the rigorous application of the patentability thresholds.
These challenges include limited human resources for patent examination, high
examiner attrition rates, surge in the number of patent applications in different
technical fields, backlogs of pending applications,6 and meeting expectations to
increase efficiency through expedited disposal of patent applications while ensuring
the robustness of the patents granted.7 Patent offices in developing countries are thus
required to make policy choices that essentially entail trade-offs between these
challenges. Depending on the policy choice that is prioritised, these could adversely
impact the ability of the patent offices to meet the other challenges.8 In the face of
3Article 27.1 of the TRIPS Agreement requires patents to be granted in all fields of technology
without discrimination as long as the patent applications satisfy the patentability criteria of novelty,
inventive step and industrial applicability. However, WTOmembers can apply their own definitions
of these criteria, and in doing so, can differentiate between fields of technology. See Correa (2012).
4The boundaries of patentability of claimed inventions have been stretched through the adoption of
a number of legal fictions. For example, it is assumed that a fictional ‘person skilled in the art’
against whose level of knowledge the inventiveness or non-obviousness of a claim is to be
determined, is a person of ordinary knowledge to whom even trivial developments would appear
to be inventive. However, there is no obligation under any international agreement to apply such
legal fictions. Correa (2014b).
5One study found that in spite of stricter thresholds of patentability established under the patent law
in India, in some instances the Indian patent office has granted patent claims that had been rejected
in the US and EU in spite of the application of liberal thresholds of patentability. Chaudhuri et al.
(2010); a recent study found a 72% error rate in the grant of secondary pharmaceutical patent
applications in India, in spite of the high threshold established under the Indian patent law (Ali et al.
2018).
6However, sometimes backlogs in processing patent applications could also lead to withdrawal of
patent applications and save the resources of a patent office.
7Cruz and Olivos (2019).
8See Shadlen (2013), p. 87.
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these conflicting policy priorities, patent offices often prioritise patent examination
speed and use of limited human resources over ensuring the quality of granted
patents.9
Patent offices can respond to these challenges by increasing human resources for
patent examination,10 use of automation technologies or by leveraging the search
and examination capacity of other national or regional patent offices. Of these,
automation and reliance on the work products of other patent offices can also
drive, and in turn thrive, under a globally harmonized patent system. Reliance on
automation and outsourcing of search and examination work to other patent offices,
depending on the nature and extent of the use of automation and outsourcing, can
have an impact on the outcome of the patent examination in terms of the examination
standards and practices applied. In the context of pharmaceutical patent applications,
if such reliance leads to the application of lower patentability requirements that
liberally allow the grant of secondary patent claims, it can have a detrimental impact
on access to medicines.11
3 Approaches to Patent Harmonisation
While patent laws are territorially limited in scope, the policy space for designing
national patent law is circumscribed by the obligations of a State under applicable
international IP treaties from the Paris Convention12 to the TRIPS Agreement, as
well as additional obligations incurred under bilateral or regional free trade agree-
ments. Certain IP treaties like the Patent Law Treaty (PLT) and the Patent Cooper-
ation Treaty (PCT) administered byWIPO also impose procedural obligations which
must be followed by patent offices. These can apply to both the formality require-
ments in patent applications as well as to the timelines and other procedures to be
followed. The scope of these treaties can also expand to shape the search and
examination processes followed by national patent offices.
9Ibid, p. 88.
10It is reported that the Indian Patent Office has substantially reduced backlogs by hugely
augmenting its human resources, alongside amendments of processing timelines and use of ICT
tools to better leverage its internal examination capacities. The Brazilian Patent and Trademark
Office has also substantially reduced backlogs through a increasing the number of patent examiners
in parallel to accelerating examination of patent applications in specific sectors and utilizing prior
art search conducted by other offices on corresponding applications. See, e.g., Jayakumar (2017)
and Nunes and Romano (2019).
11See, e.g., European Commission (2009), pp. 385–390 (describing how strategic patenting is used
by pharmaceutical companies to block the entry of generic competition).
12See generally, Dhavan (1990), p. 131 (tracing the historical evolution of the Paris Convention, its
evolution towards greater protection for the patentee and less regulatory authority for member
States, and the marked absence of any attempt to properly examine the public interest).
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Besides the pursuit of a normative approach, collaboration between patent offices
can also be used as a means of promoting harmonization. Such collaborations can be
non-binding and persuasive in nature, in the form of technical assistance or work-
sharing arrangements between patent offices. Patent office practices can acquire the
force of a customary norm13 over a long period of time.
3.1 Normative Approaches
Much of the focus on patent harmonisation has been on norm-setting processes that
aim to advance harmonisation of substantive aspects of patent law. Soon after the
establishment of WIPO in 1967 developing countries unsuccessfully moved pro-
posals to reform the Paris Convention. These attempts were countered through
attempts by the WIPO secretariat to advance proposals for a complementary treaty
to the Paris Convention, some of the provisions of which were eventually transposed
into the TRIPS Agreement in the WTO.14 Some of the other provisions of this draft
treaty were reflected in the text of the PLT that was negotiated in WIPO after the
adoption of the WTO TRIPS Agreement, as well as in the Substantive Patent Law
Treaty (SPLT) which was unsuccessfully negotiated in the WIPO Standing Com-
mittee on the Law of Patents (SCP) till 2005.15
The SPLT negotiations were part of an agenda being pursued in WIPO that
regarded full and deep harmonisation of national laws relating to patentability as
essential to the larger end “. . . to give national and regional patent authorities access
to a common operational platform that permits them to cooperate, exchange infor-
mation, share resources, and reduce duplication of their work.”16 This initiative,
known as the WIPO Patent Agenda, also suggested exploration of other mechanisms
in addition to deep substantive harmonisation, including “. . . not repeating work
done elsewhere . . .” to free up resources for the “. . . promotion of innovation,
development of IP management skills, and other areas where active engagement
may be required to realize the benefits of the patent system.”17 Rationalisation of
resource use, with a major emphasis on reducing duplication by fully or partially
relying on the work done by other offices either through formal treaty arrangements
13If States act in a certain consistent manner on a given subject matter over a period of time, it is
assumed under the general principles of international law that they are acting in such a manner
because they have a sense of a legal obligation, and hence such practice can be regarded as a rule of
customary international law. If a majority of States believe that such a customary norm cannot be
persistently objected to, it can acquire the status of a peremptory norm of international law, that
would be binding on all States. Baker (2010), p. 173.
14Syam (2019), p. 18.
15Ibid.
16Assemblies of the member States of WIPO (2002).
17Ibid [10].
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or through informal cooperation, was suggested as a matter of critical importance for
both patent offices as well as patent applicants.18
This element of the WIPO patent agenda has continued to be pursued both within
and outside of WIPO, even after the SPLT negotiations have been abandoned.
Instead of treaty making, norm-setting on enabling reliance on the work of other
patent offices is pursued through discussions on using soft law instruments such as
amendment of the PCT Regulations and Administrative Instructions, or through the
pursuit of exploratory discussions of patent office practices that draw from initiatives
pursued in the form of cooperation between patent offices outside the framework of
any WIPO treaty.
3.2 Persuasive Approaches
More than normative approaches, persuasive approaches have become the principal
mode of promoting greater use of the work of other patent offices. The major mode
of such persuasive approach has been the delivery of technical assistance and other
forms of cooperation between patent offices, which have built confidence and
reliance in the technical capacities, systems and work products of the patent offices
from developed countries that provide such assistance and cooperation.19 In some
instances, patent offices that have received such assistance and cooperation have also
agreed to fully recognise the patents granted by other patent offices without
subjecting the same to further examination.20
3.2.1 Technical Assistance
Technical assistance is a very critical feature of cooperation between patent offices.
The United States Patents and Trademarks Office (USPTO), the Japanese Patent
Office (JPO) and the European Patent Office (EPO)—collectively known as the
Trilateral Offices—act as the “. . .global hub of co-operation and convergence in
patent administration.”21 Technical assistance to patent offices in developing coun-
tries has been a mode for the Trilateral Offices to introduce their technical systems
for exchanging information and for search and examination of applications to the
recipient offices. Indeed, such technical assistance has been delivered even before
the adoption of the TRIPS Agreement.22 The delivery of technical assistance to
18Ibid [12]–[32].
19Drahos (2008a), p. 151.
20Text to n 25.
21Drahos (2008a), p. 6.
22Ibid. For example, the 1995 annual report of the EPO which tacitly admits that its technical
assistance to the ASEAN countries was driven by the objective of easing the process of prosecution
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advance the economic interests of patent applicants from Europe still continues. The
2017 annual report of the EPO states that “Joint projects with our member states and
patent offices from other regions are key to developing an efficient, quality-based
international patent system. Tools and services developed by the EPO are often at the
heart of these projects.”23
One of the focus areas of cooperation for the EPO has been to enable recognition
of European patents in foreign countries by concluding validation agreements with
the EPO. The EPO has concluded validation agreements with the patent offices of
Cambodia, Georgia, Moldova, Morocco, and Tunisia.24 Pursuant to these validation
agreements, a patent applicant may request that their patent applications filed or
granted in the EPO be extended to these countries. Thus, where an applicant makes
such a request to the EPO, the patent application filed in the EPO is recognised as a
national patent application in the country with which a validation agreement has
been concluded, and provisional protection is granted in that country. Subsequently,
if the patent is granted in the EPO, it would have the same effect as a national patent
in that country.25 The validation requests in third countries can be made in respect of
any application filed directly in the EPO as well as any international patent applica-
tion filed under the PCT which subsequently entered the national phase in EPO
region (European phase). The EPO is also negotiating similar validation agreements
with some other countries and regional patent offices such as Brunei, Jordan, Lao
PDR, the OAPI and Angola. According to the EPO, other countries in Asia have also
“. . . signaled their interest in evaluating the possibility to enter into a validation
agreement with the EPO.”26
Countries concluding such validation agreements can, in effect, limit the flexi-
bility that they have under the TRIPS Agreement to apply strict standards of
patentability to limit or restrict frivolous patents on pharmaceutical products27
granted by patent offices like the EPO, that apply patentability standards that are
very liberal and allow some of the claims that could be rejected under a strict
approach.28 It should be noted that the examination processes do not allow patent
offices to reach “definitive judgments on patentability” of a claim,29 but rather weigh
the balance of probability of a claim being patentable, without necessarily being
absolutely certain.30 If overly broad secondary pharmaceutical patents receive
of patent applications of European origin filed in those countries, through training of examiners, by
incorporating search and examination results from other offices into the patent grant procedures of
the patent offices that are given training, and automation of systems of patent administration.
23European Patent Office (2017).
24European Patent Office (n.d.)
25See, e.g., European Patent Office (2016).
26European Patent Office (2017).
27 't Hoen (2020).
28Correa (n 4), pp. 13–16.
29Ibid, pp. 2–3.
30Ibid, p. 3.
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validation outside the EPO pursuant to the validation agreements with EPO, such
patents can have a negative impact on public health and access to medicines.
3.2.2 Quality of Patents
Cooperation arrangements between patent offices have been justified as a necessity
in order to improve the quality of patents.31 In this context, some national patent
offices have focused on initiatives such as “. . . raising the threshold of inventive
step, reducing the cost to examiners of rejecting an application, and reducing
opportunities for applicants to manipulate the application process.”32 However, at
the multilateral level, the discussion on quality of patents has largely focused on
enhancing “productive efficiency”33 in the examination process of patent offices
rather than on strengthening the thresholds of patentability criteria applied in the
examination process.
In the WIPO SCP developed countries have advanced several proposals for
developing a work programme on “quality of patents” focusing on enhancing
examination resources of patent offices through technical infrastructure develop-
ment, improvement of patent office administrative processes, and exploring how
patent offices can cooperate and collaborate in conducting search and examination
work in order to improve patent granting processes.34 The proposals essentially
focus on using information technology solutions to build search and examination
capacity, exchange information on the quality of patent office processes based on
feedback given to patent offices by applicants, and identify ways in which search and
examination processes can be improved.35 Pursuant to this, the SCP has exchanged
information and shared experiences on work-sharing programmes among patent
offices and use of external information for search and examination.36
31See, Drahos (2008b).
32Ibid, p. 508. See generally, Correa (n 1), pp. 3–21 (describing legal and policy measures taken by
various countries, including major developed countries, to reduce the proliferation of patents).
33Drahos (2008b), p. 508 (explaining how the backlog of patent applications beyond their search
and examination capacity has driven the Trilateral offices to explore means to reduce pendency and
ensure timely and expedited disposal of patent applications. Long-standing cooperation with the
Trilateral Offices has also imbibed the quest for productive efficiency in the patent offices from
developing countries).
34See, e.g., WIPO (Standing Committee on the Law of Patents) (2011) and Proposal by the
delegation of Denmark (2011).
35Ibid.
36See, e.g., WIPO (Standing Committee on the Law of Patents) (2013a), Proposal by the delega-
tions of the Republic of Korea, the United Kingdom and the United States of America regarding
work sharing between offices in order to improve efficiencies of the patent system (2014), Proposal
by the delegation of the United States of America on the study of worksharing (2015), and Proposal
by the delegations of the Czech Republic, Kenya, Mexico, Singapore and the United
Kingdom (2018).
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In 2016, the twenty-fourth session of the SCP agreed to undertake a survey on
how WIPO member States understood “quality of patents” and implementation of
cooperation and collaboration between patent offices on search and examination of
patent applications. The most frequently mentioned cooperation arrangements in
responses to the survey37 were the following: access to documents/databases/search
systems of other offices; use of search and examination products from other offices;
collaborative search and examination initiatives; carrying out search and examina-
tion for other offices; exchange of examiners with other patent offices; training on
search and examination by other patent offices.
4 PCT Reforms
An important vehicle for promoting cooperation between patent offices all over the
world is the PCT administered by WIPO. The PCT essentially allows the filing of an
international patent application in the place of multiple national patent applications.
The international patent application can designate countries where national phase
entry of the application may be sought by the applicant after a preliminary review of
the application (not an examination) by patent offices which are recognised as PCT
International Search and Examination Authorities (International Authorities). This
review is called the PCT international search and examination or the “international
phase.”38 In the international phase, all PCT applications go through a mandatory
international prior art search with the applicants having an option to also seek an
international preliminary examination report after the international search report is
produced. Upon national phase entry, the patent application filed under PCT is
treated as a national patent application and examined as such by the relevant national
patent office. The reports produced during the international phase are available to the
national offices for reference, but it is not binding on them to rely on those reports in
making their decision on a patent application.
37WIPO (Standing Committee on the Law of Patents) (2017) and Responses to the questionnaire on
the term “Quality of Patents” and cooperation between patent offices in search and examination
(part 2) (2017).
38The PCT international phase timelines allowed a patent applicant to delay the start of national
processing of an international patent application. Under the Paris Convention, a patent must be filed
in a country within 12 months from the date of first filing of the application in another country.
Under PCT, while the international application must be filed within this 12-month period, the
national phase entry can be delayed to 30 months from the priority date. This was done to enable an
applicant to assess the viability of obtaining patent protection in a territory for a claimed invention
before actually pursuing national search and examination. See Mossinghof (1999) (explaining that
this was particularly important for pharmaceutical companies by enabling them to file a patent on a
promising drug and then using the opportunity of delayed national examination in designated
countries to assess the viability of pursing a national patent in a country based on factors as such
clinical trial outcomes).
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Though the reports produced in the PCT international phase are not binding upon
national offices, this system also allows patent offices that produce the international
search and examination report in their capacity as International Search and Exam-
ination Authority (ISEA) to influence the national examination of that application in
a developing country.39 As explained by the WIPO secretariat, one advantage of the
PCT system is that “. . . the search and examination work of patent offices can be
considerably reduced or virtually eliminated . . . (emphasis added).”40
The accession of developing countries to the PCT has been made an obligation in
various bilateral or regional free trade agreements.41 However, while a large number
of developing countries have acceded to the PCT, the system is predominantly used
by applicants from a few countries.42 Moreover, the international search and exam-
ination under the PCT system is conducted only by a few patent offices, and the
majority of the international search and examination reports are produced by the
EPO acting as an international search authority.43 At the same time, many develop-
ing countries that have joined the PCT system lack capacity in conducting substan-
tive examination, though they have witnessed significant increase in the number of
patent applications filed in their countries through the PCT route.44
Developed countries have consistently pursued the objective of eliminating the
need for search and examination of patent applications in the national phase inWIPO
discussions on reforming the PCT system.45 The PCT system that was established in
1970 has been significantly transformed today through incremental reforms
39Drahos (2008a).
40WIPO, ‘Patent Cooperation Treaty (“PCT”) (1970)’ (wipo.int) <http://www.wipo.int/pct/en/
treaty/about.html> accessed 9 May 2020.
41For example, article 18.7 of the Comprehensive and Progressive Trans-Pacific Partnership
Agreement makes ratification or accession to the PCT a mandatory obligation for all countries
that are party to the treaty. Government of Canada, ‘Consolidated TPP Text – Chapter 18 –
Intellectual Property’ (international.gc.ca) https://www.international.gc.ca/trade-commerce/trade-
agreements-accords-commerciaux/agr-acc/tpp-ptp/text-texte/18.aspx?lang¼eng.
42May (2007), p. 49.
43According WIPO statistics, more than 70% of International Search Reports under PCT between
2000 to 2018 have been issued by EPO, USPTO and JPO. Though the number of International
Search Reports from China and South Korea have significantly increased in recent years, the EPO,
USPTO and JPO continue to produce more than 65% of these reports between 2015 to 2018. See
World Intellectual Property Organization (n.d.).
44See, e.g., Shashikant (2014), pp. 17–21 (pointing out that most patent applications in the African
Regional Intellectual Property Office (ARIPO) are filed through the PCT route while the ARIPO has
a capacity of 12 patent examiners, and that ARIPO relies heavily on the results of the PCT or foreign
search and examination results and on the EPO guidelines).
45See, e.g., WIPO (Committee on Reform of the Patent Cooperation Treaty) (2001) (proposal to
make PCT search and examination binding on PCT Contracting Parties while simplifying PCT
procedures for patent applicants); WIPO (Patent Cooperation Treaty (PCT) Working Group)
(2018), (proposal by the WIPO secretariat to amend the PCT Regulations to enable national patent
offices to delegate their national office functions to the office of any other PCT Contracting State or
an intergovernmental organisation); also see, Rathod and Ali (2018).
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introduced through amendments to the Rules, Regulations and Administrative
Instructions through which the PCT system operates.
Several proposals have been advanced by developed countries to discourage
duplication of international phase work under the PCT system in the national
phase, encourage collaborative search and examination or work sharing between
patent offices, or enable national search and examination to be dispensed with at the
option of a PCT Contracting Party. The US had submitted a proposal at the PCT
Union Assembly of WIPO in 2000 for reform of the PCT in two stages—first,
simplifying certain procedures and aligning the PCT with the PLT, followed by a
comprehensive overhaul of the PCT system.46 This proposal had received broad
support from most developed countries.
The US proposal was transmitted to the PCT Union Assembly by the WIPO
secretariat with a recommendation to establish a special body that should consider
the proposal along with other possible proposals and report to the PCT Union
Assembly.47 The PCT Union Assembly established an ad hoc Committee on Reform
of the PCT. The committee met in two sessions from 2001 to 2002 and discussed a
number of proposals from WIPO member States and observers.48
46WIPO (International Patent Cooperation Union (PCT Union) Assembly) (2000a), (the proposal
pointed to the need to simplify PCT procedures and converge PCT and patent office practices to the
extent possible to facilitate obtaining worldwide patent protection through simplified application,
preferably in electronic format, and minimize the distinction between international and national
processing of the patent applications. Eventually, the proposal envisaged adopting procedures that
would enable substantive rights to be granted through the PCT. More specifically, the changes
proposed to the PCT system in the first stage included the following: elimination of the concept of
designation of PCT Contracting Parties in respect of which an international patent application is
filed, thus making an international application applicable to all PCT Contracting Parties and
relieving the applicant from paying the designation fees; eliminating residency and nationality
requirements for filing international patent applications, thus enabling any person regardless of
residence or nationality to file a PCT application in any patent office of a PCT Contracting Party;
aligning PCT filing date requirements to the PLT; aligning PCT rules on filing of missing parts in an
application to the rules in the PLT; enabling an applicant to request supplementary search and
examination from multiple International Search Authorities; subjecting all PCT applications to a
preliminary international examination following the international search report; enabling further
delaying of national phase entry of an application at the option of the applicant; combining search
and examination processes; and, facilitating electronic publication of the application and transmis-
sion of search and examination results. The comprehensive reforms envisaged were regional
consolidation of international search and examination authorities; eliminating the distinction
between national and international applications to avoid duplication of processing the application
in the international and national phases; making positive examination results from certain PCT
international search and examination authorities binding on Contracting States; and, allowing for
further deferment of national phase entry of an international application at the option of the
applicant).
47WIPO (International Patent Cooperation Union (PCT Union) Assembly) (2000b).
48See, WIPO (2001) (for the proposals made by the Austria, Australia, Canada, Cuba, the Czech
Republic, Denmark, EPO, France, India, Israel, Japan, Republic of Korea, the Netherlands, Spain,
Slovakia, Switzerland, Turkey, the UK and the USA).
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4.1 Working Group on PCT Reforms
The Working Group on Reform of the Patent Cooperation Treaty was established by
the PCT Union Assembly49 pursuant to the recommendation of the ad hoc commit-
tee. In its first two sessions in 2001 and 2002, the working group discussed the issues
that were identified for further examination by the committee. The WIPO secretariat
prepared draft proposals50 based on the recommendations of the working group and
submitted the same to the committee at its second session in 2001. These proposals
were broadly focused on three issues: improved coordination of international search
and international preliminary examination under the PCT and the time limit for
national phase entry; the concept and operation of the designation system; and
changes related to the PLT.
4.1.1 Establishment of a Written Opinion on Patentability
to Accompany the International Search Report
On the recommendation of the committee, the PCT Union Assembly amended the
PCT Regulations to the effect that a patent office could act as an International Search
Authority or an International Preliminary Examination Authority under the PCT if it
also held an appointment in the other capacity.51 This amendment effectively
allowed the same patent office to act as both the search and the examining authority
in the international phase. This also enabled the expansion of the role of the
International Search Authority through another amendment to the PCT Regulations
to require them to issue in addition to the International Search Report—that would
identify prior art documents in their order of relevance in relation to the claims made
in the international patent application—a Written Opinion on whether the claims
satisfy the patentability requirements in the light of the prior art revealed in the
international search. This fundamentally changed the international search phase in
the PCT to include a written opinion in the nature of a first examination report (FER)
on the patent application. If an international preliminary examination under chapter
II of the PCT was not requested by the applicant, the International Bureau of WIPO
was required to prepare an International Preliminary Report on Patentability (IPRP)
based on the Written Opinion of the International Search Authority (WOISA).52
Thus, even if the applicant does not exercise the option of seeking an international
preliminary examination following the international search report and publication of
the application, national offices today receive not just a search report but also an
49WIPO (International Patent Cooperation Union (PCT Union) Assembly) (2001).
50See, WIPO (Committee on Reform of the Patent Cooperation Treaty (PCT)) (2002) and WIPO
International Patent Cooperation Union (2002a, b, c, d).
51WIPO (International Patent Cooperation Union (PCT Union) Assembly) (2002).
52WIPO (Committee on Reform of the PCT), PCT/R/2/7 (n 51) [10].
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IPRP on whether the application prima facie meets the patentability criteria. Deeper
harmonisation of patent examination procedures was thus set in motion.
4.1.2 Automatic Designation of all PCT Contracting Parties
for National Phase Entry
The PCT Union Assembly also approved amendments to the PCT Regulations53 to
make the filing of a PCT application automatically applicable for national phase
entry in all PCT Contracting Parties.54 Thus, applicants are no longer required to
designate national or regional patent offices for national phase entry and pay
associated fees.
4.1.3 Establishment of an Optional Supplementary International
Search
The committee recommended to continue future discussions on PCT reforms in the
mode of the working group directly reporting to the PCT Union Assembly on the
basis of the proposals submitted and future proposals. Several proposals relating to
the reform of the PCT system were discussed in this working group in nine sessions
held from 2001 to 2007.
The third session of the working group discussed the outstanding proposals
relating to PCT reforms.55 These included proposals relating to further improvement
of the international search and examination system, for instance, to allow the
applicants to opt for supplementary or top-up search.56 The fourth session of the
working group discussed an options paper on the future development of the inter-
national search and examination system, which suggested that the possibility of
considering substantive revisions to the PCT for allowing search or examination by
multiple authorities, introducing a supplementary search, a “top-up” search for new
documents during the international examination, or even allowing a re-examination
53WIPO (International Patent Cooperation Union (PCT Union) Assembly), ‘Report’ (n 52).
54WIPO (Committee on Reform of the PCT), PCT/R/2/6 (n 51).
55WIPO (Working Group on Reform of the Patent Cooperation Treaty (PCT)) (2002a). The
proposals were categorized into two groups based on whether the proposal would require an
amendment of the treaty. Increasing reliance by national offices on the international search reports
and IPERs, electronic transmission of search and examination results, establishment of regional
patent offices as ISA, and technical assistance were among the issues that were deemed to not
require any treaty amendment to be implemented. The working group also discussed whether the
treaty itself should be revised, and the possible ways of undertaking its revision. It also
recommended to the PCT Union Assembly to amend the PCT Regulations to allow the applicants
to file for correction or addition of a priority claim in the international application within a stipulated
time period.
56See, WIPO (Working Group on Reform of the Patent Cooperation Treaty (PCT)) (2002b).
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by the International Authority after national phase entry of the application.57 It was
also suggested that the international examination report could also indicate whether
the application included subject matter on which there is variance in national laws
concerning their patentability.58 It was assumed that this would facilitate
non-duplication of search and examination at the national phase on subject matter
regarding which the application of the patentability criteria was relatively harmo-
nized in practice. It is pertinent to note here that such harmonisation was being
pursued by the Trilateral Offices through their technical assistance and cooperation
programmes with national and regional patent Offices of several countries.
The WIPO secretariat suggested that States that did not have their own search and
examination systems, or wished to reduce duplication of search and examination
done by other offices, or to have a system for validation of patents in certain cases,
could consider adoption of an optional protocol to register patents based on national
phase entry accompanied by the international search and examination report, or
allow the applicant to amend the application in case of a negative international
examination report so as to enter the national phase with a positive report on
patentability, or seek a re-examination at the international phase even after national
phase entry.59 The working group requested the WIPO Director-General to under-
take consultations on these options.60
At the sixth session of the working group, the WIPO secretariat submitted a
proposal for amendments to certain rules under the PCT Regulations to allow the
applicants to request for a supplementary international search by other International
Search Authorities in order to obtain a more thorough search report, and also to
request for an updated or “top-up” search during the international preliminary
examination.61 Following extended discussions over the next three sessions of the
working group, consensus could not be reached. However, the 2007 PCT Union
Assembly agreed to a proposal by France62 and a related joint proposal by Japan and
Spain63 to amend the PCT Regulations to allow the applicants to make a request for a
supplementary international search.64
57See, WIPO (Working Group on Reform of the Patent Cooperation Treaty (PCT)) (2003a).
58Ibid [18].
59WIPO (Working Group on Reform of the Patent Cooperation Treaty (PCT)) (2003b).
60WIPO (Working Group on Reform of the Patent Cooperation Treaty (PCT)) (2003c).
61WIPO (Working Group on Reform of the Patent Cooperation Treaty (PCT)) (2004).
62WIPO (International Patent Cooperation Union (PCT Union) Assembly) (2007a).
63WIPO (International Patent Cooperation Union (PCT Union) Assembly) (2007b).
64WIPO (International Patent Cooperation Union (PCT Union) Assembly) (2007c).
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4.2 New PCT Working Group
The WIPO secretariat presented a report on the PCT reforms process to the 2007
PCT Union Assembly which noted that the working group had addressed all the
issues on its agenda relating to the reform of the PCT and had reached agreement on
amending the PCT Regulations on some of those issues.65 However, it also noted
that there would be an ongoing need for minor changes to the PCT Regulations in
relation to certain proposals. It thus recommended the Assembly to formally declare
the end of the mandate of the Committee on Reform of the PCT and the working
group.66 The Assembly agreed to a proposal by the WIPO secretariat to establish a
new working group to do preparatory work on matters that would be considered by
the Assembly in future.67 This new working group—known as the PCT Working
Group—has been meeting annually since 2008 with a broad mandate to discuss any
matter which requires consideration of the PCT Union Assembly.
Discussions continued in the new PCT Working Group on promoting greater
reliance on the International Search and Examination reports under the PCT system
based on a preliminary discussion paper by the WIPO secretariat on enhancing the
value of international search and preliminary examination under the PCT.68 The
discussion paper pointed to existing mechanisms within the PCT which can deliver
similar benefits as work sharing mechanisms outside the PCT system, with the
advantage of being more effective and being able to reach out to a larger audience.
The paper raised certain questions for further consideration in order to improve the
implementation or use of those mechanisms. TheWIPO secretariat is of the view that
any deficiency within the PCT system is primarily due to the way in which the
system has been used sub-optimally by national offices, including International
Authorities, and this could be addressed within the PCT system without engaging
in any new PCT reform exercise.69 At the request of the working group the WIPO
secretariat produced another study on how to make the content of the international
preliminary examination report more useful for the purpose of patentability assess-
ment by national offices, and how to improve the international examination process
itself.70
The second session of the working group also discussed a number of other
proposals aimed at deeper reform of the PCT. These included a roadmap proposed
by the WIPO secretariat on the work that could be undertaken to facilitate a greater
use of the PCT system by national patent offices, including International Authorities,
with a focus on reduction or elimination of unnecessary duplication of search and
examination work undertaken in the international phase when the application enters
65WIPO (International Patent Cooperation Union (PCT Union) Assembly) (2007d).
66Ibid.
67WIPO (International Patent Cooperation Union (PCT Union) Assembly) (n.d.).
68WIPO (Patent Cooperation Treaty (PCT) Working Group) (2008).
69Ibid [3].
70WIPO (Patent Cooperation Treaty (PCT) Working Group) (2009a).
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the national phase, greater use of work-sharing mechanisms developed outside the
PCT system, and with the objective of ensuring high quality of granted patents while
at the same time reducing the backlog of pending patent applications.71 The working
group also discussed other related proposals by the Republic of Korea for a three-
track PCT system72 and a proposal by the US for comprehensive PCT reform.73
The proposal by the WIPO secretariat on a roadmap for PCT reforms was
discussed extensively through the session. The roadmap aimed to achieve a number
of milestones74 which included reaching agreement on establishing a second written
opinion prior to the issuance of a negative international examination report so as to
allow the applicant the opportunity to amend the claims, including a “top-up” search
in the international examination phase for prior art that may not have been available
at the time of the international search done earlier, and establishing a third party
observation system in the international phase.
Some developing countries were particularly concerned that the proposals in the
roadmap as well as the related proposals on work sharing and comprehensive PCT
reform effectively promoted harmonization of national patent examination practices,
71WIPO (Patent Cooperation Treaty (PCT) Working Group) (2009b).
72WIPO (Patent Cooperation Treaty (PCT) Working Group) (2009c) (the Korean proposal sought
to introduce amendments to the timelines in the PCT international search and examination phase to
give the applicants the option to request for either accelerated examination, regular examination or
deferred examination).
73WIPO (Patent Cooperation Treaty (PCT) Working Group) (2009d) (the US proposal suggested
the establishment of a new PCT (PCT II) which would allow the applicant to submit prior art
document along with the application, which would then be searched by two Authorities, and an
international preliminary report on patentability would be established by a third International
Authority, which would also receive third party observations. A positive international report on
patentability would automatically form the basis for the grant of a national patent, unless a national
office expressly rejects the report within a specified period).
74WIPO (Patent Cooperation Treaty (PCT) Working Group), PCT/WG/2/3 (n 71). The roadmap
aimed to achieve the following milestones to improve the PCT system: (1) obtain a commitment
from offices acting as International Search Authorities to not repeat the search done by them at the
international phase when the application enters the national phase in the same office; (2) work
towards elimination of reservations, notifications and declarations of incompatibility to the PCT,
PCT Regulations and Administrative Instructions in order to ensure a consistent effect of the
international patent applications in all Contracting States; (3) reaching an agreement that all
International Authorities will issue at least one written opinion prior to the issuance of a negative
international preliminary report on patentability, at least in cases where the applicant has provided a
substantive response to the written opinion of the International Search Authority; (4) develop a
system of third party observations on novelty and inventive step to be made available to the
International Preliminary Examination Authorities and designated offices; (5) including a “top-
up” search in international preliminary examination on patentability; (6) eliminating unnecessary
processing of an application through both the national as well as the PCT route and exploring the
reasons why applicants use different routes for filing the same application; (7) establish a pilot
project on collaborative search and examination by testing models allowing examiners from at least
3 different offices to work on the same application to establish a common international search report
or written opinion; and, (8) undertake discussion in the working group on measures that could be
undertaken to ensure that procedures and fee structures are appropriate to encourage use of the PCT
system in a manner which is efficient and beneficial for all applicants and offices.
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which could limit the ability of national Offices to undertake search and examination
of patent applications entering the national phase through the PCT route.75 The
working group agreed to undertake further discussion on the proposals based on an
assessment of the need for any change in the PCT system in the light of existing
problems and challenges facing the system, while ensuring that the freedom of
Contracting States to prescribe, interpret and apply substantive conditions of patent-
ability, and without seeking substantive harmonization or harmonization of national
search and examination procedures.76
Thus, the third session of the PCT Working Group discussed a report77 by the
WIPO secretariat analysing the functioning of the PCT system and the problems and
challenges it faced. The Working Group endorsed the recommendations made in the
report related to backlogs and improving the quality of granted patents,78 timeliness
in the international phase,79 the quality of international search and preliminary
75WIPO (Patent Cooperation Treaty (PCT) Working Group) (2009e).
76Ibid [94].
77WIPO (Patent Cooperation Treaty (PCT) Working Group) (2010a). The report advanced a
number of recommendations to address the following challenges relating to the PCT system—
assisting patent offices to address the problem of backlogs in processing patent applications and in
improving the quality of granted patents; enhancing the actual and perceived quality of international
search and examination in the PCT; creating incentives for the applicants to use the PCT system
efficiently; addressing skills and manpower shortage in patent offices; addressing the need for
access to effective search systems for national offices; addressing cost and accessibility of the PCT
system for applicants; addressing the consistency and availability of safeguards in the form of
reservations, notifications or declarations of incompatibility to the PCT, the regulations and
administrative instructions; provision of technical assistance; and use of PCT information for
technology transfer.
78Ibid [143], [146], [149]. These recommendations are the following: (1) Offices which act as
International Authorities should take steps to improve the actual and perceived quality of the reports
they establish under the PCT system to ensure that they provide content that designated and elected
offices wish to take into account; (2) designated and elected offices should review the content of
ISRs and IPRPs and make recommendations for their improvement; (3) the International Bureau of
WIPO and the International Authorities should review the proposals for changes in the content of
ISRs and IPRPs and report back to the next session of the Working Group; (4) the exercise should in
no way affect the right of designated and elected offices to use the ISRs and IPRPs as they see fit in
accordance with their national laws and policies; (5) national offices which conduct search and
examination in the national phase should consult with the International Bureau of WIPO on ways of
making their national reports available to other national Offices and the International Bureau should
ensure making these reports available through WIPO’s PATENTSCOPE database; (6) the Interna-
tional Bureau of WIPO should make available a system of allowing third party observations on
published international applications. The Working Group also recommended that the Chief Econ-
omist of WIPO should undertake a study to analyse the root causes behind the surge in patent
applications and the consequent heavy load on the international patent system.
79Ibid [152]. One of these recommendations required International Authorities to ensure they have
adequate resources to conduct the expected number of international search and preliminary exam-
ination in addition to their national work and give appropriate priority to international work in case
of backlogs to ensure timely availability of the results to the other national offices.
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examination,80 incentives for applicants to effectively use the system,81 skills and
manpower shortages,82 access to effective search systems,83 cost and other accessi-
bility issues,84 consistency and availability of safeguards,85 technical assistance,
PCT information and technology transfer.86 The Working Group also discussed a
80Ibid [165], [170]. These recommendations were the following: (1) International Authorities
should develop internal quality management systems in accordance with the quality framework
under the International Search and Preliminary Examination Guidelines, with the objective of
developing high quality ISRs and IPRPs; (2) International Authorities should seek ways to
effectively search documentation in other languages; (3) national offices whose national patent
collections are not readily available in electronic form should consider digitizing them; (4) the
international Bureau should coordinate the development of a centralized system for designated
offices to give feedback to International Authorities; (5) International Authorities should recognise
the quality of their own work and not routinely conduct more than a “top-up” search for the same
application in the national phase; (6) International Authorities should seek to make more informa-
tion available relating to search strategies so that designated offices can easily assess the scope of
the international search conducted; (7) International Authorities should seek to cite documents from
a wide range of sources where possible; (8) International Authorities should encourage examiners to
give good explanation of the relevance of cited documents, especially where the examiner considers
there is lack of inventive step.
81Ibid [176]. These recommendations were the following: (1) the International Bureau and national
offices should recommend applicants to prepare their applications in good time and conduct their
own prior art search before drafting their claims; (2) International Authorities should offer appli-
cants a good opportunity for dialogue with the examiner during the international preliminary
examination, including at least one written opinion before establishing a negative IPRP;
(3) Contracting States should consider possible incentives which could be introduced at the
international or national level to encourage applicants to file higher quality applications and have
defects corrected in the international phase.
82Ibid [181]. National offices which are able to offer training in search and substantive examination
were encouraged to coordinate their activities in order to provide complementary training.
83Ibid [185]. The International Bureau and Contracting States were encouraged to seek practical
and affordable ways for national offices to develop online searching capabilities.
84Ibid [193]. The International Bureau and Contracting States were recommended to consider ways
in which procedures could be simplified for applicants without needing to change national laws;
review the level of fees for different types of applicants; review the PCT Applicant’s Guide to
ensure that it is updated and provides information that is useful and easy to understand; ensure while
updating the PCT online systems that the language, interfaces and associated help reduce the need
to consult the PCT Regulations by the users.
85Ibid [198]. Contracting States were recommended to review their notifications of incompatibility
with the PCT Regulations and Administrative instructions and seek to determine whether they can
withdraw the notifications of incompatibility.
86Ibid. The following recommendations were adopted: (1) when requesting technical assistance in
the context of the PCT offices and Contracting States should ensure that the purpose of the request is
clear and that the International Bureau is aware of the related national policies and ensure that the
advice, training and systems which are delivered take the needs and national policies properly into
account; (2) a study be conducted by the International Bureau to look into the issue of coordination
of technical assistance for developing countries under Article 51 of the PCT; (3) that the interna-
tional Bureau work with national offices to deliver effective patent status information; (4) a system
of promoting licensing of patented technologies should be established enabling patentees to indicate
their willingness to out license their patented technologies; (5) that the International Bureau
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proposal by the WIPO secretariat for establishing a third-party observation system in
the PCT and recommended that the WIPO secretariat should begin the development
of such a system87 which has been operational since July 2012.
In the following sessions of the working group, some of PCT International
Authorities reported on implementation of pilot projects between them on collabo-
rative search and examination88 as well as integration of existing work sharing
mechanisms outside the PCT system with the PCT. The PCT Regulations and
Administrative instructions were also further amended to require International
Preliminary Examination Authorities to conduct a mandatory “top-up” search for
additional prior art that may not have been available at the time of conducting the
international search.89 Subsequent sessions of the PCT have continued to discuss
proposals on work sharing within the PCT system and share experiences of work
sharing arrangements between national offices as well as pilot projects within the
PCT system.
5 Work Sharing Arrangements Between Patent Offices
Since the 1980s, the Trilateral Offices have entered into MOUs which have effec-
tively made them “. . . the global hub of co-operation and convergence in patent
administration.”90 An integral part of this cooperation between the Trilateral Offices,
which have been gradually extended to include other patent offices, has been the
exploration of various work sharing arrangements relating to different aspects of the
work of a patent office, involving two or more patent offices. The possibility of
integration of such work sharing arrangements inside the PCT system is also being
discussed in the PCT Working Group of WIPO. The WIPO SCP discussions on
quality of patents have also focused on sharing experiences of such work sharing
arrangements.
Work sharing arrangements have typically evolved through cooperation between
patent offices over time through an incremental approach, led by the few major
patent offices that process the bulk of the world’s patent applications. Such cooper-
ation leverages the use of information and communications technologies (ICT)
through digitization of patent documents, machine translation, electronic exchange
of priority documents as well as search and examination reports. From mere
exchange of information and reports, the work sharing arrangements can develop
undertake a follow up study on how effectively the PCT system has functioned in terms of
disseminating technical information and facilitating access to technology and technical assistance
to developing countries.
87WIPO (Patent Cooperation Treaty (PCT) Working Group) (2010b).
88WIPO (Patent Cooperation Treaty (PCT) Working Group) (2012).
89WIPO (Patent Cooperation Treaty (PCT) Working Group) (2013).
90Drahos (2008a).
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further to include greater cooperation wherein offices agree to make use, sometimes
to the best possible extent, the work products of other offices. The emphasis, as
discussed previously, is on increasing productive efficiency through speeding up the
search and examination process.
5.1 Trilateral Cooperation
The EPO, JPO and the USPTO have implemented a number of work sharing
arrangements between them under the Trilateral Cooperation that was launched in
1983 in order to deal with the dramatic increase in the number of patent application
filings impacting the Trilateral Offices.91 The initial area of cooperation was focused
on digitization of all patent documents issued after 1920 and creating a common
database of such documents. This was further expanded in subsequent years by the
Trilateral Offices to develop a network for exchanging priority documents, an
electronic exchange format for priority documents and a common patent application
format.92
Digitization, creation of technology specialized databases, and creation of a
common ICT architecture facilitated electronic filing of applications and the conduct
of paperless electronic search. However, the Trilateral Cooperation was not limited
to facilitating exchange of documents. A number of comparative studies conducted
by the Trilateral Offices on examination practices and the application of patentability
criteria resulted in the harmonization of patent examination practices in various
emerging technology fields, and also led to efforts to revise the PCT international
search and examination guidelines.93
The Trilateral Offices have also explored a number of projects for collaborative
search and examination on a common patent application. In 2007 the USPTO and
JPO launched a pilot project called “New Route” under which a national or regional
patent application filed in either of the offices is deemed to be an application in the
other office, and the search and examination results produced by the office of first
filing can be used by the office of second filing in their own search and examination
of the application. The applicant is also provided additional time, similar to that
available under the PCT, to decide on whether to pursue the application in the other
office, based on the search and examination results in the office of first filing.94 The
Trilateral Offices also agreed to undertake a pilot project known as the “Triway Pilot
Programme” from 2008 to 2009, wherein all three offices agreed to conduct their




94See, Trilateral, ‘New Route’ (trilateral.net) https://www.trilateral.net/projects/worksharing/new-
route/new-route_index.
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and share the search results with each other in a timely manner.95 In 2008, the
Trilateral Offices also launched a pilot project on Strategic Handling of Applications
for Rapid Examination (SHARE) under which each office agreed to give procedural
priority to examining applications for which it is the office of first filing, with the
understanding that the office of second filing would use the search and examination
results of the office of first filing to the maximum extent practicable.96
5.2 IP5 Cooperation
With the emergence of the patent offices of China (CNIPA) and South Korea (KIPO)
among the leading patent offices in the world alongside the EPO, JPO and the
USPTO, a similar framework of cooperation as among the Trilateral Offices has
been established to include the CNIPA and KIPO.97 This group is known as the IP5.
The IP5 cooperation is particularly significant because almost 80% of the total patent
applications in the world and almost 95% of the international patent applications
under the PCT are processed by the IP5 offices.98 The IP5 was launched in 2007 as a
forum for cooperation among the leading five patent offices with a focus on “the
elimination of unnecessary duplication of work among the offices, enhancement of
patent examination efficiency and quality, and guarantee of the stability of patent
right.”99 In 2017, the IP5 expanded their vision to cooperate on “Patent harmoniza-
tion of practices and procedures, enhanced work-sharing, high-quality and timely
search and examination results, and seamless access to patent information to pro-
mote an efficient, cost-effective and user-friendly international patent landscape.”100
It should be noted, as discussed in the previous section, that around the same time
as the IP5 was launched, similar initiatives focused on promoting work sharing with
a focus on elimination of “unnecessary duplication” was also being pursued in the
WIPO discussions on PCT reforms. This means that when the proposals for reforms
in the PCT international phase were advanced in the PCT working group discus-
sions, the patent offices that handled almost the entire workload of the PCT inter-
national phase work were largely aligned to the proposed reforms. Reform of the
PCT system is an integral part of the work of the IP5 which has also initiated a pilot
project on collaborative search and examination of international applications under
the PCT. The IP5 group’s perspectives and initiatives on quality management
systems and work sharing arrangements are also discussed for possible integration
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One of the areas of cooperation among the IP5 offices is harmonization of patent
classification systems among the IP5 offices as well as revision of the International
Patent Classification (IPC) system administered by WIPO, to align the same to the
Cooperative Patent Classification (CPC) system of the IP5 and to introduce new
classifications in fast moving emerging technology areas.101 Such cooperation is
also part of the Trilateral Cooperation discussed above.
Another major area of focus for the IP5 has been the “Global Dossier” project
which seeks to offer, in a single portal, free and secure access to the dossier
information on all applications in the same patent family that have been filed in
the IP5 offices. The Global Dossier information has been expanded and linked with
the WIPO Centralized Access to Search and Examination (CASE) system to include
dossier information on patent applications under the same family filed in other patent
offices outside the IP5 group.102
Beyond the creation and expansion of systems to facilitate sharing of dossier
information and conducting collaborative search and examination, the IP5 have also
been exploring harmonisation of patent office practices within the IP5 in respect of
patent application and grant procedures. It is possible that as the office practices are
harmonised within the IP5, these could be extended through bilateral cooperation
arrangements by the any of the IP5 offices to other patent offices across the world.
5.3 The Vancouver Group
In 2008, the IP offices of Australia, Canada and the United Kingdom (UK) formed a
collaboration arrangement between them known as the Vancouver Group, with a
similar focus as the IP5 and parallel discussions in WIPO on elimination of unnec-
essary duplication and ensuring more effective work sharing. Mutual exploitation of
the work of each office with regard to patent search and examination has been a
priority area of the collaboration between the Vancouver Group offices. Thus, the
Vancouver Group has agreed on a set of principles on the basis of which mutual
exploitation can be undertaken. These include relying on the grant of patent or the
search and examination report of another Vancouver group office where possible,
taking self-initiative for such work sharing without requiring the applicant to make a
request, and utilizing the WIPO CASE system for the same.103
101
fiveIPoffices, ‘Classification (Working Group 1)’ (fiveipoffices.org) https://www.fiveipoffices.
org/activities/class.
102WIPO (n.d.-a).
103See, Vancouver Group (n.d.).
262 N. Syam
5.4 PROSUR
PROSUR is a regional collaboration initiative launched in 2010 between IP offices
of 13 Latin American countries.104 The PROPSUR initiative seeks to enhance
efficiency and quality in the search, examination and decision-making processes of
the participating IP offices through the exchange of data and information systems.
The primary focus of the PROSUR countries is on exchange of information and
opinions on patent applications, which can be available as a reference for the other
participating offices in the conduct of their own search and examination.105 The
information is shared among the PROSUR countries using ICT such asWIPO CASE
and the electronic platform for collaborative examination (e-PEC) created by the
patent offices of Argentina and Brazil.
5.5 ASPEC
In 2009 the nine member States of the Association of South-East Asian Nations
(ASEAN) launched a regional patent work sharing programme called the ASEAN
Patent Examination Cooperation (ASPEC).106 Similar to PROSUR, ASPEC allows
IP offices from ASEANMember States to utilise search and examination results on a
corresponding application in other ASEANMember States. In 2019, applicants were
also given the possibility of requesting utilizing the ASPEC mechanism to use
international search and examination reports produced under the PCT in relation to
a corresponding application by an International Authority within the ASPEC partic-
ipating countries.
5.6 IP BRICS
The IP offices of Brazil, Russia, India, China and South Africa (BRICS) launched a
cooperation among the BRICS IP offices in 2012. In 2013 the IP BRICS agreed to a
roadmap for cooperation.107 The areas of cooperation agreed upon in this forum
include exchange of IP office staff and examiner trainings, exchange of examination
related patent information data and IP documentation exchange and sharing, and
104The countries that are represented in PROSUR are Argentina, Brazil, Chile, Colombia, Costa
Rica, the Dominican Republic, Ecuador, El Salvador, Nicaragua, Panama, Paraguay, Peru, and
Uruguay. See, PROSUR (n.d.).
105Castillo (2012).
106ASEAN Intellectual Property Portal (n.d.).
107IP BRICS (2013).
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patent processes and procedures.108 As part of this cooperation, annual meetings of
the heads of the BRICS IP offices have been held since 2013, and 2 patent examiner
trainings have been organized till date.109 Studies to explore examination practices
and procedures relating to specific kinds of patent claims, such as Markush claims110
relating to pharmaceutical patents, have also been proposed.111
5.7 Patent Prosecution Highway
The Patent Prosecution Highway (PPH) is the most extensive work sharing arrange-
ment outside the PCT system. The PPH is a collaboration framework between
participating patent offices in which an applicant receiving a positive determination
on the patentability of a claim can make a request for accelerated examination of the
corresponding claim in another participating patent office by using the search and
examination results from the first office. According to the USPTO, an examiner will
generally examine the application within 2–3 months of the PPH examination
request being granted,112 though there is no maximum time-period within which
the examination should be done by the office conducting the accelerated processing.
The processing time would obviously vary from one patent office to another relative
to the number of applications they have to examine, with offices with a lower
number of applications processing PPH accelerated search and examination faster
than offices with higher number of applications.113
The PPH began in 2006 as a pilot project between the USPTO and the JPO within
the framework of the Trilateral Cooperation. Within a decade, the PPH has expanded
to include a large number of national and regional patent offices, including from
developing countries, into some form of a PPH agreement. The PPH agreements are
108IP BRICS (n.d.-a).
109IP BRICS (n.d.-b).
110Markush claims are patent claims on a general chemical formula that includes a wide range of
possible alternative chemical compounds. Drafting a Markush claim enables a patent applicant to
claim through a single application a patent covering several alternative compounds that could be
used. However, applications with Markush formulas only provide a few examples of possible
alternative compounds while claiming a much broader range of such possible compounds without
actually disclosing those compounds in the application. Thus, patents granted on Markush formulas
“. . . allow the patentee to control a large number of compounds that have not been actually
obtained. . ., but only theoretically inferred from their possible equivalence with other compounds
covered by the general formula.” Correa (n 4), pp. 16–17.
111IP BRICS, ‘Patent Processes and Procedure – Procedures for patent examination involving
Markush claims’, http://www.ipbrics.org/secondpage/project/d004.html.
112USPTO (n.d.-a).
113For instance, in 2019 the average pendency from a PPH request by the applicant to the final
decision in the second office was 1.3 months in Australia and 18.4 months in the U.S. See, Patent
Prosecution Highway Portal Site, ‘Statistics’(jpo.go.) https://www.jpo.go.jp/e/toppage/pph-portal/
statistics.html.
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in the nature of memorandum of understanding or collaboration agreements between
patent offices and not legal treaties. Hence, implementation of the PPH mechanism
does not require amendment of the national law and can be done merely through
administrative regulations or bye laws that patent offices are allowed to adopt within
the framework of the national patent law.
The PPH became a permanent mechanism between the USPTO and JPO at the
end of the pilot period and was extended as a pilot project in 2008 between the
USPTO and the EPO. In 2009, the EPO agreed to undertake a pilot PPH project with
the JPO. Thus, the PPH was seeded and began to develop several shoots of bilateral
PPH collaboration within the Trilateral Offices. The USPTO114 and the JPO have
also concluded several bilateral PPH agreements with other IP offices outside the
Trilateral. In 2014, the pilot project on a PPH mechanism between the IP5 offices
was launched by attempting leverage fast track patent examination procedures
already in place at the IP5, marking further expansion of the PPH. Existing bilateral
PPH arrangements that had been established between the offices within the Trilateral
and the IP5 group were integrated under this IP5 PPH project.115 In the same year,
three offices from the IP5—JPO, KIPO and the USPTO—launched a “Global PPH”
(GPPH) pilot project along with 23 other national and regional patent
offices—Australia, Canada, UK (the Vancouver Group), Austria, Colombia, Den-
mark, Estonia, Finland, Germany, Hungary, Iceland, Israel, New Zealand, Norway,
the Nordic Patent Institute, Peru, Poland, Portugal, the Russian Federation, Singa-
pore, Spain, Sweden, the Visegrad Patent Institute.116 Both the IP5 PPH and the
GPPH allow participating offices to use all the search and examination work
products of the office of first filing or examination among the participating patent
offices, including search and examination reports and written opinions produced by
them as International Authorities under the PCT. In parallel with these initiatives,
more countries are increasingly being brought within the ambit of the PPH through
bilateral PPH agreements. Currently, more than 50 national or regional patent offices
are part of the PPH network through a slew of bilateral or global PPH agreements.
Even where a patent office is a party to the PPH network through some form of
PPH agreement, the extent to which offices use the PPH system can vary, with some
offices using the PPH more widely than others. For example, under bilateral PPH
agreements, the PPH route is only available to the patent applicants from the
respective parties, and there can be a maximum limit on the number of applicants
who can make use of this route. The PPH agreement could be limited to certain
specific technology sectors while excluding other sectors with sensitive public
114The USPTO has bilateral PPH agreements with the IP offices of Brazil, Chile, the Czech
Republic, the Eurasian Patent Office, Mexico, Nicaragua, the Philippines, Nicaragua, Saudi Arabia,
and the Taiwan Intellectual Property Office. USPTO (n.d.-b).
115WIPO (Standing Committee on the Law of Patents) (2013b).
116Ibid.
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interest concerns, such as pharmaceuticals.117 However, like most work sharing
schemes, the PPH has also expanded through a gradual and incremental approach.
Therefore, the extension of existing PPH arrangements that are limited to specific
technology sectors could be extended to incrementally include processing of patent
applications in other technology sectors.
6 Opportunities and Challenges
Patent cooperation and work sharing between patent offices presents both opportu-
nities and challenges for patent offices. For resource constrained national patent
offices, work sharing can be an attractive mechanism to ensure timely processing of
patent applications. Use of ICT, digitization, automation, machine translation, etc.
have made work sharing an attractive and realistic proposition. At the same time,
work sharing could present the risk of trade-offs being made by patent offices in
favour of efficient, accelerated and timely completion of search and examination
work, over ensuring robustness of the search and examination itself. The risk of such
trade-off is much more where work sharing arrangements apply to fields of technol-
ogy, such as pharmaceuticals, where there can be significant variance between the
patentability thresholds under the applicable national law.
6.1 South-South Cooperation
While a number of patent offices in developing countries have bilateral MOUs on
cooperation with patent offices in developed countries, cooperation between patent
offices of developing countries has been very limited. Exploring work sharing or
collaboration between patent offices among developing countries on the basis of
South-South cooperation could be explored further. Work sharing arrangements like
PROSUR and ASPEC enable patent offices in Latin America and the ASEAN to
utilise their search and examination results on corresponding patent applications in
their respective offices. Beyond formal work sharing agreements, patent offices in
developing countries could also cooperate to undertake examiner exchange
programmes, sharing of sector specific guidelines on patent examination, sharing
of search and examination reports, objections or questions raised in first examination
reports (FER), results of pre-grant opposition proceedings, and information on post-
grant revocation or grant of any compulsory license on a patent. For instance,
initiatives similar to the project proposed by INPI of Brazil under the IP BRICS
117E.g., Intellectual Property India (n.d.) (limiting PPH requests to 100 applications per year and
excluding pharmaceutical patent applications from the scope of PPH under the bilateral PPH
between the Indian Patent Office and the Japanese Patent Office).
266 N. Syam
cooperation to undertake a study on examination procedures on patent applications
containing Markush formulas with the objective of standardizing examination
guidelines relating to such claims, could be further explored by other developing
country patent offices and also be extended to include other forms of secondary
patent claims made in the pharmaceutical sector.
It is critical that patent offices in developing countries engage in cooperation
among them within a South-South framework not only in form but also in terms of
policy orientation. The focus of South-South patent cooperation should be on
harnessing the resources of their national and regional patent offices to ensure that
those resources could be deployed efficiently to ensure robust examination of patent
applications. To persuade the patent offices to collaborate with this orientation, it
would be necessary to utilise existing forums of South-South cooperation such as
IBSA,118 MERCOSUR,119 UNASUR, the regional economic communities (REC) in
Africa,120 as well as regional cooperation forums in Asia to provide guidance to the
respective national and regional patent offices of their member States, to cooperate in
pursuit of this objective.
A priority area of focus in this regard should be on the examination of pharma-
ceutical patent applications with the objective of enabling patent offices to fully
utilise the flexibilities available under the TRIPS Agreement with regard to the
differential application of the patentability criteria of novelty, inventive step and
industrial applicability by taking into account the specificities of the technological
sector. Thus, patent offices from developing countries can collaborate to share
experience and knowledge and develop tools such as patent examination guidelines
to enable the conduct of search and examination of pharmaceutical patent applica-
tions by applying rigorous standards. Objections or clarificatory questions raised in
FERs by applying such rigorous standards could be shared through appropriate ICT
tools with other patent offices for their reference. Other offices could consider
whether similar questions could be raised in the context of the requirements under
their national law or regulations. High quality FER objections can result in the
withdrawal or abandonment of frivolous applications.
118See, e.g., India-Brazil-South Africa Dialogue Forum (Second Summit of Heads of State/Gov-
ernment) (2007) (agreeing to work towards a trilateral initiative on cooperation in the field of IP
including capacity building and human resource development).
119See,Velásquez (2015) (referring to theMERCOSUR health ministers’ declaration of 2 December
2009 calling for development and application of patentability criteria in view of proliferation of low
quality patents and particularly to adopt criteria to protect public health through patentability
guidelines).
120See, e.g., East African Community (2013); see generally, Vawda and Shozi (2020).
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6.2 Safeguarding and Utilising TRIPS Flexibilities
While South-South cooperation could be explored in the area of patent search and
examination as a means of strengthening the implementation of robust patent
examination standards, a critical challenge for patent offices from developing coun-
tries in respect of patent cooperation or work sharing arrangements with the major
patent offices such as the Trilateral or IP5 offices will be to effectively retain and
safeguard the capacity to conduct such robust search and examination. Technical
assistance programmes, examiner exchanges can expose and orient patent examiners
from developing countries not only to the search tools, systems and techniques, but
also to certain perspectives through which patent claims could be deemed to satisfy
the criteria of patentability in a flexible way. For example, though under a strict
interpretation a selection patent claim could be considered to be not novel as it is
previously disclosed in an earlier application, patent examiners receiving technical
assistance from the EPO could consider such claims to be permissible.121 Therefore,
developing countries must ensure that patent examiners are exposed to trainings that
offer different perspectives, and expose them to the development and public policy
implications of the possible approaches that could be taken to interpret the patent-
ability of a claim.
With regard to work sharing collaborations such as the PPH that go beyond
merely offering access to search and examination results of one office to another but
encourage reliance on the reports produced by an office of first filing or examination,
developing countries should exercise caution. A prudent approach in this respect,
which some developing countries have taken,122 is to limit such work sharing
arrangements to exclude particularly sensitive fields of technology such as pharma-
ceuticals, and limit the number of applications to be processed under such
arrangements.
6.3 Use of Technology
Digitization, ICT, machine translation, etc. have immensely aided patent offices to
stay connected and share information rapidly and securely. While continuing to
expand the use of such technologies to enable access to more information to conduct
121A selection patent claim is a secondary patent claim on a specific compound that is selected from
the broad range of compounds that have been claimed earlier through a Markush formula, on the
basis of a legal fiction that is followed by some patent offices influenced by the EPO, that the
compound being claimed as selected from the range under a Markush formula, was not specifically
disclosed under the earlier patent claim based on the Markush formula. In this way, selection patent
claims have been a major route for effectively extending the term of a patent by claiming a specific
selection of a compound as the term of the original patent claim nears its expiry. See Correa
(n 4), p. 17.
122E.g., Intellectual Property India (n.d.).
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more comprehensive search and examination, facilitate electronic filing of patent
applications, communication between the patent office and the applicants during the
search and examination, as well as receiving oppositions or third party observations,
there is need for caution with regard to use technologies to the decision-making
itself. A number of patent offices have undertaken projects to use artificial intelli-
gence (AI) and machine learning for patent classification as well as patent search.
However, AI and machine learning tools can be used to even conducting the patent
examination itself.123 Therein lies the risk for developing countries, particularly
those which fully rely on the decisions of foreign patent offices, such as under the
validation agreements with the EPO.
6.4 Administrative Law Oversight
The global network of patent offices is a reality. If utilized appropriately, collabo-
ration between patent offices can certainly provide efficiency gains for the conduct of
the business of patent offices. At the same time, patent offices also have a regulatory
role to play in the public interest by ensuring as far as possible that patents of
questionable validity are not granted. The patent cooperation and work sharing
arrangements that patent offices engage in with their counterparts from other coun-
tries obviously have a bearing on this function. However, these arrangements are
often implemented as pilot projects, as cooperation activities under MOUs. At most,
implementation of these activities would involve a revision of the regulations, rules
or guidelines developed by the patent office as subordinate rules under the frame-
work of the patent law enacted by the legislature. Thus, implementation of principles
of administrative law can be crucial to ensure that the functions of the patent office as
a sentinel of the public interest through the conduct of robust search and examination
to decide on the grant of a patent in accordance with the national law is safeguarded,
while attempting to secure speed and efficiency in disposal of the workload of patent
offices through mutual collaboration. Thus, patent offices should be required to
undertake sufficient public consultations prior to engaging in collaborative work
sharing arrangements, as well as when considering expansion of the scope of such
collaborations. Legislative oversight should also be exercised to ensure that collab-
orations between patent offices are effectively enabling, and not limiting, the imple-
mentation of the substantive patentability criteria under the national law.
123EPO is developing business solutions using Machine Learning and AI to manage patent files at
various degrees of implementation: Automatic annotation of patent literature; Automatic detection
of problem/solution in patent document; Automatic detection of exclusion from patentability. See
generally, WIPO (n.d.-b).
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7 Conclusion
Rigorous examination of a patent application to determine whether a patent claim
satisfies the requirements of novelty, inventive step and industrial applicability, and
sufficiently discloses the best enabling mode of working the claimed invention, is the
most important role of a patent office. This makes it critical that patent offices are
able to perform this role well by ensuring that the patentability thresholds as defined
under the national law and the public policy objectives that inform the law, are given
effect to in the process of interpretation of the patentability of a technical patent
claim. Thus, how a patent examiner views a claim matters. The perspective of the
examiner can be influenced by technical assistance or administrative collaboration
arrangements between patent offices. Patent offices in developing countries also face
challenges, such as limited human resources for patent examination, surge in the
number of patent applications in different technical fields, associated backlogs, and
the pressure to speedily dispose the applications. These challenges can impact the
rigorous application of the patentability thresholds as patent offices have to make a
choice of prioritizing between speed and efficiency in completing the search and
examination work and robustness of the examination. Increasing human resources
for search and examination, use of automation technologies and leveraging the
search and examination capacity and work products of other patent offices are
possible approaches being deployed by patent offices to address this challenge.
Digitization and use of ICT systems has enabled offices to collaborate in
conducting search and examination work more easily. However, this has also
enabled the major patent offices such as the Trilateral Offices and the IP5 to play
an influential role in influencing the work of other patent offices. Indeed, work
sharing has been explicitly recognized as part of an agenda of achieving a harmo-
nized global patent system. While the negotiations for a Substantive Patent Law
Treaty was unsuccessful in WIPO, soft law reforms of the PCT system has been
undertaken through an incremental approach, and work sharing arrangements devel-
oped by the major patent offices outside the PCT system are also being promoted
both in terms of their integration to the PCT through pilot projects (such as the
PCT-PPH pilot project by EPO) as well as experience and best practices sharing
sessions on “quality of patents” in the WIPO SCP discussions.
The nature of collaborations between patent offices vary. While some patent
offices have entered into agreements to outsource search and examination work to
the more resourceful patent offices or recognise within their territories the patents
granted by another office (such as under the EPO validation agreements), other
offices may collaborate merely to share information and documents relating to prior
art, and search and examination results. Many patent offices have also agreed to
engage in projects such as the PPH with one or more countries wherein they agree to
not only share the search and examination results, but to use the search and
examination results on a claim by one office to accelerate the examination of the
claim in the other office. While engaging in such arrangements, patent offices in
developing countries should ensure that the flexibility available to them under the
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TRIPS Agreement to apply the patentability criteria as defined under the national law
and policy is effectively safeguarded. Some patent offices have excluded sensitive
sectors such as pharmaceuticals from their PPH agreements and have limited the
number of applications to. Which the accelerated procedure could apply. However, it
is possible that over time the PPH agreements could be expanded to include
technology sectors that are currently excluded and could also be extended to patent
applications from more countries. Patent offices in developing countries should also
ensure that patent examiners are exposed to trainings that offer different perspectives
on how patent claim could be interpreted differently by application of the patent-
ability criteria under a strict or relaxed standard.
Patent cooperation and work sharing presents both opportunities and challenges
for patent offices. Patent offices in developing countries could engage in cooperation
with each other in a South-South framework to undertake examiner exchange
programmes, sharing of sector specific guidelines on patent examination, sharing
of search and examination reports, objections or questions raised in first examination
reports (FER), results of pre-grant opposition proceedings, and information on post-
grant revocation or grant of any compulsory license on a patent. South-South
cooperation should be undertaken with a focus on enabling patent offices to utilise
their resources for ensuring robust examination of patent applications. A priority
area of focus in this regard should be on the examination of pharmaceutical patent
applications.
Finally, cooperation between patent offices typically take place in the form of
projects implemented under MOUs, which are undertaken in exercise of the admin-
istrative discretion that patent offices have. While exercising such discretion, it
would be pertinent for patent offices to also assess the implications of such cooper-
ation on their regulatory function of ensuring grant of robust patents in the public
interest. It would this be pertinent to undertake public consultations and also exercise
legislative oversight by application of the principles of administrative law, to ensure
that cooperation that patent offices enter into in exercise of their discretionary
powers, are exercised in the public interest and do not impede the attainment of
the public policy objectives that inform the patent law.
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the copyright holder.
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This chapter wrestles with the interface between Intellectual Property Rights (IPRs),
competition law and access to medicines. It emphasizes the important role that
competition law may play, in addition to the internal IP flexibilities, in order to
foster access and dissemination of medical products. Of course, competition law
could also be considered as a flexibility within the TRIPS agreement. In our analysis,
we consider competition law separately given its role in creating competitive
markets within which IP products are commercialized. Relying on the recent case
law in the EU, in Italy and in South Africa on the application of competition law in
the pharmaceutical sector, with a focus on the prohibition of excessive pricing of
pharmaceuticals, this paper argues that TRIPS flexibilities are an important regula-
tory tool to control prices and to foster access to medicines. However, in certain
circumstances, IP flexibilities are operational only within a competitive market that
is guaranteed by a functioning competition law.
Section 2 of the paper, which sets the stage, discusses the interface between
TRIPS and Competition Policy and the enforcement orientation of competition law
in the pharmaceutical sector since the entry into force of the TRIPS Agreement. This
section presents the TRIPS competition-related provisions and their approach as a
flexibility instrument. In addition to serving as a technology transfer instrument,1
TRIPS competition-related provisions may also be used in order to foster access to
medicines. In this regard, this section emphasises the IP-related restrictions of
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competition in the pharmaceutical sector that can affect access to medicines. The
discussion is informed by both the findings of the 2009 and 107 EU reports on the
pharmaceutical sector and the case law on reverse payment settlements in the EU and
the US.
Section 3 of the paper focuses on the recent trends of competition law enforce-
ment in the pharmaceutical sector with the emerging case law on excessive (high)
pricing of pharmaceuticals. The discussion is informed by the Aspen Case on
excessive pricing decided by the Italian competition authority and the ongoing
investigations against Aspen in the EU and in South Africa.
Section 4 deals with excessive pricing of pharmaceuticals in relations to IP
flexibilities. It showcases that creating competitive pharmaceuticals markets by
dealing with IP related restrictions of competition is in most cases important for
TRIPS flexibilities to be operational. In addition to emphasizing the role of compe-
tition law enforcement as a complement to the TRIPS flexibilities, the section
outlines situations where competition law enforcement is warranted.
Section 5 concludes with policy recommendation on how to align IP flexibilities
and competition law enforcement in order to foster access to pharmaceuticals.
2 TRIPS and Competition Policy: Orientations
and Enforcement Trends in the Pharmaceutical Sector
This section discusses three aspects: first, from a conceptual point of view, the
interface between IP and Competition Law, second, TRIPS and Competition Policy
with a reminder of TRIPS’ approach to competition law and, third, the enforcement
trends of competition law in the pharmaceutical sector since the entry into force of
the TRIPS Agreement.
2.1 The Interface Between IPRs and Competition Law
The interplay between IP and competition law is dynamic. The IP system provides,
in theory incentives for innovation and the development of cultural markets. How-
ever, IPRs do not operate in a vacuum. IPRs are exercised and commercialized in
markets that are mostly regulated. As a market regulatory tool, competition law
determines the framework within which IPRs are commercialized. However, the
potential of competition law to serve as a market regulatory tool differs from country
to country. Hence, competition law is still not implemented everywhere and in
developing countries, strong enforcement is lacking. Competition law used to be
approached as a regulatory instrument that limits the exercise of IPRs. This “con-
ventional” and conflicting approach of the interface between IPRs and competition
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law is exemplified by the TRIPS competition-related provisions2 which are designed
as a limit to the exercise of IPRs. This approach of the interface between IPRs and
competition law is not in line with the approach of the relationship between IP and
competition law as being complementary.3
The protection granted by the IP system to the right holders is not a reward as
such. IP protection provides only to the right holder an opportunity to extract a
reward from the market4 by commercializing its invention. The development and
successful commercialisation of new technologies and products is closely related to
the competitiveness of the markets within which they are commercialized. Hence, in
most cases, the markets conditions determine whether a new technology is success-
ful or not. With regards to the flexibilities within the IP system, building competitive
markets is also a precondition for their operability. Of course, in complement to
using competition law as a regulatory tool, using IP flexibilities participate to
building competitive markets. Hence, as we shall see in this chapter, anticompetitive
behaviours may hinder the build-in flexibilities of the IP system. With regards to
access to pharmaceuticals, which is the focus of this paper, a number of anticom-
petitive behaviours (limitation of compulsory licensing, limitation of parallel import,
or extension of the duration of the patent-reverse payment settlements) that affect the
competitiveness of the pharmaceutical markets, and may affect the IP flexibilities
that are crucial to access to pharmaceuticals.
2.2 TRIPS and Competition Law: Competition Law
as Flexibility Tool
TRIPS is the first international instrument that recognizes the possibility to police the
exercise of IPRS. TRIPS prohibits IPR-related restrictions of competition. Articles
8, 31 (k) and 40 of TRIPS, which are usually referred to as the TRIPS competition-
related provisions, are largely conceived as legal tools to monitor the exercise of IPR
(s) based on competition considerations.5 Competition law is part of the flexibility
tools of the IP system. Competition related provisions within TRIPS are part of the
general architecture of the Agreement and they provide a necessary balance to
potential abusive exercise of IPRS. They should be read as part of the rights
recognized to IP owner, and, also, their limits.
The competition-related provisions in the TRIPS were a result of a compromise
between developed and developing countries during the negotiation of the TRIPS
agreement.6 Developing countries which feared a monopolistic exercise of IPRs
2Which focus on technology transfer. See for discussion, Ullrich (2005), pp. 727–756.
3Bakhoum and Gallego (2016), p. 9, see specially reference in fn. 33.
4See Ullrich and Heinemann (2007), p. 146.
5Bakhoum and Gallego (2016).
6Ullrich (2005), pp. 727–756.
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managed to have provisions on competition law included in order to mitigate
potential abuses in the exercise of IPRs.
Initially, competition law in TRIPS was associated with technology transfer.7 In
licensing agreements, competition law was considered as an instrument that protects
the weaker licensee party against potential abuses of the IP right holder. As a
consequence, TRIPS provides a detailed treatment of anticompetitive practises in
licensing agreements.8
The reach of TRIPS competition related provisions is, however, not only limited
to technology transfer. In additional to facilitating technology transfer, TRIPS
competition related provisions can be read as an innovation policy tool.9
With regards to access to pharmaceuticals/medical products, TRIPS competition-
related provisions may also be used as an access to medicines tool. This approach is
proven by the increased reliance on competition law in the pharmaceutical industry
since the entry into force of the TRIPS agreement.10 Competition enforcement is a
complement to the IP flexibilities11 stricto sensu.
TRIPS does not create a binding international framework that obliges signatory
members to apply competition law to IP-related restrictions of competition. The
effectiveness of using competition law as a flexibility tool in the pharmaceutical
sector depends on the institutional framework of each country. Unlike in IP law,
there is no binding multilateral instrument that regulates competition law.12 The use
of competition law as a flexibility tool is optional. Member States are given leeway
to define their own policies when it comes to applying their competition law to
IP-related restrictions.
This situation creates an imbalance from an international perspective. On the one
hand, there is a harmonization, from the top, of the protection of IPRs. On the other
hand, the use of competition law is ‘deregulated’ and left to the choice of each
member to define its own policy. This “deregulation” of competition law enforce-
ment has consequences, especially for developing countries, when applying com-
petition law in the pharmaceutical sector.
7Ullrich (2005), pp. 727–756.
8Article 40 TRIPS reads: “1. Members agree that some licensing practices or conditions pertaining
to intellectual property rights which restrain competition may have adverse effects on trade and may
impede the transfer and dissemination of technology.
2. Nothing in this Agreement shall prevent Members from specifying in their legislation
licensing practices or conditions that may in particular cases constitute an abuse of intellectual
property rights having an adverse effect on competition in the relevant market. As provided above, a
Member may adopt, consistently with the other provisions of this Agreement, appropriate measures
to prevent or control such practices, which may include for example exclusive grantback conditions,
conditions preventing challenges to validity and coercive package licensing, in the light of the
relevant laws and regulations of that Member”.
9Bakhoum and Gallego (2016).
10See infra, enforcement trends in the pharmaceuticals sector. See also, European Commission
(2009–2017) https://ec.europa.eu/competition/sectors/pharmaceuticals/report2019/report_en.pdf.
11See, Berger (2006), p. 182.
12Drexl (2004), pp. 419–457.
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2.3 Enforcement Trends of Competition Law
in the Pharmaceutical Sector
IPRs have expanded both in quantity and quality since the entry into force of the
TRIPS agreement. New types of technologies, works and trademarks have been
found eligible for protection;13 rights holders have been granted new exclusive
prerogatives;14 the terms of protection for certain subject matter have been
extended;15 and enforcement mechanisms and remedies have been strengthened
and taken on an increasingly punitive character.16
From an international perspective, we notice a proliferation of the so-called
TRIPS-Plus agreements through bilateral and regional trade agreements. As a result,
standards of IPR protection of developed countries have been transferred to devel-
oping countries without due regard for the socio-economic, political and social
context of the latter.17 This development reduces the policy space of developing
countries to use TRIPS flexibilities, including in order to foster access to
pharmaceuticals.
In reaction to the enhanced protection of IPRs through the TRIPS-Plus agree-
ments there is a parallel push on how to best use the flexibilities embodied within
TRIPS. The development in the framework of Doha with the Doha Declaration on IP
and public health and subsequent article 31bis, which took over a decade to be
implemented, to allow WTO members to issue compulsory licenses for export are
prime examples of this development.18 Parallel to harnessing the use of TRIPS
flexibilities, competition law enforcement is increasingly taking place in developed
countries with mature competition law system and in some developing countries
South Africa is an example of a developing countries pushing for a proactive
enforcement of competition law in the pharmaceutical sector.
Anticompetitive behaviours in the pharmaceutical sector may affect both inno-
vation and access to medicines. The 2009 Pharmaceutical Sector Inquiry Report of
the European Commission and the subsequent enforcement report of 2017 have
13See e.g. Directive 96/9/EC of the European Parliament and of the Council of 11 March 1996 on
the legal protection of databases, OJ L 77, 27 March 1996, pp. 20–28.
14In the copyright field, for example, new forms of digital infringement related to the protection of
technological protection measures have been created; see e.g. Directive 2001/29/EC of the
European Parliament and of the Council of 22 May 2001 on the harmonization of certain aspects
of copyright and related rights in the information society, OJ L 167, pp. 10–19.
15See e.g. Directive of the European Parliament and of the Council of 27 September 2011 amending
Directive 2006/116/EC on the term of protection of copyright and certain related rights, OJ L
265, 11 October 2011, pp. 1–5; Sonny Bono Copyright Term Extension Act, Pub. L. No.105-298,
112 Stat. 2827 (1998).
16See e.g. Directive 2004/48/EC of the European Parliament and of the Council of 29 April 2004 on
the enforcement of intellectual property rights, OJ L 195, 2 June 2004, pp. 16–25.
17For an overview and analysis of the most significant free trade agreements (FTAs) see Roffe
(2014), pp. 17–40.
18Bakhoum and Gallego (2016).
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identified patenting strategies that block the development of competing medicines by
reducing the incentives of other originator companies to continue their own R&D
efforts.19 With regards to access, patenting strategies may also delay competition by
generics.20 In 2007, the European Commission started an investigation against
Boehringer Ingelheim after a competing pharmaceutical company had raised con-
cerns that Boehringer’s patent applications would have the potential of blocking its
competing medicines. The case was settled between the companies.21
Since the entry into force of the TRIPS agreement, there is an increased scrutiny
by competition authorities of behaviours in the pharmaceutical sector that negatively
impact the timely entry of generics.22 In the EU, since the publication of the sector
inquiry report on the pharmaceutical sector in 2009 there is an increased scrutiny of
these practises.23
With regard to the interface between IP and Competition law, three different types
of conducts may be identified: Category one concerns practices that are within the
ambit of the patent system (Italian Pfizer, AstraZeneca) and involve the misuse of
the patent and regulatory system which may impact innovation and access. Category
two concerns behaviors that are outside of the boundaries of the patent system (such
as ever-greening) while category 3 comprises practices half-way between the other
two categories (pay for delay cases, FTC v Actavis, Lundbeck).24
19European Commission (2009), pp. 16 and 19. http://ec.europa.eu/competition/sectors/
pharmaceuticals/inquiry/staff_working_paper_part1.pdf.
Generally, the Sector Inquiry Report is concerned with two different sets of strategic patenting
practices: on the one hand, those which aim at extending the exclusivity period to delay market
entry of generics, and on the other hand, those whose objective is to block substitutive innovations
by competitors. Regarding the later, blocking patents can be applied for either to broaden the
applicant’s own field of activity (defensive blocking patents) or to limit the scope of action of
competitors (aggressive blocking patents); see Ullrich (2013), pp. 244 and 248.
20The Commission and the two European courts have confirmed the application of Article 102 of
the Treaty on the Functioning of the European Union (TFEU) to a strategic use of patent procedures
aimed at delaying generic entry in the Astra Zeneca case; see Commission Decision of 15 June 2005
relating to a proceeding under Article 82 of the EC Treaty and Article 54 of the EEA Agreement,
Case COMP/A.37.507/F3 – Astra Zeneca, http://ec.europa.eu/competition/antitrust/cases/dec_
docs/37507/37507_193_6.pdf (accessed 23 October 2014); GC, Case T-321/05, Astra Zeneca
v. Commission, [2010] ECR 2010 II-2805; CJ, Case C-457/10 P, Astra Zeneca v. Commission,
[2012] ECR I-770. On the relevance of the Astra Zeneca rulings for the assessment of blocking
patents see Drexl (2013), pp. 312 et seq.
21See European Commission, Press Release of 6 July 2011, IP/11/842. http://europa.eu/rapid/press-
release_IP-11-842_en.htm.
22See the different cases discussed in this paper: See Case T-472/13, Lundbeck v. Commission,
infra, box n 1; Case C-142/18, J&J et al. vs. Commission (“Fentanyl”), infra, box n 2; Case
U.S. Supreme Court No. 12-416, FTC v. Actavis, infra, box 3; Case T-691/14, Servier and others
v. Commission (still pending).
23See Contribution by the European Commission, UNCTAD Roundtable on The Role of Compe-
tition in the Pharmaceutical Sector and its Benefits for Consumers. https://unctad.org/system/files/
non-official-document/CCPB_7RC2015_RTPharma_EC_en.pdf.
24Such distinction was made by Gallasch (2015). http://unctad.org/meetings/en/Presentation/
CCPB_7RC2015_PRES_RTPharma_Gallasch_en.pdf.
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In addition to “traditional” types of anticompetitive behaviours that affect phar-
maceutical markets (cartels, bid rigging, and boycotts are conventional behaviours
that aim to fix prices and earn monopoly profits), a particular type of anticompetitive
agreement in the pharmaceutical industry has drawn the attention of competition law
enforcers in recent years: the practice commonly known as a “pay for delay”
agreement or, since it often involves a payment from the patentee to the alleged
infringer, a “reverse payment” settlement agreement. Basically, it concerns situa-
tions where a brand-name pharmaceutical company, as patent holder, and a generic
producer, agree to settle either a patent infringement suit or a dispute concerning the
validity of the patent under terms that require, firstly, the generic manufacturer not to
produce and/or to distribute the patented product until the expiration of the patent,
and secondly, the patent holder to “compensate” the generic company for staying out
of the market.
Both in the United States and in Europe, the competition agencies and national/
regional courts have perceived such arrangements as an attempt to allocate markets
and preserve monopolistic conditions25 and have condemned them as clear viola-
tions of competition law.26 In the United States the Supreme Court has already had
the opportunity to pronounce on the legal assessment of this kind of patent
settlements.27
In July 2013, the European Commission fined Lundbeck and several producers of
generic medicines for delaying generic market entry of Citalopram.28 In December
25Announcing the Commission’s decision on the Servier case, then Competition Commissioner
Joaquín Almunia stated “Servier had a strategy to systematically buy out any competitive threats to
make sure that they stayed out of the market. Such behavior is clearly anti-competitive and abusive.
Competitors cannot agree to share markets or market rents instead of competing, even when these
agreements are in the form of patent settlements. Such practices directly harm patients, national
health systems and taxpayers”. See European Commission, Press Release of 9 July 2014, IP/14/799.
http://europa.eu/rapid/press-release_IP-14-799_en.htm.
26In Europe, see European Commission, Press Release of 19 June 2013, IP/13/563 (Antitrust:
Commission fines Lundbeck and other pharma companies for delaying market entry of generic
medicines). http://europa.eu/rapid/press-release_IP-13-563_en.htm?locale¼en; Press Release of
10 December 2013, IP/13/1233 (Antitrust: Commission fines Johnson & Johnson and Novartis €
16 million for delaying market entry of generic pain-killer fentanyl). http://europa.eu/rapid/press-
release_IP-13-1233_en.htm; Press Release of 9 July 2014, IP/14/799 (Antitrust: Commission fines
Servier and five generic companies for curbing entry of cheaper versions of cardiovascular
medicine). http://europa.eu/rapid/press-release_IP-14-799_en.htm. All press releases accessed
23 October 2014. At the time of writing this contribution, no public version of these decisions
was yet available. For an overview of the FTC’s practice see Cook (2001), pp. 437 et seq.
(commenting particularly on In re Schering-Plough Corp., 136 F.T.C. 956 (2003); FTC
v. Watson Pharm., Inc., 611 F. Supp. 2d 1081 (C.D. Cal. 2009) and FTC v. Cephalon, Inc.,
551 F. Supp 2d 21 (D.D.C. 2008)).
27See Actavis decision.
28Press release Commission: http://europa.eu/rapid/press-release_IP-13-563_en.htm?locale¼en
Information of General Court upon time of completion not available (July 2015).
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2013, the Commission fined Novartis and J&J29 which concluded an agreement
whose aim was to delay the market entry of cheaper generic version of Fentanyl, a
painkiller. This was a straightforward pay-for-delay case as it did not involve any
patent dispute or litigation.
In the US, the Actavis decision of the Supreme Court30 sets the legal standard for
the appreciation of pay-for-delay cases. After a discrepancy of decisions from lower
courts, the Supreme Court concluded that the rule of reason should be applied to
reverse payment settlements.
3 Excessive Pricing of Pharmaceuticals: An Emerging
Enforcement Trend
Three aspects are discussed in this section: first, pricing of pharmaceuticals and
IPRs, second, the case law on excessive pricing, third, the competition related issues
raised by the case law on excessive pricing.
3.1 Pricing of Pharmaceuticals and IPRs
IPRs affect the pricing of pharmaceuticals. The IP system has two dimensions: On
the one hand, it regulates the conditions of acquisition of IPRs. On the other hand, it
allows the right holder to exercise the exclusivity of the right conferred, by, for
instance setting a given price for IP embodied products such as pharmaceuticals.
Hence, an important right of IPRs holders is the freedom of pricing of IP embodied
products. Freedom of pricing of pharmaceuticals is part of the exclusivity the IPRs
holder enjoys. However, freedom of pricing pharmaceutical, as a right, is not
absolute. It should be exercised in accordance with the principles of the market.
Hence, pricing of pharmaceuticals should not be anticompetitive.
From a competition law perspective, a core principle of the market economy and
competition is the freedom of the pharmaceutical companies to set the prices of their
products. Freedom of pricing pharmaceuticals is an expression of the general
freedom of contract (freedom to enter into business dealings) which also is a tenet
of the market economy.31 When an IPR is involved, contractual freedom may be
exercised through licensing agreements. Sometimes, as part of the general IP policy
29See press release of Commission: http://europa.eu/rapid/press-release_IP-13-1233_en.htm; full
text of judgment available at http://ec.europa.eu/competition/antitrust/cases/dec_docs/39685/
39685_1976_7.pdf.
30570 U.S. 133 S. Ct. 2233 (2013). Judgment of the US Supreme Court available at: http://www.
supremecourt.gov/opinions/12pdf/12-416_m5n0.pdf.
31For discussion on freedom of contract and competition law, see, Bakhoum (2018), pp. 157–186.
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and the need to prevent potential abuse exercise of IPRs, freedom of contract, and of
pricing, may be limited in order to protect the competitiveness of the markets and
consumers. Contractual freedom and the freedom to set prices should not lead to
anticompetitive practices that could take a form of high pricing of pharmaceuticals.
High pricing is considered, in some competition law, as a form of abuse of dominant
position.
3.2 Overview of the Case Law on Excessive Pricing
of Pharmaceuticals
Excessive pricing is considered a type of abuse of dominant position in number of
jurisdictions. This is the case in the EU and some of its Member States. In
South Africa also high pricing is considered an abuse of dominant position. If in
principle, this form of prohibition is recognized, in practice, competition authorities
have been very reluctant in dealing with excessive pricing cases.
Recently, however, high pricing of pharmaceuticals has attracted the attention of
competition authorities with a number of cases in the UK, the EU and in
South Africa. In the EU, the Aspen case on excessive pricing decided by the Italian
Competition Authority has attracted significant attention. Ongoing investigations
both in the EU and in South Africa illustrate what could be considered as an
emerging enforcement trend on the application of competition law in the pharma-
ceutical sector.
The Italian Aspen case illustrates how important it is to have competitive markets
in order to make TRIPS flexibilities operational. In this case, the Italian Competition
Authority fined Aspen for infringing Article 102 (a) of the TFEU. The Italian
Competition Authority considered that Aspen “had fixed unfair prices with increases
up to 1500%”.32 It results from the facts that Aspen had acquired an off-patent
cancer drug package from GlaxoSmithKline. The antitumor drugs are considered
life-saving and irreplaceable especially in the treatment of children and elderly
patients.
After acquiring the rights on the drugs, Aspen initiated “negotiations with the
Italian Medicines Agency (Agenzia Italiana del Farmaco - AIFA) with the sole aim
to obtain a high increase in prices, even in the absence of any necessary economic
justifications”.33 An important factual element in the Aspen case is that there was a
public procurement with the authorities purchasing directly the drugs from Aspen.
Aspen used aggressive negotiation strategy with the Italian Medicines Agency and
32See Press release on the Aspen case, 14/10/2016, available at: http://www.agcm.it/en/newsroom/
press-releases/2339-a480-price-increases-for-cancer-drugs-up-to-1500-the-ica-imposes-a-5-mil
lion-euro-fine-on-the-multinational-aspen.html. For discussion of the case, see also, Lanza and
Sfasciotti (2018), pp. 382–388.
33See Press release on the Aspen case, op. cit.
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threaten to interrupt supply to the Italian market.34 As a consequence of its negoti-
ation strategy Aspen obtained extremely high prices ranging between 300% and
1500% of the initial levels.35
Two aspects were considered by the Italian Competition Authority when
assessing the excessiveness of the prices charged by Aspen. It first considered the
disproportion between price and cost. Second, it considered additional aspects such
as the “specific context and behavioural factors, such as: the inter-temporal compar-
ison of prices, the absence of economic justifications for the increase, the absence of
any extra-economic benefits for patients, the nature of Comos’s drugs, the charac-
teristics of the Aspen group, and the damage caused to the National Health System
(Sistema Sanitario Nazionale – SSN)”.36
Similar investigations on excessive pricing have been opened by other competi-
tion authorities. In 2017 the EU Commission opened its first formal investigation on
excessive pricing against Aspen for life saving cancer medicines.37 The facts of the
ongoing case are the same as the facts in the Aspen Italian case. The medicines in
question were off-patent and Aspen acquired them after their patents had expired. As
in the Italian case, “Aspen has imposed very significant and unjustified prices
increases of up to several hundred percent (. . .)”.38 Moreover, “Aspen has threatened
to withdraw the medicines in question in some Member States and has actually done
so in certain cases”.39
In the UK, the Competition and Markets Authority (CMA) in 2016 fined Pfizer,
Inc. (Pfizer) and Flynn Pharma Limited (Flynn) for charging excessive price for an
anti-seizure drug. The CMA found that both Pfizer and Flynn were dominant in their
respective markets of manufacturing and distribution of Epanutin and had signifi-
cantly improved their cost-profit margins by increasing the sale price by 2600%.
In South Africa, the South African Competition Authority had opened investiga-
tions against Roche, Pfizer and Aspen on high pricing.40 The Commission men-
tioned that Roche has and “continue[s] to engage in excessive pricing, price
discrimination and/or exclusionary conduct in the provision of breast cancer med-
icine in South Africa”.41 The Commission added that “as a result of exorbitant
34See Press release on the Aspen case, op. cit.
35See Press release on the Aspen case, op. cit.
36See Press release on the Aspen case, op. cit.
37European Commission, Press Release, Antitrust: Commission opens formal investigation into
Aspen Pharma’s pricing practices for cancer medicines, May 15, 2017, http://europa.eu/rapid/press-
release_IP-17-1323_en.htm.
38May 2017 European Commission, Press Release, Antitrust: Commission opens formal investi-
gation into Aspen Pharma’s pricing practices for cancer medicines, May 15, 2017.
39May 2017 European Commission, Press Release, Antitrust: Commission opens formal investi-
gation into Aspen Pharma’s pricing practices for cancer medicines, May 15, 2017.
40Media release, South African Competition Commission, 13 June 2017, available at: http://www.
compcom.co.za/wp-content/uploads/2017/01/International-pharmaceutical-companies-investi
gated-for-cancer-medicine-prices.pdf.
41Media release, South African Competition Commission, 13 June 2017, op. cit.
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prices, most breast cancer patients in both the private and the public sectors are
unable to get treatment”.42 The investigation against Pfizer relates also to excessive
pricing of lung cancer medication. According to the Commission, “Pfizer is the only
provider of lung cancer treatment medication known as xalkori crizotinib in
South Africa”.43 The investigation seems to be based on the fact that lung cancer
treatment is unaffordable in South Africa given the high prices that the consumers
are unable to afford. A Parallel investigation to the ongoing investigation in the EU is
open against Aspen. The Investigation is based on a “reasonable suspicion that
Aspen has and continues to engage in excessive pricing in the provision of certain
cancer medicines (. . .)”.44
In the context of South Africa, the open investigations are in line with the earlier
trend of the Commission to investigate anticompetitive practices in the pharmaceu-
tical sector. A complaint was lodged before the South African Competition Com-
mission against GlaxoSmithKline South Africa (Pty) Ltd (“GSK”) & Boehringer
Ingelheim (Pty) (“BI”),45 (hereinafter GSK/BI case), initially for high pricing, but
then the Commission extended the investigation to include an alleged violation of
Section 8(b) and (c) of the Competition Act, which deals respectively with the
essential facilities doctrine and exclusionary conduct.46 The Competition Commis-
sion concluded its investigation with a finding that GSK and BI abused their
dominant position by charging excessive prices, refusing to grant access to essential
facilities to a competitor and engaging in exclusionary conduct. The matter did not
come before the Competition Tribunal, as GSK and BI accepted a settlement, which
resulted in a drastic reduction in the prices of the pharmaceuticals in South Africa.
What can be learned from the Aspen Italian case and the ongoing investigations
on excessive pricing of pharmaceuticals?
3.3 Competition and IP Issues Raised by the Case Law
on Excessing Pricing of Pharmaceuticals
A number of lessons can be learned from the case law on excessive pricing of
pharmaceuticals. There is an IP dimension and a competition law dimension in the
analysis.
42Media release, South African Competition Commission, 13 June 2017, op. cit.
43Media release, South African Competition Commission, 13 June 2017, op. cit.
44Media release, South African Competition Commission, 13 June 2017, op. cit.
45The case was settled. For discussion of the background of the case, see, Berger (2004),
pp. 197–201. The Commission’s comments on the case at: South African Competition Commission
Newsletter, edition.15, pp. 1–2. http://www.compcom.co.za/assets/Uploads/AttachedFiles/
MyDocuments/March-04-Newsletter.pdf.
46For a discussion of the case, see Ngobese and Mncube (2011).
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3.3.1 IP, Patent Term and Excessive Pricing of Pharmaceuticals
The case law on excessive pricing raises a number of issues that question the
rationale of the IP system regarding access to pharmaceuticals.
The Italian Aspen case is not about IPRs and an abuse of a monopoly by a right
holder during the protection term. It is true that pharmaceuticals are involved in the
case. However, the pharmaceuticals patents for the cancer drugs had already expired
when Aspen acquired them. As a consequence, IPRs cannot be invoked in order to
justify the high prices charged by Aspen. The rationale of the IP system according to
which the right holder has the exclusivity to commercialize its products at “monop-
oly price” is not applicable in this case. Aspen had acquired the pharmaceuticals at
the end of the protection period. At the end of the exclusivity term, Aspen could still
charge prices that are even higher than the prices of the pharmaceuticals when the
patents were into force. The behavior of Aspen contradicts the very rationale of the
IP system according to which price competition by generics should, in principle,
drive the prices of pharmaceuticals down. Hence, at the end of the patent term, the
rationale of the IP system that generic competition should take place and drive the
prices down is not operational in this case. This is an important aspect of the Aspen
Italian case. In Fact, the prices of the pharmaceuticals when the patents were in force
were lower than the prices charged by Aspen when the drugs were off-patent.
Price competition by generics does not necessarily follow the end of the exclu-
sivity period. For price competition by generics to take place the market conditions
have to be attractive enough for generic companies to enter the market at the end of
the patent term. If there is not price competition at the end of the exclusivity period,
the patent holder still can charge high prices.
Another important element of the analysis is that the drugs had not been devel-
oped by Aspen. The usual justification of the recognition of the right of the IP holder
to charge high prices is the investment made for the development of the IP embodied
product. In this case, this rationale does not justify the high prices charged post-
patent term. In fact, in the Italian Aspen case, the cancer drugs are produced by third
party companies without any mobilization of resources by Aspen. To the contrary,
the production costs of the medicines have considerably decreased over time.47 The
increase of prices could not be justified by any costs since Aspen did not make any
additional investment nor did it face any increase of production costs. Aspen did not
make any improvement on the medicines and their related services.48
47See Lanza and Sfasciotti (2018), p. 386.
48Ibid.
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3.3.2 Competition Law and Excessive Pricing of Pharmaceuticals:
Market Conditions and Pricing
Market Power, Size of the Market and High Pricing
The structure of a given market and its competitive conditions influence prices. If a
market is open with low entry barriers and substitute products or services are
available, there is a likelihood that the prices become competitive. If to the contrary,
a market is very small, only one undertaking offers a service or product, and there is
no substitute, there is a likelihood to have dominance and market power which allow
the undertaking to charge high prices. In pharmaceuticals markets, this may happen
even for off-patent drugs. In the Aspen case, for example, the small size of the
market of the pharmaceuticals involved afforded Aspen market power and allowed it
to charge high prices. Blood cancer drugs in the case “has a small incidence on the
population and the specific categories of patients treated with Aspen’s drugs further
restrict the market size”.49 The small size of the market for blood cancer drug
afforded Aspen sufficient power to bargain for high prices with the Italian Medicines
Agency. Aspen’s market power allowed it to charge high prices without fear of
losing market shares. Compared to the prices of the pharmaceuticals when the
patents were in force, the prices increased from 300% to 1500%. The prices of the
patented medicine were more affordable than the prices of the same medicine
off-patent. This price increase was only possible because the market was not
competitive and Aspen did not face any competition constraints that obliged it to
reduce its prices.
Market power allows an undertaking to behave into the market without taking
into account actual or potential competition. It allows, for instance, an undertaking to
set prices without fear of losing market share. The negotiation strategy adopted by
Aspen confirms its market power. Using its market power, Aspen adopted an
aggressive negotiation strategy and threatened to interrupt the supply of the Italian
market.50 Aspen was able to use its superior bargaining power since it has market
power and did not face any competition. As pointed out, “the absence of any medical
alternative for the cure of the weakest fringe of patients made them non-substitutable
(essential) for the NHS, thereby depressing AIFA’s bargaining power in the nego-
tiation with the company”.51
Absence of Substitutability and High Pricing of Pharmaceuticals
The concept of substitutability is used in competition law analysis in order to
determine whether two products or services belong to the same market. It allows
49Ibid.
50Ibid.
51Lanza and Sfasciotti (2018), p. 386.
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the competition authorities to define the relevant market and thereby determine
whether a given undertaking enjoys a dominant position. If a market is small and
there is no substitute for a given product, there is a strong likelihood that the
undertaking offering the product will be found dominant. However, as a reminder,
the simple fact of being dominant is not prohibited. Only abusive behavior resulting
from a dominant position, such as charging excessive prices, is prohibited.
In the Aspen Italian case, Aspen’s market power was reinforced by the absence of
alternative medicines in the market. Hence, no substitutable drugs existed in the
market for the category of patients in Aspen’s market. This absence of substitutabil-
ity of Aspen’s pharmaceuticals limit the ability of the consumers to turn to substitute
products when prices become high. No substitute existed for the pharmaceuticals
involved in the case which are used to treat severe oncological diseases for children
and elderly people. In other words, consumers could not shift to alternative phar-
maceuticals that have similar therapeutic virtues when the prices become high.
Given the absence of substitute pharmaceuticals, the Italian Medical Agency did
not have a choice but to accept the prices charged by Aspen.
Consumer Choice/Behavior (Rationality) and the Specificity
of Pharmaceuticals
What has been termed as “consumer rationality”52 is also an element to be consid-
ered when pharmaceuticals are involved in a given case. Hence, if life saving drugs
are involved, consumer behavior may be different. For life saving pharmaceuticals,
in the absence of alternative drugs, consumers have a strong willingness to pay, no
matter how high the prices are. Consumer rationality that commands consumers to
seek alternative, more affordable, sources of supply when prices become high is not
strong in the case of pharmaceuticals. If life saving drugs are involved, and there is
no substitute, consumer rationality becomes absent.
From a contract law perspective, an argument can be made that since consumers
are willing to pay competition authorities should not intervene in the contract
relationships. However, the absence of substitute medicines and the uneven
bargaining powers53 between consumers and Aspen, which has market power,
should limit the freedom of contract.
The combined factors which are Aspen’s market power, the lack of alternative
products (substitute) and the absence of consumer rationality allowed Aspen to
impose high prices on consumers.
52Ibid.
53For discussion on freedom of contract and competition law, see, Bakhoum (2018).
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The Issue of the Determination of an Excessive Price
Competition authorities have been very reluctant to deal with excessive pricing
given the issues raised by the assessment of high pricing. What amounts to an
excessive price is a first hurdle that makes competition law intervention difficult.
Whether dealing with excessive pricing is a form of regulation by competition
authorities is another issue. By dealing with excessive pricing, competition author-
ities can be seen as price regulators. Regulating prices is not in principle the role of
competition authorities. If from a theoretical point of view dealing with excessive
pricing raises a number of issues, a number of competition laws still consider high
pricing as a form of abuse of dominant position. A firm with a dominant position
may charge excessive prices without the risk of market entry of competitors and thus
without the risk of competition. How to determine high prices? What is the relation
between the economic value of a product or service and high prices?
Excessive pricing may be assessed in relation to costs. In the Aspen case, the
Italian Competition Authority applied the following method:
– An estimation of excessiveness based on “percentage gross margin”
– A profitability analysis—based on an approximation of the economic value of the
drugs which takes into account all overall costs of making and commercializing
the drug—compared to actual prices charged.54
The cost price analysis was the main approach of the Italian Competition Author-
ity in determining excessive pricing: As pointed out, “ICA’s investigation on the
unfair practice was carried out through a two-phase test that measured the dispro-
portion between prices and costs. The unreasonableness of the mentioned dispro-
portion resulted indicative of unfair prices also in the light of specific context and
behavioural factors, such as: the inter-temporal comparison of prices, the absence
of economic justifications for the increase, the absence of any extra-economic
benefits for patients, the nature of Comos’s drugs, the characteristics of the group
Aspen and the damage caused to the National Health System (Sistema Sanitario
Nazionale – SSN)”.55
Although Aspen did not incur any additional costs, it has substantially increased
the prices. As indicated, there was “no investment to be recovered, no risk assump-
tion by Aspen, no dry hole; no owned production facility, no freeze of financial
resources by Aspen; no need to promote the drugs, no promotional costs to be
recovered; no actual competitor, due to the absence of substitutability”.56 From a
cost perspective, Aspen did not bring forth additional arguments that justify the
increase of prices.
54See, Lanza and Sfasciotti (2018), p. 385.
55See Press release on the Aspen case, op. cit.
56See, Lanza and Sfasciotti (2018).
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4 Excessive Pricing of Pharmaceuticals and TRIPS
Flexibilities: Lessons from the Excessive Prices Cases
A number of lessons can be learned from the case law on excessive pricing,
especially the Italian Aspen case in relation to the rationale of the IP system and
Competition law as a flexibility tool.
Although pharmaceuticals were involved in the Aspen case, one can argue that
the case raised only competition law issues. Since the patents of the cancer drugs
involved in the Aspen case had already entered the public domain when Aspen
acquired them, the behavior of Aspen could not be considered as an abuse of IPRs.
The exclusivity afforded to the right holder of the pharmaceuticals ended with the
patent term. The subsequent price increase at the end of the patent period could not,
in principle, be considered an abuse of IPRs since the patented pharmaceutical has
entered the public domain. However, in practice, the right holder of the off-patent
pharmaceuticals continued to enjoy a de facto exclusivity and was able to charge
high prices. Hence, although the pharmaceuticals involved in the Aspen case were
no longer patented, the prices were not reduced. Such situation is not in line with the
very rationale of the IP system according to which at the end of the patent term
generic competition should kick in and drive the prices down. Similar to the reverse
payment settlement cases that delay the entry in the market of generics, an abuse of
dominant position post patent term may also slow the competition by generics.
Price reduction of pharmaceuticals is not automatic at the end of the patent term.
There is a close link between the competitiveness of the market post patent and the
reduction of prices at the end of the patent term. Whether prices of pharmaceuticals
would be reduced at the end of the exclusivity period depends on the competitive-
ness of the market. If the market is open and competitive at the end of the exclusivity
period with a possibility of entry of generics, prices may be reduced. However,
generic entry is not automatic either. Generic entry takes place only if the market is
attractive and that there is a strong likelihood to have return on investment. In the
Italian Aspen case, there was no competition by generics despite the absence of
patents attached to the drugs. Absent generic competition, the right holder continues
to enjoy a de facto exclusivity and to be able to charge high prices. If a given market
is small enough so that a pharmaceutical company enjoys a monopoly position, it
can continue to charge excessive prices even at the end of the exclusivity period.
Substitutability and consumer choice are important for price reduction of phar-
maceuticals to take place. Absence of substitute and consumer choice, a patent
owner may continue to have market power and to charge high prices at the end of
the patent protection. This is a de facto extension of the exclusivity rights. Patent
protection does not necessarily create market dominance. However, market domi-
nance may exist after the expiration of the exclusivity period if there is no compe-
tition in the market. Under certain market conditions at the expiration of the
exclusivity period (market power, absence of substitute, no generic competition,
price inelasticity, strong willingness of consumers to pay) the IP owner may still
charge monopoly prices without fear of losing market shares.
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The Aspen case showcases how important it is to create competitive markets and
to protect/promote competition in pharmaceuticals markets through a strong com-
petition law enforcement. When IP flexibilities and the very rationale of the IP
system are not operational at the end of the exclusivity period, competition law can
be used as a tool to correct the anticompetitive behavior and to complement the IP
system. As already pointed out, the design of TRIPS which have a competition law
dimension as a flexibility tool gives to Member States the possibility to create strong
competition law institutions in complement to the IP related flexibilities stricto
sensu.
It also results from the Aspen case that under certain circumstances, access is
more guaranteed (and prices are lower) during the exclusivity period, when the
patent is still into force. This is the case when the flexibilities are fully applicable
during the exclusivity period. It is possible during the patent term to use the
flexibilities of the IP system such as issuing compulsory licenses. This possibility
does not exist at the end of the exclusivity period.
There is a close link between the operability of the rationale of the IP system and
its flexibilities and the market conditions. As highlighted in the discussion in this
paper, having competitive markets participate to the operability of the core principles
of the IP system and its flexibilities.
5 Conclusions
Competition law enforcement is a complement of the IP system and its flexibilities.
IP and competition law are two regulatory instruments that both have their potential
and limits. IP affords rights. Competition law defines the framework for the com-
mercialization. The freedom of IP owners to determine the price of pharmaceuticals
should be exercised while respecting the market (competition) rules.
The IP system and its flexibilities of the IP system have intrinsic limitations that
affect their operability. They may not, in some situations, have the expected effect on
access to pharmaceuticals. The Doha declaration and article 31bis of the TRIPS
agreements illustrate the difficulties to use the IP system in order to foster access to
pharmaceuticals. There exist also some limits related to the scope of the IP system
and its flexibilities. The IP system does not address the behavior of right holders that
may affect prices of pharmaceuticals after the expiration of the patent term. Post
patent term abusive behavior are beyond the reach of the IP system. In such
situations, as illustrated by the Aspen case, only competition law may help reinstate
the balance of the IP system.
The scope of application of competition law is more extended than the application
of the IP flexibilities. Competition law polices the behaviors of market participants.
It addresses practices when IPRs are into force and at the end of the protection term.
Competition law is applicable when patented and off-patent products are involved
such as in the Aspen case. Competition authorities are required to evidence a clear
breach of the rules of the markets (e.g. cartels, abuse of dominance) and a clear
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framework of analysis is provided by the law. The evolution of competition enforce-
ment in the pharmaceuticals sector since the entry into force of the TRIPS agreement
has illustrated an evolutive approach that could have a positive impact of competi-
tion law enforcement on access to pharmaceuticals. The cases discussed in the UE, in
Italy and in South Africa illustrate this trend to use a proactive role of competition
law as an access to pharmaceuticals tools.
But competition law application in the pharmaceuticals sector is not without its
issues: enforcement of competition law to IP related restrictions may be problematic.
Hence, an argument can be made that strong enforcement may chill investment in
R&D and innovation. However, in addition to access, competition law takes into
account the innovation parameters when applied to IP related restrictions. With
regards to pharmaceuticals patents, the question of the balance between access and
innovation raises issues. Can lower prices of pharmaceuticals (access) and innova-
tion (bringing new pharmaceuticals into the market) be aligned? Does one want
lower prices of pharmaceuticals or is innovation more important?
In cases involving charging high prices post patent term, as it was the case in
Aspen, the innovation argument cannot be strongly supported. One could argue that
in post patent term cases, after the expiration of the patent, the incentives to innovate
argument should not be considered since the exclusivity rights have expired. The
patent holder has already reaped the benefits and rewards of the invention. However,
one also should take account of the argument that even after the expiration of the
patent, strong enforcement of competition law and regulation of prices may affect
R&D incentives.
Four different situations can be contemplated:
• If the flexibilities within the IP system work and may be used in order to enable
the reduction of prices, one could consider that there may not be an access
problem even if IP protection exists.
• IP flexibilities may work but anticompetitive conduct restricts their positive
impact on prices and access. If for instance IP flexibilities are not operational
because of anticompetitive practices, one could argue that there is a case for
competition law intervention.
• If IP flexibilities do not work the question arises as to whether there is a case for
competition law to correct the shortcomings.
• No IP flexibilities because IP protection expired: one could argue that there is a
case also for competition law intervention as illustrated by the Aspen case. IPRs
could no longer be an obstacle to competition law intervention.
The discussions of the paper is largely based on the case law in developed
jurisdictions. However, developing and LDC countries can learn a lot from the
approach of developed countries of using competition law as an external flexibility
in order to foster access to medicine during the patent term and after the expiration of
the patent. South Africa is making efforts in that direction. Developing countries
with limited competition culture and resources still face the challenge of enforcing
their competition law to restrictions of competition affecting access to medicines.
Though the lack of challenges is an issue, it is crucial for policy makers and enforcer
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to encourage the application of competition law in the pharmaceutical sector in
combination to the TRIPS flexibilities.
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The Impact of ‘TRIPS-Plus’ Rules
on the Use of TRIPS Flexibilities: Dealing
with the Implementation Challenges
Mohammed El Said
Abstract Improving the health and well-being of society is a priority to many
governments. One essential element within this debate focuses on the accessibility
and affordability of medicines for patients. Although interest in this area has
persisted for decades, the recent shift in this field is manifested by this now being
treated as a global concern, rather than as a regional or a national one. Patients in
both developed and developing countries alike are facing the same challenges and
are under an increased pressure to access and afford treatment. The recently
published UN High Level Panel for Access to Medicines Report explicitly stated
its view of ‘access to medicines, vaccines, diagnostics and related health technolo-
gies as a serious, multidimensional global problem, with challenges that affect all
people and all countries.. . .the High-Level Panel recognizes that the costs of health
technologies are rising globally and are being felt by individuals and by public and
private insurance schemes in both wealthy and resource-constrained countries alike’
(UN Secretary General High Level Panel, ‘The United Nations Secretary-General
High-Level Panel on Access to Medicines Report: Promoting Innovation and Access
to Health Technologies’, (September 2016), 12. https://apps.who.int/medicinedocs/
documents/s23068en/s23068en.pdf.). This thinking represents a fundamental depar-
ture from the previous approach which classified the problem related to access to
medicines as one mainly attributed to developing and least developed nations. It is
within this debate that the role of intellectual property protection in general and by
way of the rise of TRIPS-Plus agreements and their impact on accessibility and
affordability of medicines takes centre stage.
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There are many factors which impacts the access to medicines debate. Government
policy, industrial development, demography, manufacturing capabilities, market
conditions and procurement and tax regimes are some factors. However, for some
time, the role of intellectual property monopolies especially patents granted to
innovator drug companies to protect their research and development (R&D) invest-
ments and provide market exclusivity by restricting competition became an integral
part of this debate.1 This chapter will look at various factors affecting the accessi-
bility and affordability debate and will focus on the role of intellectual property
protection in that process. It will provide useful examples of the positive impact
arising from the use of the TRIPS flexibilities and on the other hand will explain the
dangers affiliated with adopting TRIPS-Plus regimes in this regard. It will also
provide examples of practises and strategies which would limit the impact of
TRIPS-Plus commitments under national laws.
2 Expensive Medicines: National Implications and Global
Challenges
The price of medicines has been on a steady increase for some years. In the US,
prices for branded prescription drugs doubled in five years between the period of
2011–2016.2 Further, it was projected that the prices of medicines in the US will
increase on average 5.8% in 2020.3 More than 13% of Americans—about 34 million
people—say a friend or family member recently passed away in the last five years
after being unable to afford treatment for a condition while 58 million adults report
inability to pay for needed drugs in the past year, according to a new poll from
Gallup and West Health.4 A recent study in the UK found that total National Health
Service (NHS) spending on medicines in England has grown from £13 billion in
2010/11 to £17.4 billion in 2016/17—an average growth of around 5% a year. The
1It should be highlighted that there are also other regulatory regimes and intellectual property
exclusivities—apart from patents—aimed towards extending protection including those protecting
use of test data, various regulatory linkages, and also trademarks covering not just names but also
shapes and colours.
2MSF (2016). http://apps.who.int/medicinedocs/documents/s23020en/s23020en.pdf.
3In 2019 more than 50 companies raised the prices on hundreds of drugs in the US by an average of
more than 6%, according to the analysis. Hopkins explains that the price of rheumatoid arthritis
treatment Humira, the world’s top-selling drug, was raised by 7.4%. Similarly, heparin products—
which are generic blood thinners typically administered in hospitals—prices rose by 15%. For more
see Hopkins (2020) <https://www.marketwatch.com/story/drug-prices-rise-58-on-average-in-
2020-2020-01-02>.
4Gallup and West Health (2019). https://news.gallup.com/poll/268094/millions-lost-someone-
couldn-afford-treatment.aspx?version¼print.
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same study concludes, ‘These figures are uncertain due to gaps in data, but the rate of
increase is substantially faster than for the total NHS budget over the same period’.5
With the prevalance of the COVID 19 pandamic, pressure on national health
providers have reached unprecedented levels.
The year 2019 was phenomenal in terms of setting new high records in medicines
prices. In March 2019, the United States Food and Drug Administration (USFDA)
approved the most expensive medicine in history up to date called Zolgensma
(priced at $2.125 million), a medicine used for a rare disorder that destroys a
baby’s muscle control and kills nearly all of those with the most common type of
the disease within a couple of years. Other more commonly used medicines’ prices
have also been notably high. For example, a 2018 WHO report on cancer medicines
concluded that ‘in the absence of insurance coverage, cancer treatment is
unaffordable for many patients. A course of standard treatment for early stage
HER2 positive breast cancer (doxorubicin, cyclophosphamide, docetaxel,
trastuzumab) would cost about 10 years of average annual wages in India and
South Africa and 1.7 years in the United States of America. The costs associated
with other medical care and interventions (such as surgical interventions and radio-
therapy) and supportive care (such as anti-emetics and haematopoietic growth
factors) would make overall care even more unaffordable. Even with insurance
coverage, patients living with cancer in many countries have reported financial
stress, to the extent that they may lower the treatment dose, partially fill prescriptions
or even forego treatment altogether’.6 In France, in December 2015, the Ligue contre
le cancer—which spends around €38 million ($43 million) a year on cancer research,
making it the largest French non-governmental funder of cancer R&D—condemned
cancer drug prices as ‘exorbitant, unfair and unbearable’ and warned that if
unabated, price inflation for new drugs posed a direct threat to the French medical
system7 while others have expressed that “economic considerations significantly
influence and, in some instances, take precedence over the scientific evidence” with
relation to French Guidelines on antiretroviral therapy treatment.8
Newly developed hepatitis C drugs’ prices have also raised eyebrows. The
efficient drug Sovaldi was launched at a list price of $84,000 for a standard
twelve-week treatment course, or about $1000 a pill. At the most recent average
net price of $45,000 per patient for all sofosbuvir-based products in the US, it would
cost $135 billion dollars to treat the estimated three million people with chronic
hepatitis C in the US—over one third of total annual spending on all prescription
drugs in the US.9 In the UK, the list price for a 12-week course of sofosbuvir was
5The King’s Fund (2018) https://www.kingsfund.org.uk/sites/default/files/2018-04/Rising-cost-of-
medicines.pdf.
6WHO (2018), p. xi https://apps.who.int/iris/bitstream/handle/10665/277190/9789241515115-eng.
pdf?sequence¼1&isAllowed¼y.
7Sciences Avenir with AFP (2015). http://www.sciencesetavenir.fr/sante/cancer/20151216.
OBS1499/la-ligue-contre-le-cancer-denonce-les-prixexorbitants-des-medicaments-innovants.html.
8Raffi and Reynes (2014), p. 1158.
9I-MAK (2017).
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nearly £35,000 (excluding VAT) and double that for a 24-week course.10 Notwith-
standing the high price, in early 2015 sofosbuvir was recommended for funding
based on its cost effectiveness. However, because of the budget impact of the
treatment, in the following months the NHS England delayed consistent provision
of sofosbuvir, instead phasing introduction through the use of quotas and prioritising
patients with the most severe need.11 From 2012 to 2019, the average price of
AbbVie’s rheumatoid-arthritis drug Humira climbed from $19,000 a year to
$60,000 a year.12
The effects of this are felt in both developed and developing countries. Greater
number of patients are now unable to afford medicines while governmental health
budgets are struggling to cater for the needs of its citizens, a situation made worse
during the COVID 19 pandamic. Henceforth, patients in the developing countries
are lacking essential medicines and lifesaving treatments, diabetics have died in the
US due to high price of insulin while the Dutch government has had to suspend its
acquisition of the immune-oncology drug Keytruda (despite the fact that it helped in
its development) because it was too expensive.13 The NHS in the UK—a wealthy
country which, unlike the United States, has a publicly funded and all-inclusive
health service with considerable bargaining power—is having to ration the supply of
cancer drugs due to financial restrictions on treatment14 while waiting times for those
actually offered the treatment are far too lengthy.15
3 Unequal Investment and More Monopoly
The problem which high prices of medicines poses should not be viewed in isolation
of other contributing factors engulfing this debate. One issue which ranks high
within this context is the challenge of inadequate funding for diseases primarily
affecting the financially underprivileged or for which the opportunities to make large
and long-term profits are considered by the industry to be limited.
Growing criticism has been made regarding the deficiency of the global regime in
finding solutions to long standing diseases (or as some refer to as neglected
10Boseley (2015) https://www.theguardian.com/society/2015/jan/16/sofosbuvir-hepatitis-c-drug-
nhs.
11Gornall et al. (2016), p. 4117.
12Entis (2019).
13The Economist (2019).
14Donnelly (2015). The article further identifies that in total, 17 cancer drugs for 25 different
indications will no longer be paid for in future in the UK.
15According to January 2019 NHS England data, almost 25% of cancer patients didn’t start
treatment on time despite an urgent referral by their primary care doctor. This represents the
worst performance since records began in 2009. For more see Pipes (2019). https://www.forbes.
com/sites/sallypipes/2019/04/01/britains-version-of-medicare-for-all-is-collapsing/
#4c6ebeb736b8.
300 M. El Said
diseases) or the unequal distrbution of COVID 19 vaccines as an example. One
visible area of concern is that related to the development of new antibiotics, an issue
the WHO have classified as a global challenge in recent years. According to WHO,
“No major new class of antibiotics has been discovered since 1987 and too few
antibacterial agents are in development to meet the challenge of multidrug resis-
tance.”16 One of the main issues related to lack of investment and R&D in this field is
attributed to the industry’s fear that resistance to these drugs would develop even-
tually hence eliminate the usefulness of the drug rapidly which may explain why
most major pharmaceutical companies have stopped research in this area, a situation
that has been described as a “serious market failure” and “a particular cause for
concern”.17
In a recently published two reports, the WHO warned about the adverse effects of
the declining private investment and lack of innovation in the development of new
antibiotics. The WHO further highlighted how this is also undermining efforts to
combat drug-resistant infections and diseases. The WHO reports found that the
60 products currently in development (50 antibiotics and 10 biologics) bring little
benefit over existing treatments and very few target the most critical resistant
bacteria (Gram-negative bacteria).18 The Chairman of the UK Review on Antimi-
crobial Resistance warned recently that, if left unaddressed, drug-resistant infections
could be responsible for the deaths of some ten million people a year by 2050, and
$100 trillion in economic damage.19
Other neglected diseases also share similar challenges and evident lack of invest-
ment and innovation. For example, a 2002 analysis of new chemical entities
developed between 1975 and 1999 found that only 1.1% were actually treatments
devoted to tuberculosis (TB) and tropical diseases, despite them causing 11.4% of
the global disease burden.20 Although the years between 2000 and 2011 witnessed
some improvement whereby of the 850 new therapeutic products registered, 4.4%
were for neglected diseases.21 However, according to the same study, only 4 of the
336 new chemical entities brought to the market during the same period were for
neglected diseases (including malaria)—just 1.2% of the total.
16WHO (2015), p. 5 http://apps.who.int/iris/bitstream/10665/193736/1/9789241509763_eng.pdf.
However, it was announced in late 2019 that a new antibiotic for drug-resistant tuberculosis—
pretomanid was finally approved by the FDA. Interestingly, the drug was developed by the
non-profit TB Alliance rather than the industry. For more see Dearment (2019) https://
medcitynews.com/2019/08/new-antibiotic-for-drug-resistant-tuberculosis-scores-fda-approval/.
17Ibid, 11.
18The two WHO reports cited below also found that research and development for antibiotics is
primarily driven by small- or medium-sized enterprises with large pharmaceutical companies
continuing to exit the field. For more see WHO (2017) https://apps.who.int/iris/bitstream/handle/
10665/258965/WHO-EMP-IAU-2017.11-eng.pdf?sequence¼1, and WHO (2019) https://apps.
who.int/iris/bitstream/handle/10665/330290/WHO-EMP-IAU-2019.12-eng.pdf.
19O’Neill (2015).
20Trouiller et al. (2002), p. 2188.
21Pedrique et al. (2013), p. 371.
The Impact of ‘TRIPS-Plus’ Rules on the Use of TRIPS Flexibilities:. . . 301
TB which is the biggest infectious disease killer in the world today is another case
in point, whereby the death toll alone in 2014 was 1.5 million lives. Until very
recently, no new drug was introduced for nearly 50 years.22 Furthermore, the last
treatment—largely inadequate due to its side effects—developed for Chagas disease
(leading cause of infectious heart disease in Latin America) was over 40 years ago.
Ebola also placed the global treatment regime under security. Médecins Sans
Frontières (MSF) who often operates within the disease-stricken countries further
states that the ‘fact that MSF frontline health workers lacked a treatment or a vaccine
for Ebola virus as the outbreak engulfed Guinea, Sierra Leone and Liberia in 2014 is
a poignant illustration of this problem. But the problem of inadequate or non-existent
treatments and vaccines was a challenge for MSF long before 2014’.23 Notably, it
was only in late 2019, it was announced that a new vaccine was approved in the US
and EU for Ebola.24
4 The Double Taxation of Society
One of the strongest criticisms against pharmaceutical companies is the way they
engage in business activities and R&D operations. It is vital to acknowledge that
innovator pharmaceutical companies need incentives to protect their investments.
Yet to what extent that should be sought at the expense of public health policy
concerns is questionable. The high prices of medicines does not only have a negative
effect regarding accessibility, but have also attracted criticism due to the fact that a
vast number of medicine discoveries and some of the subsequent drug development,
or indeed much of it in some cases, was funded by tax payers. The situation is made
worse by anticompetitive behaviour of some of these companies.
It is no secret that the governmental levels of financial and technical support for
biomedical innovations are considerable. The public sector makes substantial con-
tributions to research and development upfront, through grants, subsidies and tax
credits. In fact, some studies suggest that 30% of the estimated $240 billion yearly
total global investment across all health R&D comes from the public sector.25
Several cases illustrate this, including Truvada. The drug was initially developed
and patented by the US government after the Centers for Disease Control and
Prevention (CDC) received $50 million in federal grants in addition to $7 million
from the Bill and Melinda Gates Foundation in 2015. However, the government did
not receive any income and no improvement in terms of accessibility rates was
observed (it is believed that less than 10 percent of the 1.1 million people who should
be on treatment are receiving it) despite the fact that Gilead Sciences the maker of the
22See MSF (2016).
23See MSF (2016), p. 8.
24For more see Herder et al. (2020), pp. 1–14.
25Røttingen et al. (2013), p. 1286, also see MSF (2016).
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drug earned $3 billion in sales in 2018 prompting the US government to initiate legal
action against Gilead.26
Moreover, a study found that during the past four decades, 153 new
FDA-approved drugs, vaccines, or new indications for existing drugs were discov-
ered through research carried out in public sector research institutions (PSRIs). It
was reported that these drugs included 93 small-molecule drugs, 36 biologic agents,
15 vaccines, 8 in vivo diagnostic materials, and 1 over-the-counter drug. More than
half of these drugs have been used in the treatment or prevention of cancer or
infectious diseases.27
Similar trends are observed elsewhere outside the US. In 2017, campaigners in
the UK claimed that the NHS spent more than £1 billion on drugs developed from
publicly funded research in 2016. A report published by campaign groups Global
Justice Now and Stop Aids claimed that UK tax payers and patients worldwide are
being denied the medicines they need, despite the public sector playing a pivotal role
in the discovery of new medicines. It concluded that ‘In many cases, the UK
taxpayer effectively pays twice for medicines: first through investing in R&D, and
then by paying high prices for the resulting medicine once ownership has been
transferred to a private company.’28 The report cites several examples of drugs
which received public funding but now are out of the reach of majority of patients.
For example, the report explains how Alemtuzumab was originally developed at
Cambridge University and first approved for the treatment of B-cell chronic lym-
phocytic leukaemia (B-CLL). Cambridge scientists then led further investigations of
its usefulness, at a smaller dosage, in treating multiple sclerosis (MS). Sanofi
Genzyme, who had acquired the rights to the drug, removed it from the market as
a B-CLL medicine and re-launched it as a medicine for MS. The Report verifies that
‘At the time of withdrawal there was speculation that the exercise was motivated by
commercial reasons. When it was used off-label (i.e. used for a non-licenced
purpose) for MS prior to being withdrawn from the market, the price in the UK
was around £2,500 per MS treatment course in 2012’. In 2017, it costs was £56,000
per treatment course—a 22-fold increase.29
On the other hand, several anticompetitive practises have had a far-reaching
impact on prices. Even when there are opportunities to reduce prices, we find that
this is not taken advantage of (and even intentionally delayed). A recent study found
that of the more than 1600 generic drugs approved by the FDA since January 2017,
more than 700—or 43 per cent—are not for sale in the US.30
26Rowland (2019).
27Stevens et al. (2011), p. 535.
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Delaying tactics have also incurred huge costs on society. One study estimates
that the American health system is poised to incur $55 billion during the next
15 years on three drugs (related cancer and hepatitis C treatment) alone due to
patents blocking and delaying the entry of generic competition on these drugs only.
Product lifecycle management, whereby branded companies obtain unmerited pat-
ents to delay competition,31 is the primary strategy identified and evaluated by this
study. The study also highlights that another related strategy is “pay-for-delay”
whereby branded companies pay generics to stay off the market for some time.32
5 More Pharmaceutical Patents, Weaker Innovation
An equally troubling development which has contributed to the increase in medi-
cines prices and extended monopoly patent terms in recent years is the increase in the
number of drug patents granted, particularly those ‘inventions’ which are of a low
and inferior quality, or as may be referred to as frivolous/trivial patents. This process
is leading to what is referred to as the ‘evergreening’ of drugs.33
This development may be explained by looking at some national statistics in this
regard. For example, it was found that between the years 2006 and 2016, the number
of drug patents granted in the US doubled. The granted patents were mainly
dedicated to accumulating patents not for new medicines but rather for small changes
to existing ones, which allows them to build and extend monopolies, block
31It should be noted that the product lifecycle management starts at the development and regulatory
approval stages and extends beyond the expiry of the granted patent. Notably, drug manufacturers
do not only rely on patent protection when devising their lifecycle strategies. For example, reliance
on trademark protection and branding is also vital in providing effective means to secure and
maintain a strong market position. For more on this see Dutfield (2020). file:///C:/Users/melsaid/
Downloads/Not_Just_Patents_and_Data_Exclusivity_Th.pdf.
32I-MAK identifies the following three multi-billion-dollar drugs as having questionable patents
that are providing excess exclusivity periods:
• Revlimid® (lenalidomide): Unmerited patents enable a minimum exclusivity period from 2019
through 2028. Payers are projected to spend $45 billion in excess costs for the drug within this
period, prior to the first generic product entering the market.
• Sovaldi® (sofosbuvir): Unmerited patents will prevent competition from now through 2034,
when final patents held by Gilead Sciences expire on the drug. Payers are projected to incur $10
billion in excess costs.
• Gleevec® (imatinib): In the one-year period from 2015–16, approximately $700 million dollars
in excess costs were passed onto payers as a result of a pay-for-delay deal cut by Novartis to a
generic company in exchange for delaying the entry of generic imatinib.
For more see I-MAK (2017).
33The majority of these patents focuses on developing so-called ‘me-too’ drugs—medicines which
have only small clinical advantages over existing drugs, but which can be patented and bring
substantial profits. The effects of evergreening vary but the primary impact would be to extend the
monopoly term granted to patents. For more see Kesselheim et al. (2006), p. 1637.
304 M. El Said
competition and drive prices up.34 Moreover, on the 12 best-selling drugs in the US,
drug makers have filed an average of 125 patent applications and have been granted
an average of 71 patents for each.35 Another study found that 74 applications have
been filed on Lantus (it is a man-made form of a hormone (insulin) that is produced
in the body which works by lowering levels of glucose (sugar) in the blood) only in
the US, which have the potential to delay competition for 37 years.36 This kind of
“over patenting” blocks competition and enables pharmaceutical companies more
freedom to regulate the pricing market of medicines.37
Elsewhere the findings are similar. A study in Australia found an average of
49 secondary patents granted for each of the 15 highest-cost drugs over a 20-year
period. One-quarter of these secondary patents were believed to be evergreening
patents.38 The Office of Patented Medicines and Liaison at the Therapeutic Products
Directorate of Health Canada estimates that 44% of the 419 medicines on the Patent
Register are covered by more than one patent.39
Moreover, an EU investigation concluded in 2008 that out of the 219 molecules
in the sample under the investigation, originator and generic companies identified at
least 1300 patent-related out of court contacts and disputes concerning the launch of
generic products in the period 2000 to 2007. The vast majority of disputes were
initiated by the originator companies, which most often invoked their primary
patents, e.g. by sending warning letters. In this respect the inquiry finds that
individual medicines are protected by up to nearly 100 product-specific patent
families, which can lead to up to 1300 patents and/or pending patent applications
across the Member States. Despite the lower number of underlying patent families
based on European Patent Office (EPO) applications, looking from a commercial
perspective, ‘a challenger may, in the absence of a European Community patent,
need to analyse and possibly confront the sum of all existing patents and pending
patent applications in those Member States in which the generic company wishes to
enter’.40





37Amin and Kesselheim examined patents granted for two HIV drugs (ritonavir and lopinavir/
ritonavir) and found that Abbott owned 82 secondary patents and had a further 26 pending
applications in the US, all of which involved small variations on the original patents for these
drugs. They found that these evergreening patents could delay generic competition for 19 years
beyond the date from which generic entry would have been anticipated. For more see Amin and
Kesselheim (2012).
38Christie et al. (2013), p. e60812.
39Office of Patented Medicines and Liaison (2005).
40EU Commission (2008), p. 10. https://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/
communication_en.pdf.
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Elsewhere, another analysis found of the 1015 new drugs and indications
approved in France between 2004 and 2013, only 6.3% offered a clear therapeutic
advantage, almost none were considered breakthroughs, and the majority (69.3%)
offered no clear therapeutic benefit or were prematurely approved even though their
clinical evaluation showed them to be more harmful than beneficial.41 A second
analysis found that 85 to 90% of new products approved over the last four decades
have provided only limited benefits.42 A third study that looked not just at registered
products, but specifically at new chemical entities and new biologics, found that the
majority of those launched in the UK between 2001 and 2012 were only “slightly
innovative” and only a quarter (26%) were believed to be “highly innovative”.43
Rather than using the patent regime as an incentive to innovate and recoup
investment for worthy inventions, ‘evergreening’ tactics and practises are in fact
blocking accessibility and weakening innovation capabilities by undermining the
true foundations of the patent regime and turning it into monopoly creator with no
positive contribution to society’s needs.44
6 Increased IP Standards: From TRIPS-Minus
to TRIPS-Plus
The global regulation of intellectual property rights is a relatively modern concept.
Prior to the creation of the World Trade Organization (WTO) in 1996, countries had
considerable policy space and full discretion in designing their national intellectual
property legal regimes in accordance with their development stage and national
priorities.45 As such, a large number of countries did not award legal protection to
patents related to drugs and pharmaceutical products.46
This was no longer the case with the creation of the WTO. The Agreement on
Trade Related Aspects of Intellectual Property Rights (the TRIPS Agreement)47
obligated member states to provide legal protection for inventions in all technolog-
ical fields including pharmaceutical products. This was an important development
whereby for the first time in history, countries lost the ability to regulate their
41Prescrire International (2005), pp. 68, 71.
42Light and Warburton (2016), p. 34.
43Ward et al. (2014), p. 6235.
44Drahos (2010).
45See generally Machlup and Penrose (1950), p. 1.
46See El Said (2010).
47See the Agreement on Trade-Related Aspects of Intellectual Property Rights, Apr. 15, 1994,
Marrakesh Agreement Establish the World Trade Organization, Annex 1C, 1869 U.N.T.S. 299
[hereinafter TRIPS Agreement] (listing the limitations on use of intellectual property by third
parties authorized by the government).
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national intellectual property regimes freely and in accordance with their national
development plans.
Reaching consensus regarding the TRIPS agreement was not a simple act. The
intellectual property negotiations during the Uruguay Round of Trade Negotiations
were amongst the most contentious and complex. As such and in order to strike a
balance between the rights of users and intellectual property holders on the one hand,
and the society on the other, several ‘flexibilities’ were introduced within TRIPS in
order to curtail the negative impact which may arise from excessive intellectual
property protection and at the same time to enable countries to deal with their public
health challenges and emergencies.
6.1 The Flexibilities Explained
The TRIPS ‘flexibilities’ may best be explained as options available to member
states allowing them to comply with the TRIPS Agreement requirements and at the
same time maximise the implementation space available to them in accordance with
their priorities.48 Following are some examples of the health-related flexibilities
available under the agreement to member states:
– Transitional periods. According to the WTO, least developed countries (LDCs)
are given an extended transition period to protect intellectual property under the
WTO’s TRIPS Agreement. This is in recognition of their special requirements
and status, their economic, financial and administrative constraints, and the need
for flexibility so that they can create a viable technological base. Several exten-
sions of the transition period were provided by the TRIPS Council. The last 6th of
November 2016 Council decision extends until January 2033 the period during
which key provisions of the WTO’s intellectual property agreement, the TRIPS
Agreement, do not apply to pharmaceutical products in LDCs.49 This means
LDCs can choose whether or not to protect pharmaceutical patents and clinical
trial data before 2033. The decision also keeps open the option for further
extensions beyond that date.50
48There is a general differentiation in the literature between expressly provided safeguards,
limitations/exceptions and countervailing legal principles and objectives on the one hand, and
vague terminology on the other hand where there are provisions and omissions whose scope is
subject to a wide range of interpretations in accordance with national and international legal
regimes. For more see El Said (2010).
49See the Council for Trade-Related Aspects of Intellectual Property Rights, Extension of the
Transition Period under Article 66.1 of the TRIPS Agreement for Least Developed Country
Members for Certain Obligations with Respect to Pharmaceutical Products, Decision of the Council
for TRIPS of 6 November 2015.
50In 2019, Uganda notified the African Regional Intellectual Property Organisation (ARIPO) that it
is exercising its right as a least-developed country by stating that pharmaceutical inventions are not
The Impact of ‘TRIPS-Plus’ Rules on the Use of TRIPS Flexibilities:. . . 307
– Compulsory licensing. A tool through which the state authorizes a third party to
exploit patented inventions, generally against a specified royalty paid to the
patent holder provided that several conditions set under the TRIPS Agreement
(Article 31) are complied with. The objective behind this is to curtail anti-
competitive behaviour and ensure the transfer of technology and dissemination
of knowledge.51
– Government use exceptions. A tool which grants the state the right to use the
patent without obtaining the consent of the patent holder for the purpose of public
interest, including public health necessities. Although government use conditions
are similar to compulsory licensing, government use exceptions provide an added
advantage by fast-tracking the process, through granting the government the right
to use the pharmaceutical patent without the need for prior negotiations with the
owner.
– Parallel importation. This tool gives the option to member states to obtain
patented products when they are lawfully available in a foreign market at a
lower price, thus enabling countries to shop for cheaper patented products. This
requires as a prerequisite that a country adopt an exhaustion regime suitable to its
needs and priorities.52
– Exceptions to patents rights. Article 30 of TRIPS provides that members “may
provide limited exceptions to the exclusive rights conferred by a patent, provided
that such exceptions do not unreasonably conflict with a normal exploitation of
the patent and do not unreasonably prejudice the legitimate interests of the patent
owner, taking account of the legitimate interests of third parties.”53 However, the
above provision does not define the scope of the permissible exceptions thus
awarding member countries some considerable discretion to operate. Examples of
these exceptions include the Bolar exception54 and the research and experimental
use exception.
– Standards of patentability. Under TRIPS, patent protection must be granted for
products and processes which are new, involve an inventive step and are indus-
trially applicable.55 However, each of these are not defined and can be interpreted
eligible for patent protection in the country. See ‘t Hoen (2019). https://medicineslawandpolicy.org/
2019/10/uganda-tells-aripo-no-more-patents-for-pharmaceuticals/.
51The special compulsory licensing system in the amended TRIPS Agreement, and the earlier 2003
waiver decision, (sometimes called the “Paragraph 6 System” because it refers to paragraph 6 of the
Doha Declaration) only deals with compulsory licences to produce medicines expressly for export
purposes.
52See TRIPS Agreement, Article 6.
53See TRIPS Agreement, Art. 30.
54This important exception facilitates the production and introduction of generic medicines into the
market on the date of patent expiry. Accordingly, this exception permits the use of an invention for
the purpose of obtaining approval of a generic product before the patent actually expires and
without having to obtain the patentee’s approval. The WTO ruled that the use of this exception is
TRIPS-compliant. For more see the WTO (2000).
55See TRIPS Agreement, Art. 27.
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and applied by member states in accordance with their national priorities and
objectives. For example, TRIPS do not specify the patenting of new uses of
known products, including pharmaceutical drugs, thus allowing member coun-
tries the possibility of rejecting these new uses for lack of novelty, inventive step
or industrial applicability.
– Other procedural flexibilities. Another identified policy tool that may be used to
improve the quality of granted patents and limits “evergreening” is pre-grant and
post-grant patent oppositions, in addition to patent revocation proceedings. These
methods have been used at different times in a wide range of developed and
developing countries. Such proceedings enable interested parties to bring claims
before the patent office on the basis that a particular patent does not meet local
requirements.
6.2 Putting the Flexibilities into Use
We now have a considerable body of literature and empirical research dedicated to
the benefits of utilising the TRIPS Agreement’s flexibilities under national laws.
Despite this, some would still argue that the use ‘of the TRIPS flexibilities has been
sporadic and limited’56 and that more could still be achieved in this regard.57
A much widely affiliated issue with the use of the flexibilities is the issue related
to the impact of generic drugs entry into the market and the savings achieved as a
result. In many cases, this is enabled by the flexibilities effect in curtailing
‘evergreening’ and in opposing low quality patents. As such, it is common to see
medicine prices dropping substantially (ranging between 30–90 percent in some
cases) when generic medicines enter a market following the expiry of a patent.58
Compulsory licensing is the most used flexibility in this regard.59 There is no
scarcity of evidence with relation to the positive impact compulsory licensing has
had upon improving access to medicines. Malaysia was one of the latest countries to
issue a “government use” compulsory license to obtain much cheaper version of a
generic version of the famously known hepatitis C medicine Sofosbuvir in
September 2017. It is believed that compulsory license issuance have enabled
treatment cost at RM1000 to RM1200 ($240–$285) for 12 weeks course, compared
to RM300,000 (approx. $72,000) which was the cost of treatment with the patented
56‘t Hoen et al. (2018), pp. 185–193.
57For more see El Said (2014), p. 60.
58See El Said (2010).
59See number of compulsory licenses issued in ‘t Hoen et al. (2018), p. 188. However, it should be
kept in mind that the ability to use compulsory licensing is not an available option to all countries
equally but is rather more relevant to those which possess manufacturing capabilities.
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version and prior to issuance of the license.60 Moreover, it was reported that between
2013 and 2017, the Ecuadorian Institute of Intellectual Property (IEPI) issued ten
compulsory licences for various medications including antiretroviral drugs.61
According to health officials in Ecuador, the compulsory licenses granted between
2013 and 2014, generated the potential for savings of 23 per cent to 99 per cent.62
Similar findings may also be found in the case of other compulsory licenses issued
by Thailand, India, Indonesia, Brazil and Columbia.63
One of the other important flexibilities available to countries is related to the issue
of patentability standards. As highlighted, member countries have a wide discretion
and freedom to apply and define the patentability criteria of an invention under their
national regime. As such, India has applied a strict patentability criteria aimed
towards limiting the number of frivolous or secondary pharmaceutical patents
granted.64 Although we cannot measures the direct price impact this will have on
medicines nevertheless it is believed that the utilisation of this flexibility have a
substantial impact in preventing patent abuses and the granting of low quality patents
(anti-evergreening strategy).65 Other countries such as China and Philippines are
following a similar approach to the Indian one in this regard.66
Egypt provides an interesting case as well. The country is home to the highest rate
of HCV infections in the world. The Egyptian’s Patent Office practise won praise
couple of year ago when it rejected one of Sofosbuvir patent applications through its
application of a strict patentability criteria. This allowed a local generic producer to
produce the drug for less than $200 per 12-week treatment.67
60For more see Ling (2019). http://english.astroawani.com/malaysia-news/using-compulsory-
licence-affordable-medicines-200558.
61The issued compulsory license were for three ARV medicines namely Ritonavir+Lopinavir and
Lamivudine+Abacavir, for Etoricoxib (Arcoxia® for the treatment of diseases with acute pains);
Mycophenolate Sodium (MYFORTIC) used in the treatment of reception of kidney transplants;
sunitinib, an anticancer drug used for the treatment of carcinoma renal cells (CRC) and gastroin-
testinal stromal tumours (GISTs); and finally Certolizumab, used to counteract rheumatoid arthritis.




63For more see El Said (2016), p. 374.
64See Chatterjee (2013). https://www.ip-watch.org/2013/04/01/novartis-loses-patent-bid-lessons-
from-indias-3d-experience/.
65See Sampat and Shadlen (2017), p. 693.
66Other countries are increasingly following India’s patentability path. The Philippines patent law,
as amended in 2008, introduced a section similar to the Indian 3(d) section (although less stringent
than India’s Patent Act).177
China has reformed its Patent Act in 2008 and 178. See Patent Law (promulgated by the
Standing Comm. Nat’l People’s Cong., Mar. 12, 1984, rev’d Dec. 27, 2008), art. 22. For more
see El Said (2016).
67Velasquez (2019), p. 108.
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Parallel importation is another flexibility already used by several countries with
positive results. For example, six African countries (Ghana, Kenya, Mauritius,
Namibia, South Africa and Zimbabwe) have incorporated an international exhaus-
tion regime in their laws, allowing parallel imports from anywhere in the world.
More specifically, Kenya has actively and effectively used parallel importation to
improve access to antiretroviral medications.68
Opposition procedures have been applied usefully and efficiently in several
countries. This issue is posed to gain more importance due to the increased volume
of pharmaceutical patents granted worldwide. To give a glimpse, it is believed that
current estimates suggests that at least 27% of current patents would be found invalid
by US courts due to low quality.69
There are many more examples of the use of the flexibilities by both developed
and developing countries which this chapter will not delve into. However, a number
of observations could be made about the efficient and successful use and implemen-
tation of these flexibilities under national regimes. First, the need for a proactive
national legislature is fundamental for the success of this process. Although these
flexibilities are available under the international intellectual property regime, their
implementation would not take place directly without legislating—in details—them
under national laws and regulations. Second, awareness about the existence of these
flexibilities is vital for their utilisation. Thirdly, the need for an engaged public,
national entities and active civil society is essential for the success of this process as
demonstrated by many thus far. Lastly, independent and highly trained judiciary is
vital in the process of implementation and interpretation of these flexibilities under
national legal frameworks.
6.3 The Shift Towards TRIPS-Plus
The TRIPS Agreement was subsequently used as a platform for further regulation of
intellectual property rights globally. Although the initial understanding of develop-
ing countries was that TRIPS would put an end to unilateralism and coercion in the
regulation and enforcement of intellectual property by developed countries particu-
larly the United States, that vision turned out to be misguided. Within a short period
of time following the creation of the TRIPS Agreement, a new generation of bilateral
and regional Free Trade Agreements (FTAs) started to emerge, with a far-reaching
WTO-Plus agenda.
With relation to intellectual property, FTAs often contained dedicated chapters
incorporating extensive intellectual property provisions which often include TRIPS-
Plus obligations going beyond those required by the TRIPS Agreement. These
68UNAIDS (2011), p. 15. https://www.unaids.org/sites/default/files/media_asset/JC2260_DOHA
%2B10TRIPS_en_0.pdf.
69Miller (2012). https://papers.ssrn.com/sol3/papers.cfm?abstract_id¼2029263.
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TRIPS-Plus obligations restricted the available policy space of member states and
gradually eliminated the options and flexibilities available to them under the TRIPS
Agreement.70 Although the full impact of these TRIPS-Plus agreements is yet to
materialise, we already have a considerable and rather frightening understanding—
as will be explained in the next part of this chapter—about the negative impact these
agreements have on affordability and accessibility to medicines.
6.4 Impact and Examples of TRIPS-Plus Obligations
Before looking into the negative impact of TRIPS-Plus, it would be helpful to
understand how do FTAs increase intellectual property protection levels beyond
the TRIPS standards? An important objective of TRIPS-Plus obligations is to limit
the use of the flexibilities available under the international intellectual property
regime thus making it more difficult to utilise such flexibilities. There are a number
of areas where this may take place with relevance to patents and public health. These
include the following examples:
– Expanding the scope of pharmaceutical patents and creating new drug
monopolies: this is achieved through a number of ways such as:
• lowering the patentability standards,
• requiring patents be available for surgical and treatment methods,
• minor variations on old medicines, new and second uses, and71
• Further extension of protection to biological products which include vaccines,
blood and blood components, and gene therapies in addition to other forms of
protection.
– Extension of monopolies by extending patent terms if review at the patent office
or regulatory authority failed completion within a certain period of time.
– Risk facilitating patent abuse by requiring countries to condition marketing
approval on patent status (patent linkage).
– Protection and Extension of “data exclusivity”: by providing at least 5 years
exclusivity for information related to new products and 3 more in cases of new
uses for old medicines—even when that information is disclosed and available in
the public domain. More recent FTAs have also provided 10 years of “effective
market protection” for biologics.72
– Prohibition/restriction pre-grant oppositions—forbid challenges to weak or
invalid patents until after they have been granted.
70See Drahos (2001), p. 791 and El Said (2005), pp. 53–66.
71For more on this from an EU perspective please see Dutfield (2017), p. 453.
72Ney (2019). https://www.centerforbiosimilars.com/contributor/joshua-ney/2019/08/exclusivity-
for-biologic-products-under-the-usmca-what-is-changing-and-what-happens-next.
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– Regulate the decisions to reimburse new drugs: this gives drug companies new
rights to challenge decisions on reimbursements if not favourable as currently
proposed under the Transatlantic Trade and Investment Partnership (TTIP).
– Require new forms of intellectual property enforcement–grant: customs
authorities detaining shipments, including in-transit shipments, suspected of
non-criminal trademark/copyright/patent infringements; require mandatory injunc-
tions for alleged intellectual property infringements; raise damages amounts, etc.
– Introducing Investor-State Dispute Settlement (ISDS) procedures: this leads
to bypassing the WTO’s multilateral dispute settlement procedure and opting for
a more pro-investment one. This development has been highly controversial as
this grant private investors considerable power, especially big multinational
corporations, to claim high amounts of money of compensation from investor
sympathetic tribunals. Indirectly, this questions the impact of these claims on
states’ power to regulate in the public interest, in order to safeguard public
health priorities. Other flaws of the ISDS system include the lack of consistency
in decision making and the huge costs incurred. There is now growing evidence
that the threat of using these ISDS procedure is enough to obligate countries to
change their policies.73
The undisputed recommendation in this regard from a public health perspective
remains that countries should avoid entering into arrangements which obligates them to
apply TRIPS-Plus standards under national law. As states by UNDP and UNAIDS:74
Countries at minimum should avoid entering into FTAs that contain TRIPS-plus obligations
that can impact on pharmaceuticals price or availability. Where countries have undertaken
TRIPS-plus commitments, all efforts should be made to mitigate the negative impact of these
commitments on access to treatment by using to the fullest extent possible, remaining public
health related flexibilities available.
The thus far realised impact of TRIPS-Plus obligations on public health and
access to medicines is frightening upon both developed and developing nations.75 In
one of the first studies ever conducted on the impact of TRIPS-Plus obligations, a
2007 Oxfam study on the effect of the US-Jordan FTA found that since 2001 (which
is the year the FTA was signed with the US), the prices of medicines in Jordan have
increased by 20% (this led to price increases between two and ten-fold for key
medicines to treat cardiovascular disease and cancer), and data protection provisions
has resulted in delaying generic drugs entry for 79% of medicines newly launched
between the years 2002 and 2006.76 The study estimates that the availability of
73For instance, in 2016; and Ukraine de-registered a generic hepatitis C medicine after Gilead
indicated that it would pursue arbitration. For more see Gleeson et al. (2019), p. 78.
74UNDP and UNAIDS (2012) https://www.unaids.org/sites/default/files/media_asset/JC2349_
Issue_Brief_Free-TradeAgreements_en_0.pdf.
75See El Said (2010).
76Oxfam (2007), p. 5 https://oxfamilibrary.openrepository.com/bitstream/handle/10546/114080/
b p 1 0 2 - a l l - c o s t s - n o - b e n e fi t s - t r i p s - 2 1 0 3 0 7 - e n . p d f % 3 B j s e s s i o n i d %
3D089750820CF675173F0C3204C369D63F%3Fsequence%3D1. Also see El Said (2006), p. 501.
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generic equivalents would have reduced Jordan’s expenditure on medicines by $6.3
and $22 million between mid-2002 and 2006.77 The study also shows that no real
know-how transfer has occurred in the country despite the rhetoric that FTAs would
in fact encourage the flow of know-how and Foreign Direct Investment (FDI).
Although the 2007 Oxfam study was conducted under less than 5 years of the
FTA implementation, we came a long way since then in terms of assessing and
understanding the impact of FTAs on accessibility and affordability of medicines.
More and more studies are affirming and exposing the negative impact of these
obligations on public health and access to medicines.
Amin and Keselheim conducted a study on the impact of ‘evergreening’ resulting
from the granting of secondary patents. The authors concluded that secondary
patents could extend market exclusivity and thus delay generic competition from
entering the market for many years. The study identified 108 patents related to two
HIV medicines (ritonavir (Norvir) and lopinavir/ritonavir (Kaletra)) which impact
could delay generic competition until at least 2028. This is a twelve years additional
period after the expiration of the patents on the drugs’ base compounds and thirty-
nine years after the first patents on ritonavir were filed.78
For instance, research by Lexchin concluded that extension of legal protection in
data protection for biologics have resulted in increase in spending in drug expendi-
ture in Canada. He estimated the lost savings from data protection extension to range
from $0 to $305.8 million.79 Another study in Australia found:80
At the time that the EOT [extension of the term] was introduced, the annual cost to the
Pharmaceutical Benefit Scheme (PBS) was estimated to grow from $6 million in 2001-02 to
$160 million in 2005-06. This cost arises because there is a delayed entry to the PBS of
cheaper generic drugs. The estimate for 2012-13 is around $240 million in the medium term
and, in today’s dollars, around $480 million in the longer term. The total cost of the EOT to
Australia is actually about 20 per cent more than this, because the PBS is only one source of
revenue for the industry.
Another study conducted by the Australian Generic Medicines Industry Associ-
ation analysed the costs to the health system for 39 PBS-listed medicines for which
generic competition was delayed after the patent on the active pharmaceutical
ingredient expired, as a result of secondary patenting found that in the 12 months
to November 2012, the cost of delayed generic launch was calculated at $37.8–$48.4
million.81 This estimate does not include subsequent price reductions due to price
77Oxfam, Ibid.
78See Amin and Kesselheim (2012).
79Lexchin (2019), p. 10.
80Harris et al. (2013), p. vi https://www.ipaustralia.gov.au/sites/default/files/2013-05-27_ppr_
final_report.pdf?acsf_files_redirect. The Report found that about 58% of new molecules listed on
the PBS from 2003 to 2010 received extensions of term. Of the term extensions granted since 1999,
47% received the full 5 years.18 The cost of these extensions to the PBS in 2012–13 was estimated
at about $240 million in the medium term and about $480 million in the longer term.
81Gleeson et al. (2015), p. 306.
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disclosure. Another study estimated the costs of patent extensions to the PBS in
2012–13 at about $240 million in the medium term and about $480 million in the
longer term.82 It was also found that data protection had no impact on the levels of
pharmaceutical investment in the country as highlighted with the case of the US FTA
with Jordan.
There has been much more work conducted recently in terms of alerting to the
negative impact of the highly controversial Trans-Pacific Partnership Agreement
(TPPA) agreement in this regard.83 The TPPA which is widely promoted as a
“model for 21st century trade agreements” is a comprehensive trade and investment
deal covering many areas including trade, investment, labour and intellectual prop-
erty rights in in addition to its investor-state dispute settlement procedure.84 Brook
concludes that ‘Provisions in the Intellectual Property (IP) Chapter of TPP lengthen,
broaden, and strengthen patent-related monopolies on medicine and erect new
monopoly protections on regulatory data as well. IP Chapter enforcement provisions
also mandate injunctions preventing medicines sales, increase damage awards, and
expand confiscation of medicines at the border’.85
In comparing the TPPA with similar agreements, a study found that the US-
Mexico-Canada Agreement’s (USMCA) intellectual property chapter is closely
based on the corresponding chapter of the TPPA, but includes 10 years of “effective
market protection” for biologics in addition to including a broader definition of
biologics, potentially expanding the array of drugs which will be eligible for this
longer period of exclusivity, longer than the period negotiated in the TPPA.86 For
Canada, this will increase the period of market protection for biologics by 2 years;
two studies of the potential impact on pharmaceutical expenditure (using different
methods and based on different assumptions) have estimated the savings foregone at
between CDN$0 and $305.8 and up to CDN$169 by 2029.87
7 What Could Be Done and What Is Done?
As explained, we have a considerable wealth of empirical research about the positive
impact of TRIPS flexibilities use and the negative impact of TRIPS-Plus obligations
on the health care and access to medicines regimes in several developed and
developing countries. However, it has been more difficult to observe how countries
82Harris et al. (2013).
83The Office of the U.S. Trade Representative (USTR) issued a letter in 2019 to signatories of the
Trans-Pacific Partnership Agreement that the United States has formally withdrawn from the
agreement.
84The TPP is the first trade agreement to include provisions on pharmaceuticals that are, or contain,
biologics, compounds produced through biological processes and which are used primarily for
treating cancer and immune conditions.
85Baker (2016), p. e1001970.
86Swanson (2019). https://www.nytimes.com/2019/03/21/us/politics/nafta-drug-prices.html.
87Gleeson et al. (2015).
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with TRIPS-Plus regimes have in fact attempted to utilise the remaining policy space
available to them in order to mitigate the negative impact these TRIPS-Plus rules
have on their national health care regimes. This is so primarily due to the difficulty in
observing national practises and the lack of international jurisprudence arising from
disputes about the implementation of these obligations (or rather about if such an
implementation was in line with international norms or otherwise) under national
frameworks.
In addition, it should be realised from the outset that the effect of TRIPS-Plus
commitments will vary from each country and will depend on many factors,
including market side, pharmaceutical protection capacity, development of legal
regime, judiciary and so forth.
Nevertheless, and despite the above-mentioned difficulties, by looking into
several cases, we have been able to observe some important contributions in this
regard. The important aspect in this case is to continue applying and implementing a
nationally creative thinking and interpretive policy aimed towards limiting the
negative impact of the committed TRIPS-Plus rules. Following are examples of a
number of national experiences of how countries attempted to limit the negative
impact arising from TRIPS-Plus obligations.
7.1 Australia
One of the countries which have taken several serious steps in this field is Australia.
This is because the country has agreed to a TRIPS-Plus obligations regime arising
from the US-Australia FTA88 which had a huge cost on the national health budget
and the accessibility and affordability of medicines. Accordingly, in 2013,89 the
Australian legislator (following national consultation) introduced a number of
reforms aimed towards mitigating the effects of the ‘evergreening’ of patents starting
with applying a stricter patentability criteria by removing any geographical limita-
tion upon the common general knowledge and by removing the requirement for a
prior art document to be “ascertained”.90 The effect of this is to require a higher and
more consistent inventive step standard for Australian patents granted in the country.
Another area tackled by the Australian legislator is the issue of patent term
extension granted in order to compensate for the delays during marketing approval
as dictated under the FTA with the US.91 To start with, the 2013 Patent Law reform
88The US-Australia Free Trade Agreement (US-AUS FTA) signed in 2004.
89Intellectual Property Laws Amendment (Raising the Bar) Act 2012 No. 35, 2012 as amended.
Start date15 April 2013, hereafter the 2013 Patent Law.
90Dixon (2017).
91See US-AUS FTA, Art.17.9.8(b) states:
[E]ach Party shall make available an adjustment of the patent term to compensate the patent
owner for unreasonable curtailment of the effective patent term as a result of the marketing
approval process.
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attempted to limit the possibilities of allowing patent term extension by further
confining such type of extensions to certain and specific categories of products
related to patents claiming new active ingredients or formulations only.92
Moreover, the Australian 2013 Patent Law reform imposes additional substantive
conditions specifically applicable for the extension of patent duration for “pharma-
ceutical substances.” Based on this, the extension of the term is possible only if
either or both of the following conditions are satisfied:93
(a) one or more pharmaceutical substances per se must in substance be disclosed in
the complete specification of the patent and in substance fall within the scope of
the claim or claims of that specification;
(b) one or more pharmaceutical substances when produced by a process that
involves the use of recombinant DNA technology, must in substance be
disclosed in the complete specification of the patent and in substance fall within
the scope of the claim or claims of that specification.
In addition, both of the following conditions must be satisfied in relation to at
least one of those pharmaceutical substances:
(a) goods containing, or consisting of, the substance must be included in the
Australian Register of Therapeutic Goods;
(b) the period beginning on the date of the patent and ending on the first regulatory
approval date for the substance must be at least 5 years.
(4) The term of the patent must not have been previously extended under this Part.
Meaning of first regulatory approval date.
More reforms were introduced with relation to opposition procedures as well. As
such, detailed and expansive opposition grounds against patent term extension
procedures were included under the 2013 Patent Law reform. Accordingly, Article
78 of the Patent Law states:
If the Commissioner grants an extension of the term of a standard patent, the
exclusive rights of the patentee during the term of the extension are not infringed:
(a) by a person exploiting:
(i) a pharmaceutical substance per se that is in substance disclosed in the
complete specification of the patent and in substance falls within the scope
of the claim or claims of that specification; or
(ii) a pharmaceutical substance when produced by a process that involves the
use of recombinant DNA technology, that is in substance disclosed in the
complete specification of the patent and in substance falls within the scope
92See El Said (2016).
93See Patents Act 1990 (Cth) ch 6 pt 3 s 70 sub-divs (2)-(3) (Austl).
The Impact of ‘TRIPS-Plus’ Rules on the Use of TRIPS Flexibilities:. . . 317
of the claim or claims of that specification; for a purpose other than
therapeutic use; or
(b) by a person exploiting any form of the invention other than:
(i) a pharmaceutical substance per se that is in substance disclosed in the
complete specification of the patent and in substance falls within the scope
of the claim or claims of that specification; or
(ii) a pharmaceutical substance when produced by a process that involves the
use of recombinant DNA technology, that is in substance disclosed in the
complete specification of the patent and in substance falls within the scope
of the claim or claims of that specification.
Patent linkage is another TRIPS-Plus issue whereby Australia’s approach may
provide some valuable lessons for others. Article 17.10.4 (in the Intellectual Property
chapter) of the US-AUS FTA provides for an attenuated or ‘weak’ form of patent
linkage with relation to two aspects as explained by Son et al:94
(a) measures in the marketing approval process to prevent a third party from
marketing a product during the term of a patent without the consent of the patent
owner; and
(b) no provision for the owner to be notified of a marketing approval request made
during the term of a patent. This wording provided scope for Australia to
implement a patent linkage mechanism in a very different way to the United
States.
In addition, the Australian regime excludes from protection patents covering
(1) the drug substance, (2) the drug product including composition and formulation,
and (3) the approved use from the patent linkage mechanism.95 Penalties for
providing false or misleading information, however, are disproportionately higher
for a patent holder certificate than for a generic producer certificate. Moreover,
Australia’s Pharmaceutical Benefit Scheme (PBS) imposes automatic and irrevers-
ible price cuts on medicines as soon as competing versions enter the market, this
often incentivise generic companies to launch faster at risk, and innovator companies
must pursue preliminary injunctions in order to resolve patent disputes.96 At the
same time, since 2012, Australia’s Department of Health has pursued market-sized
pecuniary damages (on top of those sought by the generic company) aimed at
compensating for a delay in the PBS price reduction that would have been applied
to a patented medicine during the period of a provisional enforcement measure.97
However, there is no corresponding mechanism for the government to compensate
94Son et al. (2018), p. 101.
95Son et al. (2018), p. 101.
96GIPC (2019). https://www.theglobalipcenter.com/wp-content/uploads/2019/09/GIPC-Linkage-
Zoom-In-Report.pdf.
97Australian Government Department of Health (2016). http://www.pbs.gov.au/industry/pricing/
price-disclosure-spd/price-disclosure-operational-guidelines-06-2016.pdf.
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innovators for the aforementioned losses if an infringing product is launched
prematurely.98
Although such reforms are vital, they should not be viewed as the only solutions
to the accessibility of medicines challange and therefore the intellectual property
regime should be viewed as one of several components and government strategies—
one element of an eco-system—in this regard which would improve accessibility and
affordability of medicines. For an example, in February 2019, the Australian gov-
ernment signed a five-year deal with pharmaceutical companies, involving a lump
sum payment of about $ 766 million for an unlimited five-year supply of the most
advanced Hepatitis C (HCV) drugs.99 This innovative approach which has been
called the “subscription” or “Netflix” model, have reduced the per-patient costs of
these cutting-edge treatments by roughly 85% in the country.100
7.2 Chile
Chile also proved an interesting case of a developing country which adopted a
TRIPS-Plus regime as a result of signing an FTA with the US in 2006 (the
US-Chile FTA). Following a rigorous national debate with relation to the negative
effect of data exclusivity and patent linkage included under the FTA, the Chilean
government amended the patent law by limiting the availability of data protection
under its national law to those pharmaceutical products that have been marketed in
the national territory in the year after the grant of marketing approval and therefore if
the drug was not marketed within a year, the test data submitted for approval
purposes will not be protected.101 The rationale behind such a requirement is to
encourage early registration of drugs after first registration abroad, so that the period
of protection for the pharmaceutical test data starts early.
In addition, the law excluded several elements from the scope of protection.
Accordingly, article 91 of the Chilean law states:
The protection of this Paragraph shall not apply when:
98GIPC (2019).
99The government also announced an investment of more than 1 Billion USD to enable universal
access to HVC treatment. See Velásquez (2017). https://www.southcentre.int/wp-content/uploads/
2017/05/RP77_Access-to-Hepatitis-C-Treatment-A-Global-Problem_EN-2.pdf.
100Moon and Erickson (2019), p. 607. Furthermore, the State of Louisiana announced in January
2019 that it was pursuing a similar approach for HCV. For more see Crisp (2019) https://www.
theadvocate.com/baton_rouge/news/politics/article_614e4f42-1523-11e9-8c90-4fcb305d17e8.
html.
101Law No. 19,039 art. 90, September 30, 1991 (modified on December 1, 2005 by Law 19,996,
which classifies active ingredients as new chemical entities if they have not been marketed in the
country prior to the health registration or authorization application). See also Biadgleng and Maur
(2011), p. 20.
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(a) The owner of the test data referred to in Article 89 has engaged in forms of
conduct or practices declared as contrary to free competition in direct relation to
the use or exploitation of that information, according to the final decision of the
free competition court.
(b) For reasons of public health, national security, non-commercial public use,
national emergency or other circumstances of extreme urgency declared by the
competent authority, ending the protection referred to in Article 89 shall be
justified.
(c) The pharmaceutical or chemical-agricultural product is the subject of a compul-
sory license, according to what is established in this Law.
(d) The pharmaceutical or chemical-agricultural product has not been marketed in
the national territory after 12 months from the health certificate or clearance
granted in Chile.
(e) The pharmaceutical or chemical-agricultural product has a health certificate
Furthermore, Chile implemented the linkage obligation established by the
US-Chile FTA through the provision of information to the patent owner about a
third party intending to commercialize a product with similar characteristics to one
that is already patented.102
The aim of these measures is to explore whatever policy space remains available
to the country in order to restrict the application of data exclusivity.
7.3 What Others Are Doing and How They Are Doing It?
There are many examples of interpretations and flexibility use taking place regularly
in different parts of the globe.103 These developments are either legislative, admin-
istrative or judicial in nature. Calls are made for countries to take advantage of the
remaining policy space in this regard and share their experiences with others.
Following are some non-exhaustive recommendations.
Several recommendations were made more with connection to data exclusivity
obligations. As a result, it is advisable for those regimes’ committing to TRIPS-Plus
data exclusivity provisions not to grant protection unless a specific application is
made (within a specific period—no more than 6 months—of time after the first
approval in the world of a medicine) and where certain conditions are met. Countries
102Correa remarks that on September 2nd, 2002 the Quinta Sala from the I Corte de Apelaciones
(I Court of Appeals, Fifth Chamber) of Chile ruled that the Instituto de Salud Publica, which issues
sanitary registries, ‘had no power whatsoever to either deny a marketing approval or to acknowl-
edge rights derived from a patent’. See Correa (2017). https://www.southcentre.int/wp-content/
uploads/2017/02/RP74_Mitigating-the-Regulatory-Constraints-Imposed-by-Intellectual-Property-
Rules-under-Free-Trade-Agreements_EN-1.pdf. See also Chandler (2010), https://papers.ssrn.com/
sol3/papers.cfm?abstract_id¼1602883.
103See Correa (2017).
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may also charge for these applications and require annual maintenance fee (such as
those applicable to trademarks). In addition, detailing when protection will terminate
is recommended. Correa suggests the following situations as examples:104
– When the right-holder or a person authorised by him does not commercialise the
approved product in a manner sufficient to supply the demand within a period
(e.g. twelve months) from the date of approval for commercialisation or when the
commercialisation is interrupted, for more than x consecutive months (e.g. six
months), except in cases of force majeure or government’s acts that prevent such
commercialisation.
– For public interest reasons such as national security, emergency or circumstances
of extreme urgency that justify the termination of the period of exclusivity.
– When, as a result of administrative or judicial procedures, it is determined that the
right-holder has abused his rights, for example, through practices declared as
anticompetitive.
Keeping health out of the FTA agenda is one right step in this regard. We can
observe some positive steps taken in this area. The recently concluded FTA between
Australia and Peru have explicitly excluded public health measures and/or specific
health programs from its scope. Article 8. 16 of the FTA states:105
Nothing in this Chapter shall be construed to prevent a Party from adopting, maintaining or
enforcing any measure otherwise consistent with this Chapter that it considers appropriate to
ensure that investment activity in its territory is undertaken in a manner sensitive to
environmental, health or other regulatory objectives.
Compulsory licensing in TRIPS agreements is stated with ambiguous wording
such as ‘national emergency’, ‘other circumstances of extreme urgency’, and ‘public
non-commercial use’. To deal with this ambiguity, active interpretations of these
terms should be persued. In this context, the Thai experience is noteworthy. The
legislator there defined public non-commercial use as ‘nutrition and public health
service’ and ‘protection of natural resources and environment’. Also, the
legislater interpreted the non-use of a patent as ‘insufficient use of a patent due to
the high price’ and ‘severe shortage of food and drugs’.106
It is worth noting that the above referred to examples should not emanate from
separate national initiatives but rather as a part of a more comprehensive approach
dealing with public health challenges within these countries. As seen, several
developed countries acknowledge today the negative consequences to TRIPS-Plus
rules on public health and have taken steps to rectify the situation. Developing
countries should follow suit and take serious notice of such implications.
104Correa (2017).
105See the Australian Government Department of Foreign Affairs and Trade. Chapter 8: Invest-
ment. Peru-Australia Free Trade Agreement. https://www.dfat.gov.au/trade/agreements/in-force/
pafta/Pages/peru-australia-fta.aspx.
106Kuanpoth (2006), p. 149.
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8 Final Thoughts
The world is at a crossroads. At the time of completion of this chapter, the world was
struggling in confronting the outbreak pandemic of the Corona virus (Covid-19).
Although several vaccines are available today, the daily loss of life is having grave
ramifications for the global economic and public health regimes. These outbreaks are
not new, however how we deal with them will depend on our ability to access and
grant funding for those working around the clock to find a cure. The intellectual
property regime needs reorientation to become truly an incentive rather than an
impediment to accessibility and treatment.
Some final thoughts could be made here with relation to supressing the impact of
TRIPS-Plus conditions on access to medicines within the framework of trade and
investment agreements. First, comprehensive assessment of the health impact of
FTAs and TRIPS-Plus commitments should be undertaken by policy makers and
negotiators. This should take place before an agreement is entered into. Second,
public and stakeholder engagement and collaboration is needed and should be a
priority. A national intellectual property committee with authorities and mandates
should be tasked with implementing a balanced national intellectual property
Agenda. Alternative and new business models for research and development are
needed to achieve better pricing of medicines. Push, pull and pooling strategies
should be given more thought and experimented with in this regard.107 Finally,
transparency in drug pricing is pivotal to ensure that (i fair compensation is granted
to those who invest in finding medical solutions to diseases, and (ii affordable drug
prices are applied so that patients can afford them. The 2019 World Health
Assembly’s resolution supporting greater public disclosure of prices for medicines
and other health products is a step in the right direction.108
The legal recommendation stands today the same as before; governments should
resist accepting and introducing TRIPS-Plus obligations even if others do so. At the
same time, those who committed to such obligations should undertake a thorough
review in order to identify areas where they can still utilise the TRIPS Flexibilities.
We may not be able to stop the spread of TRIPS-Plus commitments around the
globe; however, we should try and do our best to slow down the process of eroding
the remaining policy space.
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Abstract Linking patent protection to generics’ regulatory approvals is a heated
topic of discussions and a friction point among countries proposing higher protection
for patented drugs. Patent linkage has been pushed through bilateral and regional
agreements outside of the WTO system. It is widely understood that patent linkage is
implemented to delay the market entry of generic medicines. It is argued here that
developing countries are not obliged to take up TRIPs plus patent-linkage
obligations.
A list of approved drugs and their therapeutic equivalence can be published by
every country. The patent information can also be published to be made known to
everybody. Regulatory mechanisms and patent protection should be kept in separate
parallel tracks. Any attempt to link the two streams to prevent the registration of
generics based solely on alleged patent infringement would negatively affect access
to medicines worldwide.
Patent linkage provisions are TRIPS-plus commitments, as there is no such
obligation under the WTO TRIPS Agreement. The analysis of 16 countries which
provide for patent linkage shows that it is, in most cases, a resulting commitment
from regional trade agreements or bilateral agreements. Patent linkage provisions are
not acceptable to the developing world, and any attempt to introduce these will affect
the accessibility and affordability of generic medicines in the developing world.
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Access to essential medicines is a developmental challenge to developing countries
under the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights
(TRIPs).1 Accessibility, affordability, and availability of medicines (medicines and
drugs are interchangeably used in this paper hereinafter) are the prime objectives of
any developing country’s public health policy.2 Access to drugs is vital in the
background that, after food, the second-largest household expenditure is on medi-
cation, and this is paid out of pocket in these countries due to a lack of sufficient
public health programs. Many countries drafted their medicines policies keeping this
issue in mind. The challenging problem is that pandemics’ growing burden in
developing and least developed countries raised a high demand for cost-effective
medicines. Countries like India have previously met this increased demand by
providing low-cost generic drugs to the world and helping them fight pandemics.3
Developing and developed countries alike have realized the importance of
generic drugs in healthcare.4 The European Generics Medicines Association
(EGA) formed “Medicines for Europe” in the year 2000 to support the generic and
biosimilar industry, which supplies 67% of all medicines in Europe.5
Developing countries face challenges in the form of TRIPs-plus obligations
imposed on them through various means, mainly bilateral and regional trade agree-
ments. The availability and accessibility of medicines will be affected by policy
choices, such as adopting a patent linkage. Patent linkage refers to the system or
process by which a country links drug-marketing approval to the status of the patent
(s) corresponding to the originator’s patented product.6
1WHO (2011–2016), available at https://apps.who.int/iris/bitstream/handle/10665/207519/
9789290615705_eng.pdf.
2Ravikant et al. (2013), pp. 316–322.
3India recently sent an anti-malarial drug, Hydroxychroloquine, to 55 countries hit with Corona-
virus. This drug is identified by the US Food and Drug Administration as a possible drug to treat
Covid-19 disease, though its safety and efficacy are not yet established. See India Today, New
Delhi, April 17, 2020, https://www.indiatoday.in/india/story/india-sending-hydroxychloroquine-
55-coronavirus-hit-countries-1667786-2020-04-17. Later the accepted the Solidarity Trial’s Inter-
national Steering Committee recommendation to discontinue the trial’s hydroxychloroquine and
lopinavir from the treatment of COVID-19 patients. See WHO (2020). https://www.who.int/
emergencies /di seases /novel -coronavi rus-2019/advice- for -publ ic /myth-bus te rs?
gclid¼EAIaIQobChMIjoGlirH06wIVhzMqCh3ISAVnEAAYASABEgKMz_D_BwE.
4European Generic Medicines Association (2009). https://www.medicinesforeurope.com/wp-
content/uploads/2016/03/Market_Barriers_Report_FINAL_update_How_to_Increase_Patient_
Access_to_Generic_Medicines.pdf.
5Medicines for Europe, https://www.medicinesforeurope.com/medicines-for-europe/.
6https://www.wipo.int/export/sites/www/meetings/en/2007/lifesciences/sym_regulation/lss3_ge_
07_ferrite.pdf.
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The present IP regime in 164 countries are under the WTO’s7 TRIPs Agreement
concluded in 1995. Every WTO member country has to implement minimum
standard of intellectual property at the domestic level according to TRIPs provisions.
Article 1 of the Agreement stipulates, “Members may, but shall not be obliged to,
implement in their law more extensive protection than is required by this Agree-
ment.”8 Hence, it is clear that members are not obliged to implement higher
standards than prescribed in the TRIPs agreement.9
The basic concept of patent protection is that once the patent term is over
(presently 20 years under the TRIPS agreement), the product would be in the public
domain and freely used, including for commercial purposes.10 This eclipse of patent
protection is supposed to increase consumer welfare, and society would be better off
from evergreening protection. Pharmaceutical regulatory approval is entirely differ-
ent from patent protection. Moreover, it differs from country to country based on
domestic legislation. Linking such regulatory and marketing approval to the origi-
nator’s patent status would affect the generic drug industry at large and accessibility
and affordability.
Patent linkage involves linking the marketing approval of generic drugs with
the originator drug’s patent status and refusing to allow marketing approval until the
patent is expired.11 The United States (US) first introduced the concept through the
Hatch Waxman Act, 1984.12 This law provides for protecting the interest of patent
holders through linking patent status of originators’ drugs and their regulatory
approval in the “Orange Book.”13 Thus, a generic drug would not get marketing
approval if it would potentially infringe one or more patents listed in the Orange
Book. The US patent linkage system can be seen as a ploy by the patent holder to
delay the entry of generic drugs in the market.14 However, the originator industry
argues that this will help them prevent anticipated patent infringement and promote
innovation and investment by giving inventors more certainty over their patent
rights.15 However, generic manufacturers argue that TRIPs plus commitment under-
mines the rapid approval of generic medicines. Besides, most countries’ drug
regulatory authorities need not inform the inventors about the application for
marketing approval or the actual approval of a generic version of patented drugs.
Early working allows immediate marketing at the end of the patent period, equips the
7Presently, the World Trade Organization has 164 member countries, which constitute 99 percent of
the world trade.
8Article 1 of the TRIPS Agreement. https://www.wto.org/english/docs_e/legal_e/27-trips.pdf.
9Ibid.
10Correa (2016).
11Mirandah (2012), p. 50.
12https://www.congress.gov/bill/98th-congress/senate-bill/01538.
13Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.
accessdata.fda.gov/scripts/cder/ob/index.cfm.
14Son et al. (2018), p. 101. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201583/.
15Ellis (2019). https://geneva-network.com/article/patent-linkage/.
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generic companies to provide cheap drugs in developing countries without delay.16
This early working limited exception under Article 30 of the TRIPs Agreement does
not infringe patented drug owners’ rights. Nonetheless, there is a concerted effort to
introduce a link between the patent status of drugs and the regulatory approval of
generic medicines in the recent past through regional and bilateral trade agreements.
This paper argues that linking a generic drug’s market approval to its branded
equivalent’s patent status is detrimental to access to medicines in developing coun-
tries and least developed countries. It is argued that India and other developing
countries should not statutorily link patent protection with marketing approvals of
generic drugs, which is well beyond the TRIPs obligations. The backdoor entry of
these provisions through regional trade agreements should be prevented to allow the
production of cheap drugs for the developing world.
This paper analyses the legal regimes adopted to implement drug-related patent-
linkage provisions, enforcement, and standard practices of 21 jurisdictions.17 The
legal system of patent linkage countries (15 in number) and non-patent linkage
countries (6 countries) is analyzed mainly in South-east Asian countries to under-
stand these countries’ legal obligations and its implications in access to medicines.
The Indian experience is examined carefully, along with compulsory licensing
practice. Important judicial decisions are also analyzed to understand its effect on
access to drugs. The paper concludes that linking patent rights with marketing
approvals for generic medicines has far-reaching adverse consequences in develop-
ing countries’ access to drugs. Patent linkage has an incentive for extending monop-
oly rights beyond 20 years of the patent term and will negatively affect generic
drugs’ entry after the expiry of patent rights. It is relevant to note that only
15 countries implemented patent linkage directly among the WTO Members,18 but
regional trade agreements have patent linkage provisions, and their adoption will
increase the number.19 All the countries with direct patent linkage provisions are
included for a better understanding of the provisions.
16See Chapter 5.
17This include the US, EU, Canada, Australia, Japan, South Korea, China, Taiwan, Russia,
Ukraine, Thailand, Philippines, Singapore, Malaysia, Indonesia, Vietnam, Thailand, Jordan,
UAE, Peru and India.
18US, Canada, Japan, Australia, South Korea, China, Taiwan, Russia, Ukraine, Philippines,
Singapore, Jordan, Mexico, UAE and Peru.
19Townsend et al. https://www.bilaterals.org/IMG/pdf/ssrn-id2850294.pdf.
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2 Perspectives on Patent Linkage
2.1 US
In the US, patent linkage is included in the Drug Price Competition and Patent Term
Restoration Act, 1984 (Hatch Waxman Act) to regulate the generic industry. Patent
extensions are also allowed in the US for up to five years for qualifying patents.20
The patented drug must not have been infringed until expired or held invalid.
However, the legislation also provides some benefits for the generic industry.21
The Act has passed with an objective of hassle-free approvals to generic drugs
and unnecessary disputes with branded and patented drugs. Unfortunately, the
multinational drug companies exploit the loopholes in the Act in favor of them to
extend the patent protection.
In the US, the generic drug approval is linked to pioneer drug patents under the
Hatch Waxman Act, 1984 through Orange Book, certification process, and a limited
180-day generic market exclusivity period for first generic applicants who challenge
the validity of the patent or claim it would not be infringed under the Act’s Paragraph
IV certificate system. Under the “patent linkage” provisions, the new drug applica-
tion should include patent details, and the FDA reflects the existence of patents as
part of the approval process for specific drug applications. If a valid patent exists,
marketing approval will not be granted to a generic drug until the patent has expired
or declared invalid by competent authorities. This generic marketing approval is
“linked” to the expiration of the patented drug. Such patent information can be
published in “Orange Book.” This Book lists approved drugs, discontinued drugs,
and patent and exclusivity information. It is argued that the patent linkage system
20West and Allison Hoppert. https://www.oblon.com/A11960/assets/files/News/125.pdf.
21They can be summarized as follows:
• Generic drugs need not prove their safety and efficacy but must demonstrate the product’s
bioequivalence to the original patented drug. This will reduce the cost and delay of clinical trials
of generic medicines.
• Generic drugs are granted 180 days of exclusivity limited to the first generic entrant who files a
paragraph IV certification and thereby challenges the patent’s validity or claims that it will not be
infringed.
• Abbreviated New Drug Application (ANDA) applicant is not required to produce independent
evidence of the generic drug’s safety and effectiveness. He has to prove also that the generic
drug is bio-equivalent to reference listed drug (RLD).
• If the applicant submits a paragraph I or II certification, the patent in question will not delay
ANDA approval.
• If the applicant submits a paragraph III certification, the applicant agrees to wait until the
relevant patent has expired before seeking the ANDA’s final approval.
• Paragraph IV certification does not survive the expiry of a listed patent. In making paragraph IV
certification, the generic drug maker says he believes that the patented drug is invalid, not
infringed, or unenforceable.
• If the NDA holder brings a suit for infringement, the FDA can’t approve it for 30 months or
whenever the court determines the issue.
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increased the efficiency and productivity of the research and development sector of a
generic company and patent holder company. However, generic drug approvals are
vital for developing countries in curing pandemics.
Studies have revealed that generic drug approval applications were late by
30 months due to patent linkage provisions and the infringement litigation.22
These infringement cases increase the cost of drugs, and the generics lost the right
to enter the market during the stay period. S.156 provides for patent term extension
up to five years if certain conditions are met like any patent term adjustment granted
under section 154(b).23
The Act’s misuse includes “reverse payments” from originator companies to
generic companies during the 180 days exclusive period not to enter the market.
This is popularly known as the “pay-for-delay” program adopted by the originator
companies. The FTC has taken a strong exception to this anti-competitive practice
and believes that such practices are per-se illegal. To stop this practice, Congress
passed the Medicare Prescription Drug Improvement Modernization Act, 2003. This
Act stipulates that within ten days of reverse settlements, companies to register such
settlements with FTC.24 As per the FTC estimate, consumers lost $3.5billion higher
drug cost every year due to this “pay-for-delay” tactics of the originator compa-
nies.25 But in some cases like in In re Tamoxifen Citrate Antitrust Litig.,26 the
Second Circuit rejected the per se rule and held that reverse payment settlements
do not violate anti-trust laws if they fall within the exclusionary zone of the patent.
But the US Supreme Court, in a landmark judgment, FTC v. Actavis,27 held that the
pay-for-delay practice of originator companies for settling patent disputes with
generics and delay in entering the market could have significant anti-competitive
effects and violate anti-trust laws.28
Patent linkage is similar to that of the branded drug companies’ pay-for-delay
program to delay the entry of generics into the market. Thus access to cheaper
medicines is denied in developed and developing countries if patent linkage or
similar provisions are implemented.
Other tactics used by the originator companies, including asking the FDA to take
action on any ANDA application under “Citizen Petition” provision, will likely
delay the generic version of drugs. FDA has to take a decision not longer than
150 days. Again, this will delay the generic entry for another 150 days, and
22Winkler et al. (2018). https://www.finnegan.com/en/insights/requirements-benefits-and-possible-
consequences-of-listing-patents-in-fdas-orange-book.html.
23Merc & Co.Inc v. High Tech Pharmaceuticals Inc,, US Court of Appeals No. 2006-1401, decided
on March 29, 2007.
24Meagher (2017), p. 589. Available at: https://brooklynworks.brooklaw.edu/bjcfcl/vol11/iss2/12.
25Pay for Delay, Federal Trade Commission. https://www.ftc.gov/news-events/media-resources/
mergers-competition/pay-delay.
26466 F.3d 187, 228 (2d Cir. 2006).
27570 US. 136, 2013.
28Decided on June 17, 2013, https://www.supremecourt.gov/opinions/12pdf/12-416_m5n0.pdf.
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originators can file multiple, successive petitions. Another methodology adopted by
the branded companies is “product hopping” or “forced Switch schemes.” These are
branded companies’ strategies to come up with alternative versions of the medicine
shortly before the patent expiry with the effect of withdrawing the existing product
registration, which might be thwarted registration of the generic equivalent. A
patient who is using a particular branded medicine has the least possibility of
switching to a new generic drug; instead, continue with the altered version of the
branded drug. Thus, they were compelled to use essentially the same medicine with
the same company for a higher price; this maintains the originator company’s
monopoly for a more extended period than prescribed. Since the decision in Actavis
by the US Supreme Court, the number of pay-for-delay cases has been decreased.29
2.2 EU
The EU does not follow the patent linkage system. But at any time, the patent holder
can get an injunction against any infringement throughout Europe. EU believes that
any tinkering with the bolar provision through patent linkage will delay the entry of
generic drugs into the European market.30 EU directives do not prohibit
experimenting with any patented drug during the patent term and generating test
data, which can be submitted to the regulatory authorities for marketing approval.31
EU’s Pharmaceutical Sector Inquiry preliminary report of November 28, 2008,
accounts that 700 patent litigations were filed to prevent or delay the entry of
registered generic drugs into the market.32
The European Medicines Agency is responsible for the marketing approvals of a
generic drug in the EU.33 Article 81, Regulation No.EC726/200434 and Article
126 of Directive EC 2001/83 laying down community procedures for authorization
of medicinal products.35 EU believes that patent linkage provisions are beyond the
TRIPs obligations and not desirable in the EU. The bolar rule is strictly implemented
29Michael Carrier FTC v. Actavis: Where We Stand After 5 Years, 18 June 2018.
30Article 10.6. of Directive 2001/83/EC as amended).
31Data Exclusivity/Patent Linkage in the Context of EU Generic and Biosimilar Applications.
Presentation by Suzette Kox at the WIPO Life Sciences Symposium: Intellectual Property and Life
Sciences Regulation, 16 November 2017. https://www.wipo.int/export/sites/www/meetings/en/
2007/lifesciences/sym_regulation/lss3_ge_07_kox.pdf.
32European Commission (2008). https://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/
preliminary_report.pdf.
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in the EU through Article 10.6 of Directive 2001/83/EC as amended.36 Generic
companies are applying for marketing approval to demonstrate that it is bioequiva-
lent to the originator product. For that, the generic companies can refer to the test
data submitted by the originator companies. The test data provided by the originator
firms will get data exclusivity period for eight years, but during the additional
two-year market exclusivity provision, generic producers can early work and
apply for marketing approval.37 Moreover, the EU practices a maximum of five
years of extension based on the Supplementary Protection Certificate (SPC). Sub-
mission of generic biosimilar applications only possible after the data exclusivity
period.38
In 2012, the European Commission39 formally asked Italy to remove patent
linkage provisions outlined in Law No 30 of 2005 (the IP Code), namely paragraph
1-bis of Article 68 containing a clear patent linkage., which harm and delay the entry
of generic medicines in the market.40 The provision allows generic drug manufac-
turers to start the drug registration process only during the “last year” of the patent or
supplementary protection certificate’s validity. The Italian provision violated Article
10 of Directive 2001/83/EC in the community code relating to medicinal products.
In 2012, Law No. 27/2012 made the Italian law in compliance with the EU
Regulation. Now the marketing authorization application for a generic drug can be
filed more than one year before the patent or supplementary protection certificate
expiry. But manufacture, import, or sale of the drug would be considered as an
infringement. But Law No. 189/2012 excluded generic drugs from the National
Health Care Service. It means that generic drugs cannot be listed for reimbursement
until the patent is expired. But in the name of secondary patents, the generics have to
wait until its expiry as well.41
On 1 July 2019, Regulation UE 2019/933 introduced some amendments to the
previous Regulation (EC) 469/2009 concerning the SPC, setting forth a waiver
36https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_
2001_83_cons_2012_en.pdf.
37Medicines and Law Policy (2019). https://medicineslawandpolicy.org/wp-content/uploads/2019/
06/European-Union-Review-of-Pharma-Incentives-Data-Exclusivity.pdf.
38Data Exclusivity/Patent Linkage in the Context of EU Generic and Biosimilar Applications.
Presentation by Suzette Kox at the WIPO Life Sciences Symposium: Intellectual Property and Life
Sciences Regulation, 16 November 2017. https://www.wipo.int/export/sites/www/meetings/en/
2007/lifesciences/sym_regulation/lss3_ge_07_kox.pdf.
39Daniela Ampollini (Trevisan & Cuonzo) (2011). http://patentblog.kluweriplaw.com/2011/04/08/
patent-linkage-infringement-proceedings-by-the-european-commission-against-italy/.
40Intellectual Property Watch (2012). https://www.ip-watch.org/2012/01/31/european-commis
sion-orders-italy-to-drop-patent-linkage-delaying-generics/.
41Decision of the Regional Administrative Court of Rome on January 2018 (T.A.R. Lazio, sez. III, -
Roma, 19 January 2018, No 662).
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under certain conditions to export such manufactured drugs outside the EU
jurisdictions.42
Other EU countries like Hungary, Portugal, and Czech are trying to establish
different kinds of linkages with patents.43 Italy and Belgium have restrictions on the
reimbursement by National Health Service on drugs that infringe third-party patents.
In Hungary and Egypt, declarations of non-infringement are sought by applicants at
the time of filing.
The introduction of patent linkage would increase litigation frequency in patent
enforcement and delay generics’ entry in the EU market.44 The EU Council of
Ministers expressed concern over very high, unsustainable drug prices in the
EU.45 The FDA style patent linkage cannot be implemented in the EU because
there is no single patent in the entire EU jurisdiction. Instead, it is a bundle of patents
filed in the European Patent Office (EPO). However, in the Italy case, the European
Commission made it clear that patent linkage delays the entry of generic medicines
and a clear abuse of the EU regulatory system.46 Patent linkage is considered illegal
in the EU under Regulation (EC) No 726/2004 and Directive (EC) No 2001/83).47
2.3 Canada
In 1993 Canada first adopted a patent linkage system closely patterned on US law.
These regulations were adopted to ensure that the early exception is not abused by
generic drug applicants seeking to sell their products during the patent term. Notice
of compliance provisions is similar to that of the Hatch –Waxman Act. Canada also
keeps a Patent Book like Orange Book. Notice of allegation (NOA) and notice under
Paragraph IV of the HW Act are similar. The statutory stay of approval in Canada is
24 months, and it is 30 months in the US. In 2017, significant amendments were
made to the Patented Medicines (Notice of Compliance) Regulations1993




43Research Report on Establishing System of Linking New Drug Application and Patent Protection,
BIPI Research (2016) No. 002. http://www.theglobalipcenter.com/wp-content/uploads/2017/03/
full-report-E.pdf.
44European Generic Medicines Association (2008).
45Catherine Drew (2017). https://www.pinsentmasons.com/out-law/analysis/eu-unlikely-to-fol
low-us-with-patent-linkage-system-says-expert.
46Intellectual Property Watch (2012).
47Pharmaceutical Sector Inquiry – Preliminary Report, Fact Sheet “Regulatory Framework”.
https://ec.europa.eu/competition/sectors/pharmaceuticals/archive/4_Regulator_framework.pdf.
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Canada-European Union Comprehensive Economic and Trade Agreement
(CETA).48 The changes in the amendments can be summarized below:
1. The Minister of Health was given the power to maintain the Patent Register.
2. Generic or bio-similar manufacturers are required to serve a notice of allegation
(NOA).
3. All NOAs need to include a searchable electronic copy of the second person’s
drug submissions and copies of documents to be submitted.
4. First-person cannot seek a prohibition order against the Minister of Health.
5. First-person, who brings an action under the law, will be able to renounce the
24-month stay.
6. An un-successful action for patent infringement under the law, the second person
will be able to sue all the plaintiffs for section 8 damages.49
It is worth noting that Canada introduced a Bolar exception provision in 1991.50
Section 55.2 of the Act provides for two exceptions to patent infringement. These are
“early working” and “stockpiling” exceptions. EU filed a case in the WTO dispute
settlement against this provision. In the year 2000, the Panel held that the early
working provision did not violate the TRIPs agreement.51 However, the Panel held
that the manufacturing and stockpiling of drugs in the last six months of the patent
expiry term violate the Agreement. Later on, the stockpiling provision was repealed.
2.4 Australia
Australia effectively implemented patent linkage through Section 26B of the Ther-
apeutic Goods Act 1989 and AUSFTA and consequent legislation, the US Free
Trade Agreement Act, 2004. The generic companies seeking marketing approval
must provide a patent certificate stating that the generic did not infringe any
originator drug patents and notice the patentee.
If the generic drug infringes, no marketing approval will be granted. Moreover, an
injunction will be issued, which will delay generic entry for another three years.52
The Australian courts are generally in favor of patentees, and permanent injunctions
are usually granted to the originators.53
48https://laws-lois.justice.gc.ca/eng/regulations/sor-93-133/index.html.






53Managing IP (2019). https://www.managingip.com/Article/3865388/Australia-Protecting-phar
maceutical-market-share-in-Australia.html.
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The patent linkage provision is included under Section 26B of the Therapeutic
Goods Act 1989.54 An applicant seeking marketing approval of a generic or
biosimilar medicine must certify either that:
(i) it will not market the drug in a manner that would infringe a valid patent or;
(ii) It has notified the rights holder of their intention to market the drug before the
patent term expiry.55
However, Australia claims that there is no administrative patent linkage in the
country—after the potentially infringing applicant’s notice, the patent holder must
sue to protect its rights.56 Permanent injunctions are an effective way for originators
to prevent generics from entering the market. The Australian High Court considered
the question in Aktiebolaget Hassle v. Alphapharm Pty. Ltd.57 Evergreening and
linkage of the patent were discussed by the Court in this case and discussed how the
patent owners use a regulatory process to extend their blockbuster drugs patent term
for rent-seeking. The linkage-form of evergreening is the new method developed by
the drug companies following the US Hatch – Waxman legislation. The companies
try their luck in other jurisdictions even though there are no patent linkage provisions
in Australia.58 The Astra group filed a patent infringement case against a generic
drug manufacturer, Alphapharm, who started importing the drug to the Australian
market at the end of the patent term. Justice Kirby, in his judgment, observed the
tactics of the originators to delay the generic entry even after the patent term, in its
most persuasive words:
The strategies that large pharmaceutical manufacturers have employed to avoid such generic
competition, which include the use of intellectual property law, have been detailed else-
where. They are attracted to the attention and response of the Federal Trade Commission in
the United States. Such battles have had their counterparts in many other countries. They
present serious issues for the developing world. . .in its interpretation of the legislation, and
in identifying the proper approach to the ultimate factual determination of obviousness
called for by that statute, this Court should avoid creating fail-safe opportunities for
unwarranted extensions of monopoly protection that are not sustained by law.59
AUSFTA, Article 17.10.04, provides that the branded drug manufacturer would
be informed of an anticipated product.60 The regulatory process and marketing
approval for generic pharmaceuticals would be connected with patent infringement
status through this provision. It is also required to notify the patent holder of any
54Australian Government, About the Australian therapeutic goods legislation. https://www.tga.gov.
au/about-australian-therapeutic-goods-legislation.
55Son et al. (2018).
56DrugPatentWatch Patent linkage: Balancing patent protection and generic entry https://www.
drugpatentwatch.com/blog/patent-linkage-resolving-infringement/.
57(2062) HCA 59, 12 December 2002.
58Faunce and Lexchin (2007). https://anzhealthpolicy.biomedcentral.com/articles/10.1186/1743-
8462-4-8.
59Aktiebolaget Hassle v. Alphapharm Pty Ltd, 212 CLR 411, para 101 2002.
60Faunce and Lexchin (2007).
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generic marketing approval application.61 Originators have used the preliminary
injunction route for successfully stalling the entry of generics in the market. The
high degree of proof is with the generic industry to prove that they are not violating
any patents. Besides, AUSFTA provision 17.10.4(b) required that the patent holder
be notified of a generic marketing approval application. This provision is criticized
as an attempt to delay the entry of generic medicines in the Australian market.62
2.5 Japan
Even though Japan directly did not implement the patent linkage system, the
de-facto patent linkage system was implemented through a government regulation
to approve generic drugs.63 During the active patent validity period, no generic
approval will be granted.64 The patent linkages are secured in two stages of regula-
tory approval and drug price listing.65 If there is a delay in getting marketing
approval of the patented drug, the duration can be stretched for a period of up to
five years.66
After an amendment to the Patent Act in 2018, the patentee can claim patent
extension if it is granted after five years of application. The patent extension term
will mostly depend upon the period in which the originator is unable to use the
patented drug during a marketing approval process. Japan also keeps a US-style
Orange Book67 and patent linkage.68 The Minister will not approve any generic drug
when a patent right prevents the generic drug from being marketed.69 However,
under the price regulation system, the drug prices in Japan are determined by the
state.
Any dispute between originator drug manufacturers and generic manufacturers
must be reported to the Ministry of Health, Labor and Welfare.
61AUSFTA Article 17.10.4(b).
62Faunce and Lexchin (2007).
63IP Litigation in Life Sciences – Costs, Duration and Enforceability in Japan. Presentation by
Yoichi Okumura, Global Head of IP, Takeda Pharmaceutical Company Limited. WIPO Conference





66Law No. 145 of 1960.
67Approved Drug Products with Therapeutic Equivalence Evaluations.
68Notification No. 0605001 of the Economic Affairs Division, Health Policy Bureau of 2009 and
Notification No. 0605014 of the Evaluation and Licensing Division, Pharmaceutical and Food
Safety Bureau of the Ministry of Health, Welfare and Labour of 2009.
69Koizumi et al. (2011). https://www.amt-law.com/asset/res/news_2011en_pdf/110225_2055.pdf.
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Japan allows experimentation exemption under the Patent Act 2006
(Amended).70 Tests conducted during the patent term for submission to the regula-
tory approval is not an infringement under the Japan patent law.71
Price competition between originator drug and generic drug is significantly less in
Japan due to state price control. Reverse payments are considered as an anti-
competitive activity in Japan. Unlike the US, the ANDA 180-day exclusivity to
the first filer is not available in Japan. All these measures show that patent linkage is
not so intense that compared to the US. Nevertheless, Japan is a party to the RCEP
Agreement and may be forced entirely to implement patent linkages if these are
included in the final agreement.
2.6 South Korea
South Korea is another country that implemented the patent linkage system, in line
with the US Hatch-Waxman Act of 1984. This was done through a back door of the
US – Korea Bilateral Free Trade Agreement signed in 2007,72 entered into force in
2012 (Article 18.9.5 – IP Chapter).73 The amendment introduced the patent list and
the notification system. In addition to that, the government implemented a nine-
month stay on marketing approval and nine-month first generic exclusivity in 2015.
It was reported that the amendment increased the number of patent challenges as
well as marketing approvals related litigations.74 According to the Agreement,
Korea agreed to the following additional commitments over and above the TRIPs
agreement:
• Extended patent term to compensate for the patent prosecution delays from the
Korean Intellectual Property Office and other regulatory review delays.
• Data exclusivity should be granted for efficacy information submitted to support a
prior approved drug (three years) or newly approved drug (five years).
• Patent linkage provision informing patentees of an applicant’s identity before
granting marketing approval of a generic drug.
• Marketing approval will not be granted for a generic drug without the original
patent owner’s consent during the valid patent period.
The South Korean Pharmaceutical Affairs Act permits clinical test data submitted
by originators to be used by generic drug manufactures seeking marketing approval.
Korean patent listing is also strictly policed by MFDS, and it allows Korean generic
70www.japaneselawtranslation.go.jp.
71Ono Pharmaceuticals Co., Ltd. v. Kyoto Pharmaceuticals Industries, Ltd. Judgment dated
16 April 1999.
72Son et al. (2019).
73See Raley (2019a), pp. 459–492.
74Son and Lee (2017), pp. 1169–1178.
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manufacturers to institute administrative hearings before the patent hearing. The
branded companies must petition MFDS for the stay of generic drug sales, and the
stay lasts for nine months, but the branded manufacturers to obtain a stay of generic
drug FDA approval for up to 30 months like in the US.75 South Korea also provides
patent term extension up to five years for pharmaceuticals and agrochemicals. South
Korea is a part of RCEP negotiations. The leaked Korean RCEP draft on IP provides
for patent term extension for unreasonable delays in granting patents. Unreasonable
delay is defined as the delay for more than four years from the date of filing of the
application or three years after the request for examination of the application,
whichever is later [Article X.D.1.4(a)].76
2.7 China
The Administrative Measures for Drug Registration 2002 provides for the protection
of patent rights related to drugs. The applicant has to prove the patent status and
declare that it did not infringe on any patents. Attempts were made in 2005 and 2007
to include patent linkage provisions but are never happened until 2017.
In 2017, the Chinese Communist Party proposed reforms in the medical device
approval system and issued Reform Opinion (Order No. 55) to implement the US
model patent linkage system in drug regulation.77 China implemented “bolar exemp-
tion” provisions through patent amendments laws in 2008, known as the “Naked
Bolar Exemption.”78 Article 16 of “Opinion on Deepening Approval and Review
System Reform and Encouraging Innovation of Drug and Medical Apparatus” of
2017 describes the patent linkage system in China. It includes notifying the relevant
patentee of the generic drug and patent term adjustment system’s marketing approval
process. The long term review process and delays will be compensated through a
reasonable extension of the patent period. However, the Chinese new Drug Admin-
istration Law, 2019, took effect from December 1, has a patent linkage provision.79
The new law provides for a nationwide drug marketing authorization holder sys-
tem.80 The Chinese model of Orange book now has more than 131 drugs as well.81
Order 55 provides for the following:
75Raley (2019b).
76Townsend et al. https://www.bilaterals.org/IMG/pdf/ssrn-id2850294.pdf.
77Chen and Shi (2017), pp. 1484–1487.
78Article 69.
79China IPR (2021). https://chinaipr.com/category/patent-linkage/.
80Global Legal Monitor (2019). https://www.loc.gov/law/foreign-news/article/china-drug-adminis
tration-law-revised/.
81Zhang et al. (2018). http://patentblog.kluweriplaw.com/2018/04/03/china-establish-patent-
linkage/.
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1. A generic drug applicant shall notify the known patents at the time of drug filing.
2. If the drug applicant challenges a patent, it should declare that his drug does not
infringe on any patent.
3. The patent owner should start patent infringement proceeding within 20 days
after the drug filing.
4. The CFDA has the discretion to make the application pending for 24 months
before drug approval.
5. If there is no judicial remedy within the waiting period of 24 months, CFSA can
approve the generic drug.
6. If there is any infringement suit after the generic drug’s approval, it will be subject
to the judicial decision’s outcome.
On 15th January 2020, China and the US signed an Economic and Trade
Agreement to ease trade between the countries required to build a patent linkage
and patent term restoration system in China.82 Article 1.12 of the agreement provides
for patent extensions in case of unreasonable delays while examining the patent
application and delays in marketing approvals. The excessive delay means more than
four years from filing or three years from requesting examination. The patent validity
can be extended by a maximum of five years in case of marketing approval delays.83
China was an active participant in the RCEP negotiations on patent linkage.84
2.8 Taiwan
Taiwan has implemented a patent linkage system from 20 August 2019 following
the amended Pharmaceutical Affairs Act. A new chapter of “Patent Linkage of
Western Pharmaceuticals” was added to the law.85 The new generic drug manufac-
turers seeking marketing approval of generic drugs has to submit a declaration that
the new drug is not patented, or the patent has expired, or the approval must be given
after the expiry of the patent, or the patent on the new drug is not valid or not
infringed by the generic drug. Patent listing has to be made through online systems
under the Taiwan Food and Drug Administration (TFDA). Patentees to upload
information about originator drugs within 45 days form the approval of the TFDA.
82BRIEF—China progressing drug-related patent laws, The Pharma Letter, 22 April 2020. https://
www.thepharmaletter.com/in-brief/brief-china-progressing-drug-related-patent-laws.
83Reddie & Grose LLP (2020) https://www.reddie.co.uk/2020/01/23/what-does-the-us-china-
trade-deal-mean-for-pharmaceutical-patent-holders/.
84Li and Tong (2018), pp. 270–280. See also https://www.bilaterals.org/IMG/pdf/ssrn-id2850294.
pdf.
85Reddie & Grose LLP (2020) https://www.reddie.co.uk/2020/01/23/what-does-the-us-china-
trade-deal-mean-for-pharmaceutical-patent-holders/.
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The originator can file infringement suits within this period and delay a generic
drug’s approval for up to 12 months.86
2.9 Russia
Presently there is a positive trend towards the implementation of linkage in Russia.
The Russian Civil Code provides a patent owner to file a claim to cease any activities
that infringe the patent, including marketing approvals for the generics. Infringing
activities include offering to sale, producing, storing, or distributing a general
medicine. Threatening of infringement, obtaining marketing approvals, and regis-
tering maximum sales price provided that the relevant patent is used to manufacture
the generic. The marketing authorization will be canceled if the generic is not
presented in the Russian market for three or more years. If the generic drug is
already in the market, the originators try to get a judgment from the court in their
favor and refer the matter to the Ministry of Healthcare for canceling the marketing
approval.
Russia is a member of the Eurasian Economic Union (EAEU) rules, which
entered into force in 2017. The EAEU rules stipulate that the application for generic
marketing approval must include information on patents covered and a statement to
the effect that the medicine does not infringe on any parties’ intellectual property
rights. Submission of inaccurate information is a ground for revocation of marketing
approval of the generics. From the year 2021, national legislation has to include all
obligations under EAEU rules, including patent linkage. In April 2019, Russia
launched state registration of drugs and pending applications before MoH.87
In a 2018 Judgement by the Russian Intellectual Property Court dated 24 April
2018, it was held that preparations to launch a generic drug three years before the
expiry of the patent constitutes a threat of patent infringement.88 This decision
overrules an earlier position that Russian law does not recognize generic drugs’
registration during the patent validity term as an act of infringement (Art. 1359 (2) of
the Russian Civil Code.89
The MoH has prepared an amendment to the Law on Drugs, which states that
“any company seeking to register a new drug (original or generic) shall indicate all
patents and trademarks relevant for this new drug. Another obligation is to warrant
that registration of this new drug would not infringe any third party’s intellectual
rights, under the risk of penalties.”90
86Celebrating the Start of Patent Linkage, Taiwan Business TOPICS, 9 September 2019. https://
topics.amcham.com.tw/2019/09/celebrating-patent-linkage/.
87https://grls.rosminzdrav.ru/StatementRUInfo.aspx.
88Case No. А41-85807/2016. http://www.lidings.com/eng/legalupdates2?id¼388.
89Decision of the Supreme Commercial Court in case No. A40-65668/2008, dated 06.16.2009.
90Malakhov (2019).
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2.10 Ukraine
In Ukraine, Article 9 of the Ukrainian Law on Medicines and Drugs, 199691 pro-
vides that marketing approval of a generic drug before the expiration of the origi-
nator’s drug patent may be considered a violation of the patent owner’s rights.
Medicinal products shall be allowed only after registration with the Ministry of
Health (MoH).92 A generic applicant has to file a guarantee that the generic drug is
not infringing any patented drugs. Patent infringement is a ground for the cancella-
tion of marketing approval of generic drugs.
Article 34 of the Ukrainian Law on the Protection of Rights to Inventions93
provides that the manufacturing and selling of generic drugs before the expiration
of the originator drug’s patent may be considered patent infringement. But it is not
clear whether an application for marketing approval itself violates a patent or is
regarded as an infringement. However, at the same time, a valid patent is not a
guarantee for refusing a marketing approval for a generic drug by the MoH. As the
patent linkage is not fully implemented in Ukraine, the originator patent owners have
to monitor the marketing approvals and subsequently file patent infringement suits
against generic drug applicants and cancel the marketing approval and issuance of an
injunction.94 It is also to note that in Ukraine, there is no bolar provision available in
any legislation for the early production of the generic drug before the expiry of the
patent term.
Ukrainian law provides that the applicant for marketing approval must submit a
sample of medicine to state regulatory bodies as part of the marketing authorization
procedure. Production of such a sample of the drug itself will also be considered as
patent infringement without any difference, whether it was just a non-commercial
medicine production or not.95
The Ukrainian Supreme Court made vital observations on disputes between
originator and generic drug manufacturers in Merck Sharp & Dohme Corp
v. Aurobindo Pharma Limited., and granted injunctions against the generic manu-
facturers.96 The court of appeal clarified that state registration of the pharmaceutical,
as well as any preparatory actions without the actual placing of the product on the
market, are not included in the concept of “use” of a patented invention within the
91No. 123/96BP, 4 April 1996.
92https://www.wto.org/english/thewto_e/acc_e/ukr_e/WTACCUKR139_LEG_8.pdf.
93LAW OF UKRAINE on the Protection of Rights to Inventions and Utility Models https://
ukrpatent.org/i_upload/file/law-special-1.pdf.
94H.Lundbeck A/S v.Farmak JSC, http://reyestr.court.gov.ua/Review/3683167. In this case the
patent holder, Lundbeck, brought a claim because Farmak started the procedure to prepare the
launch of a generic medicine while the patent was still in force. The court issued an injunction
against, inter alia, the production, sale and offering for sale and the launch of the marketing
authorization process.
95H. Lundbeck A/S v Chemo Iberica, S.A., http://www.reyestr.court.gov.ua/Review/10026637.
96Ukraine: Interim injunctions in pharma cases, Vasil Kisil & Partners. Lexology https://www.
lexology.com/library/detail.aspx?g¼0eb0c844-233d-4988-9774-efffe9ebcabd.
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meaning of Article 28(2) of the Law of Ukrainian Law, “On Protection of Rights to
Inventions and Utility Models.” The Supreme Court dismissed the Court of Appeal’s
order and upheld the ruling of the court of the first instance that refused to prohibit
Aurobindo pharma from placing the drug on Ukraine’s market.97 Mostly the courts
are in granting injunctions against marketing approval of generic medicines and
favor originator companies.98
2.11 Thailand
Presently there are no patent linkage laws applicable in Thailand. However, in 2017,
Thailand constituted a committee to monitor various agencies, including the Food
and Drug Administration (FDA) and 15 other governmental agencies. It establishes a
clear linkage between agencies involved in the enforcement of IP, especially the
Department of Intellectual Property (DIP) and FDA, indirectly.99
The FDA imposed a condition that all applicants of a new drug must fill a form
listing all existing patents. Section 80 is included in the draft 2018 amendment to the
Drug Act 1967.100 This is a mandatory requirement from generic drug manufacturers
to find out possible infringement.101 Thailand wants to be part of the 11 member TPP
agreement, but the discussions stalled due to the COVID-19 pandemic.102 The
Pharmaceutical Affairs Act was amended and taken effect from 13 October
2019.103 Amendment to Section 80 provides for a “new drug or a new traditional
drug applicant would be required to include documents showing patent/petty patent
rights (Patent Information) or rights related to traditional Thai medicinal wisdom for
regulatory approval of a drug.”104 This will formalize a system since 2008; the FDA
has required that all applicants for a new drug fill out a form listing all of their





100Baker McKenzie, Thailand: Proposed Addition to Drug Act - Move Towards Patent Linkage
Concept. https://www.lexology.com/library/detail.aspx?g¼f19da913-6e8d-4498-8d4e-
8b5f53da695e.
101Bangkok Post (2017). https://www.tilleke.com/resources/ip-linkage-thai-government%E2%
80%99s-efforts-connect-agencies.
102Bangkok Post, February 17, 2020. https://www.bangkokpost.com/business/1859454/thailand-
to-decide-on-trade-pact-around-april-japan-minister.
103Drug Act (No. 6), B.E. 2562 (AD 2019). https://www.lexology.com/library/detail.aspx?
g¼8f66805c-64eb-49e1-87cc-25f6c716feb0.
104Baker McKenzie, Thailand: Proposed Addition to Drug Act.
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existing patents.105 The Patent Act allows the patent owner to take criminal and civil
actions against infringers. The penalty for infringement is not more than two years
imprisonment or a fine up to THB 400,000.106
2.12 Philippines
The Philippines removed the patent linkage system in 2006. The Government Order
permits acceptance of product registration without verifying whether there is a
relevant patent. However, the FDA shall comply with any court order. An originator
cannot prevent a generic drug manufacturer from getting a Certificate of Product
Registration (CPR). The innovator must file a civil, criminal, or administrative case
and get an injunction against CPR issuance. The Intellectual Property Code provides
provisions for patent infringement. Criminal action is available only for repeated
infringers. Philippines will be affected by the RCEP agreement, which is pending for
approval from India. Then patent linkage will be implemented throughout these
countries.107
2.13 Singapore
After entering a free trade agreement with the US and both countries, Singapore
introduced a patent linkage system, and both countries implemented it from January
1, 2004.108 The system allows the patent owners to monitor the generic drug
marketing application and imposes mandatory disclosures.109 Patent linkage pro-
visions are incorporated in Regulation 23(2) of the Health Products (Therapeutic
Products) Regulations 2016 (‘TPR’). The Health Science Authority (HAS) of
Singapore administers regulation on drug approval. Registration of any therapeutic
product needs a declaration to the effect that no patent is infringed. The applicant
must also declare that (1) the patent owner has given consent to the launch of the
generic version; (2) the patent is invalid; or (3) the patent will not be infringed by acts





107Mirandah (2012), p. 50. https://www.lexology.com/library/detail.aspx?g¼73ee9ee5-1873-457e-
b24f-8af6e96721ff.
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Filing of the false information is an offense with a fine and imprisonment of up to
12 months. If a generic company applies for marketing approval in the last 18 months
of the patent’s life, to be granted after the patent period’s expiry, the marketing
approval process will continue. Upon notice to the patentee, the marketing approval
can be stalled for 45 days (notice period). The HAS may register the therapeutic
product without further notice to the patent’s proprietor if no Order or Declaration
has been made at the end of 30 months after the date of the application for the Order
or Declaration. The patent holders get a 30-month stay of approval of any product
license upon applying for the necessary Order or Declaration. This prolonged delay
of up to 31.5 months in total leads to uncertainty among generic manufacturing
seeking marketing approval and the patentee.110 A person who made a false decla-
ration shall be liable for conviction to a fine of SGD 20,000 and/or imprisonment
for a term 12 months. The result of marketing approval in such cases will depend
upon the court decision.
In AstraZeneca AB (SE) v. Sanofi-Aventis Singapore Pte. Ltd, the High Court
discussed delaying originator drug makers’ tactics.111 This case was examined under
the Medicines Act, which was replaced by the TPR, 2016. Sanofi has applied for
marketing approval for film-coated tablets comprising rosuvastatin and a stabilizer.
Sanofi declared that the product would not infringe AstraZeneca’s Singapore Patent
No.SG89993 (993), because of a different combination. AstraZeneca argued that its
patents are infringed, and hence, a 30-month stay in the application process is
applicable. Sanofi was forced to disclose its composition of their product under the
court order. High Court observed that the 30 months’ objective is to settle the dispute
before the product enters the market. However, this provision may be misused for
delaying the entry of drugs by the originators and, therefore, have the effect of
delaying public access to competitors’ products. The Court concluded that “By way
of a parenthetical concluding observation, where a claim has serious consequences
to the public and a defendant’s legitimate business, as a matter of good practice, the
plaintiff should be required to give proper particulars of its claim” to save a
considerable amount of time, energy and expense.112
What kind of information could be disclosed to the patentee during marketing
approval is also under discussion in Millaneium Pharmaceuticals, Inc. v. Drug
Houses of Australia Pte Ltd.113 Millennium Pharmaceuticals owns two patents in
Singapore nos. SG 151322 and SG 182998, which are the process for manufacturing
bortezomib. Drug Houses of Australia (DHA) obtained marketing approval of
bortezomib, an anti-cancer drug in Singapore. The declaration filed as a part of the
marketing approval process was never made available, and Millenium was not
11030 months stay period and 45 days notice period.
111[2013] SGHCR 7.
112AstraZeneca AB (SE) v Sanofi-Aventis Singapore Pte Ltd [2013] SGHCR 7 https://www.
supremecourt.gov.sg/docs/default-source/module-document/judgement/2013-sghcr-7.pdf.
113(2018) SGHC 149 (First Instance); Appeal (2019) SGCA 31.
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served notice about the application and thus prevented from commencing litigation
under the TPR.
Millennium argued before the High Court that failing to declare the patents and
lack notice is in violation of laws, and the patents are infringed and a consequent
injunction restraining DHA from infringing patents. The court held that generic
companies must declare all patents which could be considered relevant to the
product in question. The High Court sided with Millenium and confirmed that the
defendant had made a misleading statement. In this case, generic companies would
be compelled to disclose process patents formulation patents related to the generic to
be granted marketing approval.114
Singapore provides data-exclusivity for five years from the dare of the original
marketing approval. HAS will not grant authorization for a generic drug based on the
actual test data without the originator company’s approval. Patent term extensions
and adjustments are available in Singapore, similar to that of the US. Patent term
adjustments are possible only due to a delay in prosecution by the Singapore Patent
Office.
The patent linkage regime in Singapore is in favor of originator companies. The
generic drug manufacturers have to inform the innovator of any possibility of
infringing the patent, and consequent litigation prolongs the entry of generics in
the market. Failure to inform about the possible patent infringement will lead to the
cancellation of the marketing approval and even criminal sanctions.115
2.14 Malaysia
Presently, there is no patent linkage in Malaysia. The exclusive use of the patentee is
protected under section 36 of the Patent Act 1983. The drug regulatory body has no
power to contravene the rights of the patentee. The generic marketing approval
cannot be considered as an excuse for infringement.
In March 2018, Malaysia signed the Comprehensive and Progressive Agreement
for Trans-Pacific Partnership (CPTPP), and the agreement is entered into force on
30 December 2018. Chapter 18 of the CPTPP provides a patent linkage system.
However, the CPTPP has not yet been ratified by Malaysia,116 and technically there
is no patent linkage in Malaysia. However, the Drug Control Authority (DCA)
monitors newly approved drugs when patent holders commence infringement




116Trans-Pacific Partnership Agreement (TPP) & Comprehensive and Progressive Agreement for
Trans-Pacific Partnership (CPTPP) https://fta.miti.gov.my/index.php/pages/view/71#:~:
text¼Malaysia%20is%20still%20evaluating%20the,Prime%20Minister%20and%20his%
20Cabinet.
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proceedings against marketers and manufacturers of generic medicines. However,
according to Section 37(1A) of the Patent Act 1983, no action can be taken against
the generic companies registering the drug, and no commercial activities in Malaysia
before the patent expiry. Nevertheless, if the generic manufacturers manufacture the
drug and stockpile, advertise, originators can file an “imminent infringement” suit
against the company under Section 59(2) of the Patent Act. This provision is similar
to that of the US, and the originators can sue the generic manufacturer before the
expiry of the patent.
The originator companies can monitor the notifications published by the National
Pharmaceutical Regulatory Agency (NPRA) related to a new drug product that has
been approved. The legal proceeding can be commenced against the generic drug
manufacturers those who infringe any patents. The generic companies can register
their products during the validity of the patent. However, other than registration, no
commercial activity is allowed. Evidence of patent infringement can be obtained
through an Anton Piller Order.117 The court will issue such an order only when the
originator producer prima facie case against the infringer.
There is no criminal punishment for infringements; only civil action can be
initiated before the “IP High Court” bench. The remedies available are permanent
injunction, impounding of the infringed products (Discovery Order), and compen-
sation by way of damages.
In Ranbaxy (M) Sdn. Bhd. v. EI Du Pont Nemours and Co.,118 the Court of
Appeal of Malaysia upheld a decision of the High Court of Malaysia relating to
patent infringement. The Generic manufacturer Ranbaxy argued that the regulatory
approval granted by the National Pharmaceutical Control Board (NPCB) means that
the manufacturing and sale of a patented pharmaceutical product are valid and not an
infringement. The plaintiff obtained regulatory approval in Malaysia to manufacture
and market a pharmaceutical drug known as COVANCE containing potassium
losartan. The defendant alleged infringement of one of the claims. The court further
held that the patent claim’s description sufficiently and adequately described or
taught the invention and supported the invention, and there is sufficient disclosure
to understand the patent. The Court of Appeal found that the appellant to have
infringed the patent.119 The court rejected the argument of linking regulatory
approval with the patent rights of originators in this case.120 A study on the impact
117An Anton Piller Order is a form of civil search warrant which allows the plaintiff to enter the
defendant’s premises and conduct a search. It takes the name from the famous case of Anton Piller
KG v. Manufacturing Processes Ltd., [1976] 1 All. E.R. 779, [1976] Ch. 55, [1976] 2 W.L.R. 162,
[1975] EWCA Civ 12.
1182011, 1 AMCR 857.
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of patent linkage on Malaysia by Rafiq Idris reveals that patent linkage will increase
Malaysia’s drug cost.121
2.15 Vietnam
In Vietnam, also, there are no declared patent linkage provisions. Even though the
Drug Administration of Vietnam (DAV) is notified about the potential infringement,
a generic drug’s marketing approval will not be stopped. The marketing approval
will be withdrawn after a suit for infringement is successful. Usually, preliminary
injunctions have not been granted in infringement cases.122 Article 126 of the
Vietnam Intellectual Property Law, 2005 amended in 2009 and 2019. Using the
patent for personal, non-commercial purposes, for research, evaluation, analysis, and
testing, is not considered patent infringement under Article 125(2) of the IP Act.
Article 13.4 of Circular 44/2014/TT-BYT, the DAV, is obligated to revoke the
marketing approvals in case of any patent infringement. Drugs can be imported
without any license or marketing approvals under “special import quota.”A patentee
can seek revocation of such quota on the strength of a conclusion of infringement
from a competent body.
In 2015, the Ministry of Science and Technology (MOST) conducted a raid in a
generic manufacturers facility in South Vietnam, on a complaint from an American
patentee. The patentee was aware of the generic drug’s entry in 2014 for treating
diabetes and filed a possible patent infringement against the manufacturer who got a
marketing approval. MOST ceased hundreds of finished tablets and raw materials. A
cease and desist order was also passed against the manufacturer, along with revoking
marketing approvals. This case shows an effective administrative action from
originator drug manufacturers during a valid patent period.123
2.16 Indonesia
Presently there is no patent linkage system in Indonesia. In Indonesia, BPOM
Regulation No. 3/2011 deals with the registration of drugs. It allows registration of
generic drugs and issues distribution licenses, which will take effect only after the
patent period expires. Criminal actions can be taken against the infringers, including
search, seizure, and closing infringers’ business. Infringement is punishable with
121Idris (2016), pp. 1672–1676.
122Managing IP (2017). https://www.managingip.com/article/b1kbpj5jsl30y6/vietnam-improving-
pharmaceutical-ip-protection.
123Le and Mai (2015), pp. 57–58. https://www.tilleke.com/sites/default/files/2015_Apr_Pharma_
Maze_Patent_Enforcement_Vietnam.pdf.
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four years of imprisonment and a fine up to IDR 1 billion. The patent holder may file
civil proceedings as well for damages.
2.17 Jordan
Marketing approval is not provided for pharmaceutical products during the period of
patent validity. Since the WTO accession in 1999 was amended in 2001,124 Jordan
maintained a patent linkage system and prevented generics’ registration
corresponding to a patent. Before enacting the patent law in 1999, consistent with
the TRIPs agreement, Jordan was a heaven of copycat drugs infringing patents.125 In
2002, the Minister of Health clarified that there would be no acceptance of dossiers
for generics’ marketing approval during the patent period. An application for a new
drug marketing approval will be accepted by the Ministry only if the new drug
produced by the domestic manufacturer is “similar but not the same as a patented
one.”126
2.18 Mexico
In Mexico, the Mexican Institute of Industrial Property (IMPI)127 and the Federal
Commission for Protection against Health Risks (COFEPRIS)128 work together to
avoid granting marketing approvals for allopathic drugs which may infringe a patent
in force. IMPI established a system of publication of patents through special Gazette
listing patents and their non-proprietary names (INN). The linkage system is
established under Article 167 bis of the Health Supplies Regulation and Article
47 bis of the Industrial Property Regulations in 2003. An application for marketing
approval to COFEPRIS relating to “substances or active ingredients” are obligated to
indicate whether they are the patent holder or licensee of the existing patent.129 If the
applicant is not the patentee or the licensee, they must provide a declaration, under
oath, that the application for marketing approval does not infringe the patent holder’s
rights. The COFEPRIS works with IMPI for ten days to determine the product’s
124Jordan, Patents of Invention Law, Law No. 32 for the Year 19991 (and its amendment by:
Temporary Law No. 71 for the Year 2001). https://www.sabaip.com/wp-content/uploads/2018/04/
Jordan-Patent-Law.pdf.
125Armouti and Nsour (2018). http://www.hjil.org/wp-content/uploads/Nsour-FINAL.pdf.
126report.nat.gov.tw.
127https://www.gob.mx/impi/, accessed on September 30, 2020.
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patent status for a pending marketing application. If a patent is listed in the Gazette,
the Ministry of Health has not provided marketing approval for a new product that
would infringe the patent.130
2.19 United Arab Emirates (UAE)
In UAE, Pharmaceutical patent registration is governed by Federal Law No. 17 of
2002 (as amended by Federal Law No. 31 of 2006) (Patent Law) and Ministry of
Health Decree No. 404 of 2000 (Patent Resolution). The Drug Control Department
(DCD) of the Ministry of Health (MOH) reviews applications for pharmaceuticals’
marketing exclusivity under the Patent Resolution.131
Applications for generic drugs will be accepted 12 months before the expiry of
UAE patent protection provided that the application does not contain any informa-
tion relating to the patentee, which is protected under Article 36 of the TRIPS
agreement.132
The UAE Ministry of Health133 Resolution provides that the Ministry deny
marketing approval for a product that would infringe an existing patent in UAE or
the country of import of that drug. The Ministry will either reject the application or
keep abeyance of the application until the patent term expires. This system provided
patent infringements by generic drugs infringing patents.134
3 Patent Linkage Provisions in Regional and Bilateral
Trade Agreements
3.1 CPTPP
The Trans-Pacific Partnership (TPP) agreement was dropped after the US refused to
participate in the negotiations in 2017. TPP minus the US lead to the Comprehensive
and Progressive Agreement for Trans-Pacific Agreement (CPTPP) agreement, a free
trade agreement between 11 countries in the Asia-Pacific Region. The countries
involved are New Zealand, Australia, Brunei Darussalam, Canada, Chile, Japan,
130Moeller IP, Patent Linkage in Mexico. https://www.moellerip.com/patent-linkage-in-mexico/.
131https://www.firstconsulting.com.
132 Al ju r f and Murray (2018) . h t tps : / / con ten t .nex t .wes t law.com/Document /
I81997321b69811e698dc8b09b4f043e0/View/FullText.html?contextData¼(sc.Default)&
transitionType¼Default.
133United Arab Emirates Ministry of Health and Prevention, Health Legislation. https://www.
mohap.gov.ae/en/Aboutus/Pages/PublicHealthPolicies.aspx.
134http://www.theglobalipcenter.com/wp-content/uploads/2018/02/United_Arab_Emirates.pdf.
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Malaysia, Mexico, Peru, Singapore, and Viet Nam. Article 18.53 requires that the
generic manufacturer notify the patent holder about the marketing of such a phar-
maceutical product. The provision allows patent owners to intervene to prevent the
marketing approval issuing and avoids the chance of infringing their patents.135
CPTPP came into force for the first six countries, Canada, New Zealand, Australia,
Japan, Mexico, and Singapore, on December 30, 2018. On January 14, 2019, it came
to force for Viet Nam.136 Canada, Australia, Japan, and Singapore have patent
linkage provisions; others have to include provisions once they ratify the agreement.
Peru signed the CPTPP in 2018 and agreed to implement the patent linkage
provisions.
3.2 US – Peru FTA
The US-Peru Free Trade Agreement, which entered into force in 2009, Article
16.10.4, provides patent linkage. The generic drug will undergo a bioequivalence
test before getting marketing approval. Notice to the patent holder is mandatory for
getting marketing approval for the generic drug. The marketing approval will be
deferred until the patent has expired, or sufficient time has to be given for adjudi-
cating the dispute on the status of the patent. Un-authorized marketing of the product
is prohibited before the expiry of the patent. Legislative decree of Peru 1075
imposed penalties and sanctions on a party deliberately provide false information
to the regulatory authorities.137
3.3 AUSFTA
The Australia-US Free Trade Agreement (AUSFTA) 2005 provides for patent
linkage (Article 17.10.4 – IP Chapter). There are measures in the marketing approval
process to prevent others from marketing a product during the patent term without
the patent owner’s consent. The owner will be informed of a marketing approval





137Kiliç and Maybarduk (2011). https://www.citizen.org/wp-content/uploads/comparative_analy
sis_of_the_u.s._intellectual_property_proposal_and_peruvian_law.pdf.
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of Australia observed that pharmaceutical manufacturers had employed many ways
to delay the generic competition. It held that “the court should avoid creating fail-
safe opportunities for unwarranted extensions of monopoly protection that are not
sustained by law.”139
3.4 RCEP
Negotiations for a Regional Comprehensive Economic Partnership (RCEP), as
launched in 2013, involved ASEAN member states and six of its trading partners,
including; China, India, Japan, Australia, New Zealand, and South Korea. In
November 2019, India decided to pull out of the negotiations citing its internal
economic concerns, mainly the trade deficit with China. The RCEP was signed in
November 2020. The IP chapter does not provide for patent linkage. An earlier
leaked draft of the RCEP agreement140 had patent linkage provisions for “prevention
of marketing pharmaceutical products infringing effective patent.”141 This provision
sought to tie the marketing approval process to the patent validity, originators
extension of the patent, and delay in the entry of generics. It would create a burden
on the regulatory authorities to look into the validity of the patent. Presently, most of
the countries do not have patent term extension provisions. But the draft included a
patent extension provision both in Japan and South Korea’s drafts.142
3.5 KOREA - US FTA
The U.S.-Korea Free Trade Agreement (KORUS FTA) entered into force on March
15, 2012.143 Under Article 18.9.5 of the agreement provides that when a
non-originator of a pharmaceutical product applies for marketing approval, the
patent owner must be notified of the identity of the person making such a request.
The government must make administrative arrangements to see that no marketing
approvals will be granted without the patent owner’s consent. Patent linkage for
biologics and generics was included in the Korean Pharmaceutical Affairs Act,
amended in 2015 following obligations under the KORUS FTA. It is similar to
that of the US provisions, provides for notice to the patent owner not less than
139Aktiebolaget Hassle v Alphapharm Pty Ltd., 212 CLR 411, para 101. 2002.
140Weatherall (2016).
141https://www.bilaterals.org/IMG/pdf/ssrn-id2850294.pdf.
142Bouchard et al. (2010), pp. 174–227.
143U.S. - Korea Free Trade Agreement. https://ustr.gov/trade-agreements/free-trade-agreements/
korus-fta.
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180 days before the first marketing date of the bio-similar. Korea followed the US
system as it is and is severely criticized in Korea.144
4 Indian Scenario
India does not presently provide for patent linkage under its patent law. The Indian
drug industry is one of the largest in the world, with 20 percent (value)145 in all
generics and accounts for 75 percent of the Indian market share.146 The US is the
prime destination of Indian generic exports. In 2008, the Department of Pharmaceu-
ticals started a program in the name of “Jan Aushadhi” (medicine for people) shops
to made available unbranded generic drugs available to the poor people in the
country at a reasonable and affordable price. Until June 30, 2019, 5300+ “Pradhan
Mantri Bhartiya Janaushadhi Kendras” are functional spread over 35 States/UTs of
our country.147 Under the umbrella of “Bureau of Pharma PSUs of India,”more than
900 drugs and 154 surgical & consumables covering almost all major therapeutic
groups have been supplying.
The prime objective of Draft Pharmaceutical Policy, 2017148 of India, declares,
“making essential drugs accessible at affordable prices to the common masses.” To
fulfill the policy objective, the Government has come out with a price regulation
mechanism through the National List of Essential Medicines. The National Health
Policy, 2017 also emphasizes affordability as one of the fundamental principles.149
The policy’s goal is to “achieve the highest possible level of good health and well-
being for all Indians through a preventive and promotive healthcare orientation in all
developmental policies.” These policy objectives cannot be achieved without a
vibrant generic drug industry.
The Government of India’s Pharma Vision 2020150 aims to make India a global
leader in end-to-end- drug manufacturing. The export of pharma products is
expected to reach $20 billion by 2020 and the total market to the tune of USD$55
billion.151 India supplies 20 percent of the global generic drug demand.152 It is more
144Laurenza (2015), pp. 439–442.
145http://www.uniindia.com/generic-drugs-holds-70-pc-market-share-in-pharmaceutical-sector-in-
india/south/news/1512004.html.






150India Pharma 2020: Propelling access and acceptance, realising true potential https://online.wsj.
com/public/resources/documents/McKinseyPharma2020ExecutiveSummary.pdf.
151Ibid.
152Press Information Bureau (2018). https://pib.gov.in/newsite/PrintRelease.aspx?relid¼186696.
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important to note that Indian pharmaceutical firms supply over 80 percent of the
antiretroviral drugs used internationally to combat AIDS (Acquired Immune Defi-
ciency Syndrome). The Indian industry provides even 30 percent of the US generic
drug market.153 Any changes in the global and regional policies will severely affect
the Indian generic industry. There is a direct correlation between generic drugs and
price affordability. However, there is a conflict of interest between patented drug
manufacturers and the generic drug industry, and allegation of patent infringements
are common in many cases. It is alleged that the originator drug industry is charging
exorbitant prices on their patented drugs, which is no match to their investments. In
India, the Madras High Court in the famous Novartis case discussed this issue.154
4.1 Drugs and Cosmetics Act, 1940
Rule 122E (Drugs & Cosmetics Rules) 1945 defines “new drug”. A generic drug has
not been defined in the Act nor Rules. The Central Drugs Standards Control
Organization (CDSCO) under the Directorate General of Health Services is respon-
sible for the approval of drugs in India. The objective of the Act is to examine the
safety and security of drugs that are manufactured and imported. There is no
interlinkage between the Drugs and Cosmetics Act and Patent Act 2005. Grant of
a patent by the Patent Controller General of India has no impact on whether or not
marketing approval should be granted. Patents can be opposed by pre-grant [section
25(1)], and post-grant [section 25(1) (t)] opportunities, or even it can be canceled
(Section 64). The Drugs Controller of India (DCGI) under the Drugs and Cosmetics
Act, 1940, is the statutory authority to grant manufacturing and marketing approval.
However, none of the legislations in India neither permits nor intends to provide
patent linkage.
4.2 Bristol Myers Squibb v. Hetero Drugs Ltd. – 2008
The petitioner successfully got an ex-party injunction against the Hyderabad-based
Hetero Drugs, which effectively linked patent status with marketing approval of the
generic version of the originator drug, in this case, Dasatinib, a cancer drug. The
Delhi High Court granted an injunction against the defendant and restrained generic
company from “manufacturing, selling, distributing advertising, exporting, offering
for sale or in any manner dealing directly or indirectly in any product infringing the
plaintiff’s patent. . .” The court also observed that the DCGI must see that such
approvals are not infringing any patent. The court held that “It is expected that the
153https://www.ibef.org/industry/pharmaceutical-india.aspx.
154Raju (2009), pp. 7–32.
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Drugs Controller while performing statutory functions will not allow any party to
infringe any laws and if the drug for which the defendants have sought approval is in
breach of the patent of the plaintiffs, the approval ought not to be granted to the
defendant.” This judgment created unrest and concerns in the generic industry.
Unfortunately, this is far beyond the court’s jurisdiction without adequately exam-
ining the Drugs and Cosmetics Act’s provisions about the mandate of the DCGI. It is
not the duty of the DCGI to enforce the patent rights in India. Its mandate is to ensure
the safety and quality of the drugs sold or imported into India. This will automati-
cally stall India’s generics’ approval process during the patent term, which is a
derogation from the bolar provision contained in Section 107A of the Patent Act.
There is no linkage in India, and neither the Patent Act nor the Drugs and
Cosmetics Act has provisions for connecting this. The court tried to implement
patent linkage, which is not envisaged, nor the legislature intended to include in the
concerned laws during its drafting. The court has attempted to fill the gap, which is
never existed. The costly originator medicines are a severe threat to needy patients in
India. On one side, the foreign companies argue for patent linkage, and on the other
hand, the generic companies and non-governmental organizations working in access
to medicines are objecting to the patent linkage. This decision caused unrest in the
well established generic industry in India. The court had delivered this judgment
when the DCGI was not even a party to the dispute. Effectively this judgment made
patent policing by the court without any legislative sanctions.
4.3 Bayer - Cipla Case
In Bayer v. Cipla, Union of India and Others, 2009,155 the Supreme Court held that
submission of clinical data for getting marketing approval is not an infringement of
the originator. Bayer has filed a case against Cipla, an Indian generic manufacturer in
the High Court of Delhi, alleging that “sorafenib,” is a spurious drug, which is an
imitation of the originator patented drug “Sorafenib tosylate.” A single Judge of the
court dismissed the petition in August 2009, rejecting Bayer’s argument that infer-
ring drug agencies’ role in patent policing or enforcement is unacceptable. Bayer
appealed before the Division Bench of the High Court, and the judgment was
delivered by the court in February 2010,156 upholding the position of the single
judge in this case and refused to issue a restraint order against the grant of marketing
approval to Cipla for its generic drug “Soranib.” Bayer filed a Special Leave Petition
(SLP)157 before the Supreme Court, which decides the case in December 2010,
upholding the decision of the Delhi High Court.
155WP(C) No. 7833/2008.
156LPA 443/2009-9 February 2010.
157Special Leave to Appeal (CIVIL) No. 6540/2010.
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It is interesting to know that Bayer argued that S.2 of the Drugs and Cosmetics
Act (DCA) read with S.48 of the Patent Act provides for inbuilt provision for “patent
linkage.” The marketing approval granted under S.2 shall not derogate any other
legislation, i.e., Patent law S.48, patentee’s rights. Bayer argued that patent linkage
could be inferred from the joint reading of Section 2 of the Drugs and Cosmetic Act
and Section 48 of the Patent Act. On the other hand, Cipla clearly said that
submitting information to the drug regulatory is not an infringement of the patent.
The Drugs Controller, given the regulatory approval to Cipla based on the drug, was
safe, effective, and not an act of “making, using, offering for sale, selling or
importing” the petitioner’s patented product.158 Section 107A(a) is known as the
Indian “Bolar” provision, permits any drug manufacturer to experiment with any
patented drug to generate data that could then be submitted to a drug control
authority. The aim of the rule is that ensuring the immediate entry of generic drugs
on patent expiration. “Spurious drug” is defined under section 17B of the Drugs Act,
which does not include a generic version of any medicines. The court rejected
Bayer’s argument that Rule 122B(1)(b) of the Drugs Rules, read with Form
44, and the data required (Appendix 1 to Schedule Y) intends patent linkage.
To suggest that patent linkage is established only because an entry in Form
44 asks the applicant to indicate the drug’s patent status is to misconstrue the
provisions as they stand. A form in an appendix to a statutory rule (in this case,
the DCR) cannot be understood contrary to the statute’s scheme. Court agreed with
the respondent’s contention that the Drug Controller General of India’s (DCGI)
office is not equipped to deal with patents’ validity. The office and functions of
DCGI are governed under the Drugs and Cosmetics Act (DCA) and not under the
Patents Act. The court observed that “spurious drugs” and “generic drugs” are two
different concepts. The court found that patent linkage is a “TRIPs plus” obligation,
and TRIPs do not deal with the concept of patent linkage.
The court concluded that patent linkage could not be read into the provisions of
the Drugs and Cosmetics Act and Patent Act, and such systems are undesirable for
the Indian context. Some of the other observations are very pertinent, as follows:
• Policing of patent rights is not the duty of the regulators.
• Patent rights are private rights, and they cannot be mix with public rights.
• Patent linkage will undermine the “Bolar” provision.
• Article 27 of the TRIPs Agreement requires that patents are made available
without discrimination by the field of technology, patent linkage only specific
to the pharmaceutical industry alone.
The Court elaborately discussed the objectives of the two legislations. Delhi High
Court when dismissing the petition and imposed a cost of Rs. 6,75,000/- payable in
equal shares to the Union of India and Cipla for vexatious and luxury litigation. The
Supreme Court held that there is no room for patent linkage in India, and no such
system could be encompassed into the existing Indian laws. Some scholars argue
158Mittal (2010), pp. 187–196.
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that denial of patent linkage in India is a negative development, and the availability
of life-saving drugs must be ensured through compulsory licenses, not through
giving parallel approval to generic drug manufacturing by DCGI.
Access to life-saving drugs in developing countries is essential and an essential
public interest topic in India. Adopting patent linkage, either legislatively or judi-
cially, would severely affect the generic drug industry in India.
5 Conclusions
The objective of patent rights is to give incentives to the innovator for further
research and development. This protection is for a limited period, 20 years, as
fixed under the TRIPs agreement. Presently, 164 WTO members are subscribed to
this agreement and obliged to implement at the domestic level since 1995. The
protection of patent rights is inevitable to promote innovation in the pharmaceutical
sector. At the same time, generic medicines also play a crucial role in pharmaceutical
innovation, especially affordability and accessibility in developing and developed
countries. But an inappropriate extension of the monopoly rights beyond the per-
mitted period of 20 years must be considered an abuse of the patent system. Patent
linkage is how the country allows linking marketing approval of the generic drug
with the originator drug’s patent status. The practice requires that generic companies
applying for marketing approval must prove that they are not violating any valid
patent. Under the arrangement, national regulatory authorities should prevent the
registration and marketing of generic pharmaceuticals.
Originally, patent linkage introduced through the Hatch-Waxman Act 1984 in the
US intended to encourage the manufacture of generic drugs without infringing any
patents and to promote innovation in the pharmaceutical industry. However, there
were no many takers of patent linkage provisions in other countries. The declared
objective of the law is to facilitate the entry of generic drugs in the US market. But it
is turned out to be a barrier for the generic companies to get regulatory approvals by
filing an ANDA.
For the last 36 years, since the introduction of the patent linkage in the US,
approximately 15 countries have adopted patent linkage provisions. Precisely, these
provisions are pushed through regional or bilateral trade agreements by the
US. There is no obligation under the TRIPs agreement to implement patent linkage.
Originator companies argue that patent linkage is a rational means of ensuring patent
rights and regulatory agencies not helping patent infringement. However, the objec-
tive of patent law and regulatory approvals are different, and their functions are
dissimilar. Patent linkage is not mentioned in the TRIPS agreement at all. The US
has made the patent linkage provision to create a second tier of protection for a patent
monopoly. Patent rights are private rights and have to be enforced privately, and it
cannot be implemented through government regulatory authorities.
The passive approach to free trade agreements and IP standard setting is evident.
Most of the bilateral trade agreements include IP chapters. The TRIPs flexibilities are
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breathing space for many developing and least developed countries, including India.
Eroding these flexibilities will kill the golden goose who produces a significant
chunk of the generic medicines for the developing world. Patent law requires
enforcement of patent rights, but linkage inappropriately uses regulatory authorities
to prevent infringement. These authorities may not be competent enough to deter-
mine patents’ validity, and their mandates are different. Marketing regulatory pro-
cedures should not be subject to patent law. Only the courts can decide if the patent is
infringed or not after adducing sufficient evidence, and it is not the duty nor expertise
of the regulators to do it.
EU does not support the idea of patent linkage because it will adversely affect the
implementation of the bolar provision to manufacture generics and biosimilars in
advance of patent expiry. However, Patent term extension is already granted in the
EU in the form of supplementary protection certificates (SPC) on a national basis. It
is alleged that patent linkage’s main objective is to extend the patent term by
delaying generic medicines’ entry. A centralized “Orange book” also is missing in
the EU. In the Italian patent linkage provision case, the European Commission made
it clear that patent linkage delays generic medicines’ entry and a clear abuse of the
EU regulatory system. It is also noticed that the originators are misusing the system
by filing frivolous litigations against the generic industry. In 2007, 20 such cases
were filed by the originators against generics and regulators in Portugal.159
Canada amended the Patent Act in 2017 and introduced patent linkage pro-
visions. The patent register is available similar to that of the “orange book” in the
US. However, 180 days exclusivity period is absent for the generic manufacturers to
challenge the patent. The statutory stay of generic is for 24 months less than the US
period of 30 months.
Japan also implemented patent linkage in the country. The patent linkages are
secured in two stages of regulatory approval and drug price listing. During the active
patent period, no generic approvals will be granted. Patent extension up to five years
is available.
Australia implemented a patent linkage through AUSFTA and consequent
domestic legislation. South Korea also implemented patent linkage through the
US – Korea Bilateral Free Trade Agreement. China effectively implemented linkage
through the Chinese new Drug Administration Law in 2019. On 15th January 2020,
China and the US signed an Economic and Trade Agreement to effectively imple-
ment patent linkage provisions. These provisions are similar to that of the US
provisions under 35 U.S.C.§.154(b). Chinese Taipei (Taiwan) also added patent
linkage provisions to the Pharmaceutical Affairs Act in 2019. The linkage provisions
have close similarities with Chinese provisions.
Thailand effectively implemented patent linkage through “Drug Patent Approval
Linkage” in 2019. Brunei, Singapore, New Zealand, and Chile signed the Trans-
Pacific Partnership (TPP) in 2006, and patent linkage is introduced through this
159https://www.medicinesforeurope.com/wp-content/uploads/2009/06/EGA-IP_Barriers_web.pdf.
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agreement. Singapore’s judicial decisions made it clear that the courts favor more
excellent protection to the patentees and already implemented patent linkage.
Even though Malaysia claims there is no patent linkage system, but it effectively
implemented the CPTPP. The High Court and Court of Appeal of Malaysia held that
the regulatory approval is nothing to do with any authorization to work on the patent.
It means that in Malaysia, there is still room for the generic industry to get marketing
approval.
It is interesting to note that regional trade agreements are taking the main stage in
implementing the patent linkage provisions. AUSFTA and US-Peru FTA also have
patent linkage provisions. Patent linkage provisions were also proposed in RCEP.
These TRIPs-plus provisions could substantially increase generic medicines’ costs
in the countries and threaten access to essential drugs in most states.
There is no patent linkage in India so far, and the courts are made it clear that
these two systems cannot be connected. Indian courts actively prevented patent
linkage successfully. The Satwant Reddy Committee Report in 2006 suggested the
gradual adoption of patent linkage in India. However, the Indian scenario is unique,
and it is the warehouse of generic medicines. Nevertheless, the jurisprudence from
India gives mixed feelings. In the Bristol Myers Squibb dispute, Delhi High Court
held that the Drug Controller General, when granting marketing approval to the
generic drug, must see that no valid patent is infringed.
On the other hand, in Bayer v. Cipla, the same Delhi High Court (another bench)
held that patent rights are private rights, and patent rights policing is not the
regulators’ duty. Court also observed that linkage would undermine the bolar
exemption granted under the TRIPs agreement. The dispute has gone to the Division
Bench of the High Court and Supreme Court of India but confirmed the first ruling in
favor of generic drugs in India.
However, the story in Roche Ltd. & Anr. v. Cipla is protracted litigation for
almost a decade. Initially, the case was in favor of Cipla and lost the dispute up to the
Supreme Court. Nevertheless, the second phase of the dispute was absolutely in
favor of Roche. The case reached the Supreme Court in 2017 again and finally
settled out of court.
Later, Roche filed a series of suits against Indian generic pharmaceutical compa-
nies like Glenmark Pharma, Reddy’s Lab, Natco Pharma, Innova Pharma, Cipla,
Aureate Healthcare, BDR Pharma, Oncare Lifesciences, Accuracare Pharmaceuti-
cals, and Metrix. This shows the ill intentions of the originator companies for using
litigation as a coercive measure in India.
Linking patent rights with regulatory and marketing approvals will have unde-
sirable results in developing countries and have a negative effect on access to
medicines in developing and least developed countries. Patent linkage introduces a
significant obstacle to the timely availability of generic medicines. With this analysis
of many countries’ linkage provisions, it is clear that while some developed coun-
tries adopt these provisions, many do not, and imposing this in the developing
countries like SAARC has an everlasting negative impact on the availability and
accessibility of generic drugs. The comparative analysis of the patent regimes of
different jurisdictions reveals no unanimity about patent linkage’s importance or
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utility. Enforcement of regional trade agreements with patent linkage provisions will
change this scenario. Patent linkage provisions will be used as a restrictive measure
upon drug development in the developing nations. This provision favors multina-
tional pharmaceutical companies those who want to extend their patent term for
maximum exploitation.
5.1 Suggestions
• TRIPS-plus obligations such as patent linkage should not be imposed on devel-
oping countries.
• Pre-emptive patent infringement suits only delay the entry of generic drugs, and
such infringement suits may not be entertained by courts when public interest is
involved.
• The role of licensing or regulatory authority and patent granting authority has to
be separated. Regulatory officers cannot make an informed decision about the
applicability of the patented drug and generic drugs. It must leave it to the court to
decide the status.
• TRIPs plus patent linkage obligations should not be imposed on developing
countries through regional trade agreements.
• Originator companies can very well file patent infringement suits even without
patent linkage provisions and seek to enforce their private rights through courts.
• Patent infringement suits must be based on good faith. Hefty fines should be
imposed on companies who file frivolous litigations to delay marketing approvals
of generics.
• Administrative procedures may be simplified, transparent, and a national registry
should list all new drug applications.
• Declaration of non-infringement can be taken for generic approvals to avoid
unnecessary litigations.
• The originator company should disclose all its patent registrations for products/
process while filing the regulatory approval.
• The patent application status should not be a ground for refusal, suspension, or
prevention of marketing approvals.
• Patent linkage is an administrative procedure and nothing to do with the concept
of patent protection. But some of the countries like Hungary made a provision for
declaring the patent status when applying for marketing approval of the generic.
• Reject all efforts to introduce patent linkage in any form in developing countries.
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